<html lang="en" class="js"><head><link rel="preload" href="/static/fonts/HardingText-Regular-Web-cecd90984f.woff2" as="font" type="font/woff2" crossorigin=""><script async="" src="https://scripts.webcontentassessor.com/scripts/93dabb8d80079a87fec7bb6f67b807fce90e1688f8957ad7ad152bfd58ea01c2"></script><script type="text/javascript" async="" src="https://pagead2.googlesyndication.com/tag/js/gpt.js"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-MRVXSHQ"></script><script type="text/javascript" src="https://www.nature.com/s5uUJ7wxGSPjP-2ZTXGL8aIjMkvrF0D_U9wFzbCSbsyaac7c_vAVKVxmUb72FEBlH1GOaMQOzPmAedgSw7uOUw=="></script><script src="https://cmp.nature.com/production_live/en/consent-bundle-8-85.js" onload="initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"></script>
    <title>Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial | Nature Medicine</title>
    
        
<link rel="alternate" type="application/rss+xml" href="https://www.nature.com/nm.rss">


    
        

        <script id="save-data-connection-testing">
            function hasConnection() {
                return navigator.connection || navigator.mozConnection || navigator.webkitConnection || navigator.msConnection;
            }

            function createLink(src) {
                var preloadLink = document.createElement("link");
                preloadLink.rel = "preload";
                preloadLink.href = src;
                preloadLink.as = "font";
                preloadLink.type = "font/woff2";
                preloadLink.crossOrigin = "";
                document.head.insertBefore(preloadLink, document.head.firstChild);
            }

            var connectionDetail = {
                saveDataEnabled: false,
                slowConnection: false
            };

            var connection = hasConnection();
            if (connection) {
                connectionDetail.saveDataEnabled = connection.saveData;
                if (/\slow-2g|2g/.test(connection.effectiveType)) {
                    connectionDetail.slowConnection = true;
                }
            }

            if (!(connectionDetail.saveDataEnabled || connectionDetail.slowConnection)) {
                createLink("/static/fonts/HardingText-Regular-Web-cecd90984f.woff2");
            } else {
                document.documentElement.classList.add('save-data');
            }
        </script>
    

<link rel="preconnect" href="https://cmp.nature.com" crossorigin="">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="applicable-device" content="pc,mobile">
<meta name="viewport" content="width=device-width,initial-scale=1.0,maximum-scale=5,user-scalable=yes">
<meta name="360-site-verification" content="5a2dc4ab3fcb9b0393241ffbbb490480">

<script data-test="dataLayer">
    window.dataLayer = [{"content":{"category":{"contentType":"article","legacy":{"webtrendsPrimaryArticleType":"research","webtrendsSubjectTerms":"cancer-immunotherapy;pancreatic-cancer;tumour-biomarkers","webtrendsContentCategory":null,"webtrendsContentCollection":null,"webtrendsContentGroup":"Nature Medicine","webtrendsContentGroupType":null,"webtrendsContentSubGroup":"Article","status":null}},"article":{"doi":"10.1038/s41591-022-01829-9"},"attributes":{"cms":null,"deliveryPlatform":"oscar","copyright":{"open":true,"legacy":{"webtrendsLicenceType":"http://creativecommons.org/licenses/by/4.0/"}}},"contentInfo":{"authors":["Lacey J. Padrón","Deena M. Maurer","Mark H. O’Hara","Eileen M. O’Reilly","Robert A. Wolff","Zev A. Wainberg","Andrew H. Ko","George Fisher","Osama Rahma","Jaclyn P. Lyman","Christopher R. Cabanski","Jia Xin Yu","Shannon M. Pfeiffer","Marko Spasic","Jingying Xu","Pier Federico Gherardini","Joyson Karakunnel","Rosemarie Mick","Cécile Alanio","Katelyn T. Byrne","Travis J. Hollmann","Jonni S. Moore","Derek D. Jones","Marco Tognetti","Richard O. Chen","Xiaodong Yang","Lisa Salvador","E. John Wherry","Ute Dugan","Jill O’Donnell-Tormey","Lisa H. Butterfield","Vanessa M. Hubbard-Lucey","Ramy Ibrahim","Justin Fairchild","Samantha Bucktrout","Theresa M. LaVallee","Robert H. Vonderheide"],"publishedAt":1654214400,"publishedAtString":"2022-06-03","title":"Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","legacy":null,"publishedAtTime":null,"documentType":"aplusplus","subjects":"Cancer immunotherapy,Pancreatic cancer,Tumour biomarkers"},"journal":{"pcode":"nm","title":"nature medicine","volume":"28","issue":"6","id":41591,"publishingModel":"Hybrid Access"},"authorization":{"status":true},"features":[{"name":"furtherReadingSection","present":true}],"collection":null},"page":{"category":{"pageType":"article"},"attributes":{"template":"mosaic","featureFlags":[{"name":"nature-onwards-journey","active":false}],"testGroup":null},"search":null},"privacy":{},"version":"1.0.0","product":null,"session":null,"user":null,"backHalfContent":true,"country":"BR","hasBody":true,"uneditedManuscript":false,"twitterId":["o3xnx","o43y9","o3ef7"],"baiduId":"d38bce82bcb44717ccc29a90c4b781ea","japan":false}];
    window.dataLayer.push({
        ga4MeasurementId: 'G-ERRNTNZ807',
        ga360TrackingId: 'UA-71668177-1',
        twitterId: ['3xnx', 'o43y9', 'o3ef7'],
        baiduId: 'd38bce82bcb44717ccc29a90c4b781ea',
        ga4ServerUrl: 'https://collect.nature.com',
        imprint: 'nature'
    });
</script>

<script>
    (function(w, d) {
        w.config = w.config || {};
        w.config.mustardcut = false;

        
        if (w.matchMedia && w.matchMedia('only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)').matches) {
            w.config.mustardcut = true;
            d.classList.add('js');
            d.classList.remove('grade-c');
            d.classList.remove('no-js');
        }
    })(window, document.documentElement);
</script>
 



     
    
    
        
    
    <style>@media only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark) {  .c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card--major .c-card__title,.c-card__title,.u-h2,.u-h3,h2,h3{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,.u-h3,h3{font-size:1.25rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}html{line-height:1.15;text-size-adjust:100%;box-sizing:border-box;font-size:100%;height:100%;overflow-y:scroll}body{background:#eee;color:#222;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;line-height:1.76;margin:0;min-height:100%}details,main{display:block}h1{font-size:2em;margin:.67em 0}a,sup{vertical-align:baseline}a{background-color:transparent;color:#069;overflow-wrap:break-word;text-decoration:underline;text-decoration-skip-ink:auto;word-break:break-word}b{font-weight:bolder}sup{font-size:75%;line-height:0;position:relative;top:-.5em}img{border:0;height:auto;max-width:100%;vertical-align:middle}button,input,select{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=submit],button{-webkit-appearance:button}[type=checkbox]{box-sizing:border-box;padding:0}summary{display:list-item}[hidden]{display:none}button{border-radius:0;cursor:pointer;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}h1{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;font-size:2rem;letter-spacing:-.0390625rem;line-height:2.25rem}.c-card--major .c-card__title,.u-h2,.u-h3,h2{font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-card--major .c-card__title,.u-h2,h2{font-weight:700;-webkit-font-smoothing:antialiased;font-size:1.5rem;line-height:1.6rem}.u-h3{font-size:1.25rem}.c-card__title,.c-reading-companion__figure-title,.u-h3,.u-h4,h4,h5,h6{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,h3{font-family:Harding,Palatino,serif;font-size:1.25rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,h3{font-weight:700;-webkit-font-smoothing:antialiased;letter-spacing:-.0117156rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;letter-spacing:-.0117156rem}input+label{padding-left:.5em}nav ol,nav ul{list-style:none none}p:empty{display:none}.sans-serif{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.article-page{background:#fff}.c-article-header{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;margin-bottom:40px}.c-article-identifiers{color:#6f6f6f;display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3;list-style:none;margin:0 0 8px;padding:0}.c-article-identifiers__item{border-right:1px solid #6f6f6f;list-style:none;margin-right:8px;padding-right:8px}.c-article-identifiers__item:last-child{border-right:0;margin-right:0;padding-right:0}.c-article-title{font-size:1.5rem;line-height:1.25;margin:0 0 16px}@media only screen and (min-width:768px){.c-article-title{font-size:1.875rem;line-height:1.2}}.c-article-author-list{display:inline;font-size:1rem;list-style:none;margin:0 8px 0 0;padding:0;width:100%}.c-article-author-list__item{display:inline;padding-right:0}.c-article-author-list svg{margin-left:4px}.c-article-author-list__show-more{display:none;margin-right:4px}.c-article-author-list__button,.js .c-article-author-list__item--hide,.js .c-article-author-list__show-more{display:none}.js .c-article-author-list--long .c-article-author-list__show-more,.js .c-article-author-list--long+.c-article-author-list__button{display:inline}@media only screen and (max-width:539px){.js .c-article-author-list__item--hide-small-screen{display:none}.js .c-article-author-list--short .c-article-author-list__show-more,.js .c-article-author-list--short+.c-article-author-list__button{display:inline}}#uptodate-client,.js .c-article-author-list--expanded .c-article-author-list__show-more{display:none!important}.js .c-article-author-list--expanded .c-article-author-list__item--hide-small-screen{display:inline!important}.c-article-author-list__button,.c-button-author-list{background:#ebf1f5;border:4px solid #ebf1f5;border-radius:20px;color:#666;font-size:.875rem;line-height:1.4;padding:2px 11px 2px 8px;text-decoration:none}.c-article-author-list__button svg,.c-button-author-list svg{margin:1px 4px 0 0}.c-article-author-list__button:hover,.c-button-author-list:hover{background:#069;border-color:transparent;color:#fff}.c-article-info-details{font-size:1rem;margin-bottom:8px;margin-top:16px}.c-article-info-details__cite-as{border-left:1px solid #6f6f6f;margin-left:8px;padding-left:8px}.c-article-metrics-bar{display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3}.c-article-metrics-bar__wrapper{margin:16px 0}.c-article-metrics-bar__item{align-items:baseline;border-right:1px solid #6f6f6f;margin-right:8px}.c-article-metrics-bar__item:last-child{border-right:0}.c-article-metrics-bar__count{font-weight:700;margin:0}.c-article-metrics-bar__label{color:#626262;font-style:normal;font-weight:400;margin:0 10px 0 5px}.c-article-metrics-bar__details{margin:0}.c-article-main-column{font-family:Harding,Palatino,serif;margin-right:8.6%;width:60.2%}@media only screen and (max-width:1023px){.c-article-main-column{margin-right:0;width:100%}}.c-article-extras{float:left;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;width:31.2%}@media only screen and (max-width:1023px){.c-article-extras{display:none}}.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{border-bottom:2px solid #d5d5d5;font-size:1.25rem;margin:0;padding-bottom:8px}@media only screen and (min-width:768px){.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{font-size:1.5rem;line-height:1.24}}.c-article-associated-content__container .c-article-associated-content__title{margin-bottom:8px}.c-article-body p{margin-bottom:24px;margin-top:0}.c-article-section{clear:both}.c-article-section__content{margin-bottom:40px;padding-top:8px}@media only screen and (max-width:1023px){.c-article-section__content{padding-left:0}}.c-article-authors-search{margin-bottom:24px;margin-top:0}.c-article-authors-search__item,.c-article-authors-search__title{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.c-article-authors-search__title{color:#626262;font-size:1.05rem;font-weight:700;margin:0;padding:0}.c-article-authors-search__item{font-size:1rem}.c-article-authors-search__text{margin:0}.c-code-block{border:1px solid #eee;font-family:monospace;margin:0 0 24px;padding:20px}.c-code-block__heading{font-weight:400;margin-bottom:16px}.c-code-block__line{display:block;overflow-wrap:break-word;white-space:pre-wrap}.c-article-share-box__no-sharelink-info{font-size:.813rem;font-weight:700;margin-bottom:24px;padding-top:4px}.c-article-share-box__only-read-input{border:1px solid #d5d5d5;box-sizing:content-box;display:inline-block;font-size:.875rem;font-weight:700;height:24px;margin-bottom:8px;padding:8px 10px}.c-article-share-box__button--link-like{background-color:transparent;border:0;color:#069;cursor:pointer;font-size:.875rem;margin-bottom:8px;margin-left:10px}.c-article-editorial-summary__container{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem}.c-article-editorial-summary__container .c-article-editorial-summary__content p:last-child{margin-bottom:0}.c-article-editorial-summary__container .c-article-editorial-summary__content--less{max-height:9.5rem;overflow:hidden}.c-article-editorial-summary__container .c-article-editorial-summary__button{background-color:#fff;border:0;color:#069;font-size:.875rem;margin-bottom:16px}.c-article-editorial-summary__container .c-article-editorial-summary__button.active,.c-article-editorial-summary__container .c-article-editorial-summary__button.hover,.c-article-editorial-summary__container .c-article-editorial-summary__button:active,.c-article-editorial-summary__container .c-article-editorial-summary__button:hover{text-decoration:underline;text-decoration-skip-ink:auto}.c-article-associated-content__container .c-article-associated-content__collection-label{font-size:.875rem;line-height:1.4}.c-article-associated-content__container .c-article-associated-content__collection-title{line-height:1.3}.c-context-bar{box-shadow:0 0 10px 0 rgba(51,51,51,.2);position:relative;width:100%}.c-context-bar__title{display:none}.c-reading-companion{clear:both;min-height:389px}.c-reading-companion__sticky{max-width:389px}.c-reading-companion__scroll-pane{margin:0;min-height:200px;overflow:hidden auto}.c-reading-companion__tabs{display:flex;flex-flow:row nowrap;font-size:1rem;list-style:none;margin:0 0 8px;padding:0}.c-reading-companion__tabs>li{flex-grow:1}.c-reading-companion__tab{background-color:#eee;border:1px solid #d5d5d5;border-image:initial;border-left-width:0;color:#069;font-size:1rem;padding:8px 8px 8px 15px;text-align:left;width:100%}.c-reading-companion__tabs li:first-child .c-reading-companion__tab{border-left-width:1px}.c-reading-companion__tab--active{background-color:#fff;border-bottom:1px solid #fff;color:#222;font-weight:700}.c-reading-companion__sections-list{list-style:none;padding:0}.c-reading-companion__figures-list,.c-reading-companion__references-list{list-style:none;min-height:389px;padding:0}.c-reading-companion__references-list--numeric{list-style:decimal inside}.c-reading-companion__sections-list{margin:0 0 8px;min-height:50px}.c-reading-companion__section-item{font-size:1rem;padding:0}.c-reading-companion__section-item a{display:block;line-height:1.5;overflow:hidden;padding:8px 0 8px 16px;text-overflow:ellipsis;white-space:nowrap}.c-reading-companion__figure-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:16px 8px 16px 0}.c-reading-companion__figure-item:first-child{border-top:none;padding-top:8px}.c-reading-companion__reference-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:8px 8px 8px 16px}.c-reading-companion__reference-item:first-child{border-top:none}.c-reading-companion__reference-item a{word-break:break-word}.c-reading-companion__reference-citation{display:inline}.c-reading-companion__reference-links{font-size:.813rem;font-weight:700;list-style:none;margin:8px 0 0;padding:0;text-align:right}.c-reading-companion__reference-links>a{display:inline-block;padding-left:8px}.c-reading-companion__reference-links>a:first-child{display:inline-block;padding-left:0}.c-reading-companion__figure-title{display:block;margin:0 0 8px}.c-reading-companion__figure-links{display:flex;justify-content:space-between;margin:8px 0 0}.c-reading-companion__figure-links>a{align-items:center;display:flex}.c-reading-companion__figure-full-link svg{height:.8em;margin-left:2px}.c-reading-companion__panel{border-top:none;display:none;margin-top:0;padding-top:0}.c-cod,.c-reading-companion__panel--active{display:block}.c-cod{font-size:1rem;width:100%}.c-cod__form{background:#ebf0f3}.c-cod__prompt{font-size:1.125rem;line-height:1.3;margin:0 0 24px}.c-cod__label{display:block;margin:0 0 4px}.c-cod__row{display:flex;margin:0 0 16px}.c-cod__row:last-child{margin:0}.c-cod__input{border:1px solid #d5d5d5;border-radius:2px;flex-basis:75%;flex-shrink:0;margin:0;padding:13px}.c-cod__input--submit{background-color:#069;border:1px solid #069;color:#fff;flex-shrink:1;margin-left:8px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-cod__input--submit-single{flex-basis:100%;flex-shrink:0;margin:0}.c-cod__input--submit:focus,.c-cod__input--submit:hover{background-color:#fff;color:#069}.c-pdf-download__link .u-icon{padding-top:2px}.c-pdf-download{display:flex;margin-bottom:16px;max-height:48px}@media only screen and (min-width:540px){.c-pdf-download{max-height:none}}@media only screen and (min-width:1024px){.c-pdf-download{max-height:48px}}.c-pdf-download__link{display:flex;flex:1 1 0%}.c-pdf-download__link:hover{text-decoration:none}.c-pdf-download__text{padding-right:4px}@media only screen and (max-width:539px){.c-pdf-download__text{text-transform:capitalize}}@media only screen and (min-width:540px){.c-pdf-download__text{padding-right:8px}}.c-context-bar--sticky .c-pdf-download{display:block;margin-bottom:0;white-space:nowrap}@media only screen and (max-width:539px){.c-pdf-download .u-sticky-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}}.c-pdf-container{display:flex;justify-content:flex-end}@media only screen and (max-width:539px){.c-pdf-container .c-pdf-download{display:flex;flex-basis:100%}}.c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:16px}.c-article-extras .c-pdf-container .c-pdf-download{width:100%}.c-article-extras .c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:0}@media only screen and (min-width:540px){.c-context-bar--sticky .c-pdf-download__link{align-items:center;flex:1 1 183px}}@media only screen and (max-width:320px){.c-context-bar--sticky .c-pdf-download__link{padding:16px}}.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:none}@media only screen and (max-width:1023px){.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:block}}.c-recommendations-column-switch .c-meta{margin-top:auto}.c-article-recommendations-card__meta-type,.c-meta .c-meta__item:first-child{font-weight:700}.c-article-metrics__heading a,.c-article-metrics__posts .c-card__title a{color:inherit}.c-article-metrics__posts .c-card__title{font-size:1.05rem}.c-article-metrics__posts .c-card__title+span{color:#6f6f6f;font-size:1rem}p{overflow-wrap:break-word;word-break:break-word}.c-ad{text-align:center}@media only screen and (min-width:320px){.c-ad{padding:8px}}.c-ad--728x90{background-color:#ccc;display:none}.c-ad--728x90 .c-ad__inner{min-height:calc(1.5em + 94px)}@media only screen and (min-width:768px){.js .c-ad--728x90{display:none}.js .u-show-following-ad+.c-ad--728x90{display:block}}.c-ad__label{color:#333;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;font-weight:400;line-height:1.5;margin-bottom:4px}.app-author-list{color:#6f6f6f;font-family:inherit;font-size:1rem;line-height:inherit;list-style:none;margin:0;padding:0}.app-author-list>li,.c-breadcrumbs>li,.c-footer__links>li,.js .app-author-list,.u-list-comma-separated>li,.u-list-inline>li{display:inline}.app-author-list>li:not(:first-child):not(:last-child):before{content:", "}.app-author-list>li:not(:only-child):last-child:before{content:" & "}.app-author-list--compact{font-size:.875rem;line-height:1.4}.app-author-list--truncated>li:not(:only-child):last-child:before{content:" ... "}.js .app-author-list__hide{display:none;visibility:hidden}.js .app-author-list__hide:first-child+*{margin-block-start:0}.c-meta{color:inherit;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;list-style:none;margin:0;padding:0}.c-meta--large{font-size:1rem}.c-meta--large .c-meta__item{margin-bottom:8px}.c-meta__item{display:inline-block;margin-bottom:4px}.c-meta__item:not(:last-child){border-right:1px solid #d5d5d5;margin-right:4px;padding-right:4px}@media only screen and (max-width:539px){.c-meta__item--block-sm-max{display:block}.c-meta__item--block-sm-max:not(:last-child){border-right:none;margin-right:0;padding-right:0}}@media only screen and (min-width:1024px){.c-meta__item--block-at-lg{display:block}.c-meta__item--block-at-lg:not(:last-child){border-right:none;margin-right:0;padding-right:0}}.c-meta__type{font-weight:700;text-transform:none}.c-skip-link{background:#069;bottom:auto;color:#fff;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;padding:8px;position:absolute;text-align:center;transform:translateY(-100%);z-index:9999}@media (prefers-reduced-motion:reduce){.c-skip-link{transition:top .3s ease-in-out 0s}}@media print{.c-skip-link{display:none}}.c-skip-link:link{color:#fff}.c-status-message{align-items:center;box-sizing:border-box;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;position:relative;width:100%}.c-card__summary>p:last-child,.c-status-message :last-child{margin-bottom:0}.c-status-message--boxed{background-color:#fff;border:1px solid #eee;border-radius:2px;line-height:1.4;padding:16px}.c-status-message__heading{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;font-weight:700}.c-status-message__icon{fill:currentcolor;display:inline-block;flex:0 0 auto;height:1.5em;margin-right:8px;transform:translate(0);vertical-align:text-top;width:1.5em}.c-status-message__icon--top{align-self:flex-start}.c-status-message--info .c-status-message__icon{color:#003f8d}.c-status-message--boxed.c-status-message--info{border-bottom:4px solid #003f8d}.c-status-message--error .c-status-message__icon{color:#c40606}.c-status-message--boxed.c-status-message--error{border-bottom:4px solid #c40606}.c-status-message--success .c-status-message__icon{color:#00b8b0}.c-status-message--boxed.c-status-message--success{border-bottom:4px solid #00b8b0}.c-status-message--warning .c-status-message__icon{color:#edbc53}.c-status-message--boxed.c-status-message--warning{border-bottom:4px solid #edbc53}.c-breadcrumbs{color:#000;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;list-style:none;margin:0;padding:0}.c-breadcrumbs__link{color:#666}svg.c-breadcrumbs__chevron{margin:4px 4px 0;fill:#888;height:10px;width:10px}@media only screen and (max-width:539px){.c-breadcrumbs .c-breadcrumbs__item{display:none}.c-breadcrumbs .c-breadcrumbs__item:last-child,.c-breadcrumbs .c-breadcrumbs__item:nth-last-child(2){display:inline}}.c-card{background-color:transparent;border:0;box-shadow:none;display:flex;flex-direction:column;font-size:14px;min-width:0;overflow:hidden;padding:0;position:relative}.c-card--no-shape{background:0 0;border:0;box-shadow:none}.c-card__image{display:flex;justify-content:center;overflow:hidden;padding-bottom:56.25%;position:relative}@supports (aspect-ratio:1/1){.c-card__image{padding-bottom:0}}.c-card__image img{left:0;min-height:100%;min-width:100%;position:absolute}@supports ((-o-object-fit:cover) or (object-fit:cover)){.c-card__image img{height:100%;object-fit:cover;width:100%}}.c-card__body{flex:1 1 auto;padding:16px}.c-card--no-shape .c-card__body{padding:0}.c-card--no-shape .c-card__body:not(:first-child){padding-top:16px}.c-card__title{letter-spacing:-.01875rem;margin-bottom:8px;margin-top:0}[lang=de] .c-card__title{hyphens:auto}.c-card__summary{line-height:1.4}.c-card__summary>p{margin-bottom:5px}.c-card__summary a{text-decoration:underline}.c-card__link:not(.c-card__link--no-block-link):before{bottom:0;content:"";left:0;position:absolute;right:0;top:0}.c-card--flush .c-card__body{padding:0}.c-card--major{font-size:1rem}.c-card--dark{background-color:#29303c;border-width:0;color:#e3e4e5}.c-card--dark .c-card__title{color:#fff}.c-card--dark .c-card__link,.c-card--dark .c-card__summary a{color:inherit}.c-header{background-color:#fff;border-bottom:5px solid #000;font-size:1rem;line-height:1.4;margin-bottom:16px}.c-header__row{padding:0;position:relative}.c-header__row:not(:last-child){border-bottom:1px solid #eee}.c-header__split{align-items:center;display:flex;justify-content:space-between}.c-header__logo-container{flex:1 1 0px;line-height:0;margin:8px 24px 8px 0}.c-header__logo{transform:translateZ(0)}.c-header__logo img{max-height:32px}.c-header__container{margin:0 auto;max-width:1280px}.c-header__menu{align-items:center;display:flex;flex:0 1 auto;flex-wrap:wrap;font-weight:700;gap:8px 8px;line-height:1.4;list-style:none;margin:0 -8px;padding:0}@media print{.c-header__menu{display:none}}@media only screen and (max-width:1023px){.c-header__menu--hide-lg-max{display:none;visibility:hidden}}.c-header__menu--global{font-weight:400;justify-content:flex-end}.c-header__menu--global svg{display:none;visibility:hidden}.c-header__menu--global svg:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__menu--global svg{display:block;visibility:visible}}.c-header__menu--journal{font-size:.875rem;margin:8px 0 8px -8px}@media only screen and (min-width:540px){.c-header__menu--journal{flex-wrap:nowrap;font-size:1rem}}.c-header__item{padding-bottom:0;padding-top:0;position:static}.c-header__item--pipe{border-left:2px solid #eee;padding-left:8px}.c-header__item--padding{padding-bottom:8px;padding-top:8px}@media only screen and (min-width:540px){.c-header__item--dropdown-menu{position:relative}}@media only screen and (min-width:1024px){.c-header__item--hide-lg{display:none;visibility:hidden}}@media only screen and (max-width:767px){.c-header__item--hide-md-max{display:none;visibility:hidden}.c-header__item--hide-md-max:first-child+*{margin-block-start:0}}.c-header__link{align-items:center;color:inherit;display:inline-flex;gap:4px 4px;padding:8px;white-space:nowrap}.c-header__link svg{transition-duration:.2s}.c-header__show-text{display:none;visibility:hidden}.has-tethered .c-header__heading--js-hide:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__show-text{display:inline;visibility:visible}}.c-header__dropdown{background-color:#000;border-bottom:1px solid #2f2f2f;color:#eee;font-size:.875rem;line-height:1.2;padding:16px 0}@media print{.c-header__dropdown{display:none}}.c-header__heading{display:inline-block;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.25rem;font-weight:400;line-height:1.4;margin-bottom:8px}.c-header__heading--keyline{border-top:1px solid;border-color:#2f2f2f;margin-top:16px;padding-top:16px;width:100%}.c-header__list{display:flex;flex-wrap:wrap;gap:0 16px;list-style:none;margin:0 -8px}.c-header__flush{margin:0 -8px}.c-header__visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.c-header__search-form{margin-bottom:8px}.c-header__search-layout{display:flex;flex-wrap:wrap;gap:16px 16px}.c-header__search-layout>:first-child{flex:999 1 auto}.c-header__search-layout>*{flex:1 1 auto}.c-header__search-layout--max-width{max-width:720px}.c-header__search-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #fff;border-radius:2px;color:#fff;cursor:pointer;display:flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.15;margin:0;padding:8px 16px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:100%}.u-button svg,.u-button--primary svg{fill:currentcolor}.c-header__input,.c-header__select{border:1px solid;border-radius:3px;box-sizing:border-box;font-size:1rem;padding:8px 16px;width:100%}.c-header__select{-webkit-appearance:none;background-image:url("data:image/svg+xml,%3Csvg height='16' viewBox='0 0 16 16' width='16' xmlns='http://www.w3.org/2000/svg'%3E%3Cpath d='m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z' fill='%23333' fill-rule='evenodd' transform='matrix(0 1 -1 0 11 3)'/%3E%3C/svg%3E");background-position:right .7em top 50%;background-repeat:no-repeat;background-size:1em;box-shadow:0 1px 0 1px rgba(0,0,0,.04);display:block;margin:0;max-width:100%;min-width:150px}@media only screen and (min-width:540px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:auto;right:0}}@media only screen and (min-width:768px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:0;right:auto}}.c-header__dropdown.has-tethered{border-bottom:0;border-radius:0 0 2px 2px;left:0;position:absolute;top:100%;transform:translateY(5px);width:100%;z-index:1}@media only screen and (min-width:540px){.c-header__dropdown.has-tethered{transform:translateY(8px);width:auto}}@media only screen and (min-width:768px){.c-header__dropdown.has-tethered{min-width:225px}}.c-header__dropdown--full-width.has-tethered{padding:32px 0 24px;transform:none;width:100%}.has-tethered .c-header__heading--js-hide{display:none;visibility:hidden}.has-tethered .c-header__list--js-stack{flex-direction:column}.has-tethered .c-header__item--keyline,.has-tethered .c-header__list~.c-header__list .c-header__item:first-child{border-top:1px solid #d5d5d5;margin-top:8px;padding-top:8px}.c-header__item--snid-account-widget{display:flex}.c-header__container{padding:0 4px}.c-header__list{padding:0 12px}.c-header__menu .c-header__link{font-size:14px}.c-header__item--snid-account-widget .c-header__link{padding:8px}.c-header__menu--journal{margin-left:0}@media only screen and (min-width:540px){.c-header__container{padding:0 16px}.c-header__menu--journal{margin-left:-8px}.c-header__menu .c-header__link{font-size:16px}.c-header__link--search{gap:13px 13px}}.u-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #069;border-radius:2px;color:#069;cursor:pointer;display:inline-flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.3;margin:0;padding:8px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:auto}.u-button--primary{background-color:#069;background-image:none;border:1px solid #069;color:#fff}.u-button--full-width{display:flex;width:100%}.u-display-none{display:none}.js .u-js-hide,.u-hide{display:none;visibility:hidden}.u-hide:first-child+*{margin-block-start:0}.u-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}@media print{.u-hide-print{display:none}}@media only screen and (min-width:1024px){.u-hide-at-lg{display:none;visibility:hidden}.u-hide-at-lg:first-child+*{margin-block-start:0}}.u-clearfix:after,.u-clearfix:before{content:"";display:table}.u-clearfix:after{clear:both}.u-color-open-access{color:#b74616}.u-float-left{float:left}.u-icon{fill:currentcolor;display:inline-block;height:1em;transform:translate(0);vertical-align:text-top;width:1em}.u-full-height{height:100%}.u-list-reset{list-style:none;margin:0;padding:0}.u-container{margin:0 auto;max-width:1280px;padding:0 16px}.u-justify-content-space-between{justify-content:space-between}.u-mt-32{margin-top:32px}.u-mb-8{margin-bottom:8px}.u-mb-16{margin-bottom:16px}.u-mb-24{margin-bottom:24px}.u-mb-32{margin-bottom:32px}.c-nature-box svg+.c-article__button-text,.u-ml-8{margin-left:8px}.u-pa-16{padding:16px}html *,html :after,html :before{box-sizing:inherit}.c-article-section__title,.c-article-title{font-weight:700}.c-card__title{line-height:1.4em}.c-article__button{background-color:#069;border:1px solid #069;border-radius:2px;color:#fff;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;margin-bottom:16px;padding:13px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-article__button,.c-article__button:hover{text-decoration:none}.c-article__button--inverted,.c-article__button:hover{background-color:#fff;color:#069}.c-article__button--inverted:hover{background-color:#069;color:#fff}.c-header__link{text-decoration:inherit}.grade-c-hide{display:block}.c-nature-box{background-color:#fff;border:1px solid #d5d5d5;border-radius:2px;box-shadow:0 0 5px 0 rgba(51,51,51,.1);line-height:1.3;margin-bottom:24px;padding:16px 16px 3px}.c-nature-box__text{font-size:1rem;margin-bottom:16px}.c-nature-box--access-to-pdf{display:none}@media only screen and (min-width:1024px){.c-nature-box--mobile{display:none}}.c-nature-box .c-pdf-download{margin-bottom:16px!important}.c-nature-box--version{background-color:#eee}.c-nature-box__wrapper{transform:translateZ(0)}.c-nature-box__wrapper--placeholder{min-height:165px}.c-pdf-download__link{padding:13px 24px} } </style>




    
        <link data-test="critical-css-handler" data-inline-css-source="critical-css" rel="stylesheet" href="/static/css/enhanced-article-nature-branded-1dd982e2cc.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)" onload="this.media='only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)';this.onload=null">
    
    <noscript>
        <link rel="stylesheet" type="text/css" href="/static/css/enhanced-article-nature-branded-1dd982e2cc.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)">
    </noscript>

<link rel="stylesheet" type="text/css" href="/static/css/article-print-c9121fecab.css" media="print">
    



<link rel="apple-touch-icon" sizes="180x180" href="/static/images/favicons/nature/apple-touch-icon-f39cb19454.png">
<link rel="icon" type="image/png" sizes="48x48" href="/static/images/favicons/nature/favicon-48x48-b52890008c.png">
<link rel="icon" type="image/png" sizes="32x32" href="/static/images/favicons/nature/favicon-32x32-3fe59ece92.png">
<link rel="icon" type="image/png" sizes="16x16" href="/static/images/favicons/nature/favicon-16x16-951651ab72.png">
<link rel="manifest" href="/static/manifest.json" crossorigin="use-credentials">
<link rel="mask-icon" href="/static/images/favicons/nature/safari-pinned-tab-69bff48fe6.svg" color="#000000">
<link rel="shortcut icon" href="/static/images/favicons/nature/favicon.ico">
<meta name="msapplication-TileColor" content="#000000">
<meta name="msapplication-config" content="/static/browserconfig.xml">
<meta name="theme-color" content="#000000">
<meta name="application-name" content="Nature">


<script>
    (function () {
        if ( typeof window.CustomEvent === "function" ) return false;
        function CustomEvent ( event, params ) {
            params = params || { bubbles: false, cancelable: false, detail: null };
            var evt = document.createEvent( 'CustomEvent' );
            evt.initCustomEvent( event, params.bubbles, params.cancelable, params.detail );
            return evt;
        }

        CustomEvent.prototype = window.Event.prototype;

        window.CustomEvent = CustomEvent;
    })();
</script>



<!-- Google Tag Manager -->
<script data-test="gtm-head">
    window.initGTM = function() {
        if (window.config.mustardcut) {
            (function (w, d, s, l, i) {
                w[l] = w[l] || [];
                w[l].push({'gtm.start': new Date().getTime(), event: 'gtm.js'});
                var f = d.getElementsByTagName(s)[0],
                        j = d.createElement(s),
                        dl = l != 'dataLayer' ? '&l=' + l : '';
                j.async = true;
                j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl;
                f.parentNode.insertBefore(j, f);
            })(window, document, 'script', 'dataLayer', 'GTM-MRVXSHQ');
        }
    }
</script>
<!-- End Google Tag Manager -->

    <script>
    (function(w,d,t) {
        function cc() {
            var h = w.location.hostname;
            if (h.indexOf('preview-www.nature.com') > -1) return;

            var e = d.createElement(t),
                    s = d.getElementsByTagName(t)[0];

            if (h.indexOf('nature.com') > -1) {
                if (h.indexOf('test-www.nature.com') > -1) {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                } else {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                }
            } else {
                e.src = '/static/js/cookie-consent-es5-bundle-cb57c2c98a.js';
                e.setAttribute('data-consent', h);
            }
            s.insertAdjacentElement('afterend', e);
        }

        cc();
    })(window,document,'script');
</script>


<script id="js-position0">
    (function(w, d) {
        w.idpVerifyPrefix = 'https://verify.nature.com';
        w.ra21Host = 'https://wayf.springernature.com';
        var moduleSupport = (function() {
            return 'noModule' in d.createElement('script');
        })();

        if (w.config.mustardcut === true) {
            w.loader = {
                index: 0,
                registered: [],
                scripts: [
                    
                        {src: '/static/js/global-article-es6-bundle-c8a573ca90.js', test: 'global-article-js', module: true},
                        {src: '/static/js/global-article-es5-bundle-d17603b9e9.js', test: 'global-article-js', nomodule: true},
                        {src: '/static/js/shared-es6-bundle-e9d2061c95.js', test: 'shared-js', module: true},
                        {src: '/static/js/shared-es5-bundle-1cbf3a8b56.js', test: 'shared-js', nomodule: true},
                        {src: '/static/js/header-150-es6-bundle-5bb959eaa1.js', test: 'header-150-js', module: true},
                        {src: '/static/js/header-150-es5-bundle-994fde5b1d.js', test: 'header-150-js', nomodule: true}
                    
                ].filter(function (s) {
                    if (s.src === null) return false;
                    if (moduleSupport && s.nomodule) return false;
                    return !(!moduleSupport && s.module);
                }),

                register: function (value) {
                    this.registered.push(value);
                },

                ready: function () {
                    if (this.registered.length === this.scripts.length) {
                        this.registered.forEach(function (fn) {
                            if (typeof fn === 'function') {
                                setTimeout(fn, 0); 
                            }
                        });
                        this.ready = function () {};
                    }
                },

                insert: function (s) {
                    var t = d.getElementById('js-position' + this.index);
                    if (t && t.insertAdjacentElement) {
                        t.insertAdjacentElement('afterend', s);
                    } else {
                        d.head.appendChild(s);
                    }
                    ++this.index;
                },

                createScript: function (script, beforeLoad) {
                    var s = d.createElement('script');
                    s.id = 'js-position' + (this.index + 1);
                    s.setAttribute('data-test', script.test);
                    if (beforeLoad) {
                        s.defer = 'defer';
                        s.onload = function () {
                            if (script.noinit) {
                                loader.register(true);
                            }
                            if (d.readyState === 'interactive' || d.readyState === 'complete') {
                                loader.ready();
                            }
                        };
                    } else {
                        s.async = 'async';
                    }
                    s.src = script.src;
                    return s;
                },

                init: function () {
                    this.scripts.forEach(function (s) {
                        loader.insert(loader.createScript(s, true));
                    });

                    d.addEventListener('DOMContentLoaded', function () {
                        loader.ready();
                        var conditionalScripts;
                        
                            conditionalScripts = [
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es6-bundle-464a2af269.js', test: 'pan-zoom-js',  module: true },
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es5-bundle-98fb9b653b.js', test: 'pan-zoom-js',  nomodule: true },
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es6-bundle-23597ae350.js', test: 'math-js', module: true},
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es5-bundle-6532c6f78b.js', test: 'math-js', nomodule: true}
                            ];
                        

                        if (conditionalScripts) {
                            conditionalScripts.filter(function (script) {
                                return !!document.querySelector(script.match) && !((moduleSupport && script.nomodule) || (!moduleSupport && script.module));
                            }).forEach(function (script) {
                                loader.insert(loader.createScript(script));
                            });
                        }
                    }, false);
                }
            };
            loader.init();
        }
    })(window, document);
</script><script id="js-position1" data-test="global-article-js" defer="" src="/static/js/global-article-es6-bundle-c8a573ca90.js"></script><script id="js-position2" data-test="shared-js" defer="" src="/static/js/shared-es6-bundle-e9d2061c95.js"></script><script id="js-position3" data-test="header-150-js" defer="" src="/static/js/header-150-es6-bundle-5bb959eaa1.js"></script>










<meta name="robots" content="noarchive">
<meta name="access" content="Yes">


<link rel="search" href="https://www.nature.com/search">
<link rel="search" href="https://www.nature.com/opensearch/opensearch.xml" type="application/opensearchdescription+xml" title="nature.com">
<link rel="search" href="https://www.nature.com/opensearch/request" type="application/sru+xml" title="nature.com">





    
    <script type="application/ld+json">{"mainEntity":{"headline":"Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","description":"Chemotherapy combined with immunotherapy has improved the treatment of certain solid tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma (PDAC). We conducted a randomized phase 2 trial evaluating the efficacy of nivolumab (nivo; anti-PD-1) and/or sotigalimab (sotiga; CD40 agonistic antibody) with gemcitabine/nab-paclitaxel (chemotherapy) in patients with first-line metastatic PDAC (\n                NCT03214250\n                \n              ). In 105 patients analyzed for efficacy, the primary endpoint of 1-year overall survival (OS) was met for nivo/chemo (57.7%, P = 0.006 compared to historical 1-year OS of 35%, n = 34) but was not met for sotiga/chemo (48.1%, P = 0.062, n = 36) or sotiga/nivo/chemo (41.3%, P = 0.223, n = 35). Secondary endpoints were progression-free survival, objective response rate, disease control rate, duration of response and safety. Treatment-related adverse event rates were similar across arms. Multi-omic circulating and tumor biomarker analyses identified distinct immune signatures associated with survival for nivo/chemo and sotiga/chemo. Survival after nivo/chemo correlated with a less suppressive tumor microenvironment and higher numbers of activated, antigen-experienced circulating T cells at baseline. Survival after sotiga/chemo correlated with greater intratumoral CD4 T cell infiltration and circulating differentiated CD4 T cells and antigen-presenting cells. A patient subset benefitting from sotiga/nivo/chemo was not identified. Collectively, these analyses suggest potential treatment-specific correlates of efficacy and may enable biomarker-selected patient populations in subsequent PDAC chemoimmunotherapy trials. In a randomized phase 2 trial, sotigalimab, a CD40 agonist, did not significantly improve overall survival in patients with previously untreated metastatic pancreatic cancer when combined with chemotherapy or with nivolumab and chemotherapy. Multi-omic exploratory analyses provide insights into immunologic features associated with clinical benefit.","datePublished":"2022-06-03T00:00:00Z","dateModified":"2022-07-21T00:00:00Z","pageStart":"1167","pageEnd":"1177","license":"http://creativecommons.org/licenses/by/4.0/","sameAs":"https://doi.org/10.1038/s41591-022-01829-9","keywords":["Cancer immunotherapy","Pancreatic cancer","Tumour biomarkers","Biomedicine","general","Cancer Research","Metabolic Diseases","Infectious Diseases","Molecular Medicine","Neurosciences"],"image":["https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig1_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig2_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig3_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig4_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig5_HTML.png"],"isPartOf":{"name":"Nature Medicine","issn":["1546-170X","1078-8956"],"volumeNumber":"28","@type":["Periodical","PublicationVolume"]},"publisher":{"name":"Nature Publishing Group US","logo":{"url":"https://www.springernature.com/app-sn/public/images/logo-springernature.png","@type":"ImageObject"},"@type":"Organization"},"author":[{"name":"Lacey J. Padrón","url":"http://orcid.org/0000-0003-0064-5565","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy","address":{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"email":"lpadron@parkerici.org","@type":"Person"},{"name":"Deena M. Maurer","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy","address":{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Mark H. O’Hara","affiliation":[{"name":"Abramson Cancer Center of the University of Pennsylvania","address":{"name":"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Eileen M. O’Reilly","url":"http://orcid.org/0000-0002-8076-9199","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center","address":{"name":"Memorial Sloan Kettering Cancer Center, New York, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Robert A. Wolff","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","address":{"name":"The University of Texas MD Anderson Cancer Center, Houston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Zev A. Wainberg","affiliation":[{"name":"University of California, Los Angeles","address":{"name":"University of California, Los Angeles, Los Angeles, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Andrew H. Ko","affiliation":[{"name":"University of California, San Francisco","address":{"name":"University of California, San Francisco, San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"George Fisher","affiliation":[{"name":"Stanford University","address":{"name":"Stanford University, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Osama Rahma","affiliation":[{"name":"Dana-Farber Cancer Institute","address":{"name":"Dana-Farber Cancer Institute, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Jaclyn P. Lyman","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy","address":{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Christopher R. Cabanski","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy","address":{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Jia Xin Yu","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy","address":{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Shannon M. Pfeiffer","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy","address":{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Marko Spasic","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy","address":{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Jingying Xu","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy","address":{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Pier Federico Gherardini","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy","address":{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Joyson Karakunnel","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy","address":{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Rosemarie Mick","affiliation":[{"name":"Abramson Cancer Center of the University of Pennsylvania","address":{"name":"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Cécile Alanio","affiliation":[{"name":"Abramson Cancer Center of the University of Pennsylvania","address":{"name":"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Parker Institute of Cancer Immunotherapy at the University of Pennsylvania","address":{"name":"Parker Institute of Cancer Immunotherapy at the University of Pennsylvania, Philadelphia, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Pennsylvania, Perelman School of Medicine","address":{"name":"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Pennsylvania, Perelman School of Medicine","address":{"name":"Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Katelyn T. Byrne","affiliation":[{"name":"Abramson Cancer Center of the University of Pennsylvania","address":{"name":"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Parker Institute of Cancer Immunotherapy at the University of Pennsylvania","address":{"name":"Parker Institute of Cancer Immunotherapy at the University of Pennsylvania, Philadelphia, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Travis J. Hollmann","url":"http://orcid.org/0000-0003-1599-0433","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center","address":{"name":"Memorial Sloan Kettering Cancer Center, New York, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Jonni S. Moore","url":"http://orcid.org/0000-0002-2975-336X","affiliation":[{"name":"Abramson Cancer Center of the University of Pennsylvania","address":{"name":"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Derek D. Jones","affiliation":[{"name":"Abramson Cancer Center of the University of Pennsylvania","address":{"name":"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Marco Tognetti","url":"http://orcid.org/0000-0002-2379-1525","affiliation":[{"name":"Biognosys AG","address":{"name":"Biognosys AG, Schlieren, Switzerland","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Richard O. Chen","url":"http://orcid.org/0000-0002-2842-4476","affiliation":[{"name":"Personalis, Inc.","address":{"name":"Personalis, Inc., Menlo Park, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Xiaodong Yang","affiliation":[{"name":"Apexigen, Inc.","address":{"name":"Apexigen, Inc., San Carlos, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Lisa Salvador","affiliation":[{"name":"Bristol Myers Squibb","address":{"name":"Bristol Myers Squibb, New York, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"E. John Wherry","url":"http://orcid.org/0000-0003-0477-1956","affiliation":[{"name":"Abramson Cancer Center of the University of Pennsylvania","address":{"name":"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Parker Institute of Cancer Immunotherapy at the University of Pennsylvania","address":{"name":"Parker Institute of Cancer Immunotherapy at the University of Pennsylvania, Philadelphia, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Pennsylvania, Perelman School of Medicine","address":{"name":"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Pennsylvania, Perelman School of Medicine","address":{"name":"Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Ute Dugan","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy","address":{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Jill O’Donnell-Tormey","affiliation":[{"name":"Cancer Research Institute","address":{"name":"Cancer Research Institute, New York, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Lisa H. Butterfield","url":"http://orcid.org/0000-0002-3439-9844","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy","address":{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Vanessa M. Hubbard-Lucey","affiliation":[{"name":"Cancer Research Institute","address":{"name":"Cancer Research Institute, New York, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Ramy Ibrahim","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy","address":{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Justin Fairchild","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy","address":{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Samantha Bucktrout","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy","address":{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Theresa M. LaVallee","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy","address":{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Robert H. Vonderheide","url":"http://orcid.org/0000-0002-7252-954X","affiliation":[{"name":"Abramson Cancer Center of the University of Pennsylvania","address":{"name":"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Parker Institute of Cancer Immunotherapy at the University of Pennsylvania","address":{"name":"Parker Institute of Cancer Immunotherapy at the University of Pennsylvania, Philadelphia, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Pennsylvania, Perelman School of Medicine","address":{"name":"Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, USA","@type":"PostalAddress"},"@type":"Organization"}],"email":"rhv@upenn.edu","@type":"Person"}],"isAccessibleForFree":true,"@type":"ScholarlyArticle"},"@context":"https://schema.org","@type":"WebPage"}</script>




    
    
    


    
    <link rel="canonical" href="https://www.nature.com/articles/s41591-022-01829-9">
    
    
    <meta name="journal_id" content="41591">
    <meta name="dc.title" content="Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial">
    <meta name="dc.source" content="Nature Medicine 2022 28:6">
    <meta name="dc.format" content="text/html">
    <meta name="dc.publisher" content="Nature Publishing Group">
    <meta name="dc.date" content="2022-06-03">
    <meta name="dc.type" content="OriginalPaper">
    <meta name="dc.language" content="En">
    <meta name="dc.copyright" content="2022 The Author(s)">
    <meta name="dc.rights" content="2022 The Author(s)">
    <meta name="dc.rightsAgent" content="journalpermissions@springernature.com">
    <meta name="dc.description" content="Chemotherapy combined with immunotherapy has improved the treatment of certain solid tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma (PDAC). We conducted a randomized phase 2 trial evaluating the efficacy of nivolumab (nivo; anti-PD-1) and/or sotigalimab (sotiga; CD40 agonistic antibody) with gemcitabine/nab-paclitaxel (chemotherapy) in patients with first-line metastatic PDAC ( NCT03214250 ). In 105 patients analyzed for efficacy, the primary endpoint of 1-year overall survival (OS) was met for nivo/chemo (57.7%, P = 0.006 compared to historical 1-year OS of 35%, n = 34) but was not met for sotiga/chemo (48.1%, P = 0.062, n = 36) or sotiga/nivo/chemo (41.3%, P = 0.223, n = 35). Secondary endpoints were progression-free survival, objective response rate, disease control rate, duration of response and safety. Treatment-related adverse event rates were similar across arms. Multi-omic circulating and tumor biomarker analyses identified distinct immune signatures associated with survival for nivo/chemo and sotiga/chemo. Survival after nivo/chemo correlated with a less suppressive tumor microenvironment and higher numbers of activated, antigen-experienced circulating T cells at baseline. Survival after sotiga/chemo correlated with greater intratumoral CD4 T cell infiltration and circulating differentiated CD4 T cells and antigen-presenting cells. A patient subset benefitting from sotiga/nivo/chemo was not identified. Collectively, these analyses suggest potential treatment-specific correlates of efficacy and may enable biomarker-selected patient populations in subsequent PDAC chemoimmunotherapy trials. In a randomized phase 2 trial, sotigalimab, a CD40 agonist, did not significantly improve overall survival in patients with previously untreated metastatic pancreatic cancer when combined with chemotherapy or with nivolumab and chemotherapy. Multi-omic exploratory analyses provide insights into immunologic features associated with clinical benefit.">
    <meta name="prism.issn" content="1546-170X">
    <meta name="prism.publicationName" content="Nature Medicine">
    <meta name="prism.publicationDate" content="2022-06-03">
    <meta name="prism.volume" content="28">
    <meta name="prism.number" content="6">
    <meta name="prism.section" content="OriginalPaper">
    <meta name="prism.startingPage" content="1167">
    <meta name="prism.endingPage" content="1177">
    <meta name="prism.copyright" content="2022 The Author(s)">
    <meta name="prism.rightsAgent" content="journalpermissions@springernature.com">
    <meta name="prism.url" content="https://www.nature.com/articles/s41591-022-01829-9">
    <meta name="prism.doi" content="doi:10.1038/s41591-022-01829-9">
    <meta name="citation_pdf_url" content="https://www.nature.com/articles/s41591-022-01829-9.pdf">
    <meta name="citation_fulltext_html_url" content="https://www.nature.com/articles/s41591-022-01829-9">
    <meta name="citation_journal_title" content="Nature Medicine">
    <meta name="citation_journal_abbrev" content="Nat Med">
    <meta name="citation_publisher" content="Nature Publishing Group">
    <meta name="citation_issn" content="1546-170X">
    <meta name="citation_title" content="Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial">
    <meta name="citation_volume" content="28">
    <meta name="citation_issue" content="6">
    <meta name="citation_publication_date" content="2022/06">
    <meta name="citation_online_date" content="2022/06/03">
    <meta name="citation_firstpage" content="1167">
    <meta name="citation_lastpage" content="1177">
    <meta name="citation_article_type" content="Article">
    <meta name="citation_fulltext_world_readable" content="">
    <meta name="citation_language" content="en">
    <meta name="dc.identifier" content="doi:10.1038/s41591-022-01829-9">
    <meta name="DOI" content="10.1038/s41591-022-01829-9">
    <meta name="size" content="259565">
    <meta name="citation_doi" content="10.1038/s41591-022-01829-9">
    <meta name="citation_springer_api_url" content="http://api.springer.com/xmldata/jats?q=doi:10.1038/s41591-022-01829-9&amp;api_key=">
    <meta name="description" content="Chemotherapy combined with immunotherapy has improved the treatment of certain solid tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma (PDAC). We conducted a randomized phase 2 trial evaluating the efficacy of nivolumab (nivo; anti-PD-1) and/or sotigalimab (sotiga; CD40 agonistic antibody) with gemcitabine/nab-paclitaxel (chemotherapy) in patients with first-line metastatic PDAC ( NCT03214250 ). In 105 patients analyzed for efficacy, the primary endpoint of 1-year overall survival (OS) was met for nivo/chemo (57.7%, P = 0.006 compared to historical 1-year OS of 35%, n = 34) but was not met for sotiga/chemo (48.1%, P = 0.062, n = 36) or sotiga/nivo/chemo (41.3%, P = 0.223, n = 35). Secondary endpoints were progression-free survival, objective response rate, disease control rate, duration of response and safety. Treatment-related adverse event rates were similar across arms. Multi-omic circulating and tumor biomarker analyses identified distinct immune signatures associated with survival for nivo/chemo and sotiga/chemo. Survival after nivo/chemo correlated with a less suppressive tumor microenvironment and higher numbers of activated, antigen-experienced circulating T cells at baseline. Survival after sotiga/chemo correlated with greater intratumoral CD4 T cell infiltration and circulating differentiated CD4 T cells and antigen-presenting cells. A patient subset benefitting from sotiga/nivo/chemo was not identified. Collectively, these analyses suggest potential treatment-specific correlates of efficacy and may enable biomarker-selected patient populations in subsequent PDAC chemoimmunotherapy trials. In a randomized phase 2 trial, sotigalimab, a CD40 agonist, did not significantly improve overall survival in patients with previously untreated metastatic pancreatic cancer when combined with chemotherapy or with nivolumab and chemotherapy. Multi-omic exploratory analyses provide insights into immunologic features associated with clinical benefit.">
    <meta name="dc.creator" content="Padrón, Lacey J.">
    <meta name="dc.creator" content="Maurer, Deena M.">
    <meta name="dc.creator" content="O’Hara, Mark H.">
    <meta name="dc.creator" content="O’Reilly, Eileen M.">
    <meta name="dc.creator" content="Wolff, Robert A.">
    <meta name="dc.creator" content="Wainberg, Zev A.">
    <meta name="dc.creator" content="Ko, Andrew H.">
    <meta name="dc.creator" content="Fisher, George">
    <meta name="dc.creator" content="Rahma, Osama">
    <meta name="dc.creator" content="Lyman, Jaclyn P.">
    <meta name="dc.creator" content="Cabanski, Christopher R.">
    <meta name="dc.creator" content="Yu, Jia Xin">
    <meta name="dc.creator" content="Pfeiffer, Shannon M.">
    <meta name="dc.creator" content="Spasic, Marko">
    <meta name="dc.creator" content="Xu, Jingying">
    <meta name="dc.creator" content="Gherardini, Pier Federico">
    <meta name="dc.creator" content="Karakunnel, Joyson">
    <meta name="dc.creator" content="Mick, Rosemarie">
    <meta name="dc.creator" content="Alanio, Cécile">
    <meta name="dc.creator" content="Byrne, Katelyn T.">
    <meta name="dc.creator" content="Hollmann, Travis J.">
    <meta name="dc.creator" content="Moore, Jonni S.">
    <meta name="dc.creator" content="Jones, Derek D.">
    <meta name="dc.creator" content="Tognetti, Marco">
    <meta name="dc.creator" content="Chen, Richard O.">
    <meta name="dc.creator" content="Yang, Xiaodong">
    <meta name="dc.creator" content="Salvador, Lisa">
    <meta name="dc.creator" content="Wherry, E. John">
    <meta name="dc.creator" content="Dugan, Ute">
    <meta name="dc.creator" content="O’Donnell-Tormey, Jill">
    <meta name="dc.creator" content="Butterfield, Lisa H.">
    <meta name="dc.creator" content="Hubbard-Lucey, Vanessa M.">
    <meta name="dc.creator" content="Ibrahim, Ramy">
    <meta name="dc.creator" content="Fairchild, Justin">
    <meta name="dc.creator" content="Bucktrout, Samantha">
    <meta name="dc.creator" content="LaVallee, Theresa M.">
    <meta name="dc.creator" content="Vonderheide, Robert H.">
    <meta name="dc.subject" content="Cancer immunotherapy">
    <meta name="dc.subject" content="Pancreatic cancer">
    <meta name="dc.subject" content="Tumour biomarkers">
    <meta name="citation_reference" content="citation_journal_title=Cancer Res.; citation_title=Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States; citation_author=L Rahib; citation_volume=74; citation_publication_date=2014; citation_pages=2913-2921; citation_doi=10.1158/0008-5472.CAN-14-0155; citation_id=CR1">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=The next decade of immune checkpoint therapy; citation_author=P Sharma; citation_volume=11; citation_publication_date=2021; citation_pages=838-857; citation_doi=10.1158/2159-8290.CD-20-1680; citation_id=CR2">
    <meta name="citation_reference" content="citation_journal_title=JAMA Oncol.; citation_title=Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial; citation_author=EM O’Reilly; citation_volume=5; citation_publication_date=2019; citation_pages=1431-1438; citation_doi=10.1001/jamaoncol.2019.1588; citation_id=CR3">
    <meta name="citation_reference" content="citation_journal_title=J. Immunother.; citation_title=Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma; citation_author=RE Royal; citation_volume=33; citation_publication_date=2010; citation_pages=828-833; citation_doi=10.1097/CJI.0b013e3181eec14c; citation_id=CR4">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors; citation_author=A Patnaik; citation_volume=21; citation_publication_date=2015; citation_pages=4286-4293; citation_doi=10.1158/1078-0432.CCR-14-2607; citation_id=CR5">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Safety and activity of anti-PD-L1 antibody in patients with advanced cancer; citation_author=JR Brahmer; citation_volume=366; citation_publication_date=2012; citation_pages=2455-2465; citation_doi=10.1056/NEJMoa1200694; citation_id=CR6">
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer; citation_author=VP Balachandran; citation_volume=551; citation_publication_date=2017; citation_pages=512-516; citation_doi=10.1038/nature24462; citation_id=CR7">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=Immune cytolytic activity stratifies molecular subsets of human pancreatic cancer; citation_author=D Balli, AJ Rech, BZ Stanger, RH Vonderheide; citation_volume=23; citation_publication_date=2017; citation_pages=3129-3138; citation_doi=10.1158/1078-0432.CCR-16-2128; citation_id=CR8">
    <meta name="citation_reference" content="citation_journal_title=Cancer Immunol. Res.; citation_title=T-cell localization, activation, and clonal expansion in human pancreatic ductal adenocarcinoma; citation_author=IM Stromnes, A Hulbert, RH Pierce, PD Greenberg, SR Hingorani; citation_volume=5; citation_publication_date=2017; citation_pages=978-991; citation_doi=10.1158/2326-6066.CIR-16-0322; citation_id=CR9">
    <meta name="citation_reference" content="citation_journal_title=Cell Rep.; citation_title=CD40 stimulation obviates innate sensors and drives T cell immunity in cancer; citation_author=KT Byrne, RH Vonderheide; citation_volume=15; citation_publication_date=2016; citation_pages=2719-2732; citation_doi=10.1016/j.celrep.2016.05.058; citation_id=CR10">
    <meta name="citation_reference" content="citation_journal_title=Cancer Immunol. Res; citation_title=Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma; citation_author=R Winograd; citation_volume=3; citation_publication_date=2015; citation_pages=399-411; citation_doi=10.1158/2326-6066.CIR-14-0215; citation_id=CR11">
    <meta name="citation_reference" content="citation_journal_title=Lancet Oncol.; citation_title=CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study; citation_author=MH O’Hara; citation_volume=22; citation_publication_date=2021; citation_pages=118-131; citation_doi=10.1016/S1470-2045(20)30532-5; citation_id=CR12">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine; citation_author=DD Hoff; citation_volume=369; citation_publication_date=2013; citation_pages=1691-1703; citation_doi=10.1056/NEJMoa1304369; citation_id=CR13">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma; citation_author=TK Choueiri; citation_volume=22; citation_publication_date=2016; citation_pages=5461-5471; citation_doi=10.1158/1078-0432.CCR-15-2839; citation_id=CR14">
    <meta name="citation_reference" content="citation_journal_title=Science; citation_title=Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications; citation_author=D Mathew; citation_volume=369; citation_publication_date=2020; citation_pages=eabc8511; citation_doi=10.1126/science.abc8511; citation_id=CR15">
    <meta name="citation_reference" content="citation_journal_title=J. Immunol.; citation_title=Four functionally distinct populations of human effector-memory CD8+ T lymphocytes; citation_author=P Romero; citation_volume=178; citation_publication_date=2007; citation_pages=4112-4119; citation_doi=10.4049/jimmunol.178.7.4112; citation_id=CR16">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer; citation_author=KT Byrne; citation_volume=27; citation_publication_date=2021; citation_pages=4574-4586; citation_doi=10.1158/1078-0432.CCR-21-1047; citation_id=CR17">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=Open-label, phase I study of nivolumab combined with nab-paclitaxel plus gemcitabine in advanced pancreatic cancer; citation_author=ZA Wainberg; citation_volume=26; citation_publication_date=2020; citation_pages=4814-4822; citation_doi=10.1158/1078-0432.CCR-20-0099; citation_id=CR18">
    <meta name="citation_reference" content="citation_journal_title=Cancer Immunol. Immunother.; citation_title=APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application; citation_author=EL Filbert, PK Bjorck, MK Srivastava, FR Bahjat, X Yang; citation_volume=70; citation_publication_date=2021; citation_pages=1853-1865; citation_doi=10.1007/s00262-020-02814-2; citation_id=CR19">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates; citation_author=JR Brahmer; citation_volume=28; citation_publication_date=2010; citation_pages=3167-3175; citation_doi=10.1200/JCO.2009.26.7609; citation_id=CR20">
    <meta name="citation_reference" content="citation_journal_title=Front. Immunol.; citation_title=Regulation of the germinal center response; citation_author=M Stebegg; citation_volume=9; citation_publication_date=2018; citation_pages=2469; citation_doi=10.3389/fimmu.2018.02469; citation_id=CR21">
    <meta name="citation_reference" content="citation_journal_title=J. Exp. Med.; citation_title=Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation; citation_author=L Cohn; citation_volume=210; citation_publication_date=2013; citation_pages=1049-1063; citation_doi=10.1084/jem.20121251; citation_id=CR22">
    <meta name="citation_reference" content="citation_journal_title=Immunity; citation_title=Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells; citation_author=M Haniffa; citation_volume=37; citation_publication_date=2012; citation_pages=60-73; citation_doi=10.1016/j.immuni.2012.04.012; citation_id=CR23">
    <meta name="citation_reference" content="citation_journal_title=Cancer Immunol. Res.; citation_title=Site-dependent immune escape due to impaired dendritic cell cross-priming; citation_author=MS Diamond, JH Lin, RH Vonderheide; citation_volume=9; citation_publication_date=2021; citation_pages=877-890; citation_doi=10.1158/2326-6066.CIR-20-0785; citation_id=CR24">
    <meta name="citation_reference" content="citation_journal_title=Immunity; citation_title=Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy; citation_author=J Li; citation_volume=49; citation_publication_date=2018; citation_pages=178-193; citation_doi=10.1016/j.immuni.2018.06.006; citation_id=CR25">
    <meta name="citation_reference" content="citation_journal_title=Proc. Natl Acad. Sci. USA; citation_title=CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma; citation_author=P Sharma; citation_volume=104; citation_publication_date=2007; citation_pages=3967-3972; citation_doi=10.1073/pnas.0611618104; citation_id=CR26">
    <meta name="citation_reference" content="citation_journal_title=Cell; citation_title=Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy; citation_author=A Ribas; citation_volume=170; citation_publication_date=2017; citation_pages=1109-1119; citation_doi=10.1016/j.cell.2017.08.027; citation_id=CR27">
    <meta name="citation_reference" content="citation_journal_title=Eur. J. Cancer; citation_title=Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy; citation_author=T Tokito; citation_volume=55; citation_publication_date=2016; citation_pages=7-14; citation_doi=10.1016/j.ejca.2015.11.020; citation_id=CR28">
    <meta name="citation_reference" content="citation_journal_title=Front. Oncol.; citation_title=Tumor-Infiltrating PD-1hiCD8+-T-cell signature as an effective biomarker for immune checkpoint inhibitor therapy response across multiple cancers; citation_author=Z Yang; citation_volume=11; citation_publication_date=2021; citation_pages=695006; citation_doi=10.3389/fonc.2021.695006; citation_id=CR29">
    <meta name="citation_reference" content="citation_journal_title=Immunity; citation_title=Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms; citation_author=JC Beltra; citation_volume=52; citation_publication_date=2020; citation_pages=825-841 e828; citation_doi=10.1016/j.immuni.2020.04.014; citation_id=CR30">
    <meta name="citation_reference" content="citation_journal_title=Nat. Commun.; citation_title=Integrin CD11b negatively regulates BCR signalling to maintain autoreactive B cell tolerance; citation_author=C Ding; citation_volume=4; citation_publication_date=2013; citation_doi=10.1038/ncomms3813; citation_id=CR31">
    <meta name="citation_reference" content="citation_journal_title=Nat. Commun.; citation_title=Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma; citation_author=L Hooren; citation_volume=12; citation_publication_date=2021; citation_doi=10.1038/s41467-021-24347-7; citation_id=CR32">
    <meta name="citation_reference" content="citation_journal_title=Ann. Oncol.; citation_title=Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study; citation_author=M Tempero; citation_volume=32; citation_publication_date=2021; citation_pages=600-608; citation_doi=10.1016/j.annonc.2021.01.070; citation_id=CR33">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Feasibility and utility of synthetic control arms derived from real-world data to support clinical development; citation_author=JP Lyman; citation_volume=40; citation_publication_date=2022; citation_pages=528; citation_doi=10.1200/JCO.2022.40.4_suppl.528; citation_id=CR34">
    <meta name="citation_reference" content="citation_journal_title=Nat. Rev. Drug Discov.; citation_title=Combinations take centre stage in PD1/PDL1 inhibitor clinical trials; citation_author=S Upadhaya; citation_volume=20; citation_publication_date=2021; citation_pages=168-169; citation_doi=10.1038/d41573-020-00204-y; citation_id=CR35">
    <meta name="citation_reference" content="citation_journal_title=Nat. Rev. Drug Discov.; citation_title=Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors; citation_author=J Tang; citation_volume=17; citation_publication_date=2018; citation_pages=854-855; citation_doi=10.1038/nrd.2018.210; citation_id=CR36">
    <meta name="citation_reference" content="citation_journal_title=Cell Rep.; citation_title=Comprehensive immune monitoring of clinical trials to advance human immunotherapy; citation_author=FJ Hartmann; citation_volume=28; citation_publication_date=2019; citation_pages=819-831; citation_doi=10.1016/j.celrep.2019.06.049; citation_id=CR37">
    <meta name="citation_reference" content="citation_journal_title=Science; citation_title=IMMUNOLOGY. An interactive reference framework for modeling a dynamic immune system; citation_author=MH Spitzer; citation_volume=349; citation_publication_date=2015; citation_pages=1259425; citation_doi=10.1126/science.1259425; citation_id=CR38">
    <meta name="citation_reference" content="citation_journal_title=PLoS ONE; citation_title=Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability; citation_author=E Assarsson; citation_volume=9; citation_publication_date=2014; citation_pages=e95192; citation_doi=10.1371/journal.pone.0095192; citation_id=CR39">
    <meta name="citation_reference" content="citation_journal_title=Genome Med.; citation_title=Achieving high-sensitivity for clinical applications using augmented exome sequencing; citation_author=A Patwardhan; citation_volume=7; citation_publication_date=2015; citation_doi=10.1186/s13073-015-0197-4; citation_id=CR40">
    <meta name="citation_reference" content="citation_journal_title=Bioinformatics; citation_title=STAR: ultrafast universal RNA-seq aligner; citation_author=A Dobin; citation_volume=29; citation_publication_date=2013; citation_pages=15-21; citation_doi=10.1093/bioinformatics/bts635; citation_id=CR41">
    <meta name="citation_reference" content="citation_journal_title=Nat. Genet.; citation_title=A framework for variation discovery and genotyping using next-generation DNA sequencing data; citation_author=MA DePristo; citation_volume=43; citation_publication_date=2011; citation_pages=491-498; citation_doi=10.1038/ng.806; citation_id=CR42">
    <meta name="citation_reference" content="citation_journal_title=Genome Res.; citation_title=The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data; citation_author=A McKenna; citation_volume=20; citation_publication_date=2010; citation_pages=1297-1303; citation_doi=10.1101/gr.107524.110; citation_id=CR43">
    <meta name="citation_author" content="Padrón, Lacey J.">
    <meta name="citation_author_institution" content="Parker Institute for Cancer Immunotherapy, San Francisco, USA">
    <meta name="citation_author" content="Maurer, Deena M.">
    <meta name="citation_author_institution" content="Parker Institute for Cancer Immunotherapy, San Francisco, USA">
    <meta name="citation_author" content="O’Hara, Mark H.">
    <meta name="citation_author_institution" content="Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA">
    <meta name="citation_author" content="O’Reilly, Eileen M.">
    <meta name="citation_author_institution" content="Memorial Sloan Kettering Cancer Center, New York, USA">
    <meta name="citation_author" content="Wolff, Robert A.">
    <meta name="citation_author_institution" content="The University of Texas MD Anderson Cancer Center, Houston, USA">
    <meta name="citation_author" content="Wainberg, Zev A.">
    <meta name="citation_author_institution" content="University of California, Los Angeles, Los Angeles, USA">
    <meta name="citation_author" content="Ko, Andrew H.">
    <meta name="citation_author_institution" content="University of California, San Francisco, San Francisco, USA">
    <meta name="citation_author" content="Fisher, George">
    <meta name="citation_author_institution" content="Stanford University, Stanford, USA">
    <meta name="citation_author" content="Rahma, Osama">
    <meta name="citation_author_institution" content="Dana-Farber Cancer Institute, Boston, USA">
    <meta name="citation_author" content="Lyman, Jaclyn P.">
    <meta name="citation_author_institution" content="Parker Institute for Cancer Immunotherapy, San Francisco, USA">
    <meta name="citation_author" content="Cabanski, Christopher R.">
    <meta name="citation_author_institution" content="Parker Institute for Cancer Immunotherapy, San Francisco, USA">
    <meta name="citation_author" content="Yu, Jia Xin">
    <meta name="citation_author_institution" content="Parker Institute for Cancer Immunotherapy, San Francisco, USA">
    <meta name="citation_author" content="Pfeiffer, Shannon M.">
    <meta name="citation_author_institution" content="Parker Institute for Cancer Immunotherapy, San Francisco, USA">
    <meta name="citation_author" content="Spasic, Marko">
    <meta name="citation_author_institution" content="Parker Institute for Cancer Immunotherapy, San Francisco, USA">
    <meta name="citation_author" content="Xu, Jingying">
    <meta name="citation_author_institution" content="Parker Institute for Cancer Immunotherapy, San Francisco, USA">
    <meta name="citation_author" content="Gherardini, Pier Federico">
    <meta name="citation_author_institution" content="Parker Institute for Cancer Immunotherapy, San Francisco, USA">
    <meta name="citation_author" content="Karakunnel, Joyson">
    <meta name="citation_author_institution" content="Parker Institute for Cancer Immunotherapy, San Francisco, USA">
    <meta name="citation_author" content="Mick, Rosemarie">
    <meta name="citation_author_institution" content="Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA">
    <meta name="citation_author" content="Alanio, Cécile">
    <meta name="citation_author_institution" content="Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA">
    <meta name="citation_author_institution" content="Parker Institute of Cancer Immunotherapy at the University of Pennsylvania, Philadelphia, USA">
    <meta name="citation_author_institution" content="Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, USA">
    <meta name="citation_author_institution" content="Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, USA">
    <meta name="citation_author" content="Byrne, Katelyn T.">
    <meta name="citation_author_institution" content="Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA">
    <meta name="citation_author_institution" content="Parker Institute of Cancer Immunotherapy at the University of Pennsylvania, Philadelphia, USA">
    <meta name="citation_author" content="Hollmann, Travis J.">
    <meta name="citation_author_institution" content="Memorial Sloan Kettering Cancer Center, New York, USA">
    <meta name="citation_author" content="Moore, Jonni S.">
    <meta name="citation_author_institution" content="Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA">
    <meta name="citation_author" content="Jones, Derek D.">
    <meta name="citation_author_institution" content="Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA">
    <meta name="citation_author" content="Tognetti, Marco">
    <meta name="citation_author_institution" content="Biognosys AG, Schlieren, Switzerland">
    <meta name="citation_author" content="Chen, Richard O.">
    <meta name="citation_author_institution" content="Personalis, Inc., Menlo Park, USA">
    <meta name="citation_author" content="Yang, Xiaodong">
    <meta name="citation_author_institution" content="Apexigen, Inc., San Carlos, USA">
    <meta name="citation_author" content="Salvador, Lisa">
    <meta name="citation_author_institution" content="Bristol Myers Squibb, New York, USA">
    <meta name="citation_author" content="Wherry, E. John">
    <meta name="citation_author_institution" content="Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA">
    <meta name="citation_author_institution" content="Parker Institute of Cancer Immunotherapy at the University of Pennsylvania, Philadelphia, USA">
    <meta name="citation_author_institution" content="Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, USA">
    <meta name="citation_author_institution" content="Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, USA">
    <meta name="citation_author" content="Dugan, Ute">
    <meta name="citation_author_institution" content="Parker Institute for Cancer Immunotherapy, San Francisco, USA">
    <meta name="citation_author" content="O’Donnell-Tormey, Jill">
    <meta name="citation_author_institution" content="Cancer Research Institute, New York, USA">
    <meta name="citation_author" content="Butterfield, Lisa H.">
    <meta name="citation_author_institution" content="Parker Institute for Cancer Immunotherapy, San Francisco, USA">
    <meta name="citation_author" content="Hubbard-Lucey, Vanessa M.">
    <meta name="citation_author_institution" content="Cancer Research Institute, New York, USA">
    <meta name="citation_author" content="Ibrahim, Ramy">
    <meta name="citation_author_institution" content="Parker Institute for Cancer Immunotherapy, San Francisco, USA">
    <meta name="citation_author" content="Fairchild, Justin">
    <meta name="citation_author_institution" content="Parker Institute for Cancer Immunotherapy, San Francisco, USA">
    <meta name="citation_author" content="Bucktrout, Samantha">
    <meta name="citation_author_institution" content="Parker Institute for Cancer Immunotherapy, San Francisco, USA">
    <meta name="citation_author" content="LaVallee, Theresa M.">
    <meta name="citation_author_institution" content="Parker Institute for Cancer Immunotherapy, San Francisco, USA">
    <meta name="citation_author" content="Vonderheide, Robert H.">
    <meta name="citation_author_institution" content="Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA">
    <meta name="citation_author_institution" content="Parker Institute of Cancer Immunotherapy at the University of Pennsylvania, Philadelphia, USA">
    <meta name="citation_author_institution" content="Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, USA">
    <meta name="access_endpoint" content="https://www.nature.com/platform/readcube-access">
    <meta name="twitter:site" content="@naturemedicine">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:image:alt" content="Content cover image">
    <meta name="twitter:title" content="Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial">
    <meta name="twitter:description" content="Nature Medicine - In a randomized phase 2 trial, sotigalimab, a CD40 agonist, did not significantly improve overall survival in patients with previously untreated metastatic pancreatic cancer when...">
    <meta name="twitter:image" content="https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig1_HTML.png">
    

    
    
    <meta property="og:url" content="https://www.nature.com/articles/s41591-022-01829-9">
    <meta property="og:type" content="article">
    <meta property="og:site_name" content="Nature">
    <meta property="og:title" content="Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial - Nature Medicine">
    <meta property="og:description" content="In a randomized phase 2 trial, sotigalimab, a CD40 agonist, did not significantly improve overall survival in patients with previously untreated metastatic pancreatic cancer when combined with chemotherapy or with nivolumab and chemotherapy. Multi-omic exploratory analyses provide insights into immunologic features associated with clinical benefit.">
    <meta property="og:image" content="https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig1_HTML.png">
    

    <script>
        window.eligibleForRa21 = 'false'; 
    </script>
<style type="text/css">.cc-banner{background-color:#01324b;border:none!important;bottom:0;box-sizing:border-box;color:#fff!important;left:0;line-height:1.3;margin:auto 0 0;max-width:100%;outline:0;overflow:visible;padding:0;position:fixed;right:0;width:100%;z-index:99999}.cc-banner::backdrop{background-color:#0000004d}.cc-banner *{color:inherit!important}.cc-banner:focus{box-shadow:none;outline:0}.cc-banner a{color:#fff!important;text-decoration:underline}.cc-banner a:active,.cc-banner a:focus,.cc-banner a:hover{color:inherit;text-decoration:none}.cc-banner a:focus{outline:3px solid #08c!important}.cc-banner h2,.cc-banner h3,.cc-banner h4,.cc-banner h5,.cc-banner h6{font-family:sans-serif;font-style:normal;font-weight:700;margin:0 0 .5em}.cc-banner .cc-h2,.cc-banner h2{font-size:18px}.cc-banner .cc-h3,.cc-banner h3{font-size:16px}.cc-banner .cc-h4,.cc-banner .cc-h5,.cc-banner .cc-h6,.cc-banner h4,.cc-banner h5,.cc-banner h6{font-size:14px}.cc-banner .cc-button{font-size:16px}.cc-banner__content{background-color:#01324b;display:flex;flex-direction:column;margin:0 auto;max-height:90vh;max-width:100%;padding:16px;position:relative}.cc-banner__content:focus{outline:0}@media (min-width:680px){.cc-banner__content{padding:12px}}@media (min-width:980px){.cc-banner__content{max-height:60vh;padding-bottom:20px;padding-top:20px}}@media (min-width:1320px){.cc-banner__content{padding-bottom:40px;padding-top:40px}}.cc-banner__container{display:flex;flex-direction:column;margin:auto;max-width:1320px;overflow:auto}.cc-banner__title{background:none!important;border:0;flex-shrink:0;font-size:18px!important;font-size:22px!important;font-weight:700!important;letter-spacing:normal;margin:0 0 12px!important;padding:0}@media (min-width:680px){.cc-banner__title{font-size:24px!important;margin:0 0 16px!important}}@media (min-width:1320px){.cc-banner__title{font-size:26px!important;margin:0 0 24px!important}}.cc-banner__body{display:flex;flex-direction:column;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif!important;overflow-x:hidden;overflow-y:auto;padding:3px 3px 16px}@media (min-width:980px){.cc-banner__body{flex-direction:row}}.cc-banner__policy p{font-size:16px!important;margin:0;max-width:none;padding:0}.cc-banner__policy p:not(:last-child){margin:0 0 16px}@media (min-width:980px){.cc-banner__policy p:not(:last-child){margin:0 0 24px}}.cc-banner__policy p a{font-size:16px!important;font-weight:700}.cc-banner__footer{box-shadow:none;flex-shrink:0;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif !important!important;margin:0;padding:12px 0 3px 3px;position:relative}@media (min-width:380px){.cc-banner__footer{align-items:stretch;display:flex;flex-wrap:wrap}}@media (min-width:680px){.cc-banner__footer{box-shadow:none;flex-wrap:nowrap;width:40%}}.cc-banner__footer .cc-banner__button{flex:1 1 auto;font-weight:700;overflow:hidden;padding:.5em 1em;width:100%}@media (min-width:680px){.cc-banner__footer .cc-banner__button{max-width:275px}}.cc-banner__footer .cc-banner__button:not(:last-child){margin-bottom:12px}@media (min-width:680px){.cc-banner__footer .cc-banner__button:not(:last-child){margin-bottom:0;margin-right:16px}}@media (min-width:980px){.cc-banner__footer .cc-banner__button:not(:last-child){margin-right:24px}}@media (min-width:680px){html[dir=rtl] .cc-banner__footer .cc-banner__button:not(:last-child){margin-left:16px!important;margin-right:0!important}}@media (min-width:980px){html[dir=rtl] .cc-banner__footer .cc-banner__button:not(:last-child){margin-left:24px!important;margin-right:0!important}}.cc-banner__button-preferences{padding-left:0;padding-right:0}@media (min-width:380px){.cc-banner__button-preferences{flex:0 0 auto;margin:auto}}@media (min-width:680px){.cc-banner__button-preferences{margin:0}}@media (min-width:380px) and (max-width:680px){.cc-banner__button-break{display:block}}@media (min-width:680px){.cc-banner--is-tcf .cc-banner__footer{width:auto}}@media (min-width:980px){.cc-banner--is-tcf .cc-banner__footer{padding-right:48px;width:66%}}.cc-banner--is-tcf .cc-banner__stacks-intro{font-size:16px!important}.cc-banner--is-tcf .cc-banner__stacks{margin:16px 0 0}@media (min-width:980px){.cc-banner--is-tcf .cc-banner__stacks{display:flex;flex:0 0 33%;flex-direction:column;margin:0 0 0 48px;overflow:auto}}.cc-banner--is-tcf .cc-banner__stacks-intro{font-size:16px;margin:0 0 12px}.cc-banner--is-tcf .cc-banner__stacks-details{padding:0 3px}.cc-banner--is-tcf .cc-banner .cc-details{border-color:#fff3!important}.cc-box{border-radius:10px;padding:12px}.cc-box--info{background-color:#eff6fb}.cc-box--light{background-color:#faf9f6}.cc-button{border:2px solid #0000;border-radius:32px!important;color:inherit;cursor:pointer;font-size:14px;font-weight:700!important;left:auto;line-height:1.2;margin:0;padding:.5em 1em;right:auto;text-transform:none!important;transition:all .2s}@media (min-width:680px){.cc-button{font-size:14px;padding:.75em 1em}}.cc-button--sm{font-size:12px;padding:2px 8px!important}.cc-button--primary{background-color:#025e8d!important;border-color:#025e8d!important;color:#fff!important}.cc-button--primary:focus{outline:3px solid #08c}.cc-button--primary:focus,.cc-button--primary:hover,.cc-button--secondary{background-color:#fff!important;border-color:#025e8d!important;color:#025e8d!important}.cc-button--secondary:focus{background-color:#025e8d!important;border-color:#fff!important;color:#fff!important;outline:3px solid #08c!important}.cc-button--secondary:hover{background-color:#025e8d!important;border-color:#025e8d!important;color:#fff!important}.cc-button--secondary:active{border:2px solid #01324b!important}.cc-button--secondary.cc-button--contrast{border-color:#fff!important}.cc-button--secondary.cc-button--contrast:hover{background-color:initial!important;color:#fff!important}.cc-button--tertiary{background-color:#f0f7fc!important;background-image:none;border:2px solid #f0f7fc;color:#025e8d!important;text-decoration:underline!important;text-underline-offset:.25em}.cc-button--tertiary:focus{outline:3px solid #08c!important}.cc-button--tertiary:hover{text-decoration-thickness:.25em}.cc-button--tertiary:active{color:#013c5b}.cc-button--link{background-color:initial!important;border-color:#0000!important;border-radius:0!important;color:inherit!important;padding:0!important;text-decoration:underline!important;width:inherit!important}.cc-button--link:focus{outline:3px solid #08c}.cc-button--link:hover{background-color:initial!important;box-shadow:none;text-decoration:none}.cc-button--text{border-radius:0;padding:0}.cc-button--details{padding-right:24px!important;position:relative;width:auto}.cc-button--details:after,.cc-button--details:before{background-color:currentColor;content:"";position:absolute;transition:transform .25s ease-out}.cc-button--details:before{height:10px;margin-top:-5px;right:12px;top:50%;width:2px}.cc-button--details:after{height:2px;margin-top:-1px;right:8px;top:50%;width:10px}.cc-button--details.cc-active:before{transform:rotate(90deg);transform-origin:center}.cc-button--details.cc-active:after{display:none}.cc-details{border-bottom:1px solid #0000001a;padding:12px 0;position:relative;width:100%}.cc-details__summary{align-items:center;display:flex;font-size:14px;font-weight:700;list-style-type:none}.cc-details__summary:focus,.cc-details__summary:focus-visible{outline:3px solid #08c!important;will-change:auto}.cc-details__title{align-items:baseline;display:flex}.cc-details__title h2,.cc-details__title h3,.cc-details__title h4,.cc-details__title h5{line-height:1.4;margin:0!important;padding:0!important}.cc-details__title svg{flex-shrink:0;height:auto;margin-right:8px;position:relative;top:-1px;transition:all .2s;width:auto}.cc-details[open] .cc-details__title svg{top:2px;transform:rotate(90deg)}.cc-details__switch{margin-left:auto}.cc-details__section{padding:16px 0 0 18px}.cc-details__section p{margin:0}.cc-details__section p:not(:last-child){margin-bottom:12px}details summary::-webkit-details-marker{display:none}.cc-radio{align-items:center;display:flex;position:relative}.cc-radio *{cursor:pointer}.cc-radio__input{height:22px;left:0;position:absolute;top:0;width:22px}.cc-radio__input:focus{outline:none}.cc-radio__label{color:inherit;font-size:14px;font-weight:700;line-height:23px;margin:0;padding-left:28px}.cc-radio__label:after,.cc-radio__label:before{background-color:#fff;content:"";display:block;position:absolute;transition:transform .25s ease-out}.cc-radio__label:before{border:1px solid #777;border-radius:50%;height:22px;left:0;top:0;width:22px}.cc-radio__label:after{border:7px solid #025e8d;border-radius:50%;height:0;left:4px;opacity:0;top:4px;width:0}.cc-radio__input:focus+.cc-radio__label:before{box-shadow:0 0 0 2px #08c;outline:none}.cc-radio__label--hidden{display:none}.cc-radio__input:checked+.cc-radio__label:after{opacity:1}.cc-radio__input:disabled{cursor:default}.cc-radio__input:disabled+.cc-radio__label{cursor:default;opacity:.5}.cc-switch *{cursor:pointer}.cc-switch{align-items:center;display:flex;line-height:1}.cc-switch__label{cursor:pointer;display:inline-block;font-size:14px;font-weight:700;margin:0;-webkit-user-select:none;user-select:none}.cc-switch__input[type=checkbox]{-webkit-appearance:none;appearance:none;background-color:#fff!important;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='rgba(0, 0, 0, 0.25)'/%3E%3C/svg%3E")!important;background-position:0!important;background-repeat:no-repeat!important;border:1px solid #777!important;border-radius:16px!important;height:18px!important;margin:0 8px 0 0!important;transition:background-position .2s ease-in-out!important;width:32px!important}.cc-switch__input[type=checkbox]:focus{background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%2380b3cc'/%3E%3C/svg%3E")!important}.cc-switch__input[type=checkbox]:checked{background-color:#025e8d!important;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%23fff'/%3E%3C/svg%3E")!important;background-position:100%!important}.cc-switch__input[type=checkbox]:checked~.cc-switch__label>.cc-switch__text-off,.cc-switch__input[type=checkbox]:not(:checked)~.cc-switch__label>.cc-switch__text-on{display:none}.cc-switch__input[type=checkbox]:hover{cursor:pointer;outline:none}.cc-switch__input[type=checkbox]:focus-visible{cursor:pointer;outline:3px solid #fc0}.cc-switch__input[type=checkbox]:checked:before{background-color:none!important;color:#0000!important}html[dir=rtl] .cc-switch__input[type=checkbox]{margin-left:8px!important;margin-right:0!important}.cc-list>ul,ul.cc-list{list-style-type:disc;margin-left:0;padding-left:0}.cc-list>ul>li,ul.cc-list>li{margin-left:1em}.cc-list>ul>li:not(:last-child),ul.cc-list>li:not(:last-child){margin-bottom:4px}.cc-list__title{margin-bottom:8px!important}.cc-list--inline>ul,ul.cc-list--inline{display:flex;flex-wrap:wrap;list-style-type:none}.cc-list--inline>ul>li,ul.cc-list--inline>li{margin:0 .5em .5em 0}.cc-overlay{background-color:#0000004d;z-index:99998}.cc-overlay,.cc-preferences{bottom:0;left:0;position:fixed;right:0;top:0}.cc-preferences{background-color:#050a14f2!important;border:0;box-sizing:border-box;color:#111;font-family:sans-serif!important;line-height:1.4;margin:auto;max-height:100vh;overflow:auto;padding:0;z-index:100000}.cc-preferences:focus{outline:none}.cc-preferences *,.cc-preferences :after,.cc-preferences :before{box-sizing:inherit!important}.cc-preferences h2,.cc-preferences h3,.cc-preferences h4,.cc-preferences h5,.cc-preferences h6{font-family:sans-serif;font-style:normal;font-weight:700;margin:0 0 .5em}.cc-preferences .cc-h2,.cc-preferences h2{font-size:18px}.cc-preferences .cc-h3,.cc-preferences h3{font-size:16px}.cc-preferences .cc-h4,.cc-preferences .cc-h5,.cc-preferences .cc-h6,.cc-preferences h4,.cc-preferences h5,.cc-preferences h6{font-size:14px}.cc-preferences a{color:#025e8d;text-decoration:underline}.cc-preferences a:hover{color:inherit;text-decoration:none}.cc-preferences h3{background:none;color:#111;padding:0;text-transform:none}dialog.cc-preferences{background-color:initial}dialog.cc-preferences::backdrop{background-color:#000000e6}.cc-preferences__dialog{display:flex;flex-direction:column;margin:auto;max-height:100vh;max-width:860px;padding:12px;position:relative}.cc-preferences__dialog>:last-child{border-bottom-left-radius:10px;border-bottom-right-radius:10px}@media (min-width:980px){.cc-preferences__dialog{padding:16px}}.cc-preferences__close{background:#0000!important;border:1px solid #ececec;border-radius:50%;color:#111!important;cursor:pointer;font-family:Times New Roman,serif;font-size:40px;height:40px;left:auto;line-height:1;margin-top:-20px;padding:0!important;position:absolute;right:20px;top:50%;width:40px}.cc-preferences__close:focus{outline:3px solid #08c}.cc-preferences__close-label{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.cc-preferences__header{background:#fff!important;border-bottom:1px solid #0000001a;border-top-left-radius:10px;border-top-right-radius:10px;padding:16px;position:relative;text-align:center}.cc-preferences__title{background:none!important;color:#111!important;font-family:sans-serif!important;font-size:18px!important;font-weight:700!important;margin:0!important;padding:0 16px 0 0!important}@media (min-width:480px){.cc-preferences__title{padding-right:0!important}}@media (min-width:980px){.cc-preferences__title{font-size:22px!important}}.cc-preferences__body{background:#fff!important;flex:1 1 auto;min-height:200px;overflow-x:hidden;overflow-y:auto;padding:16px}.cc-preferences__footer{background:#fff!important;border-top:1px solid #d0d0d0;box-shadow:0 0 5px 0 #0003;margin-bottom:0;padding:12px;position:relative}@media (min-width:480px){.cc-preferences__footer{align-items:stretch;display:flex}}.cc-preferences__footer>.cc-button{display:block;width:100%}@media (min-width:480px){.cc-preferences__footer>.cc-button{flex:1 1 auto}}@media (min-width:980px){.cc-preferences__footer>.cc-button{flex-basis:auto}}@media (min-width:480px){.cc-preferences__footer>.cc-button:not(:first-child){margin-left:12px}}.cc-preferences__footer>.cc-button:not(:last-child){margin-bottom:8px}@media (min-width:480px){.cc-preferences__footer>.cc-button:not(:last-child){margin-bottom:0}}.cc-preferences__categories{list-style:none;margin:0;padding:0}.cc-preferences__category:not(:last-child){border-bottom:1px solid #0000001a;margin-bottom:12px;padding-bottom:12px}.cc-preferences__category-description{font-size:14px;margin:0 0 8px;padding:0}.cc-preferences__category-footer{align-items:center;display:flex;justify-content:space-between}.cc-preferences__status{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.cc-preferences__controls{display:flex;margin:0}.cc-preferences__controls>:not(:last-child){margin-right:12px}.cc-preferences__always-on{font-size:14px;font-weight:700;padding-left:26px;position:relative}.cc-preferences__always-on:before{background:#0000!important;border:solid;border-top-color:#0000;border-width:0 0 4px 4px;content:"";display:block;height:10px;left:0;position:absolute;top:2px;transform:rotate(-45deg);width:18px}.cc-preferences__details{background-color:#eff6fb!important;border-radius:10px;font-size:14px;margin:12px 0 0;padding:12px}.cc-preferences__cookie-list,.cc-preferences__provider-list{list-style:none;margin:0;padding:0}.cc-preferences__provider-list{columns:170px}.cc-preferences__cookie-title{font-size:1em;font-style:normal;font-weight:400;margin:0}.cc-preferences__cookie-description{font-size:1em;margin:0 0 8px}.cc-preferences__cookie-domain,.cc-preferences__cookie-lifespan{border-left:1px solid #999;color:#666;margin-left:8px;padding-left:4px}body.cc-has-preferences-open{overflow:hidden;position:relative}.cc-table{border-collapse:collapse;width:100%}.cc-table tbody tr{border-top:1px solid #0000001a}.cc-table td,.cc-table th{font-size:14px;padding:4px 8px;vertical-align:top}.cc-table+.cc-table{margin-top:8px}.cc-table--purposes td:first-child,.cc-table--purposes th:first-child{width:70%}@media (min-width:680px){.cc-table--purposes td:first-child,.cc-table--purposes th:first-child{width:80%}}.cc-table--purposes td:last-child,.cc-table--purposes th:last-child{padding-left:8px;width:40%}@media (min-width:680px){.cc-table--purposes td:last-child,.cc-table--purposes th:last-child{width:30%}}.cc-tabs,.cc-tabs>ul{background-color:#faf9f6;display:flex;list-style:none;margin:0;padding:0}.cc-tabs__panel{border-top:1px solid #ececec;margin-top:-1px}.cc-tabs__button{background-color:initial;border:0;border-left:1px solid #0000;border-right:1px solid #0000;color:#111;font-size:16px;font-weight:700;margin:0;padding:15px 16px 12px;position:relative}.cc-tabs__button:before{background-color:initial;content:"";display:block;height:3px;left:0;position:absolute;top:0;width:100%}.cc-tabs__button.cc-active{background-color:#fff;border-color:#025e8d #ececec #ececec;color:#111}.cc-tabs__button.cc-active:before{background-color:#025e8d}.cc-tabs__content{background-color:#fff;display:none;font-size:14px;padding:16px}.cc-tabs__section:not(:first-child){padding-top:24px}.cc-tcf{font-size:14px;margin-top:16px}.cc-tcf__list{list-style:none;margin:0;padding:0}.cc-vendor-count{color:#666;font-size:16px;margin:0 0 8px}.cc-hide{display:none!important}.cc-show{display:block!important}.cc-external-link{background-color:#ececec;background-image:url("data:image/svg+xml;base64,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");background-position:right 8px center;background-repeat:no-repeat;background-size:10px auto;border-radius:3px;box-shadow:0 1px 0 #0003;color:#111!important;display:inline-block;font-size:12px;padding:4px 26px 4px 8px;text-decoration:none!important}.cc-external-link:hover{text-decoration:underline!important}.cc-m-0{margin:0!important}.cc-grey{color:#666}</style><script async="" type="text/javascript" src="https://injections.readcube.com/nature/inject.fa744f3f.js"></script></head>
<body class="article-page"><dialog class="cc-banner" data-cc-banner="" data-nosnippet="" aria-labelledby="cc-banner-label" open="">
		<div class="cc-banner__content" autofocus="" tabindex="-1">
			<div class="cc-banner__container">
				<div class="cc-banner__header">
					<h2 class="cc-banner__title" id="cc-banner-label">Your privacy, your choice</h2>
				</div>
				<div class="cc-banner__body">
					<div class="cc-banner__policy">
						<p>We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.</p><p>By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.</p><p>See our <a href="https://www.nature.com/info/privacy" data-cc-action="privacy">privacy policy</a> for more information on the use of your personal data.</p><p><button type="button" data-cc-action="preferences" class="cc-button cc-button--link cc-button--text">Manage preferences</button> for further information and to change your choices.</p>
					</div>
					
				</div>
				<div class="cc-banner__footer">
					
			<button data-cc-action="accept" class="cc-button cc-button--secondary cc-button--contrast cc-banner__button cc-banner__button-accept">Accept all cookies</button>
			
		
				</div>
			</div>
		</div>
	</dialog>

<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-MRVXSHQ"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>



<div class="position-relative cleared z-index-50 background-white" data-test="top-containers">
    <a class="c-skip-link" href="#content">Skip to main content</a>



<div class="c-grade-c-banner u-hide">
    <div class="c-grade-c-banner__container">
        
        <p>Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
            the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
            Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
            and JavaScript.</p>

    </div>
</div>

    

    

    
    
        <div class="u-hide u-show-following-ad"></div>

    <aside class="c-ad c-ad--728x90" style="display: none !important;">
        <div class="c-ad__inner" data-container-type="banner-advert">
            <p class="c-ad__label">Advertisement</p>
            
        
            
    <div id="div-gpt-ad-top-1" class="div-gpt-ad advert leaderboard js-ad text-center hide-print grade-c-hide" data-ad-type="top" data-test="top-ad" data-pa11y-ignore="" data-gpt="" data-gpt-unitpath="/285/medicine.nature.com/article" data-gpt-sizes="728x90" data-gpt-targeting="type=article;pos=top;artid=s41591-022-01829-9;doi=10.1038/s41591-022-01829-9;subjmeta=1059,1504,1713,1857,2325,631,67,692,699;kwrd=Cancer+immunotherapy,Pancreatic+cancer,Tumour+biomarkers">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=-1546232797&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-022-01829-9%26doi%3D10.1038/s41591-022-01829-9%26subjmeta%3D1059,1504,1713,1857,2325,631,67,692,699%26kwrd%3DCancer+immunotherapy,Pancreatic+cancer,Tumour+biomarkers">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=-1546232797&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-022-01829-9%26doi%3D10.1038/s41591-022-01829-9%26subjmeta%3D1059,1504,1713,1857,2325,631,67,692,699%26kwrd%3DCancer+immunotherapy,Pancreatic+cancer,Tumour+biomarkers"
                     alt="Advertisement"
                     width="728"
                     height="90"></a>
        </noscript>
    </div>

        
    
        </div>
    </aside>


    <header class="c-header" id="header" data-header="" data-track-component="nature-150-split-header" style="border-color:#e40428">
        <div class="c-header__row">
            <div class="c-header__container">
                <div class="c-header__split">
                    
                    
                    <div class="c-header__logo-container">
                        
                        <a href="/nm" data-track="click" data-track-action="home" data-track-label="image">
                            <picture class="c-header__logo">
                                <source srcset="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" media="(min-width: 875px)">
                                <img src="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" height="32" alt="Nature Medicine">
                            </picture>
                        </a>
                    
                    </div>
                    
                    <ul class="c-header__menu c-header__menu--global">
                        <li class="c-header__item c-header__item--padding c-header__item--hide-md-max">
                            <a class="c-header__link" href="https://www.nature.com/siteindex" data-test="siteindex-link" data-track="click" data-track-action="open nature research index" data-track-label="link">
                                <span>View all journals</span>
                            </a>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--pipe">
                            <a class="c-header__link c-header__link--search" href="javascript:;" data-header-expander="" data-test="search-link" data-track="click" data-track-action="open search tray" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                <svg role="img" aria-hidden="true" focusable="false" height="22" width="22" viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg"><path d="M16.48 15.455c.283.282.29.749.007 1.032a.738.738 0 01-1.032-.007l-3.045-3.044a7 7 0 111.026-1.026zM8 14A6 6 0 108 2a6 6 0 000 12z"></path></svg><span>Search</span>
                            </a><div id="search-menu" class="c-header__dropdown c-header__dropdown--full-width has-tethered u-js-hide" data-track-component="nature-150-split-header" hidden="">
    <div class="c-header__container">
        <h2 class="c-header__visually-hidden">Search</h2>
        <form class="c-header__search-form" action="/search" method="get" role="search" autocomplete="off" data-test="inline-search">
            <label class="c-header__heading" for="keywords">Search articles by subject, keyword or author</label>
            <div class="c-header__search-layout c-header__search-layout--max-width">
                <div>
                    <input type="text" required="" class="c-header__input" id="keywords" name="q" value="">
                </div>
                <div class="c-header__search-layout">
                    <div>
                        <label for="results-from" class="c-header__visually-hidden">Show results from</label>
                        <select id="results-from" name="journal" class="c-header__select">
                            
                                
                                    <option value="" selected="">All journals</option>
                                    <option value="nm">This journal</option>
                                
                            
                        </select>
                    </div>
                    <div>
                        <button type="submit" class="c-header__search-button">Search</button>
                    </div>
                </div>

            </div>
        </form>

        <div class="c-header__flush">
            <a class="c-header__link" href="/search/advanced" data-track="click" data-track-action="advanced search" data-track-label="link">
                Advanced search
            </a>
        </div>

        <h3 class="c-header__heading c-header__heading--keyline">Quick links</h3>
        <ul class="c-header__list">
            <li><a class="c-header__link" href="/subjects" data-track="click" data-track-action="explore articles by subject" data-track-label="link">Explore articles by subject</a></li>
            <li><a class="c-header__link" href="/naturecareers" data-track="click" data-track-action="find a job" data-track-label="link">Find a job</a></li>
            <li><a class="c-header__link" href="/authors/index.html" data-track="click" data-track-action="guide to authors" data-track-label="link">Guide to authors</a></li>
            <li><a class="c-header__link" href="/authors/editorial_policies/" data-track="click" data-track-action="editorial policies" data-track-label="link">Editorial policies</a></li>
        </ul>
    </div>
</div>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--snid-account-widget c-header__item--pipe">
                            
                                <a class="c-header__link eds-c-header__link" id="identity-account-widget" data-track="click_login" data-track-context="header" href="https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-022-01829-9"><span class="eds-c-header__widget-fragment-title">Log in</span></a>
                            
                        </li>
                    </ul>
                </div>
            </div>
        </div>
        
            <div class="c-header__row">
                <div class="c-header__container" data-test="navigation-row">
                    <div class="c-header__split">
                        <ul class="c-header__menu c-header__menu--journal">
                            
                                <li class="c-header__item c-header__item--dropdown-menu" data-test="explore-content-button">
                                    <a href="javascript:;" class="c-header__link" data-header-expander="" data-test="menu-button--explore" data-track="click" data-track-action="open explore expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                        <span><span class="c-header__show-text">Explore</span> content</span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                    </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="Explore-content" data-test="Explore-content" id="explore" data-track-component="nature-150-split-header" hidden="">
            <div class="c-header__container">
                <h2 id="Explore-content" class="c-header__heading c-header__heading--js-hide">Explore content</h2>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/research-articles" data-track="click" data-track-action="research articles" data-track-label="link" data-test="explore-nav-item">
                                    Research articles
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/reviews-and-analysis" data-track="click" data-track-action="reviews &amp; analysis" data-track-label="link" data-test="explore-nav-item">
                                    Reviews &amp; Analysis
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/news-and-comment" data-track="click" data-track-action="news &amp; comment" data-track-label="link" data-test="explore-nav-item">
                                    News &amp; Comment
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/podcast" data-track="click" data-track-action="podcasts" data-track-label="link" data-test="explore-nav-item">
                                    Podcasts
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/current-issue" data-track="click" data-track-action="current issue" data-track-label="link" data-test="explore-nav-item">
                                    Current issue
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/collections" data-track="click" data-track-action="collections" data-track-label="link" data-test="explore-nav-item">
                                    Collections
                                </a>
                            </li>
                        
                    
                </ul>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        <li class="c-header__item">
                            <a class="c-header__link" href="https://www.facebook.com/Nature-Medicine-193691346949/" data-track="click" data-track-action="facebook" data-track-label="link">Follow us on Facebook
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item">
                            <a class="c-header__link" href="https://twitter.com/naturemedicine" data-track="click" data-track-action="twitter" data-track-label="link">Follow us on Twitter
                            </a>
                        </li>
                    
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link" href="https://www.nature.com/my-account/alerts/subscribe-journal?list-id=5" rel="nofollow" data-track="nav_sign_up_for_alerts" data-track-action="Sign up for alerts" data-track-external="" data-track-label="link (mobile dropdown)">Sign up for alerts<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#fff"></path></svg>
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link" href="https://www.nature.com/nm.rss" data-track="click" data-track-action="rss feed" data-track-label="link">
                                <span>RSS feed</span>
                            </a>
                        </li>
                    
                </ul>
            </div>
        </nav>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--dropdown-menu">
                                    <a href="javascript:;" class="c-header__link" data-header-expander="" data-test="menu-button--about-the-journal" data-track="click" data-track-action="open about the journal expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                        <span>About <span class="c-header__show-text">the journal</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                    </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="About-the-journal" id="about-the-journal" data-test="about-the-journal" data-track-component="nature-150-split-header" hidden="">
                <div class="c-header__container">
                    <h2 id="About-the-journal" class="c-header__heading c-header__heading--js-hide">About the journal</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/aims" data-track="click" data-track-action="aims &amp; scope" data-track-label="link">
                                    Aims &amp; Scope
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/journal-information" data-track="click" data-track-action="journal information" data-track-label="link">
                                    Journal Information
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/journal-impact" data-track="click" data-track-action="journal metrics" data-track-label="link">
                                    Journal Metrics
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editors" data-track="click" data-track-action="about the editors" data-track-label="link">
                                    About the Editors
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/research-cross-journal-editorial-team" data-track="click" data-track-action="research cross-journal editorial team" data-track-label="link">
                                    Research Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/reviews-cross-journal-editorial-team" data-track="click" data-track-action="reviews cross-journal editorial team" data-track-label="link">
                                    Reviews Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/statistics-advisory-panel" data-track="click" data-track-action="statistical advisory panel" data-track-label="link">
                                    Statistical Advisory Panel
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/our-publishing-models" data-track="click" data-track-action="our publishing models" data-track-label="link">
                                    Our publishing models
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editorial-values-statement" data-track="click" data-track-action="editorial values statement" data-track-label="link">
                                    Editorial Values Statement
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editorial-policies" data-track="click" data-track-action="editorial policies" data-track-label="link">
                                    Editorial Policies
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/content" data-track="click" data-track-action="content types" data-track-label="link">
                                    Content Types
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/web-feeds" data-track="click" data-track-action="web feeds" data-track-label="link">
                                    Web Feeds
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/contact" data-track="click" data-track-action="contact" data-track-label="link">
                                    Contact
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
                                </li>
                                
                                    <li class="c-header__item c-header__item--dropdown-menu" data-test="publish-with-us-button">
                                        <a href="javascript:;" class="c-header__link c-header__link--dropdown-menu" data-header-expander="" data-test="menu-button--publish" data-track="click" data-track-action="open publish with us expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                            <span>Publish <span class="c-header__show-text">with us</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                        </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="Publish-with-us-label" id="publish-with-us" data-test="publish-with-us" data-track-component="nature-150-split-header" hidden="">
                <div class="c-header__container">
                    <h2 id="Publish-with-us-label" class="c-header__heading c-header__heading--js-hide">Publish with us</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/submission-guidelines" data-track="click" data-track-action="submission guidelines" data-track-label="link">
                                    Submission Guidelines
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/for-reviewers" data-track="click" data-track-action="for reviewers" data-track-label="link">
                                    For Reviewers
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" data-test="nature-author-services" data-track="nav_language_services" data-track-context="header publish with us dropdown menu" data-track-action="manuscript author services" data-track-label="link manuscript author services" href="https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&amp;utm_medium=Website_Nature&amp;utm_campaign=Platform+Experimentation+2022&amp;utm_id=PE2022">
                                    Language editing services
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/open-access-funding" data-test="funding-eligibility-link" data-track="click_explore_funding" data-track-context="header publish with us" data-track-action="funding eligibility">Open access funding</a>
                            </li>
                        
                        
                            <li class="c-header__item c-header__item--keyline">
                                <a class="c-header__link" href="https://mts-nmed.nature.com/cgi-bin/main.plex" data-track="click_submit_manuscript" data-track-context="submit link in Nature header dropdown menu" data-track-action="submit manuscript" data-track-label="link (publish with us dropdown menu)" data-track-external="" data-gtm-criteo="submit-manuscript">Submit manuscript<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m15 0c1.1045695 0 2 .8954305 2 2v5.5c0 .27614237-.2238576.5-.5.5s-.5-.22385763-.5-.5v-5.5c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-9v3c0 1.1045695-.8954305 2-2 2h-3v10c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h7.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-7.5c-1.1045695 0-2-.8954305-2-2v-10.17157288c0-.53043297.21071368-1.0391408.58578644-1.41421356l3.82842712-3.82842712c.37507276-.37507276.88378059-.58578644 1.41421356-.58578644zm-.5442863 8.18867991 3.3545404 3.35454039c.2508994.2508994.2538696.6596433.0035959.909917-.2429543.2429542-.6561449.2462671-.9065387-.0089489l-2.2609825-2.3045251.0010427 7.2231989c0 .3569916-.2898381.6371378-.6473715.6371378-.3470771 0-.6473715-.2852563-.6473715-.6371378l-.0010428-7.2231995-2.2611222 2.3046654c-.2531661.2580415-.6562868.2592444-.9065605.0089707-.24295423-.2429542-.24865597-.6576651.0036132-.9099343l3.3546673-3.35466731c.2509089-.25090888.6612706-.25227691.9135302-.00001728zm-.9557137-3.18867991c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm-8.5-3.587-3.587 3.587h2.587c.55228475 0 1-.44771525 1-1zm8.5 1.587c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill="#fff"></path></svg>
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
                                    </li>
                                
                            
                            
                        </ul>
                        <ul class="c-header__menu c-header__menu--hide-lg-max">
                            
                                <li class="c-header__item" data-test="alert-link">
                                    <a class="c-header__link" href="https://journal-alerts.springernature.com/subscribe?journal_id=41591" rel="nofollow" data-track="nav_sign_up_for_alerts" data-track-action="Sign up for alerts" data-track-label="link (desktop site header)" data-track-external="">
                                        <span>Sign up for alerts</span><svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#222"></path></svg>
                                    </a>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--pipe">
                                    <a class="c-header__link" href="https://www.nature.com/nm.rss" data-track="click" data-track-action="rss feed" data-track-label="link">
                                            <span>RSS feed</span>
                                    </a>
                                </li>
                            
                        </ul>
                    </div>
                </div>
            </div>
        
    </header>


    
    
        <nav class="u-mb-16" aria-label="breadcrumbs">
            <div class="u-container">
                <ol class="c-breadcrumbs" itemscope="" itemtype="https://schema.org/BreadcrumbList">
                    <li class="c-breadcrumbs__item" id="breadcrumb0" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature"><span itemprop="name">nature</span></a><meta itemprop="position" content="1">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb1" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/nm" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature medicine"><span itemprop="name">nature medicine</span></a><meta itemprop="position" content="2">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb2" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/nm/articles?type=article" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:articles"><span itemprop="name">articles</span></a><meta itemprop="position" content="3">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb3" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem">
                                    <span itemprop="name">article</span><meta itemprop="position" content="4"></li>
                </ol>
            </div>
        </nav>
    



    

</div>


<div class="u-container u-mt-32 u-mb-32 u-clearfix" id="content" data-component="article-container" data-container-type="article">
    <main class="c-article-main-column u-float-left js-main-column" data-track-component="article body">
        
            
                <div class="c-context-bar u-hide" id="js-enable-context-bar" data-test="context-bar" data-context-bar="" aria-hidden="true">
                    <div class="c-context-bar__container u-container" data-track-context="sticky banner">
                        <div class="c-context-bar__title">
                            Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
                        </div>
                        
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-022-01829-9.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                    </div>
                </div>
            
        
        <article lang="en">
            
                <div class="c-pdf-button__container u-mb-16 u-hide-at-lg js-context-bar-sticky-point-mobile">
                    <div class="c-pdf-container" data-track-context="article body">
                        
                            
                                
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-022-01829-9.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                            
                        
                    </div>
                </div>
            
            <div class="c-article-header">
                <header>
                    <ul class="c-article-identifiers" data-test="article-identifier">
                        
        <li class="c-article-identifiers__item" data-test="article-category">Article</li>
    
        <li class="c-article-identifiers__item">
            <a href="https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research" data-track="click" data-track-action="open access" data-track-label="link" class="u-color-open-access" data-test="open-access">Open access</a>
        </li>
    
    

                        <li class="c-article-identifiers__item">Published: <time datetime="2022-06-03">03 June 2022</time></li>
                    </ul>

                    <h1 class="c-article-title" data-test="article-title" data-article-title="">Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial</h1>
                    <ul class="c-article-author-list c-article-author-list--long js-no-scroll" data-test="authors-list" data-component-authors-activator="authors-list"><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Lacey_J_-Padr_n-Aff1" data-author-popup="auth-Lacey_J_-Padr_n-Aff1" data-author-search="Padrón, Lacey J." data-corresp-id="c1" data-track-context="researcher popup with no profile" data-track-index="1_37">Lacey J. Padrón<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-0064-5565"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-0064-5565</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup><sup class="u-js-hide">&nbsp;<a href="#na1" tabindex="-1">na1</a></sup>, </li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Deena_M_-Maurer-Aff1" data-author-popup="auth-Deena_M_-Maurer-Aff1" data-author-search="Maurer, Deena M." data-track-context="researcher popup with no profile" data-track-index="2_37">Deena M. Maurer</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup><sup class="u-js-hide">&nbsp;<a href="#na1" tabindex="-1">na1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Mark_H_-O_Hara-Aff2" data-author-popup="auth-Mark_H_-O_Hara-Aff2" data-author-search="O’Hara, Mark H." data-track-context="researcher popup with no profile" data-track-index="3_37">Mark H. O’Hara</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup><sup class="u-js-hide">&nbsp;<a href="#na1" tabindex="-1">na1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Eileen_M_-O_Reilly-Aff3" data-author-popup="auth-Eileen_M_-O_Reilly-Aff3" data-author-search="O’Reilly, Eileen M." data-track-context="researcher popup with no profile" data-track-index="4_37">Eileen M. O’Reilly</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-8076-9199"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-8076-9199</a></span><sup class="u-js-hide"><a href="#Aff3" tabindex="-1">3</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Robert_A_-Wolff-Aff4" data-author-popup="auth-Robert_A_-Wolff-Aff4" data-author-search="Wolff, Robert A." data-track-context="researcher popup with no profile" data-track-index="5_37">Robert A. Wolff</a><sup class="u-js-hide"><a href="#Aff4" tabindex="-1">4</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Zev_A_-Wainberg-Aff5" data-author-popup="auth-Zev_A_-Wainberg-Aff5" data-author-search="Wainberg, Zev A." data-track-context="researcher popup with no profile" data-track-index="6_37">Zev A. Wainberg</a><sup class="u-js-hide"><a href="#Aff5" tabindex="-1">5</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Andrew_H_-Ko-Aff6" data-author-popup="auth-Andrew_H_-Ko-Aff6" data-author-search="Ko, Andrew H." data-track-context="researcher popup with no profile" data-track-index="7_37">Andrew H. Ko</a><sup class="u-js-hide"><a href="#Aff6" tabindex="-1">6</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-George-Fisher-Aff7" data-author-popup="auth-George-Fisher-Aff7" data-author-search="Fisher, George" data-track-context="researcher popup with no profile" data-track-index="8_37">George Fisher</a><sup class="u-js-hide"><a href="#Aff7" tabindex="-1">7</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Osama-Rahma-Aff8" data-author-popup="auth-Osama-Rahma-Aff8" data-author-search="Rahma, Osama" data-track-context="researcher popup with no profile" data-track-index="9_37">Osama Rahma</a><sup class="u-js-hide"><a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Jaclyn_P_-Lyman-Aff1" data-author-popup="auth-Jaclyn_P_-Lyman-Aff1" data-author-search="Lyman, Jaclyn P." data-track-context="researcher popup with no profile" data-track-index="10_37">Jaclyn P. Lyman</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Christopher_R_-Cabanski-Aff1" data-author-popup="auth-Christopher_R_-Cabanski-Aff1" data-author-search="Cabanski, Christopher R." data-track-context="researcher popup with no profile" data-track-index="11_37">Christopher R. Cabanski</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Jia_Xin-Yu-Aff1" data-author-popup="auth-Jia_Xin-Yu-Aff1" data-author-search="Yu, Jia Xin" data-track-context="researcher popup with no profile" data-track-index="12_37">Jia Xin Yu</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Shannon_M_-Pfeiffer-Aff1" data-author-popup="auth-Shannon_M_-Pfeiffer-Aff1" data-author-search="Pfeiffer, Shannon M." data-track-context="researcher popup with no profile" data-track-index="13_37">Shannon M. Pfeiffer</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Marko-Spasic-Aff1" data-author-popup="auth-Marko-Spasic-Aff1" data-author-search="Spasic, Marko" data-track-context="researcher popup with no profile" data-track-index="14_37">Marko Spasic</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Jingying-Xu-Aff1" data-author-popup="auth-Jingying-Xu-Aff1" data-author-search="Xu, Jingying" data-track-context="researcher popup with no profile" data-track-index="15_37">Jingying Xu</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Pier_Federico-Gherardini-Aff1" data-author-popup="auth-Pier_Federico-Gherardini-Aff1" data-author-search="Gherardini, Pier Federico" data-track-context="researcher popup with no profile" data-track-index="16_37">Pier Federico Gherardini</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Joyson-Karakunnel-Aff1" data-author-popup="auth-Joyson-Karakunnel-Aff1" data-author-search="Karakunnel, Joyson" data-track-context="researcher popup with no profile" data-track-index="17_37">Joyson Karakunnel</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Rosemarie-Mick-Aff2" data-author-popup="auth-Rosemarie-Mick-Aff2" data-author-search="Mick, Rosemarie" data-track-context="researcher popup with no profile" data-track-index="18_37">Rosemarie Mick</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-C_cile-Alanio-Aff2-Aff9-Aff10-Aff11" data-author-popup="auth-C_cile-Alanio-Aff2-Aff9-Aff10-Aff11" data-author-search="Alanio, Cécile" data-track-context="researcher popup with no profile" data-track-index="19_37">Cécile Alanio</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a>,<a href="#Aff9" tabindex="-1">9</a>,<a href="#Aff10" tabindex="-1">10</a>,<a href="#Aff11" tabindex="-1">11</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Katelyn_T_-Byrne-Aff2-Aff9" data-author-popup="auth-Katelyn_T_-Byrne-Aff2-Aff9" data-author-search="Byrne, Katelyn T." data-track-context="researcher popup with no profile" data-track-index="20_37">Katelyn T. Byrne</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a>,<a href="#Aff9" tabindex="-1">9</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Travis_J_-Hollmann-Aff3" data-author-popup="auth-Travis_J_-Hollmann-Aff3" data-author-search="Hollmann, Travis J." data-track-context="researcher popup with no profile" data-track-index="21_37">Travis J. Hollmann</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-1599-0433"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-1599-0433</a></span><sup class="u-js-hide"><a href="#Aff3" tabindex="-1">3</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Jonni_S_-Moore-Aff2" data-author-popup="auth-Jonni_S_-Moore-Aff2" data-author-search="Moore, Jonni S." data-track-context="researcher popup with no profile" data-track-index="22_37">Jonni S. Moore</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-2975-336X"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-2975-336X</a></span><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Derek_D_-Jones-Aff2" data-author-popup="auth-Derek_D_-Jones-Aff2" data-author-search="Jones, Derek D." data-track-context="researcher popup with no profile" data-track-index="23_37">Derek D. Jones</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Marco-Tognetti-Aff12" data-author-popup="auth-Marco-Tognetti-Aff12" data-author-search="Tognetti, Marco" data-track-context="researcher popup with no profile" data-track-index="24_37">Marco Tognetti</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-2379-1525"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-2379-1525</a></span><sup class="u-js-hide"><a href="#Aff12" tabindex="-1">12</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Richard_O_-Chen-Aff13" data-author-popup="auth-Richard_O_-Chen-Aff13" data-author-search="Chen, Richard O." data-track-context="researcher popup with no profile" data-track-index="25_37">Richard O. Chen</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-2842-4476"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-2842-4476</a></span><sup class="u-js-hide"><a href="#Aff13" tabindex="-1">13</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Xiaodong-Yang-Aff14" data-author-popup="auth-Xiaodong-Yang-Aff14" data-author-search="Yang, Xiaodong" data-track-context="researcher popup with no profile" data-track-index="26_37">Xiaodong Yang</a><sup class="u-js-hide"><a href="#Aff14" tabindex="-1">14</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Lisa-Salvador-Aff15" data-author-popup="auth-Lisa-Salvador-Aff15" data-author-search="Salvador, Lisa" data-track-context="researcher popup with no profile" data-track-index="27_37">Lisa Salvador</a><sup class="u-js-hide"><a href="#Aff15" tabindex="-1">15</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-E__John-Wherry-Aff2-Aff9-Aff10-Aff11" data-author-popup="auth-E__John-Wherry-Aff2-Aff9-Aff10-Aff11" data-author-search="Wherry, E. John" data-track-context="researcher popup with no profile" data-track-index="28_37">E. John Wherry</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-0477-1956"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-0477-1956</a></span><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a>,<a href="#Aff9" tabindex="-1">9</a>,<a href="#Aff10" tabindex="-1">10</a>,<a href="#Aff11" tabindex="-1">11</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Ute-Dugan-Aff1" data-author-popup="auth-Ute-Dugan-Aff1" data-author-search="Dugan, Ute" data-track-context="researcher popup with no profile" data-track-index="29_37">Ute Dugan</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Jill-O_Donnell_Tormey-Aff16" data-author-popup="auth-Jill-O_Donnell_Tormey-Aff16" data-author-search="O’Donnell-Tormey, Jill" data-track-context="researcher popup with no profile" data-track-index="30_37">Jill O’Donnell-Tormey</a><sup class="u-js-hide"><a href="#Aff16" tabindex="-1">16</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Lisa_H_-Butterfield-Aff1" data-author-popup="auth-Lisa_H_-Butterfield-Aff1" data-author-search="Butterfield, Lisa H." data-track-context="researcher popup with no profile" data-track-index="31_37">Lisa H. Butterfield</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-3439-9844"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-3439-9844</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Vanessa_M_-Hubbard_Lucey-Aff16" data-author-popup="auth-Vanessa_M_-Hubbard_Lucey-Aff16" data-author-search="Hubbard-Lucey, Vanessa M." data-track-context="researcher popup with no profile" data-track-index="32_37">Vanessa M. Hubbard-Lucey</a><sup class="u-js-hide"><a href="#Aff16" tabindex="-1">16</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Ramy-Ibrahim-Aff1" data-author-popup="auth-Ramy-Ibrahim-Aff1" data-author-search="Ibrahim, Ramy" data-track-context="researcher popup with no profile" data-track-index="33_37">Ramy Ibrahim</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Justin-Fairchild-Aff1" data-author-popup="auth-Justin-Fairchild-Aff1" data-author-search="Fairchild, Justin" data-track-context="researcher popup with no profile" data-track-index="34_37">Justin Fairchild</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Samantha-Bucktrout-Aff1" data-author-popup="auth-Samantha-Bucktrout-Aff1" data-author-search="Bucktrout, Samantha" data-track-context="researcher popup with no profile" data-track-index="35_37">Samantha Bucktrout</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Theresa_M_-LaVallee-Aff1" data-author-popup="auth-Theresa_M_-LaVallee-Aff1" data-author-search="LaVallee, Theresa M." data-track-context="researcher popup with no profile" data-track-index="36_37">Theresa M. LaVallee</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup> &amp; </li><li class="c-article-author-list__show-more" aria-label="Show all 37 authors for this article" title="Show all 37 authors for this article">…</li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Robert_H_-Vonderheide-Aff2-Aff9-Aff11" data-author-popup="auth-Robert_H_-Vonderheide-Aff2-Aff9-Aff11" data-author-search="Vonderheide, Robert H." data-corresp-id="c2" data-track-context="researcher popup with no profile" data-track-index="37_37">Robert H. Vonderheide<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-7252-954X"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-7252-954X</a></span><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a>,<a href="#Aff9" tabindex="-1">9</a>,<a href="#Aff11" tabindex="-1">11</a></sup>&nbsp;</li></ul><button aria-expanded="false" class="c-article-author-list__button"><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-down-medium"></use></svg><span>Show authors</span></button>

                    

                    <p class="c-article-info-details" data-container-section="info">
                        
    <a data-test="journal-link" href="/nm" data-track="click" data-track-action="journal homepage" data-track-category="article body" data-track-label="link"><i data-test="journal-title">Nature Medicine</i></a>

                        <b data-test="journal-volume"><span class="u-visually-hidden">volume</span>&nbsp;28</b>,&nbsp;<span class="u-visually-hidden">pages </span>1167–1177 (<span data-test="article-publication-year">2022</span>)<a href="#citeas" class="c-article-info-details__cite-as u-hide-print" data-track="click" data-track-action="cite this article" data-track-label="link">Cite this article</a>
                    </p>
                    
        <div class="c-article-metrics-bar__wrapper u-clear-both">
            <ul class="c-article-metrics-bar u-list-reset">
                
                    <li class=" c-article-metrics-bar__item" data-test="access-count">
                        <p class="c-article-metrics-bar__count">48k <span class="c-article-metrics-bar__label">Accesses</span></p>
                    </li>
                
                
                    <li class="c-article-metrics-bar__item" data-test="citation-count">
                        <p class="c-article-metrics-bar__count">194 <span class="c-article-metrics-bar__label">Citations</span></p>
                    </li>
                
                
                    
                        <li class="c-article-metrics-bar__item" data-test="altmetric-score">
                            <p class="c-article-metrics-bar__count">217 <span class="c-article-metrics-bar__label">Altmetric</span></p>
                        </li>
                    
                
                <li class="c-article-metrics-bar__item">
                    <p class="c-article-metrics-bar__details"><a href="/articles/s41591-022-01829-9/metrics" data-track="click" data-track-action="view metrics" data-track-label="link" rel="nofollow">Metrics <span class="u-visually-hidden">details</span></a></p>
                </li>
            </ul>
        </div>
    
                    
                </header>

                
    

                
    
    

    
        <div class="u-mb-8 c-status-message c-status-message--boxed c-status-message--info">
            
                <span class="c-status-message__icon">
                    <svg class="u-icon" width="18" height="18" aria-hidden="true" focusable="false">
                        <use xlink:href="#icon-eds-i-info-filled-medium"></use>
                    </svg>
                </span>
            
            <p class="u-mt-0">This article has been <a href="#change-history">updated</a></p>
        </div>
    
    

                
            </div>

        <div class="c-article-body">
            <section aria-labelledby="Abs1" data-title="Abstract" lang="en"><div class="c-article-section" id="Abs1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Abs1">Abstract</h2><div class="c-article-section__content" id="Abs1-content"><p>Chemotherapy combined with immunotherapy has improved the treatment of certain solid tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma (PDAC). We conducted a randomized phase 2 trial evaluating the efficacy of nivolumab (nivo; anti-PD-1) and/or sotigalimab (sotiga; CD40 agonistic antibody) with gemcitabine/nab-paclitaxel (chemotherapy) in patients with first-line metastatic PDAC (<a href="https://clinicaltrials.gov/ct2/show/NCT03214250">NCT03214250</a>). In 105 patients analyzed for efficacy, the primary endpoint of 1-year overall survival (OS) was met for nivo/chemo (57.7%, <i>P</i> = 0.006 compared to historical 1-year OS of 35%, <i>n</i> = 34) but was not met for sotiga/chemo (48.1%, <i>P</i> = 0.062, <i>n</i> = 36) or sotiga/nivo/chemo (41.3%, <i>P</i> = 0.223, <i>n</i> = 35). Secondary endpoints were progression-free survival, objective response rate, disease control rate, duration of response and safety. Treatment-related adverse event rates were similar across arms. Multi-omic circulating and tumor biomarker analyses identified distinct immune signatures associated with survival for nivo/chemo and sotiga/chemo. Survival after nivo/chemo correlated with a less suppressive tumor microenvironment and higher numbers of activated, antigen-experienced circulating T cells at baseline. Survival after sotiga/chemo correlated with greater intratumoral CD4 T cell infiltration and circulating differentiated CD4 T cells and antigen-presenting cells. A patient subset benefitting from sotiga/nivo/chemo was not identified. Collectively, these analyses suggest potential treatment-specific correlates of efficacy and may enable biomarker-selected patient populations in subsequent PDAC chemoimmunotherapy trials.</p></div></div></section>

            
                
            

            
                
                    
        
            <section aria-labelledby="inline-recommendations" data-title="Inline Recommendations" class="c-article-recommendations" data-track-component="inline-recommendations">
                <h3 class="c-article-recommendations-title" id="inline-recommendations">Similar content being viewed by others</h3>
                <div class="c-article-recommendations-list">
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41392-024-01857-6/MediaObjects/41392_2024_1857_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41392-024-01857-6?fromPaywallRec=false" data-track="select_recommendations_1" data-track-context="inline recommendations" data-track-action="click recommendations inline - 1" data-track-label="10.1038/s41392-024-01857-6">First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">07 June 2024</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41467-022-32591-8/MediaObjects/41467_2022_32591_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41467-022-32591-8?fromPaywallRec=false" data-track="select_recommendations_2" data-track-context="inline recommendations" data-track-action="click recommendations inline - 2" data-track-label="10.1038/s41467-022-32591-8">The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">26 August 2022</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs44276-023-00028-4/MediaObjects/44276_2023_28_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s44276-023-00028-4?fromPaywallRec=false" data-track="select_recommendations_3" data-track-context="inline recommendations" data-track-action="click recommendations inline - 3" data-track-label="10.1038/s44276-023-00028-4">A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">23 January 2024</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                </div>
            </section>
        
            <script>
                window.dataLayer = window.dataLayer || [];
                window.dataLayer.push({
                    recommendations: {
                        recommender: 'semantic',
                        model: 'specter',
                        policy_id: 'NA',
                        timestamp: 1749524196,
                        embedded_user: 'null'
                    }
                });
            </script>
        
    
                
                
                <div class="main-content">
                    
                        <section data-title="Main"><div class="c-article-section" id="Sec1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec1">Main</h2><div class="c-article-section__content" id="Sec1-content"><p>PDAC remains one of the most intractable challenges in oncology. Pancreatic cancer is predicted to become the second-leading cause of cancer death in the United States by 2030 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74, 2913–2921 (2014)." href="/articles/s41591-022-01829-9#ref-CR1" id="ref-link-section-d71099090e1153">1</a></sup>). Although combination chemotherapy reliably offers tumor control and clinical stabilization, both standard regimens of gemcitabine plus nab-paclitaxel and FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil and leucovorin) are limited in response durability and incur toxicity. Thus, there is urgent necessity for new treatment strategies in this disease.</p><p>Immune checkpoint inhibition has revolutionized cancer care in the past decade—with now nearly 70 distinct US Food and Drug Administration label indications across more than 18 histologies<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 2" title="Sharma, P. et al. The next decade of immune checkpoint therapy. Cancer Discov. 11, 838–857 (2021)." href="/articles/s41591-022-01829-9#ref-CR2" id="ref-link-section-d71099090e1160">2</a></sup>—but these therapies have yet to show meaningful clinical benefit in PDAC beyond rare (&lt;1%) patients exhibiting microsatellite instability (MSI) in the tumor<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="O’Reilly, E. M. et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 5, 1431–1438 (2019)." href="/articles/s41591-022-01829-9#ref-CR3" id="ref-link-section-d71099090e1164">3</a></sup>. Single-agent and combinations of PD-1, PD-L1 or CTLA-4 inhibitors in patients with advanced PDAC are ineffective (objective response rates (ORRs) &lt;5%)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Royal, R. E. et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 33, 828–833 (2010)." href="#ref-CR4" id="ref-link-section-d71099090e1168">4</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Patnaik, A. et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin. Cancer Res. 21, 4286–4293 (2015)." href="#ref-CR5" id="ref-link-section-d71099090e1168_1">5</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012)." href="/articles/s41591-022-01829-9#ref-CR6" id="ref-link-section-d71099090e1171">6</a></sup>, including in patients with positive PD-L1 expression, a biomarker that enriches for response in other cancers. Postulated mechanisms of resistance to immunotherapy in PDAC include poor T cell infiltration, low tumor mutational burden and a highly immunosuppressive tumor microenvironment (TME). However, recent in-depth profiling of PDAC tumors indicates that as many as 20–30% of patients exhibit moderate T cell content and that, in some settings, tumor immunogenic neo-epitopes and T cell immunity can correlate with OS<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Balachandran, V. P. et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551, 512–516 (2017)." href="#ref-CR7" id="ref-link-section-d71099090e1175">7</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Balli, D., Rech, A. J., Stanger, B. Z. &amp; Vonderheide, R. H. Immune cytolytic activity stratifies molecular subsets of human pancreatic cancer. Clin. Cancer Res. 23, 3129–3138 (2017)." href="#ref-CR8" id="ref-link-section-d71099090e1175_1">8</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Stromnes, I. M., Hulbert, A., Pierce, R. H., Greenberg, P. D. &amp; Hingorani, S. R. T-cell localization, activation, and clonal expansion in human pancreatic ductal adenocarcinoma. Cancer Immunol. Res. 5, 978–991 (2017)." href="/articles/s41591-022-01829-9#ref-CR9" id="ref-link-section-d71099090e1178">9</a></sup>.</p><p>Combinations of gemcitabine and nab-paclitaxel (chemo) with CD40 agonist antibody with or without immune checkpoint inhibition overcome immune suppression in genetically engineered mouse models of PDAC<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Byrne, K. T. &amp; Vonderheide, R. H. CD40 stimulation obviates innate sensors and drives T cell immunity in cancer. Cell Rep. 15, 2719–2732 (2016)." href="/articles/s41591-022-01829-9#ref-CR10" id="ref-link-section-d71099090e1185">10</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Winograd, R. et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol. Res 3, 399–411 (2015)." href="/articles/s41591-022-01829-9#ref-CR11" id="ref-link-section-d71099090e1188">11</a></sup>. In these experiments, chemotherapy drives the release of cancer cell antigens and induces tumor regression, and survival is dependent on T cells, dendritic cells (DCs) and immunologic memory—justifying testing of these strategies in clinical trials. In our recent phase 1b study of the CD40 agonist antibody sotigalimab (sotiga) with chemo, with or without nivolumab (nivo), we reported acceptable toxicity and promising rates of tumor regressions in patients with newly diagnosed metastatic PDAC (mPDAC)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="O’Hara, M. H. et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 22, 118–131 (2021)." href="/articles/s41591-022-01829-9#ref-CR12" id="ref-link-section-d71099090e1192">12</a></sup>.</p><p>Here we report clinical and translational results of a randomized, multi-center, open-label phase 2 trial for first-line treatment of patients with mPDAC randomized to receive nivo/chemo, sotiga/chemo or sotiga/nivo/chemo. The clinical study was accompanied by comprehensive and serial biospecimen acquisition and multi-omic profiling, allowing for hypothesis-generating exploratory analyses that identified multiple distinct and treatment-specific biomarkers.</p></div></div></section><section data-title="Results"><div class="c-article-section" id="Sec2-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec2">Results</h2><div class="c-article-section__content" id="Sec2-content"><h3 class="c-article__sub-heading" id="Sec3">Trial design and patient characteristics</h3><p>From 30 August 2018 through 10 June 2019, 99 patients were randomly allocated into one of three treatment arms (<i>n</i> = 37, 31 and 31 to nivo/chemo, sotiga/chemo and sotiga/nivo/chemo, respectively; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig1">1</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig6">1</a>). Six patients (<i>n</i> = 3, 1 and 2, respectively) were randomized but not dosed and were excluded from analysis (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig1">1</a>). Efficacy was assessed for 105 patients (<i>n</i> = 34, 36 and 35), which included 93 patients randomized and dosed in phase 2 and 12 dose-limiting toxicity (DLT)-evaluable patients from the non-randomized phase 1b study<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="O’Hara, M. H. et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 22, 118–131 (2021)." href="/articles/s41591-022-01829-9#ref-CR12" id="ref-link-section-d71099090e1230">12</a></sup> (six each on sotiga/chemo and sotiga/nivo/chemo). Safety was assessed for 108 patients (<i>n</i> = 36, 37 and 35, respectively), which included the 105 patients assessed for efficacy plus three non-DLT-evaluable patients from phase 1b. The cutoff date for clinical data analysis was 24 March 2021.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-1" data-title="PRINCE study design and CONSORT diagram."><figure><figcaption><b id="Fig1" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 1: PRINCE study design and CONSORT diagram.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01829-9/figures/1" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig1_HTML.png?as=webp"><img aria-describedby="Fig1" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig1_HTML.png" alt="figure 1" loading="lazy" width="685" height="595"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-1-desc"><p><b>a</b>, PRINCE was a seamless phase 1b/2 study, with the phase 2 portion randomizing patients to treatment with nivo/chemo, sotiga/chemo or sotiga/nivo/chemo. <b>b</b>, CONSORT diagram of the phase 2 portion of the study. Patients enrolled in cohorts B2 and C2 during phase 1b were included in safety and/or efficacy analyses of the phase 2 portion.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01829-9/figures/1" data-track-dest="link:Figure1 Full size image" aria-label="Full size image figure 1" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>Baseline characteristics for the efficacy population were generally balanced across arms (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-022-01829-9#Tab1">1</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">1</a>). However, a higher proportion of patients on sotiga/chemo had an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 at screening (56% versus 43–44%). Across arms, 74–79% of patients had de novo stage IV disease.</p><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-1"><figure><figcaption class="c-article-table__figcaption"><b id="Tab1" data-test="table-caption">Table 1 Demographic and baseline disease characteristics for patients in the efficacy population</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/s41591-022-01829-9/tables/1" aria-label="Full size table 1"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>Pre-treatment PD-L1<sup>+</sup> tumor percentages were similar between the nivo/chemo and sotiga/nivo/chemo arms but less in the sotiga/chemo arm (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">2</a>). Sixty-three (60%) patients had pre-treatment tumor tissue of high enough quality for whole-exome sequencing (WES). By WES, treatment arms were balanced for somatic mutation frequencies in <i>KRAS</i>, <i>SMAD4</i> and <i>TP53</i> in mPDAC (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">2</a>). The tumor tissue for one patient (in nivo/chemo) was MSI-high. Only one patient (in sotiga/nivo/chemo) had a pathogenic tumor variant of BRCA2. The BRCA variant detected in the tumor tissue was the indel tumor variant BRCA2c.5946delT; this patient experienced a partial response but withdrew consent after 2.8 months, and their 1-year OS status is unknown. Additionally, the arms were relatively balanced for gene expression signatures in pre-treatment tumor tissues and had similar baseline frequencies of immune cell populations within circulation.</p><p>At the time of analysis, median duration of follow-up for patients in the efficacy population was 24.2 months (interquartile range (IQR), 20.5–26.3) with 15 months of minimum follow-up. Two patients remained on treatment, one each on sotiga/chemo and sotiga/nivo/chemo. Median time on treatment was similar between the three arms (median (IQR), months: 5.2 (1.9–8.1), 5.1 (3.4–8.9) and 4.7 (2.4–7.9) for nivo/chemo, sotiga/chemo and sotiga/nivo/chemo, respectively). Exposure to each drug in the combination was also similar between arms (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">3</a>).</p><h3 class="c-article__sub-heading" id="Sec4">Clinical activity</h3><p>The primary endpoint was 1-year OS rate for each arm versus a historical control rate of 35%<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691–1703 (2013)." href="/articles/s41591-022-01829-9#ref-CR13" id="ref-link-section-d71099090e2083">13</a></sup>. Secondary endpoints included progression-free survival (PFS), duration of response (DOR), investigator-assessed ORR and disease control rate (DCR). This study was not powered for comparison between arms. The survival analysis was based on 78 (74%) deaths.</p><p>For nivo/chemo, the 1-year OS rate was 57.7% (one-sided <i>P</i> = 0.006, one-sided 95% lower confidence bound = 41.7%), and median OS was 16.7 months (95% confidence interval (CI): 9.8–18.4) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig2">2a</a>). Median PFS was 6.4 months (95% CI: 5.2–8.8); ORR was 50% (95% CI: 32–68); DCR was 74% (95% CI: 56–87); and median DOR was 7.4 months (95% CI: 2.1–not estimable) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig2">2b</a>, Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig7">2</a> and Extended Data Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-022-01829-9#Tab2">1</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-2" data-title="OS and tumor response."><figure><figcaption><b id="Fig2" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 2: OS and tumor response.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01829-9/figures/2" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig2_HTML.png?as=webp"><img aria-describedby="Fig2" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig2_HTML.png" alt="figure 2" loading="lazy" width="685" height="1038"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-2-desc"><p><b>a</b>, Kaplan–Meier curves of OS of patients in the efficacy population. The 1-year OS rate and corresponding one-sided, 95% lower confidence bound were estimated by the Kaplan–Meier method. <i>P</i> values were calculated using a one-sided, one-sample <i>z-</i>test of the Kaplan–Meier estimate of the 1-year OS rate (and its standard error) against the historical rate of 35%. <i>P</i> values were not adjusted for multiple comparisons. Median OS and corresponding two-sided, 95% CI were estimated by the Kaplan–Meier method. <b>b</b>, Maximum percentage change from baseline in the sum of the diameters of the target lesions for each patient with at least one post-baseline tumor assessment. Four patients in the nivo/chemo arm, one in the sotiga/chemo arm and three in the sotiga/nivo/chemo arm did not have any post-baseline tumor assessments. Confirmed CR or PR is defined as two consecutive tumor assessments at least 4 weeks apart with an overall response of CR/PR.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01829-9/figures/2" data-track-dest="link:Figure2 Full size image" aria-label="Full size image figure 2" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>For sotiga/chemo, the 1-year OS rate was 48.1% (one-sided <i>P</i> = 0.062, one-sided 95% lower confidence bound = 33.7%), and median OS was 11.4 months (95% CI: 7.2–20.1). The median PFS was 7.3 months (95% CI: 5.4–9.2); investigator-assessed ORR was 33% (95% CI: 19–51); DCR was 78% (95% CI: 61–90); and median DOR was 5.6 months (95% CI: 3.8–8.0).</p><p>For sotiga/nivo/chemo, the 1-year OS rate was 41.3% (one-sided <i>P</i> = 0.233, lower confidence bound=27.0%), and median OS was 10.1 months (95% CI: 7.9–13.2). The median PFS was 6.7 months (95% CI: 4.2–9.8); investigator-assessed ORR was 31% (95% CI: 17–49); DCR was 69% (95% CI: 51–83); and median DOR was 7.9 months (95% CI: 1.9–not estimable).</p><p>The use of subsequent systemic therapy was balanced between arms (63–67%), with chemotherapy being the most reported subsequent therapy. Post hoc subgroup analyses of baseline clinical characteristics revealed numerically improved OS in several patient subgroups, including patients initially diagnosed with stage I–III disease (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">4</a>). However, the data suggest that the survival benefit observed in patients receiving nivo/chemo was not driven solely by patient imbalances in these subgroups nor MSI-high (OS = 8.1 months in a single MSI-high patient), KRAS wild-type (balanced across arms) or BRCA.</p><h3 class="c-article__sub-heading" id="Sec5">Safety</h3><p>The spectrum, frequency and severity of treatment-related adverse events (TRAEs), a secondary endpoint, were similar across the arms and consistent with the safety profile observed in phase 1b<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="O’Hara, M. H. et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 22, 118–131 (2021)." href="/articles/s41591-022-01829-9#ref-CR12" id="ref-link-section-d71099090e2167">12</a></sup>. Overall, 106 (98%) patients reported at least one TRAE. The most common non-hematologic TRAEs of any grade were nausea, fatigue, pyrexia and chills (Extended Data Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-022-01829-9#Tab3">2</a>). The most common grade 3–4 TRAEs were hematologic and generally transient in nature.</p><p>Adverse events of special interest (AESIs), including cytokine release syndrome (CRS), infusion reactions, thrombocytopenia and elevated liver function tests (LFTs), were observed in 92 (87%) patients (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">5</a>). CRS was observed in 0, 9 (24%) and 12 (34%) patients in nivo/chemo, sotiga/chemo and sotiga/nivo/chemo, respectively, with five events assessed as grade 3 (three in sotiga/chemo and two in sotiga/nivo/chemo). Grade 4 or 5 CRS was not observed. Elevated LFTs were observed in 24 (67%), 30 (81%) and 26 (74%) patients, respectively. Infusion-related reactions were observed in 2 (6%), 5 (14%) and 5 (14%) patients, respectively. Thrombocytopenia occurred in 18 (50%), 21 (57%) and 22 (63%) patients, respectively, with 18 patients experiencing a grade 3 or 4 event (five (14%), six (16%) and seven (20%), respectively).</p><p>Six (17%) patients on nivo/chemo, one (3%) on sotiga/chemo and one (3%) on sotiga/nivo/chemo discontinued all study drugs due to an adverse event; most were grade 2 or grade 3, with one grade 4 (thrombic microangiopathy on nivo/chemo), and half were assessed by the investigator as related to chemotherapy only (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">6</a>). Two patients died due to an adverse event: acute hepatic failure on sotiga/chemo (causality could not be determined so considered possibly related to all study drugs) and intracranial hemorrhage on sotiga/nivo/chemo (possibly related to all study drugs).</p><h3 class="c-article__sub-heading" id="Sec6">Pharmacodynamic effects</h3><p>As an exploratory trial endpoint, pharmacodynamic effects and potential underlying immune mechanisms were studied via multi-omic profiling of serial patient blood samples and tumor biopsies obtained pre-treatment and on-treatment (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig6">1</a>). For all evaluable patients, tumor samples were profiled with RNA sequencing and multiplex immunofluorescence (mIF), whereas blood samples were profiled with high-dimensional flow cytometry (X50), mass cytometry time of flight (CyTOF) and serum protein profiling via Olink panels (see respective <a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-022-01829-9#Sec12">Methods</a> sections for total sample numbers).</p><p>In all three arms, longitudinal profiling of peripheral blood mononuclear cells (PBMCs) revealed increases in proliferating (Ki-67<sup>+</sup>) non-naive CD8 and CD4 T cells on-treatment (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig8">3a</a>, Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">1a</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">7</a>). This increase was strongest and observed earlier in the nivo-containing arms and, to a lesser extent, in sotiga/chemo. Patients treated with nivo/chemo also had increases in circulating activated (HLA-DR<sup>+</sup>) non-naive CD4 and CD8 T cells (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig8">3b</a> and Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">1b</a>). Additionally, increases in circulating T cells expressing other activation markers, such as CD38, were observed in all treatment arms (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">1c</a>).</p><p>To evaluate circulating proteins known to associate with immune and inflammatory activities, an array of 172 serum proteins was analyzed. Treatment of patients in all three arms resulted in significant increases in IFN-γ (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig8">3c</a>). Additionally, soluble PD-1 (sPD-1) levels increased on-treatment in sera from patients in nivo-containing arms. In contrast, sPD-1 levels remained relatively consistent in sera from patients treated with sotiga/chemo (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig8">3d</a>). Consistent with known pharmacodynamic effects of immunotherapy treatment<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 14" title="Choueiri, T. K. et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. Clin. Cancer Res. 22, 5461–5471 (2016)." href="/articles/s41591-022-01829-9#ref-CR14" id="ref-link-section-d71099090e2235">14</a></sup>, several chemokines increased in the sera in response to all treatments, including CXCL9 and CXCL10 (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig8">3e,f</a>). However, earlier increases (C1D15 and C2D1) were observed in the nivo-containing arms (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig8">3e,f</a>).</p><p>To evaluate whether any biologic associations emerged from the circulating orthogonal biomarker assays, integrated analysis of all features measured in response to chemoimmunotherapy treatment (C2D1) was performed. This analysis revealed correlations between proteins and cell populations across different platforms (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig8">3i</a>). Of note, CXCL10, CXCL9 and sPD-1 correlated with activated, proliferating T cells in all treatment arms. Changes in CD38<sup>+</sup> non-naive CD8 T cells, sPD-1 and CXCL9 were associated with the nivo-containing arms (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig8">3i</a>).</p><p>Analysis of paired pre-treatment and on-treatment (~C2D1) biopsies from individual patients revealed that nivo/chemo treatment led to a numerically decreased percentage of tumor cells expressing PD-L1 in all samples measured (<i>n</i> = 5). In contrast, changes in the percentage of PD-L1<sup>+</sup> tumor cells were heterogeneous for sotiga/chemo (<i>n</i> = 3). The combination of sotiga/nivo/chemo decreased PD-L1<sup>+</sup> tumor cells in five of six patients analyzed (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig8">3g</a>). For sotiga/chemo, two of three patients with paired biopsies exhibited increases in tumor-infiltrating iNOS<sup>+</sup>CD80<sup>+</sup>CD68<sup>+</sup> cells (macrophages), an effect that was not observed for paired biopsies from patients treated in nivo-containing arms (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig8">3h</a>). The observed pharmacodynamic effects in both circulation and the TME highlight immune modulation with immunotherapy/chemotherapy combinations in patients with mPDAC.</p><h3 class="c-article__sub-heading" id="Sec7">Assessment of correlates of clinical benefit</h3><p>To identify subsets of patients who are more likely to benefit from a specific treatment, we performed exploratory, hypothesis-generating analyses using comprehensive multi-omic, multi-parameter immune and tumor biomarker data for associations with survival. An approach of focusing on biological networks indicated across multiple assays helped to identify signals of underlying systems that are more likely to have robustness in the context of a small phase 2 study. This deep, integrated analysis approach provided a comprehensive view of tumor and immune contexture and identified distinct biomarkers that associated with survival benefit in each arm (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">8</a>). These associations frequently remained when accounting for the clinical covariates of initial stage at diagnosis and prior chemotherapy treatment (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">8</a>). Although statistical tests were used to evaluate biomarkers associated with survival, the associated <i>P</i> values were not adjusted for multiplicity as this is a post hoc, exploratory analysis. The aim of these statistical tests was to assist in ranking and identifying potential biomarker candidates that could be targets in a prospective study; the magnitude of the <i>P</i> values should not be interpreted.</p><p>It is important to note that, due to the effect on tissue of origin on bulk RNA sequencing, we chose to limit all tumor gene expression analyses to the most common biopsy site—liver metastases—which constituted 64% of biopsies. Tissue origin did not affect major immune population frequencies observed by mIF, and, because of this and the smaller numbers of biopsies profiled via mIF, we did not limit analyses by biopsy site for immunophenotyping.</p><h3 class="c-article__sub-heading" id="Sec8">Correlates of survival benefit after nivo/chemo</h3><p>Survival benefit after nivo/chemo was associated with a diverse, immunocompetent circulating T cell response pre-treatment. CD4 and CD8 T cells were classified as non-naive, central memory (CM) or effector memory (EM). EM T cells were further subdivided based on CCR7 expression: EM1, EM2 and EM3 (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Mathew, D. et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science 369, eabc8511 (2020)." href="/articles/s41591-022-01829-9#ref-CR15" id="ref-link-section-d71099090e2315">15</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Romero, P. et al. Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J. Immunol. 178, 4112–4119 (2007)." href="/articles/s41591-022-01829-9#ref-CR16" id="ref-link-section-d71099090e2318">16</a></sup>) (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">2</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">7</a>). Higher frequencies of activated (CD38<sup>+</sup>) EM CD8 T cells were associated with longer survival (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig3">3a</a>). These cells co-expressed PD-1, 2B4, Eomes and Tbet (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig3">3b</a>). Although this cell population became more abundant with treatment, only pre-treatment levels were associated with 1-year survival status (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig3">3c</a>). Similarly, antigen-experienced (PD-1<sup>+</sup>CD39<sup>+</sup>) EM1 (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig3">3d</a>) and CM CD4 T cells (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">3a</a>) were associated with longer survival. These cells co-expressed CTLA-4 and ICOS (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig3">3e</a> and Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">3b</a>). Co-expression of CCR7 and TCF-1 was unique to antigen-experienced (PD-1<sup>+</sup>CD39<sup>+</sup>) CM CD4 T cells (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">3b</a>). Patients with &gt;1 year survival expressed numerically higher frequencies of this cellular phenotype on-treatment (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig3">3f</a> and Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">3c</a>). In addition, T follicular helper (T<sub>fh</sub>) cells (CD4<sup>+</sup>PD-1<sup>+</sup>CXCR5<sup>+</sup>) were associated with longer survival (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig3">3g</a>) and had the highest predictive value of the strongest circulating biomarkers in the nivo/chemo arm in a combined multivariable model (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">4a</a>). These cells had high expression of TCF-1, CCR7 and ICOS (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig3">3h</a>). High frequencies of these cells late on-treatment (C4D1) were most differentiating between patients with &gt;1 year and &lt;1 year OS (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig3">3i</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-3" data-title="Activated, antigen-experienced non-naive T cells and Tfh cells in the periphery are associated with survival in patients with mPDAC treated with nivo/chemo."><figure><figcaption><b id="Fig3" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 3: Activated, antigen-experienced non-naive T cells and T<sub>fh</sub> cells in the periphery are associated with survival in patients with mPDAC treated with nivo/chemo.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01829-9/figures/3" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig3_HTML.png?as=webp"><img aria-describedby="Fig3" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig3_HTML.png" alt="figure 3" loading="lazy" width="685" height="662"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-3-desc"><p><b>a</b>, Kaplan–Meier curves for OS stratified by frequencies of circulating CD38<sup>+</sup> EM CD8 T cells by flow cytometry, pre-treatment (C1D1) above and below the median frequency. <b>b</b>, Heat map of relative median fluorescence intensity of markers on CD38<sup>+</sup> EM CD8 T cells from pre-treatment PBMC samples across patients in the nivo/chemo arm. <b>c</b>, Frequencies of CD38<sup>+</sup> EM CD8 T cells pre-treatment (C1D1) and on-treatment PBMC samples (C1D15, C2D1 and C4D1), grouped by patient survival status at 1 year. <b>d</b>, Kaplan–Meier curves for OS stratified by frequencies of circulating PD-1<sup>+</sup>CD39<sup>+</sup> EM1 CD4 T cells. <b>e</b>, Heat map of relative median fluorescence intensity of markers present on PD-1<sup>+</sup>CD39<sup>+</sup> EM1 CD4 T cell population from pre-treatment PBMC samples across patients in the nivo/chemo arm. <b>f</b>, Frequencies of PD-1<sup>+</sup>CD39<sup>+</sup> EM1 CD4 T cells in pre-treatment (C1D1) and on-treatment PBMC samples (C1D15, C2D1 and C4D1), grouped by patient survival status at 1 year. <b>g</b>, Kaplan–Meier curves for OS stratified by frequencies of circulating T<sub>fh</sub> (CXCR5<sup>+</sup>PD-1<sup>+</sup>CD4<sup>+</sup>) cells. <b>h</b>, Heat map of relative median fluorescence intensity of markers present on pre-treatment T<sub>fh</sub> cells across all patients from pre-treatment PBMC samples in the nivo/chemo arm. <b>i</b>, Frequencies of T<sub>fh</sub> cells pre-treatment and on-treatment (C1D15, C2D1 and C4D1). For all cell populations shown, frequencies are out of parent population. Box plots show median and quartiles, and whiskers depict 95% CI. Individual patient values are shown in thin lines. Color depicts survival status at 1 year. <i>P</i> values for time series represent two-sided Wilcoxon signed-rank tests between time points, illustrating changes on-treatment (<b>c</b>) or survival groups at each time point (<b>f</b> and <b>i</b>). On Kaplan–Meier curves, median values were determined using all data across the three arms; <i>P</i> values are from a log-rank test between groups; and shaded regions illustrate 95% CI. Sample sizes for cell populations are shown (<b>c</b>, <b>f</b> and <b>i</b>): <i>n</i> = 26, 21, 25 and 19 biologically independent samples at C1D1, C1D15, C2D1 and C4D1, respectively.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01829-9/figures/3" data-track-dest="link:Figure3 Full size image" aria-label="Full size image figure 3" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>We identified 15 gene expression signatures that associated with survival (<i>P</i> &lt; 0.1) in the nivo/chemo arm and used unsupervised clustering to group patients by expression of these signatures to study associations with 1-year OS (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig9">4a</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">8</a>). Among these signatures, higher expression of genes associated with oxidative phosphorylation, fatty acid metabolism, xenobiotic metabolism and bile acid metabolism were associated with longer survival, whereas higher expression of TGF-β, TNF-α signaling via NFκB and IL6/JAK STAT3 gene signatures were associated with shorter survival (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig9">4a</a>). The association with TNF-α signaling via NFκB and survival was unique to the nivo/chemo arm (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig9">4b</a>). Patients with lower frequencies of tumor-infiltrating iNOS<sup>+</sup> macrophages also had longer survival after nivo/chemo (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig9">4c</a>). Higher frequencies of PD-L1<sup>+</sup> tumor cells had a weak association with more than 1-year survival (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">5</a>). Intratumoral metabolic gene expression signatures displayed a negative correlation with TGF- β and TNF-α signatures (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig9">4d</a>).</p><p>Multi-omic dimensionality reduction analysis of both circulating and tumor factors recapitulated these findings and revealed the primary axes of independent variance in the data, showing a separation between patients with survival &gt;1 year and &lt;1 year (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig9">4e</a>). Overall, patients with longer survival after nivo/chemo had lower pre-treatment immunosuppressive molecules and higher pre-treatment frequencies of activated, type-1 (Tbet<sup>+</sup>) T cells (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig9">4e</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">8</a>).</p><h3 class="c-article__sub-heading" id="Sec9">Correlates of survival benefit after sotiga/chemo</h3><p>We hypothesized that patients who experienced survival benefit after sotiga/chemo would have differentiating attributes of the APC compartment in circulation compared to patients who did not experience survival benefit based on earlier pre-clinical and clinical data<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Byrne, K. T. &amp; Vonderheide, R. H. CD40 stimulation obviates innate sensors and drives T cell immunity in cancer. Cell Rep. 15, 2719–2732 (2016)." href="/articles/s41591-022-01829-9#ref-CR10" id="ref-link-section-d71099090e2557">10</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Byrne, K. T. et al. Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer. Clin. Cancer Res. 27, 4574–4586 (2021)." href="/articles/s41591-022-01829-9#ref-CR17" id="ref-link-section-d71099090e2560">17</a></sup>. We used unsupervised clustering to identify multiple circulating DC subsets (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig4">4a</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">8</a>) associated with survival as measured before and after treatment with sotiga/chemo. After using manual gating to delineate these DC subsets, we found that patients with longer OS had higher pre-treatment frequencies of cross-presenting DCs (CD1c<sup>+</sup>CD141<sup>+</sup> DCs; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig4">4b</a>) and higher on-treatment frequencies of CD141<sup>+</sup> DCs, with reduced CD1c co-expression associated with longer survival (C1D15; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig4">4c,d</a>). Pre-treatment cross-presenting DCs had the greatest predictive value of the strongest circulating biomarkers in the sotiga/chemo arm in a combined multivariable survival model (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">4b</a>). Higher on-treatment (C2D1) frequencies of conventional DCs (cDCs; Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">6</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">7</a>) were also associated with longer survival (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig4">4e</a>). Furthermore, when circulating proteins associated with DC maturation were examined, higher on-treatment (C1D15) concentrations of soluble CD83 and soluble ICOSL associated with longer survival (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">7</a>). In addition, higher pre-treatment frequencies of circulating HLA-DR<sup>+</sup>CCR7<sup>+</sup> B cells associated with longer survival (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig10">5a,b</a>). Overall, patients with longer survival after sotiga/chemo treatment, in contrast to patients who survived longer following nivo/chemo, had higher pre-treatment frequencies of circulating DCs and B cells and DC phenotypic changes on-treatment.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-4" data-title="Cross-presenting, activated APCs and type-1 helper T cells in circulation associate with survival in patients receiving sotiga/chemo treatment."><figure><figcaption><b id="Fig4" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 4: Cross-presenting, activated APCs and type-1 helper T cells in circulation associate with survival in patients receiving sotiga/chemo treatment.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01829-9/figures/4" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig4_HTML.png?as=webp"><img aria-describedby="Fig4" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig4_HTML.png" alt="figure 4" loading="lazy" width="685" height="918"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-4-desc"><p><b>a</b>, Force-directed graph visualization of unsupervised clustering of cells from CyTOF across all patients and time points, with callout box of DC phenotypes associating with survival and followed up on with gating analysis in further panels. <b>b</b>–<b>f</b>, Kaplan–Meier curve for OS stratified by median values. <b>b</b>, Circulating CD1c<sup>+</sup> cross-presenting DCs (CD141<sup>+</sup>) at C1D1 <b>c</b>, Cross-presenting DCs (CD141<sup>+</sup>) at C1D15. <b>d</b>, CD1c<sup>−</sup> cross-presenting DCs (CD141<sup>+</sup>) at C1D15. cDCs at C2D1 (<b>e</b>) and pre-treatment PD-1<sup>+</sup>Tbet<sup>+</sup> non-naive CD4 T cells (<b>f</b>). <b>g</b>, Heat map of pre-treatment median fluorescence intensity of markers present on PD-1<sup>+</sup>Tbet<sup>+</sup> non-naive CD4 T cells. <b>h</b>, Frequencies of PD-1<sup>+</sup>Tbet<sup>+</sup> non-naive CD4 T cells pre-treatment (C1D1) and on-treatment (C1D15, C2D1 and C4D1), grouped by survival status at 1 year. <b>i</b>, Kaplan–Meier curves for OS stratified by frequency of pre-treatment Tbet<sup>+</sup>Eomes<sup>+</sup> non-naive CD4 T cells. <b>j</b>, Heat map of pre-treatment median fluorescence intensity of markers present on Tbet<sup>+</sup>Eomes<sup>+</sup> non-naive CD4 T cells. <b>k</b>, Frequencies of Tbet<sup>+</sup>Eomes<sup>+</sup> non-naive CD4 T cells pre-treatment (C1D1) and on-treatment (C1D15, C2D1 and C4D1), grouped by survival status at 1 year. For DC populations, frequencies are out of total leukocytes. For T cell populations, frequencies are out of parent. Box plots show median and quartiles, and whiskers depict 95% CI. Individual patient values are shown in thin lines and colored by survival status at 1 year. <i>P</i> values for time series represent two-sided Wilcoxon signed-rank tests between survival groups at each time point. On Kaplan–Meier curves, median values were determined using all data across the three arms; <i>P</i> values are from a log-rank test between groups; and shaded regions illustrate 95% CI. Sample sizes for cell populations (<b>a</b>−<b>e</b>): <i>n</i> = 29, 23, 24 and 22 biologically independent samples at C1D1, C1D15, C2D1 and C4D1, respectively. Sample sizes for cell populations are shown (<b>f</b>–<b>k</b>): <i>n</i> = 28, 23, 27 and 18 biologically independent samples at C1D1, C1D15, C2D1 and C4D1, respectively.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01829-9/figures/4" data-track-dest="link:Figure4 Full size image" aria-label="Full size image figure 4" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>Pre-treatment frequencies of some CD4 T cell populations also associated with survival benefit after sotiga/chemo treatment. Higher pre-treatment frequencies of circulating antigen-experienced (PD-1<sup>+</sup>Tbet<sup>+</sup>) non-naive CD4 T cells associated with longer survival (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig4">4f</a>). These cells co-expressed high levels of TCF-1 (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig4">4g</a>). Patients with &gt;1 year survival expressed numerically higher frequencies of this cellular phenotype on-treatment (C1D15 and C2D1) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig4">4h</a>). Additionally, type-1 helper (Tbet<sup>+</sup>Eomes<sup>+</sup>) non-naive CD4 T cells associated with longer survival (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig4">4i</a>). These cells co-expressed high levels of PD-1 (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig4">4j</a>). Patients with &gt;1 year survival expressed numerically higher frequencies of this cellular phenotype on-treatment (C2D1 and C4D1) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig4">4k</a>). Lower pre-treatment frequencies of circulating non-naive CD4 T cells expressing 2B4 also associated with longer survival (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig10">5c</a>). These cells co-expressed other molecules associated with exhausted or anti-inflammatory phenotypes (PD-1, CTLA-4 and LAG-3) and did not express Ki-67 (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig10">5d</a>). Additionally, the frequency of this phenotype increased on-treatment (C4D1) in circulation but did not remain associated with survival status (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig10">5e</a>). Overall, pre-treatment type-1 (Tbet<sup>+</sup>) CD4 T cells in circulation associated with survival benefit after sotiga/chemo, whereas higher levels of potentially dysfunctional 2B4<sup>+</sup> CD4 T cells were associated with shorter survival.</p><p>Patients with longer survival had a distinct CD4 helper T cell infiltrate in the tumor tissue lower immunosuppressive tumor gene expression signatures and frequencies of immune cell types associated with immune suppression. We identified nine gene expression signatures associated with survival (<i>P</i> &lt; 0.1) and used unsupervised clustering to group patients by expression of these signatures to study associations with 1-year OS (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig11">6a</a> and Supplementary Tables <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">8</a> and <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">9</a>). CD4 T cell gene expression signatures associated with longer survival included Th2, Th1 and IFN-γ response signatures (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig11">6a</a>). Higher expression of TGF-β, E2F signaling and glycolysis gene signatures was associated with shorter survival (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig11">6a</a>). The association between survival and higher expression of Th1 and IFN-γ response signaling signatures was specific to the sotiga/chemo arm (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig11">6b,c</a>). Similarly, the association observed between survival and lower expression of E2F signaling was unique to sotiga/chemo (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig11">6d</a>). In addition, patients with longer survival had higher frequencies of tumor-infiltrating non-proliferating (Ki-67<sup>−</sup>) conventional and regulatory (Foxp3<sup>+</sup>) CD4 T cells (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig11">6e</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">8</a>) and lower frequencies of infiltrating proliferating (Ki-67<sup>+</sup>) CD4 T cells (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">8</a>). Tumor-infiltrating proliferating conventional and regulatory CD4 T cells were positively correlated with increased E2F signaling as well as hypoxic and glycolytic gene signatures. In contrast, non-proliferative conventional and regulatory CD4 T cells positively correlated with CD4 helper immune gene signatures (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig11">6f</a>). Multi-omic dimensionality reduction analysis of both circulating and tumor factors at baseline showed that patients were separated by OS status in the reduced dimensional space, and this separation was driven by circulating CD4<sup>+</sup> T cells and immunosuppressive markers in the circulation and tumor-infiltrating macrophages (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig11">6g</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">8</a>).</p><p>Thus, pre-treatment biomarker profiles in both blood and tumor tissue that associated with survival benefit after sotiga/chemo and nivo/chemo treatment were distinct (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig5">5</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">8</a>). As all patients received chemotherapy, these potential predictive markers may not merely relate with prognosis or chemotherapy treatment. This conclusion is strengthened by the strong mechanistic relationship of each set of biomarkers to the PD-1 and CD40 axis.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-5" data-title="Biomarkers of survival after nivo/chemo and sotiga/chemo and their overlap."><figure><figcaption><b id="Fig5" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 5: Biomarkers of survival after nivo/chemo and sotiga/chemo and their overlap.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01829-9/figures/5" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig5_HTML.png?as=webp"><img aria-describedby="Fig5" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig5_HTML.png" alt="figure 5" loading="lazy" width="685" height="755"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-5-desc"><p>Venn diagrams of broad categories of circulating biomarkers (top). Left circle shows biomarkers of survival after nivo/chemo; right circle shows biomarkers of survival after sotiga/chemo; and center shows overlapping biomarkers that are associated with survival in both treatment groups. Color indicates direction of association, with blue for higher values associating with longer survival and red for higher values associating with shorter survival by log-rank test. The same structure is shown for tumor biomarkers (bottom).</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01829-9/figures/5" data-track-dest="link:Figure5 Full size image" aria-label="Full size image figure 5" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec10">Correlates of survival benefit after sotiga/nivo/chemo</h3><p>We found that, for sotiga/nivo/chemo, many biomarkers that associated with longer survival after sotiga/chemo and nivo/chemo individually were not predictive (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">8</a>). However, we identified several unique cell populations that were associated with longer survival after sotiga/nivo/chemo treatment, including lower frequencies of activated (CD38<sup>+</sup>) non-naive CD4 T cells (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig12">7a</a>). The CD38<sup>+</sup> non-naive CD4 T cell population co-expressed CCR7, TCF-1, CTLA-4, PD-1 and ICOS (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig12">7b</a>, left column). The frequency of this cellular phenotype numerically increased on-treatment but was not related to survival status (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig12">7c</a>). Similarly, lower frequencies of activated (CD38<sup>+</sup>) non-naive CD8 T cells were associated with longer survival (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig12">7d</a>). These cells co-expressed CCR7, PD-1, Tbet, Eomes, TCF-1 and 2B4 (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig12">7b</a>, right column). The frequency of these cells numerically increased on-treatment but was not related to survival status (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig12">7e</a>). Using unsupervised clustering analysis for discovery, followed by manual gating, we identified lower frequencies of CCR7<sup>+</sup>CD11b<sup>+</sup>CD27<sup>−</sup> B cells in circulation on-treatment (C1D15) associated with longer survival (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig13">8a</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">8</a>). No association between survival and CCR7<sup>+</sup>CD11b<sup>+</sup>CD27<sup>−</sup> B cells was observed in the nivo/chemo or sotiga/chemo arms. In the nivo/sotiga/chemo arm, these cells co-expressed CD40L, HLA-DR, CD11c and CD38 (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig13">8b</a>). On-treatment (C2D1 and C4D1), these cells did not associate with survival status (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig13">8c</a>). Collectively, these data suggest that higher frequencies of chronically activated T cells before treatment and on-treatment and the presence of CCR7<sup>+</sup>CD11b<sup>+</sup>CD27<sup>−</sup> B cells on-treatment relate to shorter survival after sotiga/nivo/chemo.</p></div></div></section><section data-title="Discussion"><div class="c-article-section" id="Sec11-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec11">Discussion</h2><div class="c-article-section__content" id="Sec11-content"><p>The non-randomized phase 1b portion of the PRINCE trial demonstrated that sotiga/chemo +/- nivo is tolerable, clinically active and a potential chemoimmunotherapy combination for this disease<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="O’Hara, M. H. et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 22, 118–131 (2021)." href="/articles/s41591-022-01829-9#ref-CR12" id="ref-link-section-d71099090e2933">12</a></sup>. In the randomized phase 2 portion of this study, modest OS increases were observed for the nivo/chemo and sotiga/chemo arms versus historical control, and only the nivo/chemo arm met the primary endpoint. Although the ORR of nivo/chemo was 50%, many of the responses had short duration and were not confirmed by a subsequent scan. A previous study of nivo/chemo failed to demonstrate clinical benefit in first-line therapy for patients with mPDAC<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Wainberg, Z. A. et al. Open-label, phase I study of nivolumab combined with nab-paclitaxel plus gemcitabine in advanced pancreatic cancer. Clin. Cancer Res. 26, 4814–4822 (2020)." href="/articles/s41591-022-01829-9#ref-CR18" id="ref-link-section-d71099090e2937">18</a></sup>. Acknowledging the limitations of cross-study comparisons, possible explanations for the contradictory results include our study having a larger proportion of patients with baseline PD-L1 &gt;1% (56% versus 30%), our prohibition of steroids as premedication with chemotherapy and ~1.5× higher chemotherapy exposure in our study. Post hoc subgroup analyses of OS did not reveal any imbalances in clinical characteristics to which the survival increases could be solely attributed. No clear benefit was observed for ORR or PFS in any arm. This study was not powered to compare between arms; therefore, we cannot conclude that sotiga/chemo is inferior to nivo/chemo. The data suggest that these treatment regimens are not appropriate for an all-comers mPDAC population but that a biomarker selection strategy may be warranted for future studies of both nivo/chemo and sotiga/chemo.</p><p>Our exploratory data on pharmacodynamic effects aligned with the expected mechanism of action of either PD-1 blockade or CD40 activation<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Filbert, E. L., Bjorck, P. K., Srivastava, M. K., Bahjat, F. R. &amp; Yang, X. APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application. Cancer Immunol. Immunother. 70, 1853–1865 (2021)." href="/articles/s41591-022-01829-9#ref-CR19" id="ref-link-section-d71099090e2944">19</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167–3175 (2010)." href="/articles/s41591-022-01829-9#ref-CR20" id="ref-link-section-d71099090e2947">20</a></sup>. Additionally, unique immune pharmacodynamic effects for nivo/chemo and sotiga/chemo were individually identified. These data indicate that the immune therapies evaluated here have distinct activity over and above the chemotherapeutic effect.</p><p>In addition to pharmacodynamic effects, we examined biomarkers associated with survival. This exploratory analysis demonstrated that patients with longer survival after nivo/chemo and sotiga/chemo can be identified by various predictive biomarkers from the circulation and tumor and that these predictive biomarkers are distinct for the two treatment arms. In the nivo/chemo arm, most circulating predictive biomarkers were T cell subsets. In particular, many subsets of antigen-experienced, type-1 (Tbet<sup>+</sup>) CD4 T cells before treatment were strongly predictive. In the tumor, gene expression signatures of immune suppression and metabolic state were predictive of shorter survival. In the sotiga/chemo arm, CD4 T cell, B cell and DC subsets were strongly associated with longer survival. The particular B cell subsets associated with survival align with the expected mechanism of the CD40 agonist and may relate to the presence of germinal centers<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21" title="Stebegg, M. et al. Regulation of the germinal center response. Front. Immunol. 9, 2469 (2018)." href="/articles/s41591-022-01829-9#ref-CR21" id="ref-link-section-d71099090e2956">21</a></sup>. Furthermore, the pre-treatment and on-treatment DC subsets observed to associate with survival suggest the benefit of stronger cross-presentation on-treatment, aligning with previous studies that have suggested that agonistic CD40 treatment induces cross-presenting DCs and may promote epitope spreading<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Cohn, L. et al. Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation. J. Exp. Med. 210, 1049–1063 (2013)." href="#ref-CR22" id="ref-link-section-d71099090e2960">22</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Haniffa, M. et al. Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity 37, 60–73 (2012)." href="#ref-CR23" id="ref-link-section-d71099090e2960_1">23</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24" title="Diamond, M. S., Lin, J. H. &amp; Vonderheide, R. H. Site-dependent immune escape due to impaired dendritic cell cross-priming. Cancer Immunol. Res. 9, 877–890 (2021)." href="/articles/s41591-022-01829-9#ref-CR24" id="ref-link-section-d71099090e2963">24</a></sup>. In the tumor, several pre-treatment gene expression signatures and immune cell population abundances associated with shorter survival, including many observed in preclinical KPC mouse models<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Li, J. et al. Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy. Immunity 49, 178–193 (2018)." href="/articles/s41591-022-01829-9#ref-CR25" id="ref-link-section-d71099090e2967">25</a></sup>.</p><p>A prospective study is needed to demonstrate that these biomarkers are truly predictive of survival with these regimens. Based on our data, T<sub>fh</sub> cells could make a good target for patient selection for nivo/chemo, as these cells are found in relatively high abundance and have the highest predictive value against all circulating biomarkers in the nivo/chemo arm. Baseline assessment of circulating CD4 T cells may provide the most tractable biomarker for patient selection for sotiga/chemo in subsequent studies. Several predictive biomarkers found in our study could inform mechanisms and future therapies for patients with mPDAC. Notably, unlike data reported from other solid cancers<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Sharma, P. et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc. Natl Acad. Sci. USA 104, 3967–3972 (2007)." href="#ref-CR26" id="ref-link-section-d71099090e2976">26</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109–1119 (2017)." href="#ref-CR27" id="ref-link-section-d71099090e2976_1">27</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Tokito, T. et al. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Eur. J. Cancer 55, 7–14 (2016)." href="#ref-CR28" id="ref-link-section-d71099090e2976_2">28</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Yang, Z. et al. Tumor-Infiltrating PD-1hiCD8+-T-cell signature as an effective biomarker for immune checkpoint inhibitor therapy response across multiple cancers. Front. Oncol. 11, 695006 (2021)." href="/articles/s41591-022-01829-9#ref-CR29" id="ref-link-section-d71099090e2979">29</a></sup>, circulating antigen-experienced CD8 T cells or infiltrating CD8 T cells were not associated with OS after either immunotherapy regimen. In contrast, the associations with survival were mainly observed with higher frequencies of circulating CD4 T cells before treatment. Furthermore, infiltrating T cells in all tumor samples were largely CD4 T cells, and, surprisingly, very few patients’ tumor samples had CD8 T cell infiltration. We hypothesize that the CD4 T cell compartment may have a critical role in response to chemoimmunotherapy treatment in mPDAC.</p><p>The sotiga/nivo/chemo arm did not demonstrate a meaningful improvement in the 1-year OS rate, and relatively few tumor and circulating immune biomarkers were associated with survival. In particular, biomarkers associated with longer survival in the sotiga/chemo and nivo/chemo monotherapy immunotherapy treatment arms were not relevant. In addition, many of the pharmacodynamic effects observed in the other two arms were somewhat attenuated in the sotiga/nivo/chemo arm, potentially indicative of a decreased or antagonistic effect when the dual immunotherapies and chemotherapy are used in combination. We hypothesize that this treatment resulted in systemic hyperactivation of the immune system, leading to a less functional immune state and, thus, decreased anti-tumor immunity. Indeed, a specific population of CD38<sup>+</sup> CD4 and CD8 T cells associated with shorter survival in response to sotiga/nivo/chemo treatment. The immunologic phenotype of these cells suggests that excessive T cell activation on-treatment could be leading to a terminally exhausted state<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Beltra, J. C. et al. Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity 52, 825–841 e828, (2020)." href="/articles/s41591-022-01829-9#ref-CR30" id="ref-link-section-d71099090e2989">30</a></sup>. Additionally, sotiga/nivo/chemo treatment led to increases in circulating CCR7<sup>+</sup>CD11b<sup>+</sup>CD27<sup>−</sup> B cells that tracked with shorter survival at two time points after treatment. The expression of CD11b on B cells has been associated with a tolerogenic or regulatory response in the lupus setting<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 31" title="Ding, C. et al. Integrin CD11b negatively regulates BCR signalling to maintain autoreactive B cell tolerance. Nat. Commun. 4, 2813 (2013)." href="/articles/s41591-022-01829-9#ref-CR31" id="ref-link-section-d71099090e3000">31</a></sup> and is postulated to have a dampening effect on anti-tumor immunity. Preclinical work in glioma has suggested that agonistic CD40 impairs response to PD-1 blockade in part through the induction of regulatory B cells<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="van Hooren, L. et al. Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma. Nat. Commun. 12, 4127 (2021)." href="/articles/s41591-022-01829-9#ref-CR32" id="ref-link-section-d71099090e3004">32</a></sup>. Thus, we hypothesize that regulatory B cells could contribute to suppressed immunity after the dual immunotherapy combination in mPDAC. However, mechanistic studies need to be conducted to further understand these findings and how B cells potentially affect anti-tumor immune responses and durable clinical benefit in the mPDAC setting.</p><p>One inherent limitation of this study design is the intentional omission of a chemotherapy control arm, which accelerated enrollment of patients unwilling to be randomized to control chemotherapy arms but, analytically, hampers our ability to assess the survival benefit against contemporaneous control patients. Although we benchmarked OS against the initial, definitive study of gemcitabine/nab-paclitaxel, a subsequent phase 3 study reported a higher 1-year OS rate of approximately 40–45%<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33" title="Tempero, M. et al. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Ann. Oncol. 32, 600–608 (2021)." href="/articles/s41591-022-01829-9#ref-CR33" id="ref-link-section-d71099090e3011">33</a></sup>. Second, this study enrolled patients across a small number of tertiary care cancer centers. To assess whether this introduced bias, we generated a synthetic control arm of patients receiving chemotherapy from PRINCE’s top enrolling sites who met this study’s inclusion and exclusion criteria and observed a 45% 1-year OS rate<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Lyman, J. P. et al. Feasibility and utility of synthetic control arms derived from real-world data to support clinical development. J. Clin. Oncol. 40, 528 (2022)." href="/articles/s41591-022-01829-9#ref-CR34" id="ref-link-section-d71099090e3015">34</a></sup>. These updated rates are still numerically smaller than the 1-year OS observed for nivo/chemo and sotiga/chemo, suggesting that the addition of nivo or sotiga may provide additional clinical benefit. Regarding the translational analyses, a chemotherapy control arm will eventually be needed to ensure that the identified biomarkers are truly predictive of an immunotherapy response. However, very few biomarkers are overlapping between the arms, suggesting that the identified biomarkers are related to a specific immunotherapy response rather than a chemotherapy response.</p><p>The phase 1b/2 PRINCE trial leveraged a unique study design, relatively rapid enrollment<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Upadhaya, S. et al. Combinations take centre stage in PD1/PDL1 inhibitor clinical trials. Nat. Rev. Drug Discov. 20, 168–169 (2021)." href="/articles/s41591-022-01829-9#ref-CR35" id="ref-link-section-d71099090e3022">35</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 36" title="Tang, J. et al. Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat. Rev. Drug Discov. 17, 854–855 (2018)." href="/articles/s41591-022-01829-9#ref-CR36" id="ref-link-section-d71099090e3025">36</a></sup>, centralized sample processing and multi-omic profiling to generate a sizable clinical–translational dataset to identify potential mechanisms of response and resistance to chemoimmunotherapy regimens in mPDAC. Our findings do not support additional trials testing these chemoimmunotherapy combinations in an all-comer mPDAC population because only a subset of patients is likely to realize the full benefits of these regimens. Rather, as a first step toward characterizing which patients derive clinical benefit, we have identified here potential biomarkers that can now be tested prospectively to determine if this allows for minimally invasive biomarker-enrichment designs for chemoimmunotherapy treatment in mPDAC.</p></div></div></section><section data-title="Methods"><div class="c-article-section" id="Sec12-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec12">Methods</h2><div class="c-article-section__content" id="Sec12-content"><h3 class="c-article__sub-heading" id="Sec13">Study design and safety monitoring</h3><p>In this phase 1b/2 study, patients 18 years of age or older with mPDAC were enrolled from seven academic hospitals in the United States that are part of the Parker Institute for Cancer Immunotherapy pancreas cancer consortium. Inclusion and exclusion criteria were identical for the phase 1b and phase 2 portions of the study. Prior treatment for metastatic disease was not allowed, although prior adjuvant and neoadjuvant chemo/radiotherapy was allowed if completed &gt;4 months before enrollment. Patients were required to have archival or fresh tumor specimens available before treatment or be able to undergo a biopsy to acquire tissue. Additional key eligibility criteria included ECOG performance status score of 0–1, adequate organ function and the presence of at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Patients were excluded if they had previous exposure to agonistic CD40, anti-PD-1, anti-PD-L1 monoclonal antibodies or any other immunomodulatory anti-cancer agent. Patients were also excluded if they had ongoing or recent autoimmune disease requiring systemic immunosuppressive therapy, had undergone solid organ transplantation or had a concurrent cancer, unless indolent or not considered to be life-threatening (for example, basal cell carcinoma).</p><p>The phase 1b trial was a non-randomized, open-label, multi-center, four-cohort, dose-ranging study that aimed to identify the recommended phase 2 dose (RP2D) of anti-CD40 sotigalimab (sotiga) in combination with chemotherapy (gemcitabine (gem) and nab-paclitaxel (NP)), with or without anti-PD1 nivolumab (nivo)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="O’Hara, M. H. et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 22, 118–131 (2021)." href="/articles/s41591-022-01829-9#ref-CR12" id="ref-link-section-d71099090e3044">12</a></sup>. The phase 2 trial was a randomized, open-label, multi-center, three-arm study of chemotherapy combined with nivo, sotiga or both immune modulating agents.</p><p>An RP2D of 0.3 mg kg<sup>−1</sup> of sotiga was defined during the phase 1b portion of the study by a data review team (DRT) comprised of investigators and sponsor clinical staff. During phase 2, the DRT met to review all safety data for each study arm on a quarterly basis. A Bayesian termination rule was employed to monitor toxicity and determine whether enrollment or dosing in a study arm(s) needed to be halted. A minimally informative beta (0.5, 2.5) prior was assumed. For each treatment arm, if the number of patients with an unacceptable toxicity (as defined in Section 6.1 of the Study Protocol) was greater than or equal to the number provided in Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">19</a> of the study protocol, then termination of that particular treatment arm would be considered, as it is likely that the true toxicity rate is over 30%, as noted by Bayesian posterior probabilities. This rule was intentionally conservative early in the enrollment phase.</p><p>The protocol and all amendments were approved by the lead institutional review board at the University of Pennsylvania and were accepted at all participating sites. The study was conducted in accordance with the principles of the Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice guidelines. All patients provided written informed consent before enrollment. The Study Protocol and Statistical Analysis Plan are available as part of the Supplementary Information.</p><h3 class="c-article__sub-heading" id="Sec14">Randomization and blinding</h3><p>The phase 2 trial was open label with no blinding. Patients were randomly assigned to one of three arms: nivo/chemo, sotiga/chemo or sotiga/nivo/chemo. Twelve DLT-evaluable patients (six each on sotiga/chemo and sotiga/nivo/chemo) from the non-randomized phase 1b study were included in analyses of phase 2 efficacy (see the ‘Statistical analysis’ section for details on analysis population definitions). To achieve balance in the total number of patients enrolled in each arm, the first 12 patients enrolled in phase 2 were randomly allocated in a 4:1:1 ratio to nivo/chemo, sotiga/chemo or sotiga/nivo/chemo, respectively (because nivo/chemo did not accrue patients in phase 1b, more patients needed to be enrolled in that arm). The remaining patients were randomly allocated in a 1:1:1 ratio. Randomization was managed by the Parker Institute for Cancer Immunotherapy using an interactive voice/web response system (IxRS). A permuted block design, without stratification by baseline patient or tumor characteristics, was used for randomization. Patients who were randomized but did not receive any study drug were replaced via randomization of additional patients.</p><h3 class="c-article__sub-heading" id="Sec15">Procedures</h3><p>For each 28-day cycle, gem/NP at 1,000 mg m<sup>−</sup><sup>2</sup> and 125 mg m<sup>−</sup><sup>2</sup>, respectively, were administered intravenously on days 1, 8 and 15 for each arm. Nivo was administered at 240 mg intravenously on days 1 and 15. Sotiga was administered at 0.3 mg kg<sup>−1</sup> intravenously on day 3, 2 days after chemotherapy. Alternatively, sotiga could be administered on day 10 if not administered on day 3, provided patients received chemotherapy on day 8. Investigators were also given the option to use 21-day chemotherapy cycles, in which case the day 15 dose was not administered. Up to two dose reductions were permitted for sotiga and gem, and up to three dose reductions were permitted for NP for management of toxicity. Nivo was allowed to be withheld, but dose reductions were not permitted. A maximum interruption of 4 weeks was permitted per protocol before study discontinuation was required.</p><p>Patients were assessed radiographically every 8 weeks for the first year and every 3 months thereafter, regardless of dose delays. Disease assessments were collected until radiographic progression or initiation of subsequent therapy, whichever occurred first. Patients were subsequently followed for survival. Safety assessments included vital signs, physical examinations, electrocardiograms and laboratory tests. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. Adverse event terms were coded using the Medical Dictionary for Regulatory Activities version 23.0.</p><p>Blood samples for isolation of PBMCs were collected longitudinally at participating clinical sites, shipped overnight and processed at a central location (Infinity Biologix) over a Ficoll gradient and cryopreserved. Serum was processed within 2 hours of collection at each site and frozen immediately at −80 °C and then batch shipped to a central biorepository. Blood sampling for immune biomarkers occurred during screening, at cycle 1 days 1 and 15, at cycles 2–4 day 1 and at treatment discontinuation. If a patient began any new anti-cancer therapy before their end-of-treatment visit, samples were not collected. For patients who remained on treatment for at least 1 year, blood was collected at 1 year and every 6 months thereafter.</p><p>Baseline or archival as well as post-treatment tumor specimens were collected for biomarker analyses. Fresh tumor biopsies were immediately snap-frozen or formalin-fixed and paraffin-embedded (FFPE). Any medically feasible post-treatment tumor samples were accepted; however, the preference was for a sample during cycle 2, after the second dose of sotiga or third dose of nivo depending on the assigned treatment arm. Additional biopsies were allowed for patients who had prolonged stable disease, defined as more than two consecutive disease assessments demonstrating response via RECIST version 1.1 as well as at the time of disease progression. Ad hoc biopsy collection was permitted with the approval of the medical monitor.</p><h3 class="c-article__sub-heading" id="Sec16">Outcomes</h3><p>The primary endpoint was the 1-year OS rate of each treatment arm, compared to the historical rate of 35% for gem/NP<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691–1703 (2013)." href="/articles/s41591-022-01829-9#ref-CR13" id="ref-link-section-d71099090e3100">13</a></sup>. Secondary endpoints were PFS, DOR, ORR, DCR and the incidence of adverse events. Key exploratory endpoints included the evaluation of immune pharmacodynamic effects and tumor and immune biomarker analyses.</p><h3 class="c-article__sub-heading" id="Sec17">Statistical analysis of clinical data</h3><p>Efficacy analyses were conducted on the efficacy population, defined as (1) all patients who were randomized in phase 2 and received at least one dose of any study drug and (2) the 12 DLT-evaluable patients (six on sotiga/chemo and six on sotiga/nivo/chemo; defined as experiencing a DLT or receiving at least two doses of chemotherapy and one dose of sotiga during cycle 1) who were enrolled at the RP2D in phase 1b<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="O’Hara, M. H. et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 22, 118–131 (2021)." href="/articles/s41591-022-01829-9#ref-CR12" id="ref-link-section-d71099090e3113">12</a></sup>. For efficacy analyses, patients were grouped according to the treatment arm assigned at randomization. Safety analysis was conducted on all phase 1b (DLT-evaluable and non-DLT-evaluable) and phase 2 patients who received at least one dose of any study drug at the RP2D (defined as the safety population). For safety analyses, patients were grouped according to the study treatment actually received (that is, ‘as treated’). Specifically, two phase 2 patients were randomly allocated to sotiga/nivo/chemo but only received doses of chemotherapy and nivo (that is, sotiga was not received); these patients were grouped as sotiga/nivo/chemo for efficacy analyses (that is, the arm assigned at randomization) and as nivo/chemo for safety and biomarker analyses (that is, using an ‘as treated’ approach).</p><p>This study did not include a control arm of gem/NP (chemotherapy). Therefore, the 1-year OS rate for each arm was estimated and compared to a historical value of 35%<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691–1703 (2013)." href="/articles/s41591-022-01829-9#ref-CR13" id="ref-link-section-d71099090e3120">13</a></sup>. This study was not powered for statistical comparison between arms, and no adjustment for multiple comparisons was performed for the clinical endpoints.</p><p>OS was defined as the time from treatment initiation until death from any cause. Patients who were not reported as having died at the time of analysis were censored at the most recent contact date. OS and the 1-year OS rate were estimated by the Kaplan–Meier method for each treatment arm. The 1-year OS rate and corresponding one-sided, 95% CI were calculated to determine whether the lower bound of the CI excluded the assumed historical value of 35%. <i>P</i> values were calculated using a one-sided, one-sample <i>z-</i>test of the Kaplan–Meier estimate of the 1-year OS rate (and its standard error) against the historical rate of 35%. The null hypothesis was a 1-year OS rate of 35%, and the alternative hypothesis was a 1-year OS rate of 55%. Planned enrollment was 105 patients (35 per arm), which included 12 DLT-evaluable patients from the non-randomized phase 1b. A sample size of 35 patients per arm provided 81% power to test this hypothesis, using a one-sample <i>z-</i>test with a one-sided 5% type I error rate.</p><p>ORR was defined as the proportion of patients with an investigator-assessed partial response (PR) or complete response (CR) per RECIST version 1.1—confirmation of response was not required. DCR was the proportion of patients with a PR, CR or stable disease lasting at least 7 weeks as best response; DOR was the time from the first tumor assessment demonstrating response until the date of radiographic disease progression; and PFS was the time from treatment initiation until radiographic disease progression or death (whichever occurred first). CIs for ORRs were calculated using the Clopper–Pearson method. The Kaplan–Meier method was used to estimate DOR and PFS and the corresponding CIs. Safety and tolerability were summarized descriptively in terms of adverse events. Statistical analyses were performed using R version 4.1.0 or higher.</p><h3 class="c-article__sub-heading" id="Sec18">Interim analysis</h3><p>Two pre-specified interim analyses (IAs) of phase 2 clinical data were performed. These IAs were strictly meant to support decision marking for future studies. No adaptations to the study design or conduct, including termination due to lack of efficacy, were planned based on the interim results, and no control of type I error was applied for any of the endpoints at the interim or final analysis. The IAs were performed by the Parker Institute for Cancer Immunotherapy, and results were shared with the study investigators and pharmaceutical partners (Apexigen and Bristol Myers Squibb).</p><p>The first IA occurred approximately 4 months after the last patient was randomized in phase 2, and the second IA occurred approximately 9 months after the last patient was randomized. Both IAs assessed safety and all efficacy endpoints (ORR, DCR, DOR, OS and PFS) for patients enrolled in phase 1b. In addition, the first IA included phase 2 analysis of ORR and DCR, and the second IA included phase 2 analysis of all efficacy endpoints excluding OS (that is, ORR, DCR, DOR and PFS). Phase 2 OS data were not analyzed during any IA.</p><h3 class="c-article__sub-heading" id="Sec19">Immunophenotyping by CyTOF</h3><p>A broad immunophenotyping panel was used on cryopreserved PBMCs by CyTOF analysis run under uniform protocols (PMID: 31315057) at Primity Bio in a blinded fashion. Cryopreserved PBMCs were thawed in 37 °C pre-warmed RPMI-1640 containing 10% FBS and 25 U ml<sup>−1</sup> of benzonase. Samples were washed once more in RPMI-1640 containing 10% FBS and 25 U ml<sup>−1</sup> of benzonase and a third time in 37 °C pre-warmed RPMI-1640 containing 10% FBS. Samples were resuspended in 1,000 nM of cisplatin for viability discrimination, prepared in PBS containing 0.1% BSA, for 5 minutes at room temperature, and then washed with staining buffer. Human BD Fc block was added to the cells for 10 minutes at 4 °C, followed by the surface antibody cocktail. The surface staining cocktail was incubated for 30 minutes at 4 °C. Samples were washed out of the stain twice with staining buffer. The cells were then resuspended in FoxP3 Transcription Factor 1× Fix/Perm buffer (eBioscience) for 1 hour at room temperature to prepare the cells for intracellular staining. The fixation was then followed by a wash in 1× permeabilization buffer. The intracellular staining cocktail was prepared in the permeabilization buffer and added to the samples and incubated at room temperature for 1 hour. After the intracellular stain, the samples were washed twice with the permeabilization buffer and once with staining buffer. Before acquisition on the CyTOF, samples were resuspended in an iridium-intercalating solution for at least 24 hours and stored at 4 °C. On the day of acquisition, the samples were washed five times in cell culture grade water (HyClone) and run on the CyTOF Helios instrument (Fluidigm). Details on the CyTOF panel are displayed in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">10</a>. Data were analyzed using CellEngine version 1 cloud-based flow cytometry analysis software (CellCarta).</p><p>Supervised gating was performed manually by a scientist without reference to clinical outcome. High-level gates were tailored per sample. Single marker gates were drawn uniformly for analysis across patients and time points, with example gating strategy provided in Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">6</a>.</p><p>After gating for live singlets, immune populations were defined as follows, as shown in Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">6</a>. CD4 and CD8 T naive, effector and memory populations were identified based on CD45RA, CD27 and CCR7 expression. Tregs were identified based on Foxp3, CD25 and CD127 expression. B cells were identified based on CD19 expression and further distinguished into memory versus naive versus plasmablast based on expression of CD38 versus CD27. NK cells were identified based on CD56 expression and further subdivided based on CD56 versus CD16 expression. Monocytes were identified based on expression of CD14 and HLA-DR and further subdivided in classical, non-classical and intermediate based on the expression of CD14 versus CD16. DCs were defined as HLA-DR<sup>+</sup>CD14<sup>−</sup>CD16<sup>−</sup> non-lymphocytes and further distinguished between myeloid and plasmacytoid based on expression of CD11c versus CD123, respectively. Myeloid DCs were further subdivided on the basis of CD141 expression into cDCs type 1 (cDC1; CD141<sup>+</sup>) and conventional DCs type 2 (cDC2; CD141<sup>−</sup>).</p><p>In addition to manual gating of defined populations, data were analyzed in an unsupervised fashion. To do this, all samples for all patients and all time points were combined together and run through a clustering algorithm<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 37" title="Hartmann, F. J. et al. Comprehensive immune monitoring of clinical trials to advance human immunotherapy. Cell Rep. 28, 819–831 (2019)." href="/articles/s41591-022-01829-9#ref-CR37" id="ref-link-section-d71099090e3191">37</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 38" title="Spitzer, M. H. et al. IMMUNOLOGY. An interactive reference framework for modeling a dynamic immune system. Science 349, 1259425 (2015)." href="/articles/s41591-022-01829-9#ref-CR38" id="ref-link-section-d71099090e3194">38</a></sup>. After clustering, clusters were visualized using a force-directed graph layout<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 37" title="Hartmann, F. J. et al. Comprehensive immune monitoring of clinical trials to advance human immunotherapy. Cell Rep. 28, 819–831 (2019)." href="/articles/s41591-022-01829-9#ref-CR37" id="ref-link-section-d71099090e3198">37</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 38" title="Spitzer, M. H. et al. IMMUNOLOGY. An interactive reference framework for modeling a dynamic immune system. Science 349, 1259425 (2015)." href="/articles/s41591-022-01829-9#ref-CR38" id="ref-link-section-d71099090e3201">38</a></sup> and colored by association with OS. Using this visualization, clusters of interest were identified, and then the relevant populations were added to the manual gating hierarchy. All time series and survival analyses shown in the results are derived from gated populations, whether discovered by manual gating or unsupervised analysis.</p><p>Optimized concentrations/dilutions for antibodies used in CyTOF experiments were: CD45, CD3, CD19, CD117, CD11b, CD4, CD8a, CD11c, CD14, FcER1, CD123, gdTCR, CD45RA, CD366, CD274, CD27, Tbet, CD152, FoxP3, CD33, CD45RO, CD127, CD197, Ki-67, CD25, TCRVa24-Ja18, CD38, HLA-DR, CD56 and CD16 (all used at 1:100 per the manufacturer’s recommendation); CD66d, 3 µg ml<sup>−1</sup>; CD7, 3 µg ml<sup>−1</sup>; CD86, 6 µg ml<sup>−1</sup>; CD1c, 3 µg ml<sup>−1</sup>; CD64, 6 µg ml<sup>−1</sup>; CD206, 3 µg ml<sup>−1</sup>; CD141, 3 µg ml<sup>−1</sup>; CD154, 3 µg ml<sup>−1</sup>; CD40, 1.5 µg ml<sup>−1</sup>; CD192, 6 µg ml<sup>−1</sup>; nivolumab, 1 µg ml<sup>−1</sup>; and anti-human IgG4, 1 µg ml<sup>−1</sup>.</p><p>Sample sizes for all cell populations identified through CyTOF analysis (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig4">4a-e</a> and Extended Data Figs. 3b, <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig10">5a,b</a> and <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig13">8a–c</a>) are listed as follows: nivo/chemo: C1D1 (<i>n</i> = 25), C1D15 (<i>n</i> = 20), C2D1 (<i>n</i> = 23) and C4D1 (<i>n</i> = 13); sotiga/chemo: C1D1 (<i>n</i> = 29), C1D15 (<i>n</i> = 23), C2D1 (<i>n</i> = 24) and C4D1 (<i>n</i> = 22); and sotiga/nivo/chemo: C1D1 (<i>n</i> = 26), C1D15 (<i>n</i> = 20), C2D1 (<i>n</i> = 26) and C4D1 (<i>n</i> = 13).</p><h3 class="c-article__sub-heading" id="Sec20">High-parameter flow cytometry of T lymphocytes</h3><p>Cryopreserved PBMC samples for fluorescent flow cytometry were analyzed in the Translational Cytometry Laboratory of the Penn Cytomics and Cell Sorting Shared Resource (University of Pennsylvania) on an extensively pre-qualified 28-color BD Symphony A5 cytometer (BD Biosciences). Staff were blinded to treatment arm and clinical outcome. At the time of analysis, cryopreserved PBMC samples were thawed in 37 °C pre-warmed RPMI-1640 medium (Gibco) containing 10% FBS and 100 U ml<sup>−1</sup> of penicillin–streptomycin (Gibco). Samples were washed, counted and resuspended in medium containing 1 mg ml<sup>−1</sup> of DNase I (Roche) and 5 mM magnesium chloride and incubated at 37 °C for 1 hour. After resting, cells were washed with PBS without additives (Corning) and transferred to staining tubes. PBMCs were incubated with 1 ul (0.2 µg) of 0.2 mg ml<sup>−1</sup> of nivolumab antibody (Selleck Chemicals) for 5 minutes at room temperature, followed by the addition of a Fixable Viability Stain 510 for 10 minutes at room temperature in the dark. Cells were then washed twice with FACS wash buffer (PBS, 1% BSA, 2 mM EDTA). A surface antibody cocktail (T cell phenotyping antibody panel; Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">11</a>) was prepared daily and used to stain up to 1 × 10<sup>7</sup> cells per tube. Cells were incubated for 20 minutes at room temperature, followed by washing twice with FACS staining buffer. The cells were resuspended in FoxP3 Transcription Factor Staining Buffer Fix/Perm solution (eBiosciences) and incubated for 1 hour at room temperature to prepare the cells for intracellular staining. After fixation, the samples were washed with Foxp3 permeabilization buffer. A freshly prepared cytoplasmic/intracellular staining cocktail master mix was added to the samples and incubated overnight at 4 °C. The next day, the samples were washed with permeabilization buffer and resuspended in FACS wash buffer. Cells were stored at 4 °C in the dark and acquired within 2 hours. After daily quality control, the instrument was standardized by setting hard dyed beads (BD Biosciences, Cytometer Setup and Tracking Beads (CS&amp;T)) to predetermined target channels. Compensation controls (Invitrogen UltraComp eBeads or cells for Live/Dead stain) were prepared daily along with a frozen PBMC process control. The compensation matrix was calculated in Diva software (BD Biosciences) and used only for that day’s run. Data were analyzed using CellEngine cloud-based flow cytometry analysis software. High-level gates were tailored per patient across all time points by at least two investigators blinded to patient outcome. Single marker gates were drawn uniformly for analysis across patients and time points, with representative gating strategy provided in Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">2</a>.</p><p>After gating for live cells and the CD3<sup>+</sup> population, T cell populations were defined as following, as shown in Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">2</a>. A combination of CD45RA, CD27 and CCR7 expression on CD4<sup>+</sup> and CD8<sup>+</sup> T cells was used to define naive (CD45RA<sup>+</sup>CD27<sup>+</sup>CCR7<sup>+</sup>), T central memory (CM; CD45RA<sup>−</sup>CD27<sup>+</sup>CCR7<sup>+</sup>), T effector memory 1 (EM1; CD45RA<sup>−</sup>CD27<sup>+</sup>CCR7<sup>−</sup>), T effector memory 2 (EM2; CD45RA<sup>−</sup>CD27<sup>−</sup>CCR7<sup>+</sup>), T effector memory 3 (EM3; CD45RA<sup>−</sup>CD27<sup>−</sup>CCR7<sup>−</sup>) and terminally differentiated effector memory (TEMRA) (CD45RA<sup>+</sup>CD27<sup>−</sup>CCR7<sup>–</sup>) subpopulations. CD4<sup>+</sup> regulatory T cells were defined as Foxp3<sup>+</sup>CD25<sup>hi</sup>CD127<sup>−/low</sup>. The non-naive CD4<sup>+</sup> and CD8<sup>+</sup> T cell populations used in time series and survival analyses included the defined EM, CM and TEMRA populations defined above. Expression of additional differentiation, activation and inhibitory markers were evaluated within each of these compartments.</p><p>In addition to manual gating of defined populations, data were analyzed in an unsupervised fashion. To do this, all samples for all patients and all time points were combined together and run through a clustering algorithm<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 37" title="Hartmann, F. J. et al. Comprehensive immune monitoring of clinical trials to advance human immunotherapy. Cell Rep. 28, 819–831 (2019)." href="/articles/s41591-022-01829-9#ref-CR37" id="ref-link-section-d71099090e3375">37</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 38" title="Spitzer, M. H. et al. IMMUNOLOGY. An interactive reference framework for modeling a dynamic immune system. Science 349, 1259425 (2015)." href="/articles/s41591-022-01829-9#ref-CR38" id="ref-link-section-d71099090e3378">38</a></sup>. After clustering, clusters were visualized using a force-directed graph layout<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 37" title="Hartmann, F. J. et al. Comprehensive immune monitoring of clinical trials to advance human immunotherapy. Cell Rep. 28, 819–831 (2019)." href="/articles/s41591-022-01829-9#ref-CR37" id="ref-link-section-d71099090e3382">37</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 38" title="Spitzer, M. H. et al. IMMUNOLOGY. An interactive reference framework for modeling a dynamic immune system. Science 349, 1259425 (2015)." href="/articles/s41591-022-01829-9#ref-CR38" id="ref-link-section-d71099090e3385">38</a></sup> and colored by association with OS. Using this visualization, clusters of interest were identified, and then the relevant populations were added to the manual gating hierarchy. All time series and survival analyses shown in the results are derived from gated populations, whether discovered by manual gating or unsupervised analysis.</p><p>Optimized concentrations/dilutions for antibodies used in the high-parameter flow cytometry experiments were: CD45RA, 1:200; CD8a, 1:160; CD185, 1:400; CD25, 1:200; CD226, 1:65; CD27, 1:500; CD4, 1:800; CD197, 1:40; CD223, 1:100; CD14, 1:40; CD19, 1:160; CD41a, 1:260; CD3, 1:65; CD137, 1:100; CD244, 1:20; CD366, 1:200; CD39, 1:100; CD28, 1:100; CD278, 1:100; CD127, 1:160; CD38, 1:160; TIGIT, 1:40; Eomes, 1:100; CD152, 1:400; FoxP3, 1:400; T-bet, 1:600; TCF1, 1:125; Ki-67, 1:600; KLRG1, 1:100; nivolumab, 1 mg ml<sup>−1</sup>; and anti-human IgG4, 1:200.</p><p>Sample sizes for all cell populations identified through X50 analysis (Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig2">3a-i</a> and <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig5">4f–k</a>, Supplementary Figs. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">1c and 3a-c</a> and Extended Data Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig9">3a</a>, <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig10">5c–e</a> and <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig12">7a–e</a>) are listed as follows: nivo/chemo: C1D1 (<i>n</i> = 26), C1D15 (<i>n</i> = 21), C2D1 (<i>n</i> = 25) and C4D1 (<i>n</i> = 19); sotiga/chemo: C1D1 (<i>n</i> = 28), C1D15 (<i>n</i> = 23), C2D1 (<i>n</i> = 27) and C4D1 (<i>n</i> = 18); sotiga/nivo/chemo: C1D1 (<i>n</i> = 32), C1D15 (<i>n</i> = 27), C2D1 (<i>n</i> = 29) and C4D1 (<i>n</i> = 14).</p><h3 class="c-article__sub-heading" id="Sec21">Serum proteomics profiling</h3><p>Serum proteins were quantified using Olink multiplex proximity extension assay (PEA) panels (Olink Proteomics, <a href="http://www.olink.com">www.olink.com</a>) according to the manufacturer’s instructions<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 39" title="Assarsson, E. et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE 9, e95192 (2014)." href="/articles/s41591-022-01829-9#ref-CR39" id="ref-link-section-d71099090e3470">39</a></sup>. The assay was performed at the Olink Analysis Service Center. The basis of PEA is a dual-recognition immunoassay, where two matched antibodies labelled with unique DNA oligonucleotides simultaneously bind to a target protein in solution. This brings the two antibodies into proximity, allowing their DNA oligonucleotides to hybridize, serving as template for a DNA polymerase-dependent extension step. This creates a double-stranded DNA ‘barcode’ that is unique for the specific antigen and quantitatively proportional to the initial concentration of target protein. The hybridization and extension are immediately followed by PCR amplification, and the amplicon is then finally quantified by microfluidic qPCR using the Fluidigm BioMark HD system (Fluidigm). Data were normalized using internal controls in every single sample, inter-plate control and negative controls and correction factor and expressed as log<sub>2</sub> scale, which is proportional to the protein concentration. The final assay readout is reported as normalized protein expression (NPX) values, which is an arbitrary unit on a log<sub>2</sub> scale where a higher value corresponds to a higher protein expression. One NPX difference equals to the doubling of the protein concentration. In this study, two Olink panels (Target96 Immuno-Oncology and Target96 Immune Response) were used, which consist of 172 unique analytes. Additional details about the analytes, detection range, data normalization and standardization are available at <a href="https://www.olink.com/resources-support/document-download-center/">https://www.olink.com/resources-support/document-download-center/</a>.</p><p>Sample sizes for all soluble proteins identified through targeted Olink platforms (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig8">3e,h</a> and Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">7a,b</a>) are listed as follows: nivo/chemo: C1D1 (<i>n</i> = 32), C1D15 (<i>n</i> = 25), C2D1 (<i>n</i> = 27), C3D1 (<i>n</i> = 25) and C4D1 (<i>n</i> = 23); sotiga/chemo: C1D1 (<i>n</i> = 36), C1D15 (<i>n</i> = 29), C2D1 (<i>n</i> = 31), C3D1 (<i>n</i> = 25) and C4D1 (<i>n</i> = 27); sotiga/nivo/chemo: C1D1 (<i>n</i> = 35), C1D15 (<i>n</i> = 27), C2D1 (<i>n</i> = 32), C3D1 (<i>n</i> = 26) and C4D1 (<i>n</i> = 25).</p><h3 class="c-article__sub-heading" id="Sec22">Whole-exome and transcriptome sequencing</h3><p>FFPE tumor and normal PBMC samples were profiled using ImmunoID NeXT (Personalis)—an augmented exome/transcriptome platform and analysis pipeline that produces comprehensive tumor mutation information, gene expression quantification, neoantigen characterization, HLA typing and allele-specific HLA loss-of-heterozygosity data (HLA LOH), TCR repertoire profiling and TME profiling. Whole-exome library preparation and sequencing were performed by Personalis as a service using augmented exome sequencing<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 40" title="Patwardhan, A. et al. Achieving high-sensitivity for clinical applications using augmented exome sequencing. Genome Med. 7, 71 (2015)." href="/articles/s41591-022-01829-9#ref-CR40" id="ref-link-section-d71099090e3549">40</a></sup>. DNA extracted from tumor and PBMCs was used to generate whole-exome capture libraries using the KAPA HyperPrep Kit and Agilent’s SureSelect Target Enrichment Kit, according to manufacturer recommendations, with the following amendments. (1) Target probes were used to enhance coverage of biomedically and clinically relevant genes. (2) Protocols were modified to yield an average library insert length of approximately 250 base pairs. And (3) KAPA HiFi DNA Polymerase (Kapa Biosystems) was used in place of Herculase II DNA polymerase (Agilent). Paired-end sequencing was performed on NovaSeq instrumentation (Illumina).</p><p>Whole-transcriptome sequencing results were aligned using STAR<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 41" title="Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013)." href="/articles/s41591-022-01829-9#ref-CR41" id="ref-link-section-d71099090e3556">41</a></sup>, and normalized expression values in transcripts per million (TPM) were calculated using the ImmunoID NeXT tool, Expressionist (Personalis). For RNA sequencing and alignment quality control, the following metrics were evaluated: average read length, average mapped read pair length, percentage of uniquely mapped reads, number of splice sites, mismatch rate per base, deletion/insertion rate per base, mean deletion/insertion length and anomalous read pair alignments, including inter-chromosomal and orphaned reads. The ImmunoID NeXT DNA and RNA Analysis Pipeline aligns reads to the hs37d5 reference genome build. The pipeline performs alignment, duplicate removal and base quality score recalibration using best practices outlined by the Broad Institute<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 42" title="DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491–498 (2011)." href="/articles/s41591-022-01829-9#ref-CR42" id="ref-link-section-d71099090e3560">42</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 43" title="McKenna, A. et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010)." href="/articles/s41591-022-01829-9#ref-CR43" id="ref-link-section-d71099090e3563">43</a></sup>. The pipeline uses Picard to remove duplicates and the Genome Analysis Toolkit to improve sequence alignment and correct base quality scores. Aligned sequence data are returned in BAM format according to SAM specification. Raw read counts from were also normalized using R to get weighted trimmed mean of the log expression ratios (trimmed mean of M values (TMM)).</p><p>To calculate gene expression signatures on a given gene set, scores were determined via geometric mean of the normalized count values of respective gene signatures. Patient tumor samples were collected from a range of primary tumors and metastatic sites. Sample sizes from pre-treatment liver biopsies for all gene signatures identified are as follows: nivo/chemo (<i>n</i> = 17); sotiga/chemo (<i>n</i> = 12); and sotiga/nivo/chemo (<i>n</i> = 12).</p><h3 class="c-article__sub-heading" id="Sec23">Multiplex tissue staining and imaging</h3><p>Tumor tissue was collected before treatment (fresh baseline biopsy or archival tissue), on-treatment (during cycle 2) and optionally at the end of treatment. Tissues were fixed in formalin followed by paraffin embedding. All tissue imaging was performed under the guidance of an expert pathologist (T.J.H.) in the Advanced Immunomorphology Platform Laboratory at Memorial Sloan Kettering Cancer Center. Primary antibody staining conditions were optimized using standard immunohistochemical staining on the Leica Bond RX automated research stainer with DAB detection (Leica Bond Polymer Refine Detection DS9800). Using 4-µm tissue sections and serial antibody titrations on control tonsil tissue, the optimal antibody concentration was determined, followed by transition to a seven-color multiplex assay with equivalency (see Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">8</a> for control staining). Four antibody panels were used for staining. Panels A1 and B1 were used for tissues collected in phase 1b. Panels A2 and B2 were further optimized for distribution of cellular markers and were used for tissues collected in phase 2. Multiplex assay antibodies and conditions are described in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">12</a>.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec24">Seven-color multiplex imaging assay</h4><p>FFPE tissue sections were baked for 3 hours at 62 °C in a vertical slide orientation with subsequent deparaffinization performed on the Leica Bond RX, followed by 30 minutes of antigen retrieval with Leica Bond ER2, followed by six sequential cycles of staining with each round including a 30-minute combined block and primary antibody incubation (Akoya antibody diluent/block). For Ki-67 and panCK, detection was performed using a secondary horseradish peroxidase (HRP)-conjugated polymer (Akoya Opal polymer HRP Ms+Rb; 10-minute incubation). Detection of all other primary antibodies was performed using a goat anti-mouse Poly HRP secondary antibody or goat anti-rabbit Poly HRP secondary antibody (Invitrogen, 10-minute incubation). The HRP-conjugated secondary antibody polymer was detected using fluorescent tyramide signal amplification using Opal dyes 520, 540, 570, 620, 650 and 690 (Akoya Biosciences). The covalent tyramide reaction was followed by heat-induced stripping of the primary/secondary antibody complex using Akoya AR9 buffer and Leica Bond ER2 (90% AR9 and 10% ER2) at 100 °C for 20 minutes preceding the next cycle. After six sequential rounds of staining, sections were stained with Hoechst 33342 (Invitrogen) to visualize nuclei and mounted with ProLong Gold antifade reagent mounting medium (Invitrogen).</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec25">Multispectral imaging and spectral unmixing</h4><p>Seven-color multiplex stained slides were imaged using the Vectra Multispectral Imaging System version 3 (Akoya Biosciences). Scanning was performed at ×20 (×200 final magnification). Filter cubes used for multispectral imaging were DAPI, FITC, Cy3, Texas Red and Cy5. A spectral library containing the emitted spectral peaks of the fluorophores in this study was created using the Vectra image analysis software (Akoya Biosciences). Using multispectral images from single-stained slides for each marker, the spectral library was used to separate each multispectral cube into individual components (spectral unmixing), allowing for identification of the seven marker channels of interest using Inform 2.4 image analysis software.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec26">mIF image analysis</h4><p>Individual region of interest (ROI) images were exported to TIFF files and run through a pipeline for multiplexed imaging quality control and processing under the supervision of an expert pathologist. A machine learning cell segmentation algorithm was used to segment individual whole cells along the membrane border using nuclear as well as multiple membrane markers to enable drawing borders for all cell types. For each cell segment, pixel values within each region were averaged to give a single intensity value per cell and per marker. Using these single-cell intensity values, cell type assignments were made manually by a scientist determining cutoff points for positive marker expression for each sample. To do this manual thresholding, the distribution of single-cell marker values and the appearance of fluorescence on the images themselves were simultaneously inspected using CellEngine software along with Mantis Viewer, a custom in-house open-source software used for fluorescent image visualization (<a href="https://doi.org/10.5281/zenodo.4009579">https://doi.org/10.5281/zenodo.4009579</a>), and thresholds for each marker were drawn per sample. Using these individual marker thresholds, cell types were defined by positivity of combined associated markers in the panel as described in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">13</a>. Once cell types were defined, the percentage out of total cells and out of the parent population was calculated for each ROI. Then, for each sample, the median across ROIs was taken for percent of total cells, percent of parent population and occasionally percent of other relevant populations.</p><p>Sample sizes for cell populations identified using mIF (Extended Data Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig8">3g,h</a>, <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig8">4c,d</a> and <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig11">6d,e</a> and Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">5</a>) from pre-treatment biopsies are as follows: nivo/chemo (<i>n</i> = 25); sotiga/chemo (<i>n</i> = 25); and sotiga/nivo/chemo (<i>n</i> = 29). Sample sizes for cell populations identified using mIF (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01829-9#Fig8">3g,h</a>) from on-treatment biopsies are as follows: nivo/chemo (<i>n</i> = 5); sotiga/chemo (<i>n</i> = 3); and sotiga/nivo/chemo (<i>n</i> = 6).</p><h3 class="c-article__sub-heading" id="Sec27">Analysis of all data for association with survival and pharmacodynamic changes</h3><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec28">Data storage and structure</h4><p>All processed biomarker data were combined with cleaned clinical data and loaded into a proprietary in-house database called the Cancer Data &amp; Evidence Library (CANDEL). CANDEL uses the database technology Datomic (<a href="http://www.datomic.com">www.datomic.com</a>) and a suite of tools built to enable storage of molecular and clinical data and fast query and visualization from the R programming language.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec29">Data analysis in R</h4><p>All molecular data were analyzed for association with outcomes and treatment using the R programming language with the packages and versions listed in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">14</a>. Association with survival was analyzed for cell population percentages, protein values and gene expression signatures by calculating the median value across all patients in all arms and then separating patients into two groups below the median and above or equal to the median. Between these two groups, for each arm, Kaplan–Meier plots were created, and log-rank <i>P</i> value significance was determined using the survminer and survival packages. To visualize differences between any defined groups or to visualize changes on treatment, ggplot2 and base R plotting were used. To determine differences between pre-treatment and on-treatment values, as well as differences between survival groups (&gt;1 year and &lt;1 year) at any given time point, a two-sided Wilcoxon sign-rank test with a significance cutoff of <i>P</i> = 0.05 was used. Median log fold change was calculated to determine additional pharmacodynamic differences seen from pre-treatment to on-treatment. Multivariable Cox proportional hazard models were also generated in relation to survival in each arm, with individual biomarkers in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM1">8</a> controlling for an additional clinical variable, de novo/recurrent staging at initial diagnosis or prior chemotherapy usage, using the survival and survminer packages. Forest plots were generated for most significant circulating biomarkers in each arm to determine hazard ratio and CI of each biomarker in relation to each other. Circus plots for multi-omic analysis were generated using the DIABLO method in the mixOmics R package. Heat maps were generated using pheatmap, and correlations were calculated using the Spearman method.</p><h3 class="c-article__sub-heading" id="Sec30">Reporting Summary</h3><p>Further information on research design is available in the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01829-9#MOESM2">Nature Research Reporting Summary</a> linked to this article.</p></div></div></section>
                    
                </div>
            

            <div class="u-mt-32">
                <section data-title="Data availability"><div class="c-article-section" id="data-availability-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="data-availability">Data availability</h2><div class="c-article-section__content" id="data-availability-content">
              
              <p>Summary datasets generated during and/or analyzed during the current study are available in the GitHub repository <a href="https://github.com/ParkerICI/prince-trial-data">ParkerICI/prince-trial-data</a>. These datasets include a de-identified limited clinical dataset with demographic and response information for each patient, processed RNA sequencing files and summary tables of cell proportions found via mIF, CyTOF and flow cytometry. The full clinical dataset generated in this study is considered commercially sensitive and, therefore, is not publicly available. Requests for additional clinical data should be emailed to the corresponding author and should include a brief description of the proposed analysis. Requests for data access will be reviewed individually, and a decision will be communicated within 4 weeks of receipt. Data might be shared in the form of aggregate data summaries and via a data transfer agreement, which will outline any potential restrictions on data use. Individual patient-level raw data containing confidential or identifiable patient information are subject to patient privacy and cannot be shared.</p>
            </div></div></section><section data-title="Code availability"><div class="c-article-section" id="code-availability-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="code-availability">Code availability</h2><div class="c-article-section__content" id="code-availability-content">
              
              <p>Mantis Viewer, a custom in-house, open-source software used for fluorescent image visualization, is available at <a href="https://doi.org/10.5281/zenodo.4009579">https://doi.org/10.5281/zenodo.4009579</a>.</p>
            </div></div></section><section data-title="Change history"><div class="c-article-section" id="change-history-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="change-history">Change history</h2><div class="c-article-section__content" id="change-history-content"><ul class="c-article-change-list"><li class="c-article-change-list__item u-mb-24" id="chg1"><ins datetime="2022-07-21"><h3 class="c-article-change-list__heading u-h3 u-pr-8 u-display-inline">21 July 2022</h3><div class="c-article-change-list__details"><p>In the version of this article initially published, the Supplementary information file was missing Supplementary Tables 1–14, Clinical Study Protocol and Statistical Analysis Plan, which have now been restored in the online version of the article.</p></div></ins></li></ul></div></div></section><div id="MagazineFulltextArticleBodySuffix"><section aria-labelledby="Bib1" data-title="References"><div class="c-article-section" id="Bib1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Bib1">References</h2><div class="c-article-section__content" id="Bib1-content"><div data-container-section="references"><ol class="c-article-references" data-track-component="outbound reference" data-track-context="references section"><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="1."><p class="c-article-references__text" id="ref-CR1">Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. <i>Cancer Res.</i> <b>74</b>, 2913–2921 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/0008-5472.CAN-14-0155" data-track-item_id="10.1158/0008-5472.CAN-14-0155" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F0008-5472.CAN-14-0155" aria-label="Article reference 1" data-doi="10.1158/0008-5472.CAN-14-0155">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXovFalur0%3D" aria-label="CAS reference 1">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24840647" aria-label="PubMed reference 1">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 1" href="http://scholar.google.com/scholar_lookup?&amp;title=Projecting%20cancer%20incidence%20and%20deaths%20to%202030%3A%20the%20unexpected%20burden%20of%20thyroid%2C%20liver%2C%20and%20pancreas%20cancers%20in%20the%20United%20States&amp;journal=Cancer%20Res.&amp;doi=10.1158%2F0008-5472.CAN-14-0155&amp;volume=74&amp;pages=2913-2921&amp;publication_year=2014&amp;author=Rahib%2CL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="2."><p class="c-article-references__text" id="ref-CR2">Sharma, P. et al. The next decade of immune checkpoint therapy. <i>Cancer Discov.</i> <b>11</b>, 838–857 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-20-1680" data-track-item_id="10.1158/2159-8290.CD-20-1680" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-20-1680" aria-label="Article reference 2" data-doi="10.1158/2159-8290.CD-20-1680">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtlKqurbN" aria-label="CAS reference 2">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33811120" aria-label="PubMed reference 2">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 2" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20next%20decade%20of%20immune%20checkpoint%20therapy&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-20-1680&amp;volume=11&amp;pages=838-857&amp;publication_year=2021&amp;author=Sharma%2CP">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="3."><p class="c-article-references__text" id="ref-CR3">O’Reilly, E. M. et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. <i>JAMA Oncol.</i> <b>5</b>, 1431–1438 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1001/jamaoncol.2019.1588" data-track-item_id="10.1001/jamaoncol.2019.1588" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1001%2Fjamaoncol.2019.1588" aria-label="Article reference 3" data-doi="10.1001/jamaoncol.2019.1588">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31318392" aria-label="PubMed reference 3">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647002" aria-label="PubMed Central reference 3">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 3" href="http://scholar.google.com/scholar_lookup?&amp;title=Durvalumab%20with%20or%20without%20tremelimumab%20for%20patients%20with%20metastatic%20pancreatic%20ductal%20adenocarcinoma%3A%20a%20phase%202%20randomized%20clinical%20trial&amp;journal=JAMA%20Oncol.&amp;doi=10.1001%2Fjamaoncol.2019.1588&amp;volume=5&amp;pages=1431-1438&amp;publication_year=2019&amp;author=O%E2%80%99Reilly%2CEM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="4."><p class="c-article-references__text" id="ref-CR4">Royal, R. E. et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. <i>J. Immunother.</i> <b>33</b>, 828–833 (2010).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1097/CJI.0b013e3181eec14c" data-track-item_id="10.1097/CJI.0b013e3181eec14c" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1097%2FCJI.0b013e3181eec14c" aria-label="Article reference 4" data-doi="10.1097/CJI.0b013e3181eec14c">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3cXht1Wju77O" aria-label="CAS reference 4">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20842054" aria-label="PubMed reference 4">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322622" aria-label="PubMed Central reference 4">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 4" href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%202%20trial%20of%20single%20agent%20ipilimumab%20%28anti-CTLA-4%29%20for%20locally%20advanced%20or%20metastatic%20pancreatic%20adenocarcinoma&amp;journal=J.%20Immunother.&amp;doi=10.1097%2FCJI.0b013e3181eec14c&amp;volume=33&amp;pages=828-833&amp;publication_year=2010&amp;author=Royal%2CRE">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="5."><p class="c-article-references__text" id="ref-CR5">Patnaik, A. et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. <i>Clin. Cancer Res.</i> <b>21</b>, 4286–4293 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-14-2607" data-track-item_id="10.1158/1078-0432.CCR-14-2607" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-14-2607" aria-label="Article reference 5" data-doi="10.1158/1078-0432.CCR-14-2607">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXhs1antL3L" aria-label="CAS reference 5">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25977344" aria-label="PubMed reference 5">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 5" href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20I%20study%20of%20pembrolizumab%20%28MK-3475%3B%20anti-PD-1%20monoclonal%20antibody%29%20in%20patients%20with%20advanced%20solid%20tumors&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-14-2607&amp;volume=21&amp;pages=4286-4293&amp;publication_year=2015&amp;author=Patnaik%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="6."><p class="c-article-references__text" id="ref-CR6">Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. <i>N. Engl. J. Med.</i> <b>366</b>, 2455–2465 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1200694" data-track-item_id="10.1056/NEJMoa1200694" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1200694" aria-label="Article reference 6" data-doi="10.1056/NEJMoa1200694">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38XhtV2rsbnJ" aria-label="CAS reference 6">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22658128" aria-label="PubMed reference 6">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563263" aria-label="PubMed Central reference 6">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 6" href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%20and%20activity%20of%20anti-PD-L1%20antibody%20in%20patients%20with%20advanced%20cancer&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1200694&amp;volume=366&amp;pages=2455-2465&amp;publication_year=2012&amp;author=Brahmer%2CJR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="7."><p class="c-article-references__text" id="ref-CR7">Balachandran, V. P. et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. <i>Nature</i> <b>551</b>, 512–516 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nature24462" data-track-item_id="10.1038/nature24462" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnature24462" aria-label="Article reference 7" data-doi="10.1038/nature24462">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhslygtLjP" aria-label="CAS reference 7">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29132146" aria-label="PubMed reference 7">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145146" aria-label="PubMed Central reference 7">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 7" href="http://scholar.google.com/scholar_lookup?&amp;title=Identification%20of%20unique%20neoantigen%20qualities%20in%20long-term%20survivors%20of%20pancreatic%20cancer&amp;journal=Nature&amp;doi=10.1038%2Fnature24462&amp;volume=551&amp;pages=512-516&amp;publication_year=2017&amp;author=Balachandran%2CVP">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="8."><p class="c-article-references__text" id="ref-CR8">Balli, D., Rech, A. J., Stanger, B. Z. &amp; Vonderheide, R. H. Immune cytolytic activity stratifies molecular subsets of human pancreatic cancer. <i>Clin. Cancer Res.</i> <b>23</b>, 3129–3138 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-16-2128" data-track-item_id="10.1158/1078-0432.CCR-16-2128" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-16-2128" aria-label="Article reference 8" data-doi="10.1158/1078-0432.CCR-16-2128">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtVSqurbE" aria-label="CAS reference 8">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28007776" aria-label="PubMed reference 8">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 8" href="http://scholar.google.com/scholar_lookup?&amp;title=Immune%20cytolytic%20activity%20stratifies%20molecular%20subsets%20of%20human%20pancreatic%20cancer&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-16-2128&amp;volume=23&amp;pages=3129-3138&amp;publication_year=2017&amp;author=Balli%2CD&amp;author=Rech%2CAJ&amp;author=Stanger%2CBZ&amp;author=Vonderheide%2CRH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="9."><p class="c-article-references__text" id="ref-CR9">Stromnes, I. M., Hulbert, A., Pierce, R. H., Greenberg, P. D. &amp; Hingorani, S. R. T-cell localization, activation, and clonal expansion in human pancreatic ductal adenocarcinoma. <i>Cancer Immunol. Res.</i> <b>5</b>, 978–991 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2326-6066.CIR-16-0322" data-track-item_id="10.1158/2326-6066.CIR-16-0322" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2326-6066.CIR-16-0322" aria-label="Article reference 9" data-doi="10.1158/2326-6066.CIR-16-0322">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhslGisrrJ" aria-label="CAS reference 9">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29066497" aria-label="PubMed reference 9">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802342" aria-label="PubMed Central reference 9">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 9" href="http://scholar.google.com/scholar_lookup?&amp;title=T-cell%20localization%2C%20activation%2C%20and%20clonal%20expansion%20in%20human%20pancreatic%20ductal%20adenocarcinoma&amp;journal=Cancer%20Immunol.%20Res.&amp;doi=10.1158%2F2326-6066.CIR-16-0322&amp;volume=5&amp;pages=978-991&amp;publication_year=2017&amp;author=Stromnes%2CIM&amp;author=Hulbert%2CA&amp;author=Pierce%2CRH&amp;author=Greenberg%2CPD&amp;author=Hingorani%2CSR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="10."><p class="c-article-references__text" id="ref-CR10">Byrne, K. T. &amp; Vonderheide, R. H. CD40 stimulation obviates innate sensors and drives T cell immunity in cancer. <i>Cell Rep.</i> <b>15</b>, 2719–2732 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.celrep.2016.05.058" data-track-item_id="10.1016/j.celrep.2016.05.058" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.celrep.2016.05.058" aria-label="Article reference 10" data-doi="10.1016/j.celrep.2016.05.058">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28Xps1SktLw%3D" aria-label="CAS reference 10">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27292635" aria-label="PubMed reference 10">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917417" aria-label="PubMed Central reference 10">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 10" href="http://scholar.google.com/scholar_lookup?&amp;title=CD40%20stimulation%20obviates%20innate%20sensors%20and%20drives%20T%20cell%20immunity%20in%20cancer&amp;journal=Cell%20Rep.&amp;doi=10.1016%2Fj.celrep.2016.05.058&amp;volume=15&amp;pages=2719-2732&amp;publication_year=2016&amp;author=Byrne%2CKT&amp;author=Vonderheide%2CRH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="11."><p class="c-article-references__text" id="ref-CR11">Winograd, R. et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. <i>Cancer Immunol. Res</i> <b>3</b>, 399–411 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2326-6066.CIR-14-0215" data-track-item_id="10.1158/2326-6066.CIR-14-0215" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2326-6066.CIR-14-0215" aria-label="Article reference 11" data-doi="10.1158/2326-6066.CIR-14-0215">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXlvFemtb8%3D" aria-label="CAS reference 11">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25678581" aria-label="PubMed reference 11">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390506" aria-label="PubMed Central reference 11">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 11" href="http://scholar.google.com/scholar_lookup?&amp;title=Induction%20of%20T-cell%20immunity%20overcomes%20complete%20resistance%20to%20PD-1%20and%20CTLA-4%20blockade%20and%20improves%20survival%20in%20pancreatic%20carcinoma&amp;journal=Cancer%20Immunol.%20Res&amp;doi=10.1158%2F2326-6066.CIR-14-0215&amp;volume=3&amp;pages=399-411&amp;publication_year=2015&amp;author=Winograd%2CR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="12."><p class="c-article-references__text" id="ref-CR12">O’Hara, M. H. et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. <i>Lancet Oncol.</i> <b>22</b>, 118–131 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S1470-2045(20)30532-5" data-track-item_id="10.1016/S1470-2045(20)30532-5" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS1470-2045%2820%2930532-5" aria-label="Article reference 12" data-doi="10.1016/S1470-2045(20)30532-5">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33387490" aria-label="PubMed reference 12">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 12" href="http://scholar.google.com/scholar_lookup?&amp;title=CD40%20agonistic%20monoclonal%20antibody%20APX005M%20%28sotigalimab%29%20and%20chemotherapy%2C%20with%20or%20without%20nivolumab%2C%20for%20the%20treatment%20of%20metastatic%20pancreatic%20adenocarcinoma%3A%20an%20open-label%2C%20multicentre%2C%20phase%201b%20study&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2820%2930532-5&amp;volume=22&amp;pages=118-131&amp;publication_year=2021&amp;author=O%E2%80%99Hara%2CMH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="13."><p class="c-article-references__text" id="ref-CR13">Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. <i>N. Engl. J. Med.</i> <b>369</b>, 1691–1703 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1304369" data-track-item_id="10.1056/NEJMoa1304369" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1304369" aria-label="Article reference 13" data-doi="10.1056/NEJMoa1304369">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 13" href="http://scholar.google.com/scholar_lookup?&amp;title=Increased%20survival%20in%20pancreatic%20cancer%20with%20nab-paclitaxel%20plus%20gemcitabine&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1304369&amp;volume=369&amp;pages=1691-1703&amp;publication_year=2013&amp;author=Hoff%2CDD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="14."><p class="c-article-references__text" id="ref-CR14">Choueiri, T. K. et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. <i>Clin. Cancer Res.</i> <b>22</b>, 5461–5471 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-15-2839" data-track-item_id="10.1158/1078-0432.CCR-15-2839" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-15-2839" aria-label="Article reference 14" data-doi="10.1158/1078-0432.CCR-15-2839">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XhvVCqur3L" aria-label="CAS reference 14">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27169994" aria-label="PubMed reference 14">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106340" aria-label="PubMed Central reference 14">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 14" href="http://scholar.google.com/scholar_lookup?&amp;title=Immunomodulatory%20activity%20of%20nivolumab%20in%20metastatic%20renal%20cell%20carcinoma&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-15-2839&amp;volume=22&amp;pages=5461-5471&amp;publication_year=2016&amp;author=Choueiri%2CTK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="15."><p class="c-article-references__text" id="ref-CR15">Mathew, D. et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. <i>Science</i> <b>369</b>, eabc8511 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1126/science.abc8511" data-track-item_id="10.1126/science.abc8511" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1126%2Fscience.abc8511" aria-label="Article reference 15" data-doi="10.1126/science.abc8511">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXhslCltrnF" aria-label="CAS reference 15">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32669297" aria-label="PubMed reference 15">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402624" aria-label="PubMed Central reference 15">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 15" href="http://scholar.google.com/scholar_lookup?&amp;title=Deep%20immune%20profiling%20of%20COVID-19%20patients%20reveals%20distinct%20immunotypes%20with%20therapeutic%20implications&amp;journal=Science&amp;doi=10.1126%2Fscience.abc8511&amp;volume=369&amp;publication_year=2020&amp;author=Mathew%2CD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="16."><p class="c-article-references__text" id="ref-CR16">Romero, P. et al. Four functionally distinct populations of human effector-memory CD8<sup>+</sup> T lymphocytes. <i>J. Immunol.</i> <b>178</b>, 4112–4119 (2007).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.4049/jimmunol.178.7.4112" data-track-item_id="10.4049/jimmunol.178.7.4112" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.4049%2Fjimmunol.178.7.4112" aria-label="Article reference 16" data-doi="10.4049/jimmunol.178.7.4112">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2sXjt1WltLY%3D" aria-label="CAS reference 16">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17371966" aria-label="PubMed reference 16">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 16" href="http://scholar.google.com/scholar_lookup?&amp;title=Four%20functionally%20distinct%20populations%20of%20human%20effector-memory%20CD8%2B%20T%20lymphocytes&amp;journal=J.%20Immunol.&amp;doi=10.4049%2Fjimmunol.178.7.4112&amp;volume=178&amp;pages=4112-4119&amp;publication_year=2007&amp;author=Romero%2CP">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="17."><p class="c-article-references__text" id="ref-CR17">Byrne, K. T. et al. Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer. <i>Clin. Cancer Res.</i> <b>27</b>, 4574–4586 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-21-1047" data-track-item_id="10.1158/1078-0432.CCR-21-1047" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-21-1047" aria-label="Article reference 17" data-doi="10.1158/1078-0432.CCR-21-1047">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXit1CkurfE" aria-label="CAS reference 17">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34112709" aria-label="PubMed reference 17">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667686" aria-label="PubMed Central reference 17">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 17" href="http://scholar.google.com/scholar_lookup?&amp;title=Neoadjuvant%20selicrelumab%2C%20an%20agonist%20CD40%20antibody%2C%20induces%20changes%20in%20the%20tumor%20microenvironment%20in%20patients%20with%20resectable%20pancreatic%20cancer&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-21-1047&amp;volume=27&amp;pages=4574-4586&amp;publication_year=2021&amp;author=Byrne%2CKT">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="18."><p class="c-article-references__text" id="ref-CR18">Wainberg, Z. A. et al. Open-label, phase I study of nivolumab combined with nab-paclitaxel plus gemcitabine in advanced pancreatic cancer. <i>Clin. Cancer Res.</i> <b>26</b>, 4814–4822 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-20-0099" data-track-item_id="10.1158/1078-0432.CCR-20-0099" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-20-0099" aria-label="Article reference 18" data-doi="10.1158/1078-0432.CCR-20-0099">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXisFSrtr%2FL" aria-label="CAS reference 18">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32554514" aria-label="PubMed reference 18">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 18" href="http://scholar.google.com/scholar_lookup?&amp;title=Open-label%2C%20phase%20I%20study%20of%20nivolumab%20combined%20with%20nab-paclitaxel%20plus%20gemcitabine%20in%20advanced%20pancreatic%20cancer&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-20-0099&amp;volume=26&amp;pages=4814-4822&amp;publication_year=2020&amp;author=Wainberg%2CZA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="19."><p class="c-article-references__text" id="ref-CR19">Filbert, E. L., Bjorck, P. K., Srivastava, M. K., Bahjat, F. R. &amp; Yang, X. APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application. <i>Cancer Immunol. Immunother.</i> <b>70</b>, 1853–1865 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1007/s00262-020-02814-2" data-track-item_id="10.1007/s00262-020-02814-2" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1007/s00262-020-02814-2" aria-label="Article reference 19" data-doi="10.1007/s00262-020-02814-2">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXht1Oktbg%3D" aria-label="CAS reference 19">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33392713" aria-label="PubMed reference 19">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195934" aria-label="PubMed Central reference 19">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 19" href="http://scholar.google.com/scholar_lookup?&amp;title=APX005M%2C%20a%20CD40%20agonist%20antibody%20with%20unique%20epitope%20specificity%20and%20Fc%20receptor%20binding%20profile%20for%20optimal%20therapeutic%20application&amp;journal=Cancer%20Immunol.%20Immunother.&amp;doi=10.1007%2Fs00262-020-02814-2&amp;volume=70&amp;pages=1853-1865&amp;publication_year=2021&amp;author=Filbert%2CEL&amp;author=Bjorck%2CPK&amp;author=Srivastava%2CMK&amp;author=Bahjat%2CFR&amp;author=Yang%2CX">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="20."><p class="c-article-references__text" id="ref-CR20">Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. <i>J. Clin. Oncol.</i> <b>28</b>, 3167–3175 (2010).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.2009.26.7609" data-track-item_id="10.1200/JCO.2009.26.7609" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2009.26.7609" aria-label="Article reference 20" data-doi="10.1200/JCO.2009.26.7609">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3cXpslajtLw%3D" aria-label="CAS reference 20">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20516446" aria-label="PubMed reference 20">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834717" aria-label="PubMed Central reference 20">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 20" href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20I%20study%20of%20single-agent%20anti-programmed%20death-1%20%28MDX-1106%29%20in%20refractory%20solid%20tumors%3A%20safety%2C%20clinical%20activity%2C%20pharmacodynamics%2C%20and%20immunologic%20correlates&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2009.26.7609&amp;volume=28&amp;pages=3167-3175&amp;publication_year=2010&amp;author=Brahmer%2CJR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="21."><p class="c-article-references__text" id="ref-CR21">Stebegg, M. et al. Regulation of the germinal center response. <i>Front. Immunol.</i> <b>9</b>, 2469 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.3389/fimmu.2018.02469" data-track-item_id="10.3389/fimmu.2018.02469" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.3389%2Ffimmu.2018.02469" aria-label="Article reference 21" data-doi="10.3389/fimmu.2018.02469">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30410492" aria-label="PubMed reference 21">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209676" aria-label="PubMed Central reference 21">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 21" href="http://scholar.google.com/scholar_lookup?&amp;title=Regulation%20of%20the%20germinal%20center%20response&amp;journal=Front.%20Immunol.&amp;doi=10.3389%2Ffimmu.2018.02469&amp;volume=9&amp;publication_year=2018&amp;author=Stebegg%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="22."><p class="c-article-references__text" id="ref-CR22">Cohn, L. et al. Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3<sup>+</sup> dendritic cells at cross presentation. <i>J. Exp. Med.</i> <b>210</b>, 1049–1063 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1084/jem.20121251" data-track-item_id="10.1084/jem.20121251" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1084%2Fjem.20121251" aria-label="Article reference 22" data-doi="10.1084/jem.20121251">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXntlKjs78%3D" aria-label="CAS reference 22">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23569326" aria-label="PubMed reference 22">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646496" aria-label="PubMed Central reference 22">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 22" href="http://scholar.google.com/scholar_lookup?&amp;title=Antigen%20delivery%20to%20early%20endosomes%20eliminates%20the%20superiority%20of%20human%20blood%20BDCA3%2B%20dendritic%20cells%20at%20cross%20presentation&amp;journal=J.%20Exp.%20Med.&amp;doi=10.1084%2Fjem.20121251&amp;volume=210&amp;pages=1049-1063&amp;publication_year=2013&amp;author=Cohn%2CL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="23."><p class="c-article-references__text" id="ref-CR23">Haniffa, M. et al. Human tissues contain CD141<sup>hi</sup> cross-presenting dendritic cells with functional homology to mouse CD103<sup>+</sup> nonlymphoid dendritic cells. <i>Immunity</i> <b>37</b>, 60–73 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.immuni.2012.04.012" data-track-item_id="10.1016/j.immuni.2012.04.012" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.immuni.2012.04.012" aria-label="Article reference 23" data-doi="10.1016/j.immuni.2012.04.012">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38XhtVKntL7E" aria-label="CAS reference 23">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22795876" aria-label="PubMed reference 23">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3476529" aria-label="PubMed Central reference 23">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 23" href="http://scholar.google.com/scholar_lookup?&amp;title=Human%20tissues%20contain%20CD141hi%20cross-presenting%20dendritic%20cells%20with%20functional%20homology%20to%20mouse%20CD103%2B%20nonlymphoid%20dendritic%20cells&amp;journal=Immunity&amp;doi=10.1016%2Fj.immuni.2012.04.012&amp;volume=37&amp;pages=60-73&amp;publication_year=2012&amp;author=Haniffa%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="24."><p class="c-article-references__text" id="ref-CR24">Diamond, M. S., Lin, J. H. &amp; Vonderheide, R. H. Site-dependent immune escape due to impaired dendritic cell cross-priming. <i>Cancer Immunol. Res.</i> <b>9</b>, 877–890 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2326-6066.CIR-20-0785" data-track-item_id="10.1158/2326-6066.CIR-20-0785" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2326-6066.CIR-20-0785" aria-label="Article reference 24" data-doi="10.1158/2326-6066.CIR-20-0785">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXit1eisrzO" aria-label="CAS reference 24">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34145076" aria-label="PubMed reference 24">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655819" aria-label="PubMed Central reference 24">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 24" href="http://scholar.google.com/scholar_lookup?&amp;title=Site-dependent%20immune%20escape%20due%20to%20impaired%20dendritic%20cell%20cross-priming&amp;journal=Cancer%20Immunol.%20Res.&amp;doi=10.1158%2F2326-6066.CIR-20-0785&amp;volume=9&amp;pages=877-890&amp;publication_year=2021&amp;author=Diamond%2CMS&amp;author=Lin%2CJH&amp;author=Vonderheide%2CRH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="25."><p class="c-article-references__text" id="ref-CR25">Li, J. et al. Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy. <i>Immunity</i> <b>49</b>, 178–193 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.immuni.2018.06.006" data-track-item_id="10.1016/j.immuni.2018.06.006" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.immuni.2018.06.006" aria-label="Article reference 25" data-doi="10.1016/j.immuni.2018.06.006">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXht1Smu7nL" aria-label="CAS reference 25">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29958801" aria-label="PubMed reference 25">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707727" aria-label="PubMed Central reference 25">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 25" href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor%20cell-intrinsic%20factors%20underlie%20heterogeneity%20of%20immune%20cell%20infiltration%20and%20response%20to%20immunotherapy&amp;journal=Immunity&amp;doi=10.1016%2Fj.immuni.2018.06.006&amp;volume=49&amp;pages=178-193&amp;publication_year=2018&amp;author=Li%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="26."><p class="c-article-references__text" id="ref-CR26">Sharma, P. et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. <i>Proc. Natl Acad. Sci. USA</i> <b>104</b>, 3967–3972 (2007).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1073/pnas.0611618104" data-track-item_id="10.1073/pnas.0611618104" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1073%2Fpnas.0611618104" aria-label="Article reference 26" data-doi="10.1073/pnas.0611618104">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2sXjt1ymu7g%3D" aria-label="CAS reference 26">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17360461" aria-label="PubMed reference 26">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1820692" aria-label="PubMed Central reference 26">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 26" href="http://scholar.google.com/scholar_lookup?&amp;title=CD8%20tumor-infiltrating%20lymphocytes%20are%20predictive%20of%20survival%20in%20muscle-invasive%20urothelial%20carcinoma&amp;journal=Proc.%20Natl%20Acad.%20Sci.%20USA&amp;doi=10.1073%2Fpnas.0611618104&amp;volume=104&amp;pages=3967-3972&amp;publication_year=2007&amp;author=Sharma%2CP">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="27."><p class="c-article-references__text" id="ref-CR27">Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. <i>Cell</i> <b>170</b>, 1109–1119 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.cell.2017.08.027" data-track-item_id="10.1016/j.cell.2017.08.027" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cell.2017.08.027" aria-label="Article reference 27" data-doi="10.1016/j.cell.2017.08.027">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhsVOhu7rJ" aria-label="CAS reference 27">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28886381" aria-label="PubMed reference 27">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034392" aria-label="PubMed Central reference 27">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 27" href="http://scholar.google.com/scholar_lookup?&amp;title=Oncolytic%20virotherapy%20promotes%20intratumoral%20T%20cell%20infiltration%20and%20improves%20anti-PD-1%20immunotherapy&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2017.08.027&amp;volume=170&amp;pages=1109-1119&amp;publication_year=2017&amp;author=Ribas%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="28."><p class="c-article-references__text" id="ref-CR28">Tokito, T. et al. Predictive relevance of PD-L1 expression combined with CD8<sup>+</sup> TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. <i>Eur. J. Cancer</i> <b>55</b>, 7–14 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.ejca.2015.11.020" data-track-item_id="10.1016/j.ejca.2015.11.020" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ejca.2015.11.020" aria-label="Article reference 28" data-doi="10.1016/j.ejca.2015.11.020">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXitV2ntbvI" aria-label="CAS reference 28">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26771872" aria-label="PubMed reference 28">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 28" href="http://scholar.google.com/scholar_lookup?&amp;title=Predictive%20relevance%20of%20PD-L1%20expression%20combined%20with%20CD8%2B%20TIL%20density%20in%20stage%20III%20non-small%20cell%20lung%20cancer%20patients%20receiving%20concurrent%20chemoradiotherapy&amp;journal=Eur.%20J.%20Cancer&amp;doi=10.1016%2Fj.ejca.2015.11.020&amp;volume=55&amp;pages=7-14&amp;publication_year=2016&amp;author=Tokito%2CT">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="29."><p class="c-article-references__text" id="ref-CR29">Yang, Z. et al. Tumor-Infiltrating PD-1<sup>hi</sup>CD8<sup>+</sup>-T-cell signature as an effective biomarker for immune checkpoint inhibitor therapy response across multiple cancers. <i>Front. Oncol.</i> <b>11</b>, 695006 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.3389/fonc.2021.695006" data-track-item_id="10.3389/fonc.2021.695006" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.3389%2Ffonc.2021.695006" aria-label="Article reference 29" data-doi="10.3389/fonc.2021.695006">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34604032" aria-label="PubMed reference 29">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479164" aria-label="PubMed Central reference 29">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 29" href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor-Infiltrating%20PD-1hiCD8%2B-T-cell%20signature%20as%20an%20effective%20biomarker%20for%20immune%20checkpoint%20inhibitor%20therapy%20response%20across%20multiple%20cancers&amp;journal=Front.%20Oncol.&amp;doi=10.3389%2Ffonc.2021.695006&amp;volume=11&amp;publication_year=2021&amp;author=Yang%2CZ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="30."><p class="c-article-references__text" id="ref-CR30">Beltra, J. C. et al. Developmental relationships of four exhausted CD8<sup>+</sup> T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. <i>Immunity</i> <b>52</b>, 825–841 e828, (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.immuni.2020.04.014" data-track-item_id="10.1016/j.immuni.2020.04.014" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.immuni.2020.04.014" aria-label="Article reference 30" data-doi="10.1016/j.immuni.2020.04.014">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXptVCmtro%3D" aria-label="CAS reference 30">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32396847" aria-label="PubMed reference 30">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360766" aria-label="PubMed Central reference 30">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 30" href="http://scholar.google.com/scholar_lookup?&amp;title=Developmental%20relationships%20of%20four%20exhausted%20CD8%2B%20T%20cell%20subsets%20reveals%20underlying%20transcriptional%20and%20epigenetic%20landscape%20control%20mechanisms&amp;journal=Immunity&amp;doi=10.1016%2Fj.immuni.2020.04.014&amp;volume=52&amp;pages=825-841%20e828&amp;publication_year=2020&amp;author=Beltra%2CJC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="31."><p class="c-article-references__text" id="ref-CR31">Ding, C. et al. Integrin CD11b negatively regulates BCR signalling to maintain autoreactive B cell tolerance. <i>Nat. Commun.</i> <b>4</b>, 2813 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/ncomms3813" data-track-item_id="10.1038/ncomms3813" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fncomms3813" aria-label="Article reference 31" data-doi="10.1038/ncomms3813">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24264377" aria-label="PubMed reference 31">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 31" href="http://scholar.google.com/scholar_lookup?&amp;title=Integrin%20CD11b%20negatively%20regulates%20BCR%20signalling%20to%20maintain%20autoreactive%20B%20cell%20tolerance&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fncomms3813&amp;volume=4&amp;publication_year=2013&amp;author=Ding%2CC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="32."><p class="c-article-references__text" id="ref-CR32">van Hooren, L. et al. Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma. <i>Nat. Commun.</i> <b>12</b>, 4127 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41467-021-24347-7" data-track-item_id="10.1038/s41467-021-24347-7" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41467-021-24347-7" aria-label="Article reference 32" data-doi="10.1038/s41467-021-24347-7">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34226552" aria-label="PubMed reference 32">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257767" aria-label="PubMed Central reference 32">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 32" href="http://scholar.google.com/scholar_lookup?&amp;title=Agonistic%20CD40%20therapy%20induces%20tertiary%20lymphoid%20structures%20but%20impairs%20responses%20to%20checkpoint%20blockade%20in%20glioma&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-021-24347-7&amp;volume=12&amp;publication_year=2021&amp;author=Hooren%2CL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="33."><p class="c-article-references__text" id="ref-CR33">Tempero, M. et al. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. <i>Ann. Oncol.</i> <b>32</b>, 600–608 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.annonc.2021.01.070" data-track-item_id="10.1016/j.annonc.2021.01.070" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.annonc.2021.01.070" aria-label="Article reference 33" data-doi="10.1016/j.annonc.2021.01.070">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XhvVKqs74%3D" aria-label="CAS reference 33">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33539945" aria-label="PubMed reference 33">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 33" href="http://scholar.google.com/scholar_lookup?&amp;title=Ibrutinib%20in%20combination%20with%20nab-paclitaxel%20and%20gemcitabine%20for%20first-line%20treatment%20of%20patients%20with%20metastatic%20pancreatic%20adenocarcinoma%3A%20phase%20III%20RESOLVE%20study&amp;journal=Ann.%20Oncol.&amp;doi=10.1016%2Fj.annonc.2021.01.070&amp;volume=32&amp;pages=600-608&amp;publication_year=2021&amp;author=Tempero%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="34."><p class="c-article-references__text" id="ref-CR34">Lyman, J. P. et al. Feasibility and utility of synthetic control arms derived from real-world data to support clinical development. <i>J. Clin. Oncol.</i> <b>40</b>, 528 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.2022.40.4_suppl.528" data-track-item_id="10.1200/JCO.2022.40.4_suppl.528" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2022.40.4_suppl.528" aria-label="Article reference 34" data-doi="10.1200/JCO.2022.40.4_suppl.528">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 34" href="http://scholar.google.com/scholar_lookup?&amp;title=Feasibility%20and%20utility%20of%20synthetic%20control%20arms%20derived%20from%20real-world%20data%20to%20support%20clinical%20development&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2022.40.4_suppl.528&amp;volume=40&amp;publication_year=2022&amp;author=Lyman%2CJP">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="35."><p class="c-article-references__text" id="ref-CR35">Upadhaya, S. et al. Combinations take centre stage in PD1/PDL1 inhibitor clinical trials. <i>Nat. Rev. Drug Discov.</i> <b>20</b>, 168–169 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/d41573-020-00204-y" data-track-item_id="10.1038/d41573-020-00204-y" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fd41573-020-00204-y" aria-label="Article reference 35" data-doi="10.1038/d41573-020-00204-y">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXlvFSgtro%3D" aria-label="CAS reference 35">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33177720" aria-label="PubMed reference 35">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 35" href="http://scholar.google.com/scholar_lookup?&amp;title=Combinations%20take%20centre%20stage%20in%20PD1%2FPDL1%20inhibitor%20clinical%20trials&amp;journal=Nat.%20Rev.%20Drug%20Discov.&amp;doi=10.1038%2Fd41573-020-00204-y&amp;volume=20&amp;pages=168-169&amp;publication_year=2021&amp;author=Upadhaya%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="36."><p class="c-article-references__text" id="ref-CR36">Tang, J. et al. Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. <i>Nat. Rev. Drug Discov.</i> <b>17</b>, 854–855 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nrd.2018.210" data-track-item_id="10.1038/nrd.2018.210" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnrd.2018.210" aria-label="Article reference 36" data-doi="10.1038/nrd.2018.210">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXitlalu7%2FM" aria-label="CAS reference 36">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30482962" aria-label="PubMed reference 36">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 36" href="http://scholar.google.com/scholar_lookup?&amp;title=Trial%20watch%3A%20the%20clinical%20trial%20landscape%20for%20PD1%2FPDL1%20immune%20checkpoint%20inhibitors&amp;journal=Nat.%20Rev.%20Drug%20Discov.&amp;doi=10.1038%2Fnrd.2018.210&amp;volume=17&amp;pages=854-855&amp;publication_year=2018&amp;author=Tang%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="37."><p class="c-article-references__text" id="ref-CR37">Hartmann, F. J. et al. Comprehensive immune monitoring of clinical trials to advance human immunotherapy. <i>Cell Rep.</i> <b>28</b>, 819–831 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.celrep.2019.06.049" data-track-item_id="10.1016/j.celrep.2019.06.049" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.celrep.2019.06.049" aria-label="Article reference 37" data-doi="10.1016/j.celrep.2019.06.049">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtl2gsLrE" aria-label="CAS reference 37">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31315057" aria-label="PubMed reference 37">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656694" aria-label="PubMed Central reference 37">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 37" href="http://scholar.google.com/scholar_lookup?&amp;title=Comprehensive%20immune%20monitoring%20of%20clinical%20trials%20to%20advance%20human%20immunotherapy&amp;journal=Cell%20Rep.&amp;doi=10.1016%2Fj.celrep.2019.06.049&amp;volume=28&amp;pages=819-831&amp;publication_year=2019&amp;author=Hartmann%2CFJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="38."><p class="c-article-references__text" id="ref-CR38">Spitzer, M. H. et al. IMMUNOLOGY. An interactive reference framework for modeling a dynamic immune system. <i>Science</i> <b>349</b>, 1259425 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1126/science.1259425" data-track-item_id="10.1126/science.1259425" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1126%2Fscience.1259425" aria-label="Article reference 38" data-doi="10.1126/science.1259425">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26160952" aria-label="PubMed reference 38">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537647" aria-label="PubMed Central reference 38">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 38" href="http://scholar.google.com/scholar_lookup?&amp;title=IMMUNOLOGY.%20An%20interactive%20reference%20framework%20for%20modeling%20a%20dynamic%20immune%20system&amp;journal=Science&amp;doi=10.1126%2Fscience.1259425&amp;volume=349&amp;publication_year=2015&amp;author=Spitzer%2CMH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="39."><p class="c-article-references__text" id="ref-CR39">Assarsson, E. et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. <i>PLoS ONE</i> <b>9</b>, e95192 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1371/journal.pone.0095192" data-track-item_id="10.1371/journal.pone.0095192" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.pone.0095192" aria-label="Article reference 39" data-doi="10.1371/journal.pone.0095192">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24755770" aria-label="PubMed reference 39">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995906" aria-label="PubMed Central reference 39">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 39" href="http://scholar.google.com/scholar_lookup?&amp;title=Homogenous%2096-plex%20PEA%20immunoassay%20exhibiting%20high%20sensitivity%2C%20specificity%2C%20and%20excellent%20scalability&amp;journal=PLoS%20ONE&amp;doi=10.1371%2Fjournal.pone.0095192&amp;volume=9&amp;publication_year=2014&amp;author=Assarsson%2CE">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="40."><p class="c-article-references__text" id="ref-CR40">Patwardhan, A. et al. Achieving high-sensitivity for clinical applications using augmented exome sequencing. <i>Genome Med.</i> <b>7</b>, 71 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/s13073-015-0197-4" data-track-item_id="10.1186/s13073-015-0197-4" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/s13073-015-0197-4" aria-label="Article reference 40" data-doi="10.1186/s13073-015-0197-4">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26269718" aria-label="PubMed reference 40">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534066" aria-label="PubMed Central reference 40">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 40" href="http://scholar.google.com/scholar_lookup?&amp;title=Achieving%20high-sensitivity%20for%20clinical%20applications%20using%20augmented%20exome%20sequencing&amp;journal=Genome%20Med.&amp;doi=10.1186%2Fs13073-015-0197-4&amp;volume=7&amp;publication_year=2015&amp;author=Patwardhan%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="41."><p class="c-article-references__text" id="ref-CR41">Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. <i>Bioinformatics</i> <b>29</b>, 15–21 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/bioinformatics/bts635" data-track-item_id="10.1093/bioinformatics/bts635" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fbioinformatics%2Fbts635" aria-label="Article reference 41" data-doi="10.1093/bioinformatics/bts635">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38XhvV2gsbnF" aria-label="CAS reference 41">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23104886" aria-label="PubMed reference 41">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 41" href="http://scholar.google.com/scholar_lookup?&amp;title=STAR%3A%20ultrafast%20universal%20RNA-seq%20aligner&amp;journal=Bioinformatics&amp;doi=10.1093%2Fbioinformatics%2Fbts635&amp;volume=29&amp;pages=15-21&amp;publication_year=2013&amp;author=Dobin%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="42."><p class="c-article-references__text" id="ref-CR42">DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. <i>Nat. Genet.</i> <b>43</b>, 491–498 (2011).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/ng.806" data-track-item_id="10.1038/ng.806" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fng.806" aria-label="Article reference 42" data-doi="10.1038/ng.806">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3MXksFWguro%3D" aria-label="CAS reference 42">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21478889" aria-label="PubMed reference 42">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083463" aria-label="PubMed Central reference 42">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 42" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20framework%20for%20variation%20discovery%20and%20genotyping%20using%20next-generation%20DNA%20sequencing%20data&amp;journal=Nat.%20Genet.&amp;doi=10.1038%2Fng.806&amp;volume=43&amp;pages=491-498&amp;publication_year=2011&amp;author=DePristo%2CMA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="43."><p class="c-article-references__text" id="ref-CR43">McKenna, A. et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. <i>Genome Res.</i> <b>20</b>, 1297–1303 (2010).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1101/gr.107524.110" data-track-item_id="10.1101/gr.107524.110" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1101%2Fgr.107524.110" aria-label="Article reference 43" data-doi="10.1101/gr.107524.110">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3cXhtFeru7jM" aria-label="CAS reference 43">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20644199" aria-label="PubMed reference 43">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928508" aria-label="PubMed Central reference 43">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 43" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20genome%20analysis%20toolkit%3A%20a%20MapReduce%20framework%20for%20analyzing%20next-generation%20DNA%20sequencing%20data&amp;journal=Genome%20Res.&amp;doi=10.1101%2Fgr.107524.110&amp;volume=20&amp;pages=1297-1303&amp;publication_year=2010&amp;author=McKenna%2CA">
                    Google Scholar</a>&nbsp;
                </p></li></ol><p class="c-article-references__download u-hide-print"><a data-track="click" data-track-action="download citation references" data-track-label="link" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-022-01829-9?format=refman&amp;flavour=references">Download references<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p></div></div></div></section></div><section data-title="Acknowledgements"><div class="c-article-section" id="Ack1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Ack1">Acknowledgements</h2><div class="c-article-section__content" id="Ack1-content"><p>This study was sponsored by the Parker Institute for Cancer Immunotherapy (PICI) and funded by the Cancer Research Institute, Bristol Myers Squibb and PICI. Study drugs were provided by Bristol Myers Squibb and Apexigen. We extend our gratitude to the patients, their families, the clinical investigators and their site staff members who are making this trial possible. We would also like to thank S. Nawabi at PICI for operations leadership of the trial. We thank C. Spencer, M. Travers and R. Kageyama at PICI for aiding in data analysis review and figure formatting; D. DaSilva at PICI for writing and collaborating with the authors on the Methods section of the manuscript; and the Research Operations team at PICI for sample management. We thank S. M. Domchek from the Basser Center of the University of Pennsylvania for expertise and discussion on genomic alterations in patients with mPDAC. We thank R. Schretzenmair, J. Jakobowski and G. Brake-Silla from the University of Pennsylvania Flow Core for handling and running X50 analysis on patient PBMC samples. We thank A. Ruiz and Y. Li from Memorial Sloan Kettering Cancer Center for handling and tissue preparation and analysis of patient tumor biopsies for Vectra analysis. We thank C. Abbott, L. McDaniel and S. Boyle at Personalis for whole-exome sequencing and transcriptomics analyses of patient biopsies and thoughtful discussions. We thank K. Sklodowski, R. Bruderer and L. Reiter from Biognosys for their contributions in mass spectrometry proteomic data. We thank Sean Parker for his support and helpful scientific discussions. We thank Bristol Myers Squibb and Apexigen for collaboration and study drugs.</p></div></div></section><section aria-labelledby="author-information" data-title="Author information"><div class="c-article-section" id="author-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="author-information">Author information</h2><div class="c-article-section__content" id="author-information-content"><span class="c-article-author-information__subtitle u-visually-hidden" id="author-notes">Author notes</span><ol class="c-article-author-information__list"><li class="c-article-author-information__item" id="na1"><p>These authors contributed equally: Lacey J. Padrón, Deena M. Maurer, Mark H. O’Hara.</p></li></ol><h3 class="c-article__sub-heading" id="affiliations">Authors and Affiliations</h3><ol class="c-article-author-affiliation__list"><li id="Aff1"><p class="c-article-author-affiliation__address">Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA</p><p class="c-article-author-affiliation__authors-list">Lacey J. Padrón,&nbsp;Deena M. Maurer,&nbsp;Jaclyn P. Lyman,&nbsp;Christopher R. Cabanski,&nbsp;Jia Xin Yu,&nbsp;Shannon M. Pfeiffer,&nbsp;Marko Spasic,&nbsp;Jingying Xu,&nbsp;Pier Federico Gherardini,&nbsp;Joyson Karakunnel,&nbsp;Ute Dugan,&nbsp;Lisa H. Butterfield,&nbsp;Ramy Ibrahim,&nbsp;Justin Fairchild,&nbsp;Samantha Bucktrout&nbsp;&amp;&nbsp;Theresa M. LaVallee</p></li><li id="Aff2"><p class="c-article-author-affiliation__address">Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA</p><p class="c-article-author-affiliation__authors-list">Mark H. O’Hara,&nbsp;Rosemarie Mick,&nbsp;Cécile Alanio,&nbsp;Katelyn T. Byrne,&nbsp;Jonni S. Moore,&nbsp;Derek D. Jones,&nbsp;E. John Wherry&nbsp;&amp;&nbsp;Robert H. Vonderheide</p></li><li id="Aff3"><p class="c-article-author-affiliation__address">Memorial Sloan Kettering Cancer Center, New York, NY, USA</p><p class="c-article-author-affiliation__authors-list">Eileen M. O’Reilly&nbsp;&amp;&nbsp;Travis J. Hollmann</p></li><li id="Aff4"><p class="c-article-author-affiliation__address">The University of Texas MD Anderson Cancer Center, Houston, TX, USA</p><p class="c-article-author-affiliation__authors-list">Robert A. Wolff</p></li><li id="Aff5"><p class="c-article-author-affiliation__address">University of California, Los Angeles, Los Angeles, CA, USA</p><p class="c-article-author-affiliation__authors-list">Zev A. Wainberg</p></li><li id="Aff6"><p class="c-article-author-affiliation__address">University of California, San Francisco, San Francisco, CA, USA</p><p class="c-article-author-affiliation__authors-list">Andrew H. Ko</p></li><li id="Aff7"><p class="c-article-author-affiliation__address">Stanford University, Stanford, CA, USA</p><p class="c-article-author-affiliation__authors-list">George Fisher</p></li><li id="Aff8"><p class="c-article-author-affiliation__address">Dana-Farber Cancer Institute, Boston, MA, USA</p><p class="c-article-author-affiliation__authors-list">Osama Rahma</p></li><li id="Aff9"><p class="c-article-author-affiliation__address">Parker Institute of Cancer Immunotherapy at the University of Pennsylvania, Philadelphia, PA, USA</p><p class="c-article-author-affiliation__authors-list">Cécile Alanio,&nbsp;Katelyn T. Byrne,&nbsp;E. John Wherry&nbsp;&amp;&nbsp;Robert H. Vonderheide</p></li><li id="Aff10"><p class="c-article-author-affiliation__address">Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA</p><p class="c-article-author-affiliation__authors-list">Cécile Alanio&nbsp;&amp;&nbsp;E. John Wherry</p></li><li id="Aff11"><p class="c-article-author-affiliation__address">Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA</p><p class="c-article-author-affiliation__authors-list">Cécile Alanio,&nbsp;E. John Wherry&nbsp;&amp;&nbsp;Robert H. Vonderheide</p></li><li id="Aff12"><p class="c-article-author-affiliation__address">Biognosys AG, Schlieren, Switzerland</p><p class="c-article-author-affiliation__authors-list">Marco Tognetti</p></li><li id="Aff13"><p class="c-article-author-affiliation__address">Personalis, Inc., Menlo Park, CA, USA</p><p class="c-article-author-affiliation__authors-list">Richard O. Chen</p></li><li id="Aff14"><p class="c-article-author-affiliation__address">Apexigen, Inc., San Carlos, CA, USA</p><p class="c-article-author-affiliation__authors-list">Xiaodong Yang</p></li><li id="Aff15"><p class="c-article-author-affiliation__address">Bristol Myers Squibb, New York, NY, USA</p><p class="c-article-author-affiliation__authors-list">Lisa Salvador</p></li><li id="Aff16"><p class="c-article-author-affiliation__address">Cancer Research Institute, New York, NY, USA</p><p class="c-article-author-affiliation__authors-list">Jill O’Donnell-Tormey&nbsp;&amp;&nbsp;Vanessa M. Hubbard-Lucey</p></li></ol><div class="u-js-hide u-hide-print" data-test="author-info"><span class="c-article__sub-heading">Authors</span><ol class="c-article-authors-search u-list-reset"><li id="auth-Lacey_J_-Padr_n-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Lacey J. Padrón</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Lacey%20J.%20Padr%C3%B3n" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Lacey%20J.%20Padr%C3%B3n" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Lacey%20J.%20Padr%C3%B3n%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Deena_M_-Maurer-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Deena M. Maurer</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Deena%20M.%20Maurer" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Deena%20M.%20Maurer" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Deena%20M.%20Maurer%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Mark_H_-O_Hara-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Mark H. O’Hara</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Mark%20H.%20O%E2%80%99Hara" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Mark%20H.%20O%E2%80%99Hara" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Mark%20H.%20O%E2%80%99Hara%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Eileen_M_-O_Reilly-Aff3"><span class="c-article-authors-search__title u-h3 js-search-name">Eileen M. O’Reilly</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Eileen%20M.%20O%E2%80%99Reilly" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Eileen%20M.%20O%E2%80%99Reilly" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Eileen%20M.%20O%E2%80%99Reilly%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Robert_A_-Wolff-Aff4"><span class="c-article-authors-search__title u-h3 js-search-name">Robert A. Wolff</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Robert%20A.%20Wolff" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Robert%20A.%20Wolff" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Robert%20A.%20Wolff%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Zev_A_-Wainberg-Aff5"><span class="c-article-authors-search__title u-h3 js-search-name">Zev A. Wainberg</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Zev%20A.%20Wainberg" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Zev%20A.%20Wainberg" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Zev%20A.%20Wainberg%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Andrew_H_-Ko-Aff6"><span class="c-article-authors-search__title u-h3 js-search-name">Andrew H. Ko</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Andrew%20H.%20Ko" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Andrew%20H.%20Ko" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Andrew%20H.%20Ko%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-George-Fisher-Aff7"><span class="c-article-authors-search__title u-h3 js-search-name">George Fisher</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=George%20Fisher" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=George%20Fisher" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22George%20Fisher%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Osama-Rahma-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Osama Rahma</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Osama%20Rahma" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Osama%20Rahma" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Osama%20Rahma%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Jaclyn_P_-Lyman-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Jaclyn P. Lyman</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Jaclyn%20P.%20Lyman" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Jaclyn%20P.%20Lyman" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Jaclyn%20P.%20Lyman%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Christopher_R_-Cabanski-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Christopher R. Cabanski</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Christopher%20R.%20Cabanski" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Christopher%20R.%20Cabanski" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Christopher%20R.%20Cabanski%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Jia_Xin-Yu-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Jia Xin Yu</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Jia%20Xin%20Yu" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Jia%20Xin%20Yu" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Jia%20Xin%20Yu%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Shannon_M_-Pfeiffer-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Shannon M. Pfeiffer</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Shannon%20M.%20Pfeiffer" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Shannon%20M.%20Pfeiffer" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Shannon%20M.%20Pfeiffer%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Marko-Spasic-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Marko Spasic</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Marko%20Spasic" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Marko%20Spasic" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Marko%20Spasic%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Jingying-Xu-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Jingying Xu</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Jingying%20Xu" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Jingying%20Xu" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Jingying%20Xu%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Pier_Federico-Gherardini-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Pier Federico Gherardini</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Pier%20Federico%20Gherardini" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Pier%20Federico%20Gherardini" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Pier%20Federico%20Gherardini%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Joyson-Karakunnel-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Joyson Karakunnel</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Joyson%20Karakunnel" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Joyson%20Karakunnel" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Joyson%20Karakunnel%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Rosemarie-Mick-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Rosemarie Mick</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Rosemarie%20Mick" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Rosemarie%20Mick" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Rosemarie%20Mick%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-C_cile-Alanio-Aff2-Aff9-Aff10-Aff11"><span class="c-article-authors-search__title u-h3 js-search-name">Cécile Alanio</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=C%C3%A9cile%20Alanio" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=C%C3%A9cile%20Alanio" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22C%C3%A9cile%20Alanio%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Katelyn_T_-Byrne-Aff2-Aff9"><span class="c-article-authors-search__title u-h3 js-search-name">Katelyn T. Byrne</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Katelyn%20T.%20Byrne" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Katelyn%20T.%20Byrne" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Katelyn%20T.%20Byrne%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Travis_J_-Hollmann-Aff3"><span class="c-article-authors-search__title u-h3 js-search-name">Travis J. Hollmann</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Travis%20J.%20Hollmann" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Travis%20J.%20Hollmann" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Travis%20J.%20Hollmann%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Jonni_S_-Moore-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Jonni S. Moore</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Jonni%20S.%20Moore" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Jonni%20S.%20Moore" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Jonni%20S.%20Moore%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Derek_D_-Jones-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Derek D. Jones</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Derek%20D.%20Jones" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Derek%20D.%20Jones" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Derek%20D.%20Jones%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Marco-Tognetti-Aff12"><span class="c-article-authors-search__title u-h3 js-search-name">Marco Tognetti</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Marco%20Tognetti" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Marco%20Tognetti" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Marco%20Tognetti%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Richard_O_-Chen-Aff13"><span class="c-article-authors-search__title u-h3 js-search-name">Richard O. Chen</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Richard%20O.%20Chen" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Richard%20O.%20Chen" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Richard%20O.%20Chen%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Xiaodong-Yang-Aff14"><span class="c-article-authors-search__title u-h3 js-search-name">Xiaodong Yang</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Xiaodong%20Yang" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Xiaodong%20Yang" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Xiaodong%20Yang%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Lisa-Salvador-Aff15"><span class="c-article-authors-search__title u-h3 js-search-name">Lisa Salvador</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Lisa%20Salvador" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Lisa%20Salvador" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Lisa%20Salvador%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-E__John-Wherry-Aff2-Aff9-Aff10-Aff11"><span class="c-article-authors-search__title u-h3 js-search-name">E. John Wherry</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=E.%20John%20Wherry" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=E.%20John%20Wherry" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22E.%20John%20Wherry%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Ute-Dugan-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Ute Dugan</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Ute%20Dugan" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Ute%20Dugan" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Ute%20Dugan%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Jill-O_Donnell_Tormey-Aff16"><span class="c-article-authors-search__title u-h3 js-search-name">Jill O’Donnell-Tormey</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Jill%20O%E2%80%99Donnell-Tormey" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Jill%20O%E2%80%99Donnell-Tormey" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Jill%20O%E2%80%99Donnell-Tormey%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Lisa_H_-Butterfield-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Lisa H. Butterfield</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Lisa%20H.%20Butterfield" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Lisa%20H.%20Butterfield" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Lisa%20H.%20Butterfield%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Vanessa_M_-Hubbard_Lucey-Aff16"><span class="c-article-authors-search__title u-h3 js-search-name">Vanessa M. Hubbard-Lucey</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Vanessa%20M.%20Hubbard-Lucey" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Vanessa%20M.%20Hubbard-Lucey" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Vanessa%20M.%20Hubbard-Lucey%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Ramy-Ibrahim-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Ramy Ibrahim</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Ramy%20Ibrahim" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Ramy%20Ibrahim" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Ramy%20Ibrahim%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Justin-Fairchild-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Justin Fairchild</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Justin%20Fairchild" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Justin%20Fairchild" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Justin%20Fairchild%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Samantha-Bucktrout-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Samantha Bucktrout</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Samantha%20Bucktrout" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Samantha%20Bucktrout" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Samantha%20Bucktrout%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Theresa_M_-LaVallee-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Theresa M. LaVallee</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Theresa%20M.%20LaVallee" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Theresa%20M.%20LaVallee" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Theresa%20M.%20LaVallee%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Robert_H_-Vonderheide-Aff2-Aff9-Aff11"><span class="c-article-authors-search__title u-h3 js-search-name">Robert H. Vonderheide</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Robert%20H.%20Vonderheide" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Robert%20H.%20Vonderheide" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Robert%20H.%20Vonderheide%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li></ol></div><h3 class="c-article__sub-heading" id="contributions">Contributions</h3><p>M.H.O., E.M.O., Z.A.W., A.H.K., G.F., J.P.L., C.R.C., M.S., J.X., J.K., R.M., X.Y., L.S., U.D., J.O.-T., V.M.H.-L., R.I., J.F., T.M.L. and R.H.V. designed the clinical study. M.H.O., E.M.O., R.A.W., Z.A.W., A.H.K., G.F. and O.R. informed patients and were responsible for patient care. M.H.O., E.M.O., Z.A.W., A.H.K., G.F., J.P.L., C.R.C., M.S., J.X., J.K., R.M., R.I., J.F., T.M.L. and R.H.V. provided scientific input during protocol design and interpretation of the study. J.P.L., C.R.C., M.S., J.X., J.K., R.I. and J.F. analyzed and interpreted the clinical data. C.R.C. and R.M. performed statistical analysis. T.H., J.M., D.J., M.T. and R.O.C. performed biomarker experiments. L.J.P., D.M.M., J.X.Y., S.M.P., P.F.G. and M.T. performed biomarker computational analysis. L.J.P., D.M.M., J.P.L., C.R.C., J.X.Y., S.M.P., P.F.G., C.A., K.T.B., T.H., E.J.W., L.H.B., S.B., T.M.L. and R.H.V. analyzed and interpreted the biomarker data. L.J.P., D.M.M., M.H.O., C.R.C., L.H.B., J.F., S.B., T.M.L. and R.H.V. wrote the manuscript. All authors edited and approved the manuscript.</p><h3 class="c-article__sub-heading" id="corresponding-author">Corresponding authors</h3><p id="corresponding-author-list">Correspondence to
                <a id="corresp-c1" href="mailto:lpadron@parkerici.org">Lacey J. Padrón</a> or <a id="corresp-c2" href="mailto:rhv@upenn.edu">Robert H. Vonderheide</a>.</p></div></div></section><section data-title="Ethics declarations"><div class="c-article-section" id="ethics-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="ethics">Ethics declarations</h2><div class="c-article-section__content" id="ethics-content">
              
                <h3 class="c-article__sub-heading" id="FPar4">Competing interests</h3>
                <p>A.H.K., E.M.O., R.H.V., M.H.O., G.F. and E.J.W. report grants from the Parker Institute for Cancer Immunotherapy (PICI) during the conduct of this study. A.H.K. reports grants from Celgene, Apexigen and Bristol Myers Squibb (BMS) outside the submitted work. E.M.O. reports research funding from MSK, Genentech/Roche, Celgene/BMS, BioNTech, AstraZeneca, Arcus and Elicio and consulting/DSMB for Cytomx Therapeutics, Rafael Therapeutics, Silenseed, Tyme, Seagen, Boehringer Ingelheim, BioNTech, Ipsen, Merck, IDEAYA, AstraZeneca, Noxxon, BioSapien, Cend Therapeutics, Thetis, Bayer (spouse), Genentech/Roche (spouse), Celgene/BMS (spouse) and Eisai (spouse). L.H.B. declares the following unrelated advisory activities: StemImmune/Calidi, Western Oncolytics, Torque Therapeutics, Khloris, Pyxis, Cytomix, DCprime, RAPT, Takeda and EnaraBio. O.R. reports personal fees from Merck, Celgene, Five Prime Therapeutics, GlaxoSmithKline, Bayer, Roche/Genentech, Puretech, Imvax and Sobi outside the submitted work and has a patent pending for methods that make use of pembrolizumab and trebananib. P.F.G. reports stock ownership in Teiko.bio. R.H.V. reports grants from FibroGen, Inovio, Janssen and Eli Lilly and personal fees from MedImmune, Eli Lilly, Celgene, Celldex Therapeutics and Verastem Oncology outside the submitted work; is an inventor on a licensed patent relating to cancer cellular immunotherapy and cancer vaccines; and receives royalties from Children’s Hospital Boston for a licensed research-only monoclonal antibody. R.O.C. is an employee of Personalis, a company that PICI paid to produce sequence information for some samples reported in this paper as part of a collaboration. R.O.C. is also an inventor on US patent number 09183496 issued to Personalis, which describes the genomic analyses in the Personalis sequencing platform used to sequence the samples in this study. T.M.L. reports Coherus Biosciences employment; LISCure Biosciences Scientific Advisory Board membership; stock ownership in AstraZenca; and consulting outside the submitted work for Grey Wolf Therapeutics and BiOneCure. V.M.H.-L. is an employee of BMS and holds stock. Z.A.W. reports grants from Novartis, Five Prime Therapeutics, Plexxikon and BMS and personal fees from Merck, Eli Lilly, Daiichi, AstraZeneca and Bayer outside the submitted work. M.S. reports consulting for Natera. M.H.O. reports grants from BMS and Celldex; grants and non-financial support from Stand Up To Cancer; and personal fees from Natera outside the submitted work. M.T. is an employee of Biognosys AG. G.F. reports personal fees from Merck, Roche/Genentech and CytomX outside the submitted work; and his spouse owns stock in Seattle Genetics. E.J.W. is a consultant or an advisor for Merck, Elstar, Janssen, Related Sciences, Synthekine and Surface Oncology; is a founder of Surface Oncology and Arsenal Biosciences; and is an inventor on US patent number 10,370,446, submitted by Emory University that covers the use of PD-1 blockade to treat infections and cancer. L.J.P., D.M.M., R.A.W., J.P.L., C.R.C., J.X.Y., S.M.P., J.X., J.K., R.M., C.A., K.T.B., T.J.H., J.S.M., D.D.J., X.Y., L.S., U.D., J.O.-T., R.I., J.F. and S.B. report no competing interests related to the work presented.</p>
              
            </div></div></section><section data-title="Peer review"><div class="c-article-section" id="peer-review-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="peer-review">Peer review</h2><div class="c-article-section__content" id="peer-review-content">
              
              
                <h3 class="c-article__sub-heading" id="FPar3">Peer review information</h3>
                <p><i>Nature Medicine</i> thanks Marina Pasca di Magliano and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Saheli Sadanand was the primary editor on this manuscript, in collaboration with the <i>Nature Medicine</i> team.</p>
              
            </div></div></section><section data-title="Additional information"><div class="c-article-section" id="additional-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="additional-information">Additional information</h2><div class="c-article-section__content" id="additional-information-content"><p><b>Publisher’s note</b> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div></div></section><section data-title="Extended data"><div class="c-article-section" id="Sec32-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec32">Extended data</h2><div class="c-article-section__content" id="Sec32-content"><div data-test="supplementary-info"><div id="figshareContainer" class="c-article-figshare-container" data-test="figshare-container"></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig6"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 1 prince schema for dosing and " href="/articles/s41591-022-01829-9/figures/6" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig6_ESM.jpg">Extended Data Fig. 1 PRINCE schema for dosing and sample collection schedule.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Schema shows standard dosing schedule and relevant sample collection timepoints for each treatment arm. All drugs were given intravenously. The study protocol provides additional details on allowable modifications to the dosing schedule.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig7"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 2 kaplan-meier curves of progre" href="/articles/s41591-022-01829-9/figures/7" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig7_ESM.jpg">Extended Data Fig. 2 Kaplan-Meier curves of progression-free survival and duration of response.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>a</b>, Progression-free survival (PFS) of patients in the efficacy population. <b>b</b>, Duration of response (DOR) of patients in the efficacy population who had a partial or complete response. PFS, DOR and the corresponding 2-sided 95% confidence interval (CI) were estimated by the Kaplan-Meier method. CI = confidence interval; NE = not estimable.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig8"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 3 biomarker signatures in blood" href="/articles/s41591-022-01829-9/figures/8" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig8_ESM.jpg">Extended Data Fig. 3 Biomarker signatures in blood and tumor reveal specific immune mechanisms of activation in response to nivo/chemo and sotiga/chemo treatment in patients with mPDAC.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>a</b>, Change in frequencies of circulating Ki-67+ non-naïve CD8 (left panel) and CD4 (right panel) T cells, as a fraction of total non-naïve CD8 or CD4 T cells respectively, in patients from each arm over the course of treatment by flow cytometry. <b>b</b>, Change in frequencies of circulating HLA-DR+ non-naïve CD8 (b, left panel) and CD4 (b, right panel) T cells, as a fraction of total non-naïve CD8 or CD4 T cells respectively, in patients from each arm over the course of treatment by Cytof. <b>c,d,e,f</b>, Change in Log2 expression of circulating IFN-γ (c), PD-1 (d), CXCL9 (e) and CXCL10 (f) from pretreatment values from each arm by Olink analysis. Timeseries box plots in a-f are shown as fold change relative to C1D1 and plotted on a pseudo-log scale. Median values and quartiles are shown. The whiskers depict 95% CI. Individual patient values are shown in thin lines and colored by survival status at 1 year. P-values represent two-sided Wilcoxon signed-rank tests between timepoints, illustrating increases on-treatment. <b>g, h</b>, Frequencies of PD-L1+ tumor cells (g) and intratumoral iNOS+CD80+ macrophages (h) from mIF of on-treatment biopsies (C2D1 when feasible, see <a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-022-01829-9#Sec12">methods</a> for details), shown as a fold change relative to pretreatment biopsy for each arm. <b>i</b>, DIABLO Circos plot showing results of integrative analysis where select factors from CyTOF, X50 flow cytometry and Olink, significantly associated with on-treatment (C2D1) effects and correlations among these factors and treatment arms. In the Circos plot, lines outside the circle indicate magnitude and direction of treatment association (the further distance from the circle, the greater the association). Lines inside the plot indicate positive (blue) correlations between biomarker factors. For all cell populations shown, frequencies are out of parent population. Sample sizes for all cell populations identified through CyTOF analysis (<b>b</b>): n = 25, 20, 23, 13; n = 29, 23, 24, 22; n = 26, 20, 26, 13 biologically independent samples at C1D1, C1D15, C2D1 and C4D1 in nivo/chemo, sotiga/chemo, sotiga/nivo/chemo treatment arms, respectively. Sample sizes for all cell populations identified through flow cytometry analysis (<b>a</b>): n = 26, 21, 25, 19; n = 28, 23, 27, 18; n = 32, 27, 29, 14 biologically independent samples at C1D1, C1D15, C2D1 and C4D1 in nivo/chemo, sotiga/chemo, sotiga/nivo/chemo treatment arms, respectively. Sample sizes for all soluble proteins identified through proteomic analysis (<b>c,d,e,f</b>): n = 32, 25, 27, 25, 23; n = 36, 29, 31, 25, 27; n = 35, 27, 32, 26, 25 biologically independent samples at C1D1, C1D15, C2D1, C3D1, and C4D1 in nivo/chemo, sotiga/chemo, sotiga/nivo/chemo treatment arms, respectively. Sample sizes for all cell populations identified through mIF (<b>g,h</b>): n = 5, 3, 6, biologically independent matched paired samples at C1D1 and approximately C2D1 in nivo/chemo, sotiga/chemo, sotiga/nivo/chemo treatment arms, respectively. (<b>i</b>): n = 22, 23, 21 biologically independent matched samples at C2D1 in nivo/chemo, sotiga/chemo, sotiga/nivo/chemo treatment arms respectively for CyTOF, X50 flow cytometry and Olink integrative analysis.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig9"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 4 a non-immunosuppressive tumor" href="/articles/s41591-022-01829-9/figures/9" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig9_ESM.jpg">Extended Data Fig. 4 A non-immunosuppressive tumor microenvironment and activated circulating CD8 T cells before treatment are associated with survival in mPDAC patients treated with nivo/chemo.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>a</b>, Heatmap showing results of unsupervised clustering of gene expression signatures and survival status in the nivo/chemo arm. Individual patients are shown in columns and annotated by survival status at 1 year to illustrate association. Gene expression signature labels are color coded based on survival association by log-rank test. KM curves for overall survival stratified by median values at baseline of <b>b</b>, TNF-α via NFκB hallmark pathway signature score and <b>c</b>, Percentage of iNOS+ intratumoral macrophages out of total cells from mIF (c, top panel). Representative pretreatment tumor mIF images showing iNOS+ cells from two patients with labels showing marker grouping (low = below median, high= above median) and individual patient survival (c, bottom panel). <b>d</b>, Spearman correlation matrix of tumor immune populations and gene expression signatures in pretreatment tumor biopsies, with labels color coded by association with survival association by log-rank test. Note the Y-axis labels are to be repeated along the X-axis (bottom to top on Y-axis corresponding to left to right on X-axis). <b>e</b>, Multi-omic dimensionality reduction of circulating factors and tumor data using Independent Component Analysis, with each dot representing a single patient colored by survival status at one year and with position determined by reduced dimensionality across all tumor and circulating biomarkers. Black separating line serves to illustrate a separation and is not computationally derived. On all KM curves, median values were determined using all data across the 3 arms, P-values are from a log-rank test between groups, and shaded regions illustrate 95% CI.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig10"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 5 higher frequencies of specifi" href="/articles/s41591-022-01829-9/figures/10" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig10_ESM.jpg">Extended Data Fig. 5 Higher frequencies of specific B cell populations and lower concentrations of 2B4+ T cells are associated with survival in patients treated with sotiga/chemo.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>a</b>, Force-directed graph visualization of unsupervised clustering of cells from CyTOF across all patients and timepoints, illustrating a specific population of B cells (CD19+, CCR7+, HLA-DR+) associating with survival and followed up on with gating analysis in further panels. <b>b</b>, KM curves for overall survival stratified by frequencies of pretreatment circulating HLA-DR+ CCR7+ B cells out of total leukocytes, above and below the median frequency. <b>c</b>, KM curves for overall survival stratified by frequency of pretreatment circulating 2B4+ non-naïve CD4 T cells out of total non-naïve CD4 T cells. <b>d</b>, Heatmap of pretreatment relative median fluorescence intensity of markers present on 2B4+ non-naïve CD4 T cells across all patients. <b>e</b>, Frequencies of 2B4+ non-naïve CD4 T cells pretreatment (C1D1) and on-treatment (C1D15, C2D1, and C4D1), grouped by survival status at 1 year. Box plots show median and quartiles and whiskers depict 95% CI. Individual patient values are shown in thin lines and colored by survival status at 1 year. P-values represent two-sided Wilcoxon signed-rank tests between timepoints, illustrating changes on-treatment. On all KM curves, median values were determined using all data across the 3 arms, P-values are from a log-rank test between groups, and shaded regions illustrate 95% CI. Sample sizes for cell populations shown in e: n = 28, 23, 27 and 18 biologically independent samples at C1D1, C1D15, C2D1 and C4D1.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig11"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 6 t helper signatures and proli" href="/articles/s41591-022-01829-9/figures/11" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig11_ESM.jpg">Extended Data Fig. 6 T helper signatures and proliferating CD4 T cells in the tumor associate with survival in patients receiving sotiga/chemo treatment.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>a</b>, Heatmap showing results of unsupervised clustering of gene expression signatures and survival status in the sotiga/chemo arm. Individual patients are shown in columns and annotated by survival status at 1 year to illustrate association. Gene expression signature labels are color coded based on survival association by log-rank test, calculated independently from unsupervised clustering. <b>b, c, d</b>, KM curves for overall survival stratified by median values of Th1 (b), IFNγ (c), and E2F (d) gene expression signatures. <b>e</b>, KM curve for overall survival stratified by median values of Ki-67<sup>−</sup> Foxp3- CD4 T cells from mIF on pretreatment tumor samples (e, top panel) and representative images from tumor samples high and low in Ki-67- Foxp3- CD4 T cells (e, bottom panel). Labels indicate marker grouping and patient survival values. <b>f</b>, Spearman correlation matrix of tumor immune infiltrate and gene expression signatures in pretreatment tumor biopsies, with labels colored by association with overall survival by log-rank test. <b>g</b>, Multi-omic dimensionality reduction of circulating factors and tumor data using Independent Component Analysis, with each dot representing a single patient colored by survival status at one year and with position determined by reduced dimensionality across all tumor and circulating biomarkers. Black separating line serves to illustrate a separation and is not computationally derived. On all KM curves, median values were determined using all data across the 3 arms, P-values are from a log-rank test between groups, and shaded regions illustrate 95% CI.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig12"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 7 lower frequencies of circulat" href="/articles/s41591-022-01829-9/figures/12" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig12_ESM.jpg">Extended Data Fig. 7 Lower frequencies of circulating CD38+ non-naïve T cells are associated with longer survival in patients treated with sotiga/nivo/chemo.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>a,d</b>, KM curves for overall survival stratified by frequencies of circulating CD38+ non-naïve CD4 (a) and CD8 (d) T cells at baseline, above and below the median frequency value. <b>b</b>, Heatmaps of relative median fluorescent intensity of pretreatment markers present on CD38+ non-naïve CD4 and CD8 T cells across all patients. <b>c, e</b>, Frequencies of CD38+ non-naïve CD4 (c) and CD8 (e) T cells pretreatment (C1D1) and on-treatment (C1D15, C2D1, and C4D1), grouped by survival status at 1 year. For all cell populations shown, frequencies are out of parent. Box plots show median and quartiles and whiskers depict 95% CI. Individual patient values are shown in thin lines and colored by survival status at 1 year. P-values for timeseries represent two-sided Wilcoxon signed-rank tests between timepoints, illustrating changes on-treatment. On KM curves, median values were determined using all data across the 3 arms, P-values are from a log-rank test between groups, and shaded regions illustrate 95% CI. Sample sizes for cell populations shown (c, e): n = 32, 27, 29 and 14 biologically independent samples at C1D1, C1D15, C2D1 and C4D1.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig13"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 8 survival in response to combi" href="/articles/s41591-022-01829-9/figures/13" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig13_ESM.jpg">Extended Data Fig. 8 Survival in response to combinational therapy of sotiga/nivo/chemo may be affected by regulatory B cells in circulation.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>a</b>, KM curves for overall survival stratified by CCR7+ CD11b+ CD27- B cells above and below the median frequency value. <b>b</b>, Heatmap of relative median signal intensity of different proteins present on CCR7+ CD11b+ CD27- B cells on-treatment (C1D15) across all patients. <b>c</b>, Frequencies of CCR7+ CD11b+ CD27- B cells pretreatment (C1D1) and on-treatment (C1D15, C2D1, C4D1), grouped by survival status at 1 year, for each treatment arm. For all cell populations shown, frequencies are out of total leukocytes. On KM curves, median values were determined using all data across the 3 arms, P-values are from a log-rank test between groups, and shaded regions illustrate 95% CI. Box plots show median and quartiles and whiskers depict 95% CI. Individual patient values are shown in thin lines and colored by survival status at 1 year. P-values for timeseries represent two-sided Wilcoxon signed-rank tests between survival groups at each timepoint. Sample sizes for cell populations shown (c): n = 25, 20, 23, 13; n = 29, 23, 24, 22; n = 26, 20, 26, 13 biologically independent samples at C1D1, C1D15, C2D1 and C4D1 in nivo/chemo, sotiga/chemo, sotiga/nivo/chemo treatment arms, respectively.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item"><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-2"><figure><figcaption class="c-article-table__figcaption"><b id="Tab2" data-test="table-caption">Extended Data Table 1 Clinical activity in the efficacy population</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/s41591-022-01829-9/tables/2" aria-label="Full size table 2"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div></div><div class="c-article-supplementary__item" data-test="supp-item"><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-3"><figure><figcaption class="c-article-table__figcaption"><b id="Tab3" data-test="table-caption">Extended Data Table 2 Treatment-related adverse events with incidence ≥ 20% in any arm</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/s41591-022-01829-9/tables/3" aria-label="Full size table 3"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div></div></div></div></div></section><section data-title="Supplementary information"><div class="c-article-section" id="Sec33-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec33">Supplementary information</h2><div class="c-article-section__content" id="Sec33-content"><div data-test="supplementary-info"><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM1"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supplementary information" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_MOESM1_ESM.pdf" data-supp-info-image="">Supplementary Information</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Supplementary Figs. 1–8, Supplementary Tables 1–14, Clinical Study Protocol and Statistical Analysis Plan</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM2"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="reporting summary" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_MOESM2_ESM.pdf" data-supp-info-image="">Reporting Summary</a></h3></div></div></div></div></section><section data-title="Rights and permissions"><div class="c-article-section" id="rightslink-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="rightslink">Rights and permissions</h2><div class="c-article-section__content" id="rightslink-content">
                <p><b>Open Access</b>  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by/4.0/" rel="license">http://creativecommons.org/licenses/by/4.0/</a>.</p>
              <p class="c-article-rights"><a data-track="click" data-track-action="view rights and permissions" data-track-label="link" href="https://s100.copyright.com/AppDispatchServlet?title=Sotigalimab%20and%2For%20nivolumab%20with%20chemotherapy%20in%20first-line%20metastatic%20pancreatic%20cancer%3A%20clinical%20and%20immunologic%20analyses%20from%20the%20randomized%20phase%202%20PRINCE%20trial&amp;author=Lacey%20J.%20Padr%C3%B3n%20et%20al&amp;contentID=10.1038%2Fs41591-022-01829-9&amp;copyright=The%20Author%28s%29&amp;publication=1078-8956&amp;publicationDate=2022-06-03&amp;publisherName=SpringerNature&amp;orderBeanReset=true&amp;oa=CC%20BY">Reprints and permissions</a></p></div></div></section><section aria-labelledby="article-info" data-title="About this article"><div class="c-article-section" id="article-info-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="article-info">About this article</h2><div class="c-article-section__content" id="article-info-content"><div class="c-bibliographic-information"><div class="u-hide-print c-bibliographic-information__column c-bibliographic-information__column--border"><a data-crossmark="10.1038/s41591-022-01829-9" target="_blank" rel="noopener" href="https://crossmark.crossref.org/dialog/?doi=10.1038/s41591-022-01829-9" data-track="click" data-track-action="Click Crossmark" data-track-label="link" data-test="crossmark"><img loading="lazy" width="57" height="81" alt="Check for updates. Verify currency and authenticity via CrossMark" src="data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>"></a></div><div class="c-bibliographic-information__column"><h3 class="c-article__sub-heading" id="citeas">Cite this article</h3><p class="c-bibliographic-information__citation">Padrón, L.J., Maurer, D.M., O’Hara, M.H. <i>et al.</i> Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.
                    <i>Nat Med</i> <b>28</b>, 1167–1177 (2022). https://doi.org/10.1038/s41591-022-01829-9</p><p class="c-bibliographic-information__download-citation u-hide-print"><a data-test="citation-link" data-track="click" data-track-action="download article citation" data-track-label="link" data-track-external="" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-022-01829-9?format=refman&amp;flavour=citation">Download citation<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p><ul class="c-bibliographic-information__list" data-test="publication-history"><li class="c-bibliographic-information__list-item"><p>Received<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2021-12-20">20 December 2021</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Accepted<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2022-04-15">15 April 2022</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Published<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2022-06-03">03 June 2022</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Issue Date<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2022-06">June 2022</time></span></p></li><li class="c-bibliographic-information__list-item c-bibliographic-information__list-item--full-width"><p><abbr title="Digital Object Identifier">DOI</abbr><span class="u-hide">: </span><span class="c-bibliographic-information__value">https://doi.org/10.1038/s41591-022-01829-9</span></p></li></ul><div data-component="share-box"><div class="c-article-share-box u-display-block"><h3 class="c-article__sub-heading">Share this article</h3><p class="c-article-share-box__description">Anyone you share the following link with will be able to read this content:</p><button class="js-get-share-url c-article-share-box__button" type="button" id="get-share-url" data-track="click" data-track-label="button" data-track-external="" data-track-action="get shareable link">Get shareable link</button><div class="js-no-share-url-container u-display-none" hidden=""><p class="js-c-article-share-box__no-sharelink-info c-article-share-box__no-sharelink-info">Sorry, a shareable link is not currently available for this article.</p></div><div class="js-share-url-container u-display-none" hidden=""><p class="js-share-url c-article-share-box__only-read-input" id="share-url" data-track="click" data-track-label="button" data-track-action="select share url"></p><button class="js-copy-share-url c-article-share-box__button--link-like" type="button" id="copy-share-url" data-track="click" data-track-label="button" data-track-action="copy share url" data-track-external="">Copy to clipboard</button></div><p class="js-c-article-share-box__additional-info c-article-share-box__additional-info">
                            Provided by the Springer Nature SharedIt content-sharing initiative
                        </p></div></div><div data-component="article-info-list">
        <h3 class="c-article__sub-heading">Subjects</h3>
        <ul class="c-article-subject-list">
            <li class="c-article-subject-list__subject"><a href="/subjects/cancer-immunotherapy" data-track="click" data-track-action="view subject" data-track-label="link">Cancer immunotherapy</a></li><li class="c-article-subject-list__subject"><a href="/subjects/pancreatic-cancer" data-track="click" data-track-action="view subject" data-track-label="link">Pancreatic cancer</a></li><li class="c-article-subject-list__subject"><a href="/subjects/tumour-biomarkers" data-track="click" data-track-action="view subject" data-track-label="link">Tumour biomarkers</a></li>
        </ul>
    </div></div></div></div></div></section>
            </div>

            
        <section>
            <div class="c-article-section js-article-section" id="further-reading-section" data-test="further-reading-section">
                <h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="further-reading">This article is cited by</h2>
                <div class="c-article-section__content js-collapsible-section" id="further-reading-content">
                    <ul class="c-article-further-reading__list" id="further-reading-list">
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Novel cisplatin-magnetoliposome complex shows enhanced antitumor activity via Hyperthermia" href="https://doi.org/10.1038/s41598-025-88533-z">
                                        Novel cisplatin-magnetoliposome complex shows enhanced antitumor activity via Hyperthermia
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>M. Carmen Jiménez-López</li><li>Ana Carolina Moreno-Maldonado</li><li>Ignacio J. Molina</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Scientific Reports</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Evaluation of the efficacy and predictive indicators of PD- 1 inhibitors combined with chemotherapy in advanced pancreatic cancer" href="https://doi.org/10.1038/s41598-025-97233-7">
                                        Evaluation of the efficacy and predictive indicators of PD- 1 inhibitors combined with chemotherapy in advanced pancreatic cancer
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Tiantian Zhang</li><li>Yangyang Zhou</li><li>Rui Wang</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Scientific Reports</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges" href="https://doi.org/10.1038/s41575-025-01062-y">
                                        CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Hinrich Abken</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Nature Reviews Gastroenterology &amp; Hepatology</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Macrophages and fibroblasts as regulators of the immune response in pancreatic cancer" href="https://doi.org/10.1038/s41590-025-02134-6">
                                        Macrophages and fibroblasts as regulators of the immune response in pancreatic cancer
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Mojdeh Shakiba</li><li>David A. Tuveson</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Nature Immunology</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Digestive cancers: mechanisms, therapeutics and management" href="https://doi.org/10.1038/s41392-024-02097-4">
                                        Digestive cancers: mechanisms, therapeutics and management
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Tianzuo Zhan</li><li>Johannes Betge</li><li>Matthias P. Ebert</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Signal Transduction and Targeted Therapy</i> (2025)</p>
                            </li>
                        
                    </ul>
                </div>
            </div>
        </section>
    

        </div>
</article>
</main>

<aside class="c-article-extras u-hide-print" aria-label="Article navigation" data-component-reading-companion="" data-container-type="reading-companion" data-track-component="reading companion">
    <div class="js-context-bar-sticky-point-desktop" data-track-context="reading companion">
        

        
            
                
                    
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-022-01829-9.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                
            
        
    </div>

    
        
    

    
    

    <div class="c-reading-companion">
        <div class="c-reading-companion__sticky" data-component="reading-companion-sticky" data-test="reading-companion-sticky" style="top: 40px;">
            <ul class="c-reading-companion__tabs" role="tablist"><li role="presentation"><button data-tab-target="sections" role="tab" id="tab-sections" aria-controls="tabpanel-sections" aria-selected="true" class="c-reading-companion__tab c-reading-companion__tab--active" data-track="click" data-track-action="sections tab" data-track-label="tab">Sections</button></li><li role="presentation"><button data-tab-target="figures" role="tab" id="tab-figures" aria-controls="tabpanel-figures" aria-selected="false" tabindex="-1" class="c-reading-companion__tab" data-track="click" data-track-action="figures tab" data-track-label="tab">Figures</button></li><li role="presentation"><button data-tab-target="references" role="tab" id="tab-references" aria-controls="tabpanel-references" aria-selected="false" tabindex="-1" class="c-reading-companion__tab" data-track="click" data-track-action="references tab" data-track-label="tab">References</button></li></ul><div class="c-reading-companion__panel c-reading-companion__sections c-reading-companion__panel--active" id="tabpanel-sections" aria-labelledby="tab-sections" role="tabpanel"><div class="c-reading-companion__scroll-pane" style="max-height: none;"><ul class="c-reading-companion__sections-list"><li id="rc-sec-Abs1" class="c-reading-companion__section-item"><a href="#Abs1" data-track="click" data-track-action="section anchor" data-track-label="link:Abstract">Abstract</a></li><li id="rc-sec-Sec1" class="c-reading-companion__section-item"><a href="#Sec1" data-track="click" data-track-action="section anchor" data-track-label="link:Main">Main</a></li><li id="rc-sec-Sec2" class="c-reading-companion__section-item"><a href="#Sec2" data-track="click" data-track-action="section anchor" data-track-label="link:Results">Results</a></li><li id="rc-sec-Sec11" class="c-reading-companion__section-item"><a href="#Sec11" data-track="click" data-track-action="section anchor" data-track-label="link:Discussion">Discussion</a></li><li id="rc-sec-Sec12" class="c-reading-companion__section-item"><a href="#Sec12" data-track="click" data-track-action="section anchor" data-track-label="link:Methods">Methods</a></li><li id="rc-sec-data-availability" class="c-reading-companion__section-item"><a href="#data-availability" data-track="click" data-track-action="section anchor" data-track-label="link:Data availability">Data availability</a></li><li id="rc-sec-code-availability" class="c-reading-companion__section-item"><a href="#code-availability" data-track="click" data-track-action="section anchor" data-track-label="link:Code availability">Code availability</a></li><li id="rc-sec-change-history" class="c-reading-companion__section-item"><a href="#change-history" data-track="click" data-track-action="section anchor" data-track-label="link:Change history">Change history</a></li><li id="rc-sec-Bib1" class="c-reading-companion__section-item"><a href="#Bib1" data-track="click" data-track-action="section anchor" data-track-label="link:References">References</a></li><li id="rc-sec-Ack1" class="c-reading-companion__section-item"><a href="#Ack1" data-track="click" data-track-action="section anchor" data-track-label="link:Acknowledgements">Acknowledgements</a></li><li id="rc-sec-author-information" class="c-reading-companion__section-item"><a href="#author-information" data-track="click" data-track-action="section anchor" data-track-label="link:Author information">Author information</a></li><li id="rc-sec-ethics" class="c-reading-companion__section-item"><a href="#ethics" data-track="click" data-track-action="section anchor" data-track-label="link:Ethics declarations">Ethics declarations</a></li><li id="rc-sec-peer-review" class="c-reading-companion__section-item"><a href="#peer-review" data-track="click" data-track-action="section anchor" data-track-label="link:Peer review">Peer review</a></li><li id="rc-sec-additional-information" class="c-reading-companion__section-item"><a href="#additional-information" data-track="click" data-track-action="section anchor" data-track-label="link:Additional information">Additional information</a></li><li id="rc-sec-Sec32" class="c-reading-companion__section-item"><a href="#Sec32" data-track="click" data-track-action="section anchor" data-track-label="link:Extended data">Extended data</a></li><li id="rc-sec-Sec33" class="c-reading-companion__section-item"><a href="#Sec33" data-track="click" data-track-action="section anchor" data-track-label="link:Supplementary information">Supplementary information</a></li><li id="rc-sec-rightslink" class="c-reading-companion__section-item"><a href="#rightslink" data-track="click" data-track-action="section anchor" data-track-label="link:Rights and permissions">Rights and permissions</a></li><li id="rc-sec-article-info" class="c-reading-companion__section-item"><a href="#article-info" data-track="click" data-track-action="section anchor" data-track-label="link:About this article">About this article</a></li><li id="rc-sec-further-reading" class="c-reading-companion__section-item"><a href="#further-reading" data-track="click" data-track-action="section anchor" data-track-label="link:This article is cited by">This article is cited by</a></li></ul></div>
                <div class="u-lazy-ad-wrapper u-mt-16 u-show" data-component-mpu="" style="display: none !important;">
                    <div class="c-ad c-ad--300x250">
                        <div class="c-ad__inner">
                            <p class="c-ad__label">Advertisement</p>
                            
    <div id="div-gpt-ad-right-2" class="div-gpt-ad advert medium-rectangle js-ad text-center hide-print grade-c-hide" data-ad-type="right" data-test="right-ad" data-pa11y-ignore="" data-gpt="" data-gpt-unitpath="/285/medicine.nature.com/article" data-gpt-sizes="300x250" data-gpt-targeting="type=article;pos=right;artid=s41591-022-01829-9;doi=10.1038/s41591-022-01829-9;subjmeta=1059,1504,1713,1857,2325,631,67,692,699;kwrd=Cancer+immunotherapy,Pancreatic+cancer,Tumour+biomarkers">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=153606920&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-022-01829-9%26doi%3D10.1038/s41591-022-01829-9%26subjmeta%3D1059,1504,1713,1857,2325,631,67,692,699%26kwrd%3DCancer+immunotherapy,Pancreatic+cancer,Tumour+biomarkers">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=153606920&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-022-01829-9%26doi%3D10.1038/s41591-022-01829-9%26subjmeta%3D1059,1504,1713,1857,2325,631,67,692,699%26kwrd%3DCancer+immunotherapy,Pancreatic+cancer,Tumour+biomarkers"
                     alt="Advertisement"
                     width="300"
                     height="250"></a>
        </noscript>
    </div>

                        </div>
                    </div>
                </div>
            </div>
            <div class="c-reading-companion__panel c-reading-companion__figures c-reading-companion__panel--full-width" id="tabpanel-figures" aria-labelledby="tab-figures" role="tabpanel"><div class="c-reading-companion__scroll-pane"><ul class="c-reading-companion__figures-list"><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig1">Fig. 1: PRINCE study design and CONSORT diagram.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig1_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig1_HTML.png" alt="figure 1" aria-describedby="rc-Fig1"></picture><p class="c-reading-companion__figure-links"><a href="#Fig1" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01829-9/figures/1" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig2">Fig. 2: OS and tumor response.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig2_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig2_HTML.png" alt="figure 2" aria-describedby="rc-Fig2"></picture><p class="c-reading-companion__figure-links"><a href="#Fig2" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01829-9/figures/2" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig3">Fig. 3: Activated, antigen-experienced non-naive T cells and T<sub>fh</sub> cells in the periphery are associated with survival in patients with mPDAC treated with nivo/chemo.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig3_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig3_HTML.png" alt="figure 3" aria-describedby="rc-Fig3"></picture><p class="c-reading-companion__figure-links"><a href="#Fig3" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01829-9/figures/3" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig4">Fig. 4: Cross-presenting, activated APCs and type-1 helper T cells in circulation associate with survival in patients receiving sotiga/chemo treatment.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig4_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig4_HTML.png" alt="figure 4" aria-describedby="rc-Fig4"></picture><p class="c-reading-companion__figure-links"><a href="#Fig4" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01829-9/figures/4" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig5">Fig. 5: Biomarkers of survival after nivo/chemo and sotiga/chemo and their overlap.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig5_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig5_HTML.png" alt="figure 5" aria-describedby="rc-Fig5"></picture><p class="c-reading-companion__figure-links"><a href="#Fig5" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01829-9/figures/5" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig6">Extended Data Fig. 1 PRINCE schema for dosing and sample collection schedule.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig6_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig6_ESM.jpg" alt="extended data figure 6" aria-describedby="rc-Fig6"></picture><p class="c-reading-companion__figure-links"><a href="#Fig6" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01829-9/figures/6" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig7">Extended Data Fig. 2 Kaplan-Meier curves of progression-free survival and duration of response.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig7_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig7_ESM.jpg" alt="extended data figure 7" aria-describedby="rc-Fig7"></picture><p class="c-reading-companion__figure-links"><a href="#Fig7" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01829-9/figures/7" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig8">Extended Data Fig. 3 Biomarker signatures in blood and tumor reveal specific immune mechanisms of activation in response to nivo/chemo and sotiga/chemo treatment in patients with mPDAC.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig8_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig8_ESM.jpg" alt="extended data figure 8" aria-describedby="rc-Fig8"></picture><p class="c-reading-companion__figure-links"><a href="#Fig8" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01829-9/figures/8" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig9">Extended Data Fig. 4 A non-immunosuppressive tumor microenvironment and activated circulating CD8 T cells before treatment are associated with survival in mPDAC patients treated with nivo/chemo.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig9_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig9_ESM.jpg" alt="extended data figure 9" aria-describedby="rc-Fig9"></picture><p class="c-reading-companion__figure-links"><a href="#Fig9" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01829-9/figures/9" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig10">Extended Data Fig. 5 Higher frequencies of specific B cell populations and lower concentrations of 2B4+ T cells are associated with survival in patients treated with sotiga/chemo.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig10_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig10_ESM.jpg" alt="extended data figure 10" aria-describedby="rc-Fig10"></picture><p class="c-reading-companion__figure-links"><a href="#Fig10" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01829-9/figures/10" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig11">Extended Data Fig. 6 T helper signatures and proliferating CD4 T cells in the tumor associate with survival in patients receiving sotiga/chemo treatment.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig11_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig11_ESM.jpg" alt="extended data figure 11" aria-describedby="rc-Fig11"></picture><p class="c-reading-companion__figure-links"><a href="#Fig11" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01829-9/figures/11" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig12">Extended Data Fig. 7 Lower frequencies of circulating CD38+ non-naïve T cells are associated with longer survival in patients treated with sotiga/nivo/chemo.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig12_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig12_ESM.jpg" alt="extended data figure 12" aria-describedby="rc-Fig12"></picture><p class="c-reading-companion__figure-links"><a href="#Fig12" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01829-9/figures/12" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig13">Extended Data Fig. 8 Survival in response to combinational therapy of sotiga/nivo/chemo may be affected by regulatory B cells in circulation.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig13_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig13_ESM.jpg" alt="extended data figure 13" aria-describedby="rc-Fig13"></picture><p class="c-reading-companion__figure-links"><a href="#Fig13" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01829-9/figures/13" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li></ul></div></div>
            <div class="c-reading-companion__panel c-reading-companion__references c-reading-companion__panel--full-width" id="tabpanel-references" aria-labelledby="tab-references" role="tabpanel"><div class="c-reading-companion__scroll-pane"><ol class="c-reading-companion__references-list c-reading-companion__references-list--numeric" data-track-context="article references sidebar"><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR1">Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. <i>Cancer Res.</i> <b>74</b>, 2913–2921 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F0008-5472.CAN-14-0155" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/0008-5472.CAN-14-0155" data-track-item_id="10.1158/0008-5472.CAN-14-0155">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXovFalur0%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24840647" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Projecting%20cancer%20incidence%20and%20deaths%20to%202030%3A%20the%20unexpected%20burden%20of%20thyroid%2C%20liver%2C%20and%20pancreas%20cancers%20in%20the%20United%20States&amp;journal=Cancer%20Res.&amp;doi=10.1158%2F0008-5472.CAN-14-0155&amp;volume=74&amp;pages=2913-2921&amp;publication_year=2014&amp;author=Rahib%2CL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR2">Sharma, P. et al. The next decade of immune checkpoint therapy. <i>Cancer Discov.</i> <b>11</b>, 838–857 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-20-1680" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-20-1680" data-track-item_id="10.1158/2159-8290.CD-20-1680">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtlKqurbN" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33811120" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20next%20decade%20of%20immune%20checkpoint%20therapy&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-20-1680&amp;volume=11&amp;pages=838-857&amp;publication_year=2021&amp;author=Sharma%2CP" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR3">O’Reilly, E. M. et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. <i>JAMA Oncol.</i> <b>5</b>, 1431–1438 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1001%2Fjamaoncol.2019.1588" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1001/jamaoncol.2019.1588" data-track-item_id="10.1001/jamaoncol.2019.1588">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31318392" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647002" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Durvalumab%20with%20or%20without%20tremelimumab%20for%20patients%20with%20metastatic%20pancreatic%20ductal%20adenocarcinoma%3A%20a%20phase%202%20randomized%20clinical%20trial&amp;journal=JAMA%20Oncol.&amp;doi=10.1001%2Fjamaoncol.2019.1588&amp;volume=5&amp;pages=1431-1438&amp;publication_year=2019&amp;author=O%E2%80%99Reilly%2CEM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR4">Royal, R. E. et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. <i>J. Immunother.</i> <b>33</b>, 828–833 (2010).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1097%2FCJI.0b013e3181eec14c" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1097/CJI.0b013e3181eec14c" data-track-item_id="10.1097/CJI.0b013e3181eec14c">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3cXht1Wju77O" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20842054" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322622" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%202%20trial%20of%20single%20agent%20ipilimumab%20%28anti-CTLA-4%29%20for%20locally%20advanced%20or%20metastatic%20pancreatic%20adenocarcinoma&amp;journal=J.%20Immunother.&amp;doi=10.1097%2FCJI.0b013e3181eec14c&amp;volume=33&amp;pages=828-833&amp;publication_year=2010&amp;author=Royal%2CRE" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR5">Patnaik, A. et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. <i>Clin. Cancer Res.</i> <b>21</b>, 4286–4293 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-14-2607" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-14-2607" data-track-item_id="10.1158/1078-0432.CCR-14-2607">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhs1antL3L" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25977344" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20I%20study%20of%20pembrolizumab%20%28MK-3475%3B%20anti-PD-1%20monoclonal%20antibody%29%20in%20patients%20with%20advanced%20solid%20tumors&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-14-2607&amp;volume=21&amp;pages=4286-4293&amp;publication_year=2015&amp;author=Patnaik%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR6">Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. <i>N. Engl. J. Med.</i> <b>366</b>, 2455–2465 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1200694" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1200694" data-track-item_id="10.1056/NEJMoa1200694">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XhtV2rsbnJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22658128" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563263" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%20and%20activity%20of%20anti-PD-L1%20antibody%20in%20patients%20with%20advanced%20cancer&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1200694&amp;volume=366&amp;pages=2455-2465&amp;publication_year=2012&amp;author=Brahmer%2CJR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR7">Balachandran, V. P. et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. <i>Nature</i> <b>551</b>, 512–516 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnature24462" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nature24462" data-track-item_id="10.1038/nature24462">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhslygtLjP" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29132146" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145146" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Identification%20of%20unique%20neoantigen%20qualities%20in%20long-term%20survivors%20of%20pancreatic%20cancer&amp;journal=Nature&amp;doi=10.1038%2Fnature24462&amp;volume=551&amp;pages=512-516&amp;publication_year=2017&amp;author=Balachandran%2CVP" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR8">Balli, D., Rech, A. J., Stanger, B. Z. &amp; Vonderheide, R. H. Immune cytolytic activity stratifies molecular subsets of human pancreatic cancer. <i>Clin. Cancer Res.</i> <b>23</b>, 3129–3138 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-16-2128" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-16-2128" data-track-item_id="10.1158/1078-0432.CCR-16-2128">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtVSqurbE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28007776" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Immune%20cytolytic%20activity%20stratifies%20molecular%20subsets%20of%20human%20pancreatic%20cancer&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-16-2128&amp;volume=23&amp;pages=3129-3138&amp;publication_year=2017&amp;author=Balli%2CD&amp;author=Rech%2CAJ&amp;author=Stanger%2CBZ&amp;author=Vonderheide%2CRH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR9">Stromnes, I. M., Hulbert, A., Pierce, R. H., Greenberg, P. D. &amp; Hingorani, S. R. T-cell localization, activation, and clonal expansion in human pancreatic ductal adenocarcinoma. <i>Cancer Immunol. Res.</i> <b>5</b>, 978–991 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2326-6066.CIR-16-0322" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2326-6066.CIR-16-0322" data-track-item_id="10.1158/2326-6066.CIR-16-0322">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhslGisrrJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29066497" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802342" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=T-cell%20localization%2C%20activation%2C%20and%20clonal%20expansion%20in%20human%20pancreatic%20ductal%20adenocarcinoma&amp;journal=Cancer%20Immunol.%20Res.&amp;doi=10.1158%2F2326-6066.CIR-16-0322&amp;volume=5&amp;pages=978-991&amp;publication_year=2017&amp;author=Stromnes%2CIM&amp;author=Hulbert%2CA&amp;author=Pierce%2CRH&amp;author=Greenberg%2CPD&amp;author=Hingorani%2CSR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR10">Byrne, K. T. &amp; Vonderheide, R. H. CD40 stimulation obviates innate sensors and drives T cell immunity in cancer. <i>Cell Rep.</i> <b>15</b>, 2719–2732 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.celrep.2016.05.058" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.celrep.2016.05.058" data-track-item_id="10.1016/j.celrep.2016.05.058">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28Xps1SktLw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27292635" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917417" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=CD40%20stimulation%20obviates%20innate%20sensors%20and%20drives%20T%20cell%20immunity%20in%20cancer&amp;journal=Cell%20Rep.&amp;doi=10.1016%2Fj.celrep.2016.05.058&amp;volume=15&amp;pages=2719-2732&amp;publication_year=2016&amp;author=Byrne%2CKT&amp;author=Vonderheide%2CRH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR11">Winograd, R. et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. <i>Cancer Immunol. Res</i> <b>3</b>, 399–411 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2326-6066.CIR-14-0215" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2326-6066.CIR-14-0215" data-track-item_id="10.1158/2326-6066.CIR-14-0215">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXlvFemtb8%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25678581" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390506" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Induction%20of%20T-cell%20immunity%20overcomes%20complete%20resistance%20to%20PD-1%20and%20CTLA-4%20blockade%20and%20improves%20survival%20in%20pancreatic%20carcinoma&amp;journal=Cancer%20Immunol.%20Res&amp;doi=10.1158%2F2326-6066.CIR-14-0215&amp;volume=3&amp;pages=399-411&amp;publication_year=2015&amp;author=Winograd%2CR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR12">O’Hara, M. H. et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. <i>Lancet Oncol.</i> <b>22</b>, 118–131 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2FS1470-2045%2820%2930532-5" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/S1470-2045(20)30532-5" data-track-item_id="10.1016/S1470-2045(20)30532-5">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33387490" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=CD40%20agonistic%20monoclonal%20antibody%20APX005M%20%28sotigalimab%29%20and%20chemotherapy%2C%20with%20or%20without%20nivolumab%2C%20for%20the%20treatment%20of%20metastatic%20pancreatic%20adenocarcinoma%3A%20an%20open-label%2C%20multicentre%2C%20phase%201b%20study&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2820%2930532-5&amp;volume=22&amp;pages=118-131&amp;publication_year=2021&amp;author=O%E2%80%99Hara%2CMH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR13">Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. <i>N. Engl. J. Med.</i> <b>369</b>, 1691–1703 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1304369" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1304369" data-track-item_id="10.1056/NEJMoa1304369">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Increased%20survival%20in%20pancreatic%20cancer%20with%20nab-paclitaxel%20plus%20gemcitabine&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1304369&amp;volume=369&amp;pages=1691-1703&amp;publication_year=2013&amp;author=Hoff%2CDD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR14">Choueiri, T. K. et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. <i>Clin. Cancer Res.</i> <b>22</b>, 5461–5471 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-15-2839" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-15-2839" data-track-item_id="10.1158/1078-0432.CCR-15-2839">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XhvVCqur3L" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27169994" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106340" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Immunomodulatory%20activity%20of%20nivolumab%20in%20metastatic%20renal%20cell%20carcinoma&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-15-2839&amp;volume=22&amp;pages=5461-5471&amp;publication_year=2016&amp;author=Choueiri%2CTK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR15">Mathew, D. et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. <i>Science</i> <b>369</b>, eabc8511 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1126%2Fscience.abc8511" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1126/science.abc8511" data-track-item_id="10.1126/science.abc8511">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhslCltrnF" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32669297" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402624" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Deep%20immune%20profiling%20of%20COVID-19%20patients%20reveals%20distinct%20immunotypes%20with%20therapeutic%20implications&amp;journal=Science&amp;doi=10.1126%2Fscience.abc8511&amp;volume=369&amp;publication_year=2020&amp;author=Mathew%2CD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR16">Romero, P. et al. Four functionally distinct populations of human effector-memory CD8<sup>+</sup> T lymphocytes. <i>J. Immunol.</i> <b>178</b>, 4112–4119 (2007).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.4049%2Fjimmunol.178.7.4112" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.4049/jimmunol.178.7.4112" data-track-item_id="10.4049/jimmunol.178.7.4112">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXjt1WltLY%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17371966" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Four%20functionally%20distinct%20populations%20of%20human%20effector-memory%20CD8%2B%20T%20lymphocytes&amp;journal=J.%20Immunol.&amp;doi=10.4049%2Fjimmunol.178.7.4112&amp;volume=178&amp;pages=4112-4119&amp;publication_year=2007&amp;author=Romero%2CP" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR17">Byrne, K. T. et al. Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer. <i>Clin. Cancer Res.</i> <b>27</b>, 4574–4586 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-21-1047" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-21-1047" data-track-item_id="10.1158/1078-0432.CCR-21-1047">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXit1CkurfE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34112709" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667686" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Neoadjuvant%20selicrelumab%2C%20an%20agonist%20CD40%20antibody%2C%20induces%20changes%20in%20the%20tumor%20microenvironment%20in%20patients%20with%20resectable%20pancreatic%20cancer&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-21-1047&amp;volume=27&amp;pages=4574-4586&amp;publication_year=2021&amp;author=Byrne%2CKT" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR18">Wainberg, Z. A. et al. Open-label, phase I study of nivolumab combined with nab-paclitaxel plus gemcitabine in advanced pancreatic cancer. <i>Clin. Cancer Res.</i> <b>26</b>, 4814–4822 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-20-0099" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-20-0099" data-track-item_id="10.1158/1078-0432.CCR-20-0099">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXisFSrtr%2FL" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32554514" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Open-label%2C%20phase%20I%20study%20of%20nivolumab%20combined%20with%20nab-paclitaxel%20plus%20gemcitabine%20in%20advanced%20pancreatic%20cancer&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-20-0099&amp;volume=26&amp;pages=4814-4822&amp;publication_year=2020&amp;author=Wainberg%2CZA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR19">Filbert, E. L., Bjorck, P. K., Srivastava, M. K., Bahjat, F. R. &amp; Yang, X. APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application. <i>Cancer Immunol. Immunother.</i> <b>70</b>, 1853–1865 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1007/s00262-020-02814-2" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1007/s00262-020-02814-2" data-track-item_id="10.1007/s00262-020-02814-2">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXht1Oktbg%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33392713" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195934" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=APX005M%2C%20a%20CD40%20agonist%20antibody%20with%20unique%20epitope%20specificity%20and%20Fc%20receptor%20binding%20profile%20for%20optimal%20therapeutic%20application&amp;journal=Cancer%20Immunol.%20Immunother.&amp;doi=10.1007%2Fs00262-020-02814-2&amp;volume=70&amp;pages=1853-1865&amp;publication_year=2021&amp;author=Filbert%2CEL&amp;author=Bjorck%2CPK&amp;author=Srivastava%2CMK&amp;author=Bahjat%2CFR&amp;author=Yang%2CX" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR20">Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. <i>J. Clin. Oncol.</i> <b>28</b>, 3167–3175 (2010).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.2009.26.7609" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.2009.26.7609" data-track-item_id="10.1200/JCO.2009.26.7609">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3cXpslajtLw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20516446" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834717" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20I%20study%20of%20single-agent%20anti-programmed%20death-1%20%28MDX-1106%29%20in%20refractory%20solid%20tumors%3A%20safety%2C%20clinical%20activity%2C%20pharmacodynamics%2C%20and%20immunologic%20correlates&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2009.26.7609&amp;volume=28&amp;pages=3167-3175&amp;publication_year=2010&amp;author=Brahmer%2CJR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR21">Stebegg, M. et al. Regulation of the germinal center response. <i>Front. Immunol.</i> <b>9</b>, 2469 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.3389%2Ffimmu.2018.02469" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.3389/fimmu.2018.02469" data-track-item_id="10.3389/fimmu.2018.02469">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30410492" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209676" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Regulation%20of%20the%20germinal%20center%20response&amp;journal=Front.%20Immunol.&amp;doi=10.3389%2Ffimmu.2018.02469&amp;volume=9&amp;publication_year=2018&amp;author=Stebegg%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR22">Cohn, L. et al. Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3<sup>+</sup> dendritic cells at cross presentation. <i>J. Exp. Med.</i> <b>210</b>, 1049–1063 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1084%2Fjem.20121251" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1084/jem.20121251" data-track-item_id="10.1084/jem.20121251">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXntlKjs78%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23569326" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646496" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Antigen%20delivery%20to%20early%20endosomes%20eliminates%20the%20superiority%20of%20human%20blood%20BDCA3%2B%20dendritic%20cells%20at%20cross%20presentation&amp;journal=J.%20Exp.%20Med.&amp;doi=10.1084%2Fjem.20121251&amp;volume=210&amp;pages=1049-1063&amp;publication_year=2013&amp;author=Cohn%2CL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR23">Haniffa, M. et al. Human tissues contain CD141<sup>hi</sup> cross-presenting dendritic cells with functional homology to mouse CD103<sup>+</sup> nonlymphoid dendritic cells. <i>Immunity</i> <b>37</b>, 60–73 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.immuni.2012.04.012" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.immuni.2012.04.012" data-track-item_id="10.1016/j.immuni.2012.04.012">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XhtVKntL7E" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22795876" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3476529" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Human%20tissues%20contain%20CD141hi%20cross-presenting%20dendritic%20cells%20with%20functional%20homology%20to%20mouse%20CD103%2B%20nonlymphoid%20dendritic%20cells&amp;journal=Immunity&amp;doi=10.1016%2Fj.immuni.2012.04.012&amp;volume=37&amp;pages=60-73&amp;publication_year=2012&amp;author=Haniffa%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR24">Diamond, M. S., Lin, J. H. &amp; Vonderheide, R. H. Site-dependent immune escape due to impaired dendritic cell cross-priming. <i>Cancer Immunol. Res.</i> <b>9</b>, 877–890 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2326-6066.CIR-20-0785" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2326-6066.CIR-20-0785" data-track-item_id="10.1158/2326-6066.CIR-20-0785">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXit1eisrzO" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34145076" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655819" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Site-dependent%20immune%20escape%20due%20to%20impaired%20dendritic%20cell%20cross-priming&amp;journal=Cancer%20Immunol.%20Res.&amp;doi=10.1158%2F2326-6066.CIR-20-0785&amp;volume=9&amp;pages=877-890&amp;publication_year=2021&amp;author=Diamond%2CMS&amp;author=Lin%2CJH&amp;author=Vonderheide%2CRH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR25">Li, J. et al. Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy. <i>Immunity</i> <b>49</b>, 178–193 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.immuni.2018.06.006" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.immuni.2018.06.006" data-track-item_id="10.1016/j.immuni.2018.06.006">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXht1Smu7nL" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29958801" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707727" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor%20cell-intrinsic%20factors%20underlie%20heterogeneity%20of%20immune%20cell%20infiltration%20and%20response%20to%20immunotherapy&amp;journal=Immunity&amp;doi=10.1016%2Fj.immuni.2018.06.006&amp;volume=49&amp;pages=178-193&amp;publication_year=2018&amp;author=Li%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR26">Sharma, P. et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. <i>Proc. Natl Acad. Sci. USA</i> <b>104</b>, 3967–3972 (2007).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1073%2Fpnas.0611618104" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1073/pnas.0611618104" data-track-item_id="10.1073/pnas.0611618104">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXjt1ymu7g%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17360461" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1820692" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=CD8%20tumor-infiltrating%20lymphocytes%20are%20predictive%20of%20survival%20in%20muscle-invasive%20urothelial%20carcinoma&amp;journal=Proc.%20Natl%20Acad.%20Sci.%20USA&amp;doi=10.1073%2Fpnas.0611618104&amp;volume=104&amp;pages=3967-3972&amp;publication_year=2007&amp;author=Sharma%2CP" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR27">Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. <i>Cell</i> <b>170</b>, 1109–1119 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.cell.2017.08.027" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.cell.2017.08.027" data-track-item_id="10.1016/j.cell.2017.08.027">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhsVOhu7rJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28886381" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034392" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Oncolytic%20virotherapy%20promotes%20intratumoral%20T%20cell%20infiltration%20and%20improves%20anti-PD-1%20immunotherapy&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2017.08.027&amp;volume=170&amp;pages=1109-1119&amp;publication_year=2017&amp;author=Ribas%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR28">Tokito, T. et al. Predictive relevance of PD-L1 expression combined with CD8<sup>+</sup> TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. <i>Eur. J. Cancer</i> <b>55</b>, 7–14 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.ejca.2015.11.020" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.ejca.2015.11.020" data-track-item_id="10.1016/j.ejca.2015.11.020">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXitV2ntbvI" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26771872" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Predictive%20relevance%20of%20PD-L1%20expression%20combined%20with%20CD8%2B%20TIL%20density%20in%20stage%20III%20non-small%20cell%20lung%20cancer%20patients%20receiving%20concurrent%20chemoradiotherapy&amp;journal=Eur.%20J.%20Cancer&amp;doi=10.1016%2Fj.ejca.2015.11.020&amp;volume=55&amp;pages=7-14&amp;publication_year=2016&amp;author=Tokito%2CT" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR29">Yang, Z. et al. Tumor-Infiltrating PD-1<sup>hi</sup>CD8<sup>+</sup>-T-cell signature as an effective biomarker for immune checkpoint inhibitor therapy response across multiple cancers. <i>Front. Oncol.</i> <b>11</b>, 695006 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.3389%2Ffonc.2021.695006" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.3389/fonc.2021.695006" data-track-item_id="10.3389/fonc.2021.695006">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34604032" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479164" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor-Infiltrating%20PD-1hiCD8%2B-T-cell%20signature%20as%20an%20effective%20biomarker%20for%20immune%20checkpoint%20inhibitor%20therapy%20response%20across%20multiple%20cancers&amp;journal=Front.%20Oncol.&amp;doi=10.3389%2Ffonc.2021.695006&amp;volume=11&amp;publication_year=2021&amp;author=Yang%2CZ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR30">Beltra, J. C. et al. Developmental relationships of four exhausted CD8<sup>+</sup> T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. <i>Immunity</i> <b>52</b>, 825–841 e828, (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.immuni.2020.04.014" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.immuni.2020.04.014" data-track-item_id="10.1016/j.immuni.2020.04.014">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXptVCmtro%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32396847" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360766" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Developmental%20relationships%20of%20four%20exhausted%20CD8%2B%20T%20cell%20subsets%20reveals%20underlying%20transcriptional%20and%20epigenetic%20landscape%20control%20mechanisms&amp;journal=Immunity&amp;doi=10.1016%2Fj.immuni.2020.04.014&amp;volume=52&amp;pages=825-841%20e828&amp;publication_year=2020&amp;author=Beltra%2CJC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR31">Ding, C. et al. Integrin CD11b negatively regulates BCR signalling to maintain autoreactive B cell tolerance. <i>Nat. Commun.</i> <b>4</b>, 2813 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fncomms3813" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/ncomms3813" data-track-item_id="10.1038/ncomms3813">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24264377" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Integrin%20CD11b%20negatively%20regulates%20BCR%20signalling%20to%20maintain%20autoreactive%20B%20cell%20tolerance&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fncomms3813&amp;volume=4&amp;publication_year=2013&amp;author=Ding%2CC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR32">van Hooren, L. et al. Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma. <i>Nat. Commun.</i> <b>12</b>, 4127 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41467-021-24347-7" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41467-021-24347-7" data-track-item_id="10.1038/s41467-021-24347-7">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34226552" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257767" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Agonistic%20CD40%20therapy%20induces%20tertiary%20lymphoid%20structures%20but%20impairs%20responses%20to%20checkpoint%20blockade%20in%20glioma&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-021-24347-7&amp;volume=12&amp;publication_year=2021&amp;author=Hooren%2CL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR33">Tempero, M. et al. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. <i>Ann. Oncol.</i> <b>32</b>, 600–608 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.annonc.2021.01.070" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.annonc.2021.01.070" data-track-item_id="10.1016/j.annonc.2021.01.070">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XhvVKqs74%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33539945" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Ibrutinib%20in%20combination%20with%20nab-paclitaxel%20and%20gemcitabine%20for%20first-line%20treatment%20of%20patients%20with%20metastatic%20pancreatic%20adenocarcinoma%3A%20phase%20III%20RESOLVE%20study&amp;journal=Ann.%20Oncol.&amp;doi=10.1016%2Fj.annonc.2021.01.070&amp;volume=32&amp;pages=600-608&amp;publication_year=2021&amp;author=Tempero%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR34">Lyman, J. P. et al. Feasibility and utility of synthetic control arms derived from real-world data to support clinical development. <i>J. Clin. Oncol.</i> <b>40</b>, 528 (2022).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.2022.40.4_suppl.528" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.2022.40.4_suppl.528" data-track-item_id="10.1200/JCO.2022.40.4_suppl.528">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Feasibility%20and%20utility%20of%20synthetic%20control%20arms%20derived%20from%20real-world%20data%20to%20support%20clinical%20development&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2022.40.4_suppl.528&amp;volume=40&amp;publication_year=2022&amp;author=Lyman%2CJP" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR35">Upadhaya, S. et al. Combinations take centre stage in PD1/PDL1 inhibitor clinical trials. <i>Nat. Rev. Drug Discov.</i> <b>20</b>, 168–169 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fd41573-020-00204-y" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/d41573-020-00204-y" data-track-item_id="10.1038/d41573-020-00204-y">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXlvFSgtro%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33177720" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Combinations%20take%20centre%20stage%20in%20PD1%2FPDL1%20inhibitor%20clinical%20trials&amp;journal=Nat.%20Rev.%20Drug%20Discov.&amp;doi=10.1038%2Fd41573-020-00204-y&amp;volume=20&amp;pages=168-169&amp;publication_year=2021&amp;author=Upadhaya%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR36">Tang, J. et al. Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. <i>Nat. Rev. Drug Discov.</i> <b>17</b>, 854–855 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnrd.2018.210" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nrd.2018.210" data-track-item_id="10.1038/nrd.2018.210">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXitlalu7%2FM" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30482962" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Trial%20watch%3A%20the%20clinical%20trial%20landscape%20for%20PD1%2FPDL1%20immune%20checkpoint%20inhibitors&amp;journal=Nat.%20Rev.%20Drug%20Discov.&amp;doi=10.1038%2Fnrd.2018.210&amp;volume=17&amp;pages=854-855&amp;publication_year=2018&amp;author=Tang%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR37">Hartmann, F. J. et al. Comprehensive immune monitoring of clinical trials to advance human immunotherapy. <i>Cell Rep.</i> <b>28</b>, 819–831 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.celrep.2019.06.049" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.celrep.2019.06.049" data-track-item_id="10.1016/j.celrep.2019.06.049">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtl2gsLrE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31315057" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656694" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Comprehensive%20immune%20monitoring%20of%20clinical%20trials%20to%20advance%20human%20immunotherapy&amp;journal=Cell%20Rep.&amp;doi=10.1016%2Fj.celrep.2019.06.049&amp;volume=28&amp;pages=819-831&amp;publication_year=2019&amp;author=Hartmann%2CFJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR38">Spitzer, M. H. et al. IMMUNOLOGY. An interactive reference framework for modeling a dynamic immune system. <i>Science</i> <b>349</b>, 1259425 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1126%2Fscience.1259425" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1126/science.1259425" data-track-item_id="10.1126/science.1259425">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26160952" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537647" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=IMMUNOLOGY.%20An%20interactive%20reference%20framework%20for%20modeling%20a%20dynamic%20immune%20system&amp;journal=Science&amp;doi=10.1126%2Fscience.1259425&amp;volume=349&amp;publication_year=2015&amp;author=Spitzer%2CMH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR39">Assarsson, E. et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. <i>PLoS ONE</i> <b>9</b>, e95192 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1371%2Fjournal.pone.0095192" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1371/journal.pone.0095192" data-track-item_id="10.1371/journal.pone.0095192">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24755770" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995906" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Homogenous%2096-plex%20PEA%20immunoassay%20exhibiting%20high%20sensitivity%2C%20specificity%2C%20and%20excellent%20scalability&amp;journal=PLoS%20ONE&amp;doi=10.1371%2Fjournal.pone.0095192&amp;volume=9&amp;publication_year=2014&amp;author=Assarsson%2CE" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR40">Patwardhan, A. et al. Achieving high-sensitivity for clinical applications using augmented exome sequencing. <i>Genome Med.</i> <b>7</b>, 71 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1186/s13073-015-0197-4" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1186/s13073-015-0197-4" data-track-item_id="10.1186/s13073-015-0197-4">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26269718" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534066" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Achieving%20high-sensitivity%20for%20clinical%20applications%20using%20augmented%20exome%20sequencing&amp;journal=Genome%20Med.&amp;doi=10.1186%2Fs13073-015-0197-4&amp;volume=7&amp;publication_year=2015&amp;author=Patwardhan%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR41">Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. <i>Bioinformatics</i> <b>29</b>, 15–21 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fbioinformatics%2Fbts635" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/bioinformatics/bts635" data-track-item_id="10.1093/bioinformatics/bts635">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XhvV2gsbnF" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23104886" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=STAR%3A%20ultrafast%20universal%20RNA-seq%20aligner&amp;journal=Bioinformatics&amp;doi=10.1093%2Fbioinformatics%2Fbts635&amp;volume=29&amp;pages=15-21&amp;publication_year=2013&amp;author=Dobin%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR42">DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. <i>Nat. Genet.</i> <b>43</b>, 491–498 (2011).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fng.806" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/ng.806" data-track-item_id="10.1038/ng.806">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3MXksFWguro%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21478889" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083463" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=A%20framework%20for%20variation%20discovery%20and%20genotyping%20using%20next-generation%20DNA%20sequencing%20data&amp;journal=Nat.%20Genet.&amp;doi=10.1038%2Fng.806&amp;volume=43&amp;pages=491-498&amp;publication_year=2011&amp;author=DePristo%2CMA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR43">McKenna, A. et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. <i>Genome Res.</i> <b>20</b>, 1297–1303 (2010).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1101%2Fgr.107524.110" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1101/gr.107524.110" data-track-item_id="10.1101/gr.107524.110">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3cXhtFeru7jM" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20644199" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928508" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20genome%20analysis%20toolkit%3A%20a%20MapReduce%20framework%20for%20analyzing%20next-generation%20DNA%20sequencing%20data&amp;journal=Genome%20Res.&amp;doi=10.1101%2Fgr.107524.110&amp;volume=20&amp;pages=1297-1303&amp;publication_year=2010&amp;author=McKenna%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li></ol></div></div>
        </div>
    </div>
</aside>
</div>


    
        
    
    
        
            
        

        
            
        
    
    <script>
        window.dataLayer = window.dataLayer || [];
        window.dataLayer.push({
            page: {
                content: {
                    fundingWidget: "true",
                        }
                    }
                });
    </script>




<footer class="composite-layer" itemscope="" itemtype="http://schema.org/Periodical">
        <meta itemprop="publisher" content="Springer Nature">
        

        <div class="u-mt-16 u-mb-16">
    <div class="u-container">
        <div class="u-display-flex u-flex-wrap u-justify-content-space-between">
            

            <div class="c-meta u-ma-0 u-flex-shrink">
                <p class="c-meta__item c-meta__type u-mt-0">
                    <span itemprop="name">
                        Nature Medicine
                    </span>
                    (<i itemprop="alternateName">Nat Med</i>)
                </p>
                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1546-170X</span> (online)
        </p>
    

                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1078-8956</span> (print)
        </p>
    

            </div>
        </div>
    </div>
</div>

    <div class="c-footer">
        <div class="u-hide-print" data-track-component="footer">
    <h2 class="u-visually-hidden">nature.com sitemap</h2>
    <div class="c-footer__container">
        <div class="c-footer__grid c-footer__group--separator">
            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">About Nature Portfolio</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/npg_/company_info/index.html" data-track="click" data-track-action="about us" data-track-label="link">About us</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/npg_/press_room/press_releases.html" data-track="click" data-track-action="press releases" data-track-label="link">Press releases</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://press.nature.com/" data-track="click" data-track-action="press office" data-track-label="link">Press office</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://support.nature.com/support/home" data-track="click" data-track-action="contact us" data-track-label="link">Contact us</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Discover content</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/siteindex" data-track="click" data-track-action="journals a-z" data-track-label="link">Journals A-Z</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/subjects" data-track="click" data-track-action="article by subject" data-track-label="link">Articles by subject</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.protocols.io/" data-track="click" data-track-action="protocols.io" data-track-label="link">protocols.io</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureindex.com/" data-track="click" data-track-action="nature index" data-track-label="link">Nature Index</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Publishing policies</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/authors/editorial_policies" data-track="click" data-track-action="Nature portfolio policies" data-track-label="link">Nature portfolio policies</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nature-research/open-access" data-track="click" data-track-action="open access" data-track-label="link">Open access</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Author &amp; Researcher services</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/reprints" data-track="click" data-track-action="reprints and permissions" data-track-label="link">Reprints &amp; permissions</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/authors/research-data" data-track="click" data-track-action="data research service" data-track-label="link">Research data</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://authorservices.springernature.com/language-editing/" data-track="click" data-track-action="language editing" data-track-label="link">Language editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://authorservices.springernature.com/scientific-editing/" data-track="click" data-track-action="scientific editing" data-track-label="link">Scientific editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://masterclasses.nature.com/" data-track="click" data-track-action="nature masterclasses" data-track-label="link">Nature Masterclasses</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://solutions.springernature.com/" data-track="click" data-track-action="research solutions" data-track-label="link">Research Solutions</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Libraries &amp; institutions</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/tools-services" data-track="click" data-track-action="librarian service and tools" data-track-label="link">Librarian service &amp; tools</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/manage-your-account/librarianportal" data-track="click" data-track-action="librarian portal" data-track-label="link">Librarian portal</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/openresearch/about-open-access/information-for-institutions" data-track="click" data-track-action="open research" data-track-label="link">Open research</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/recommend-to-your-library" data-track="click" data-track-action="Recommend to library" data-track-label="link">Recommend to library</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Advertising &amp; partnerships</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/product/digital-advertising/" data-track="click" data-track-action="advertising" data-track-label="link">Advertising</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/" data-track="click" data-track-action="partnerships and services" data-track-label="link">Partnerships &amp; Services</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/media-kits/" data-track="click" data-track-action="media kits" data-track-label="link">Media kits</a>
                    </li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/product/branded-content-native-advertising/" data-track-action="branded content" data-track-label="link">Branded
                        content</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Professional development</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/naturecareers/" data-track="click" data-track-action="nature careers" data-track-label="link">Nature Careers</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://conferences.nature.com" data-track="click" data-track-action="nature conferences" data-track-label="link">Nature<span class="u-visually-hidden"> </span>
                        Conferences</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Regional websites</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natafrica" data-track="click" data-track-action="nature africa" data-track-label="link">Nature Africa</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="http://www.naturechina.com" data-track="click" data-track-action="nature china" data-track-label="link">Nature China</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nindia" data-track="click" data-track-action="nature india" data-track-label="link">Nature India</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natitaly" data-track="click" data-track-action="nature Italy" data-track-label="link">Nature Italy</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureasia.com/ja-jp" data-track="click" data-track-action="nature japan" data-track-label="link">Nature Japan</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nmiddleeast" data-track="click" data-track-action="nature middle east" data-track-label="link">Nature Middle East</a></li>
                </ul>
            </div>

        </div>
    </div>
    <div class="c-footer__container">
        <ul class="c-footer__links">
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/privacy" data-track="click" data-track-action="privacy policy" data-track-label="link">Privacy
                Policy</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/cookies" data-track="click" data-track-action="use of cookies" data-track-label="link">Use
                of cookies</a></li>
            <li class="c-footer__item">
                <button class="optanon-toggle-display c-footer__link" onclick="javascript:;" data-cc-action="preferences" data-track="click" data-track-action="manage cookies" data-track-label="link">Your privacy choices/Manage cookies
                </button>
            </li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/legal-notice" data-track="click" data-track-action="legal notice" data-track-label="link">Legal
                notice</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/accessibility-statement" data-track="click" data-track-action="accessibility statement" data-track-label="link">Accessibility
                statement</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/terms-and-conditions" data-track="click" data-track-action="terms and conditions" data-track-label="link">Terms &amp; Conditions</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/ccpa" data-track="click" data-track-action="california privacy statement" data-track-label="link">Your US state privacy rights</a></li>
            
        </ul>
    </div>
</div>


        <div class="c-footer__container">
    <a href="https://www.springernature.com/" class="c-footer__link">
        <img src="/static/images/logos/sn-logo-white-ea63208b81.svg" alt="Springer Nature" loading="lazy" width="200" height="20">
    </a>
    <p class="c-footer__legal" data-test="copyright">© 2025 Springer Nature Limited</p>
</div>

    </div>
    <div class="u-visually-hidden" aria-hidden="true">
    
    <!--?xml version="1.0" encoding="UTF-8"?--><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><defs><path id="a" d="M0 .74h56.72v55.24H0z"></path></defs><symbol id="icon-access" viewBox="0 0 18 18"><path d="m14 8c.5522847 0 1 .44771525 1 1v7h2.5c.2761424 0 .5.2238576.5.5v1.5h-18v-1.5c0-.2761424.22385763-.5.5-.5h2.5v-7c0-.55228475.44771525-1 1-1s1 .44771525 1 1v6.9996556h8v-6.9996556c0-.55228475.4477153-1 1-1zm-8 0 2 1v5l-2 1zm6 0v7l-2-1v-5zm-2.42653766-7.59857636 7.03554716 4.92488299c.4162533.29137735.5174853.86502537.226108 1.28127873-.1721584.24594054-.4534847.39241464-.7536934.39241464h-14.16284822c-.50810197 0-.92-.41189803-.92-.92 0-.30020869.1464741-.58153499.39241464-.75369337l7.03554714-4.92488299c.34432015-.2410241.80260453-.2410241 1.14692468 0zm-.57346234 2.03988748-3.65526982 2.55868888h7.31053962z" fill-rule="evenodd"></path></symbol><symbol id="icon-account" viewBox="0 0 18 18"><path d="m10.2379028 16.9048051c1.3083556-.2032362 2.5118471-.7235183 3.5294683-1.4798399-.8731327-2.5141501-2.0638925-3.935978-3.7673711-4.3188248v-1.27684611c1.1651924-.41183641 2-1.52307546 2-2.82929429 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.30621883.83480763 2.41745788 2 2.82929429v1.27684611c-1.70347856.3828468-2.89423845 1.8046747-3.76737114 4.3188248 1.01762123.7563216 2.22111275 1.2766037 3.52946833 1.4798399.40563808.0629726.81921174.0951949 1.23790281.0951949s.83226473-.0322223 1.2379028-.0951949zm4.3421782-2.1721994c1.4927655-1.4532925 2.419919-3.484675 2.419919-5.7326057 0-4.418278-3.581722-8-8-8s-8 3.581722-8 8c0 2.2479307.92715352 4.2793132 2.41991895 5.7326057.75688473-2.0164459 1.83949951-3.6071894 3.48926591-4.3218837-1.14534283-.70360829-1.90918486-1.96796271-1.90918486-3.410722 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.44275929-.763842 2.70711371-1.9091849 3.410722 1.6497664.7146943 2.7323812 2.3054378 3.4892659 4.3218837zm-5.580081 3.2673943c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-alert" viewBox="0 0 18 18"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-broad" viewBox="0 0 16 16"><path d="m6.10307866 2.97190702v7.69043288l2.44965196-2.44676915c.38776071-.38730439 1.0088052-.39493524 1.38498697-.01919617.38609051.38563612.38643641 1.01053024-.00013864 1.39665039l-4.12239817 4.11754683c-.38616704.3857126-1.01187344.3861062-1.39846576-.0000311l-4.12258206-4.11773056c-.38618426-.38572979-.39254614-1.00476697-.01636437-1.38050605.38609047-.38563611 1.01018509-.38751562 1.4012233.00306241l2.44985644 2.4469734v-8.67638639c0-.54139983.43698413-.98042709.98493125-.98159081l7.89910522-.0043627c.5451687 0 .9871152.44142642.9871152.98595351s-.4419465.98595351-.9871152.98595351z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 14 15)"></path></symbol><symbol id="icon-arrow-down" viewBox="0 0 16 16"><path d="m3.28337502 11.5302405 4.03074001 4.176208c.37758093.3912076.98937525.3916069 1.367372-.0000316l4.03091977-4.1763942c.3775978-.3912252.3838182-1.0190815.0160006-1.4001736-.3775061-.39113013-.9877245-.39303641-1.3700683.003106l-2.39538585 2.4818345v-11.6147896l-.00649339-.11662112c-.055753-.49733869-.46370161-.88337888-.95867408-.88337888-.49497246 0-.90292107.38604019-.95867408.88337888l-.00649338.11662112v11.6147896l-2.39518594-2.4816273c-.37913917-.39282218-.98637524-.40056175-1.35419292-.0194697-.37750607.3911302-.37784433 1.0249269.00013556 1.4165479z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-left" viewBox="0 0 16 16"><path d="m4.46975946 3.28337502-4.17620792 4.03074001c-.39120768.37758093-.39160691.98937525.0000316 1.367372l4.1763942 4.03091977c.39122514.3775978 1.01908149.3838182 1.40017357.0160006.39113012-.3775061.3930364-.9877245-.00310603-1.3700683l-2.48183446-2.39538585h11.61478958l.1166211-.00649339c.4973387-.055753.8833789-.46370161.8833789-.95867408 0-.49497246-.3860402-.90292107-.8833789-.95867408l-.1166211-.00649338h-11.61478958l2.4816273-2.39518594c.39282216-.37913917.40056173-.98637524.01946965-1.35419292-.39113012-.37750607-1.02492687-.37784433-1.41654791.00013556z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-right" viewBox="0 0 16 16"><path d="m11.5302405 12.716625 4.176208-4.03074003c.3912076-.37758093.3916069-.98937525-.0000316-1.367372l-4.1763942-4.03091981c-.3912252-.37759778-1.0190815-.38381821-1.4001736-.01600053-.39113013.37750607-.39303641.98772445.003106 1.37006824l2.4818345 2.39538588h-11.6147896l-.11662112.00649339c-.49733869.055753-.88337888.46370161-.88337888.95867408 0 .49497246.38604019.90292107.88337888.95867408l.11662112.00649338h11.6147896l-2.4816273 2.39518592c-.39282218.3791392-.40056175.9863753-.0194697 1.3541929.3911302.3775061 1.0249269.3778444 1.4165479-.0001355z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-sub" viewBox="0 0 16 16"><path d="m7.89692134 4.97190702v7.69043288l-2.44965196-2.4467692c-.38776071-.38730434-1.0088052-.39493519-1.38498697-.0191961-.38609047.3856361-.38643643 1.0105302.00013864 1.3966504l4.12239817 4.1175468c.38616704.3857126 1.01187344.3861062 1.39846576-.0000311l4.12258202-4.1177306c.3861843-.3857298.3925462-1.0047669.0163644-1.380506-.3860905-.38563612-1.0101851-.38751563-1.4012233.0030624l-2.44985643 2.4469734v-8.67638639c0-.54139983-.43698413-.98042709-.98493125-.98159081l-7.89910525-.0043627c-.54516866 0-.98711517.44142642-.98711517.98595351s.44194651.98595351.98711517.98595351z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-up" viewBox="0 0 16 16"><path d="m12.716625 4.46975946-4.03074003-4.17620792c-.37758093-.39120768-.98937525-.39160691-1.367372.0000316l-4.03091981 4.1763942c-.37759778.39122514-.38381821 1.01908149-.01600053 1.40017357.37750607.39113012.98772445.3930364 1.37006824-.00310603l2.39538588-2.48183446v11.61478958l.00649339.1166211c.055753.4973387.46370161.8833789.95867408.8833789.49497246 0 .90292107-.3860402.95867408-.8833789l.00649338-.1166211v-11.61478958l2.39518592 2.4816273c.3791392.39282216.9863753.40056173 1.3541929.01946965.3775061-.39113012.3778444-1.02492687-.0001355-1.41654791z" fill-rule="evenodd"></path></symbol><symbol id="icon-article" viewBox="0 0 18 18"><path d="m13 15v-12.9906311c0-.0073595-.0019884-.0093689.0014977-.0093689l-11.00158888.00087166v13.00506804c0 .5482678.44615281.9940603.99415146.9940603h10.27350412c-.1701701-.2941734-.2675644-.6357129-.2675644-1zm-12 .0059397v-13.00506804c0-.5562408.44704472-1.00087166.99850233-1.00087166h11.00299537c.5510129 0 .9985023.45190985.9985023 1.0093689v2.9906311h3v9.9914698c0 1.1065798-.8927712 2.0085302-1.9940603 2.0085302h-12.01187942c-1.09954652 0-1.99406028-.8927712-1.99406028-1.9940603zm13-9.0059397v9c0 .5522847.4477153 1 1 1s1-.4477153 1-1v-9zm-10-2h7v4h-7zm1 1v2h5v-2zm-1 4h7v1h-7zm0 2h7v1h-7zm0 2h7v1h-7z" fill-rule="evenodd"></path></symbol><symbol id="icon-audio" viewBox="0 0 18 18"><path d="m13.0957477 13.5588459c-.195279.1937043-.5119137.193729-.7072234.0000551-.1953098-.193674-.1953346-.5077061-.0000556-.7014104 1.0251004-1.0168342 1.6108711-2.3905226 1.6108711-3.85745208 0-1.46604976-.5850634-2.83898246-1.6090736-3.85566829-.1951894-.19379323-.1950192-.50782531.0003802-.70141028.1953993-.19358497.512034-.19341614.7072234.00037709 1.2094886 1.20083761 1.901635 2.8250555 1.901635 4.55670148 0 1.73268608-.6929822 3.35779608-1.9037571 4.55880738zm2.1233994 2.1025159c-.195234.193749-.5118687.1938462-.7072235.0002171-.1953548-.1936292-.1954528-.5076613-.0002189-.7014104 1.5832215-1.5711805 2.4881302-3.6939808 2.4881302-5.96012998 0-2.26581266-.9046382-4.3883241-2.487443-5.95944795-.1952117-.19377107-.1950777-.50780316.0002993-.70141031s.5120117-.19347426.7072234.00029682c1.7683321 1.75528196 2.7800854 4.12911258 2.7800854 6.66056144 0 2.53182498-1.0120556 4.90597838-2.7808529 6.66132328zm-14.21898205-3.6854911c-.5523759 0-1.00016505-.4441085-1.00016505-.991944v-3.96777631c0-.54783558.44778915-.99194407 1.00016505-.99194407h2.0003301l5.41965617-3.8393633c.44948677-.31842296 1.07413994-.21516983 1.39520191.23062232.12116339.16823446.18629727.36981184.18629727.57655577v12.01603479c0 .5478356-.44778914.9919441-1.00016505.9919441-.20845738 0-.41170538-.0645985-.58133413-.184766l-5.41965617-3.8393633zm0-.991944h2.32084805l5.68047235 4.0241292v-12.01603479l-5.68047235 4.02412928h-2.32084805z" fill-rule="evenodd"></path></symbol><symbol id="icon-block" viewBox="0 0 24 24"><path d="m0 0h24v24h-24z" fill-rule="evenodd"></path></symbol><symbol id="icon-book" viewBox="0 0 18 18"><path d="m4 13v-11h1v11h11v-11h-13c-.55228475 0-1 .44771525-1 1v10.2675644c.29417337-.1701701.63571286-.2675644 1-.2675644zm12 1h-13c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1h13zm0 3h-13c-1.1045695 0-2-.8954305-2-2v-12c0-1.1045695.8954305-2 2-2h13c.5522847 0 1 .44771525 1 1v14c0 .5522847-.4477153 1-1 1zm-8.5-13h6c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1 2h4c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-4c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-broad" viewBox="0 0 24 24"><path d="m9.18274226 7.81v7.7999954l2.48162734-2.4816273c.3928221-.3928221 1.0219731-.4005617 1.4030652-.0194696.3911301.3911301.3914806 1.0249268-.0001404 1.4165479l-4.17620796 4.1762079c-.39120769.3912077-1.02508144.3916069-1.41671995-.0000316l-4.1763942-4.1763942c-.39122514-.3912251-.39767006-1.0190815-.01657798-1.4001736.39113012-.3911301 1.02337106-.3930364 1.41951349.0031061l2.48183446 2.4818344v-8.7999954c0-.54911294.4426881-.99439484.99778758-.99557515l8.00221246-.00442485c.5522847 0 1 .44771525 1 1s-.4477153 1-1 1z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 20.182742 24.805206)"></path></symbol><symbol id="icon-calendar" viewBox="0 0 18 18"><path d="m12.5 0c.2761424 0 .5.21505737.5.49047852v.50952148h2c1.1072288 0 2 .89451376 2 2v12c0 1.1072288-.8945138 2-2 2h-12c-1.1072288 0-2-.8945138-2-2v-12c0-1.1072288.89451376-2 2-2h1v1h-1c-.55393837 0-1 .44579254-1 1v3h14v-3c0-.55393837-.4457925-1-1-1h-2v1.50952148c0 .27088381-.2319336.49047852-.5.49047852-.2761424 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.2319336-.49047852.5-.49047852zm3.5 7h-14v8c0 .5539384.44579254 1 1 1h12c.5539384 0 1-.4457925 1-1zm-11 6v1h-1v-1zm3 0v1h-1v-1zm3 0v1h-1v-1zm-6-2v1h-1v-1zm3 0v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-3-2v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-5.5-9c.27614237 0 .5.21505737.5.49047852v.50952148h5v1h-5v1.50952148c0 .27088381-.23193359.49047852-.5.49047852-.27614237 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.23193359-.49047852.5-.49047852z" fill-rule="evenodd"></path></symbol><symbol id="icon-cart" viewBox="0 0 18 18"><path d="m5 14c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm10 0c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm-10 1c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1 1-.4477153 1-1-.44771525-1-1-1zm10 0c-.5522847 0-1 .4477153-1 1s.4477153 1 1 1 1-.4477153 1-1-.4477153-1-1-1zm-12.82032249-15c.47691417 0 .88746157.33678127.98070211.80449199l.23823144 1.19501025 13.36277974.00045554c.5522847.00001882.9999659.44774934.9999659 1.00004222 0 .07084994-.0075361.14150708-.022474.2107727l-1.2908094 5.98534344c-.1007861.46742419-.5432548.80388386-1.0571651.80388386h-10.24805106c-.59173366 0-1.07142857.4477153-1.07142857 1 0 .5128358.41361449.9355072.94647737.9932723l.1249512.0067277h10.35933776c.2749512 0 .4979349.2228539.4979349.4978051 0 .2749417-.2227336.4978951-.4976753.4980063l-10.35959736.0041886c-1.18346732 0-2.14285714-.8954305-2.14285714-2 0-.6625717.34520317-1.24989198.87690425-1.61383592l-1.63768102-8.19004794c-.01312273-.06561364-.01950005-.131011-.0196107-.19547395l-1.71961253-.00064219c-.27614237 0-.5-.22385762-.5-.5 0-.27614237.22385763-.5.5-.5zm14.53193359 2.99950224h-13.11300004l1.20580469 6.02530174c.11024034-.0163252.22327998-.02480398.33844139-.02480398h10.27064786z"></path></symbol><symbol id="icon-chevron-less" viewBox="0 0 10 10"><path d="m5.58578644 4-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 -1 -1 0 9 9)"></path></symbol><symbol id="icon-chevron-more" viewBox="0 0 10 10"><path d="m5.58578644 6-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4.00000002c-.39052429.3905243-1.02368927.3905243-1.41421356 0s-.39052429-1.02368929 0-1.41421358z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"></path></symbol><symbol id="icon-chevron-right" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-circle-fill" viewBox="0 0 16 16"><path d="m8 14c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"></path></symbol><symbol id="icon-circle" viewBox="0 0 16 16"><path d="m8 12c2.209139 0 4-1.790861 4-4s-1.790861-4-4-4-4 1.790861-4 4 1.790861 4 4 4zm0 2c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"></path></symbol><symbol id="icon-citation" viewBox="0 0 18 18"><path d="m8.63593473 5.99995183c2.20913897 0 3.99999997 1.79084375 3.99999997 3.99996146 0 1.40730761-.7267788 2.64486871-1.8254829 3.35783281 1.6240224.6764218 2.8754442 2.0093871 3.4610603 3.6412466l-1.0763845.000006c-.5310008-1.2078237-1.5108121-2.1940153-2.7691712-2.7181346l-.79002167-.329052v-1.023992l.63016577-.4089232c.8482885-.5504661 1.3698342-1.4895187 1.3698342-2.51898361 0-1.65683828-1.3431457-2.99996146-2.99999997-2.99996146-1.65685425 0-3 1.34312318-3 2.99996146 0 1.02946491.52154569 1.96851751 1.36983419 2.51898361l.63016581.4089232v1.023992l-.79002171.329052c-1.25835905.5241193-2.23817037 1.5103109-2.76917113 2.7181346l-1.07638453-.000006c.58561612-1.6318595 1.8370379-2.9648248 3.46106024-3.6412466-1.09870405-.7129641-1.82548287-1.9505252-1.82548287-3.35783281 0-2.20911771 1.790861-3.99996146 4-3.99996146zm7.36897597-4.99995183c1.1018574 0 1.9950893.89353404 1.9950893 2.00274083v5.994422c0 1.10608317-.8926228 2.00274087-1.9950893 2.00274087l-3.0049107-.0009037v-1l3.0049107.00091329c.5490631 0 .9950893-.44783123.9950893-1.00275046v-5.994422c0-.55646537-.4450595-1.00275046-.9950893-1.00275046h-14.00982141c-.54906309 0-.99508929.44783123-.99508929 1.00275046v5.9971821c0 .66666024.33333333.99999036 1 .99999036l2-.00091329v1l-2 .0009037c-1 0-2-.99999041-2-1.99998077v-5.9971821c0-1.10608322.8926228-2.00274083 1.99508929-2.00274083zm-8.5049107 2.9999711c.27614237 0 .5.22385547.5.5 0 .2761349-.22385763.5-.5.5h-4c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm3 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-1c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm4 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238651-.5-.5 0-.27614453.2238576-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-close" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"></path></symbol><symbol id="icon-collections" viewBox="0 0 18 18"><path d="m15 4c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2h1c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-1v-1zm-4-3c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2v-9c0-1.1045695.8954305-2 2-2zm0 1h-8c-.51283584 0-.93550716.38604019-.99327227.88337887l-.00672773.11662113v9c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227zm-1.5 7c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-compare" viewBox="0 0 18 18"><path d="m12 3c3.3137085 0 6 2.6862915 6 6s-2.6862915 6-6 6c-1.0928452 0-2.11744941-.2921742-2.99996061-.8026704-.88181407.5102749-1.90678042.8026704-3.00003939.8026704-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6c1.09325897 0 2.11822532.29239547 3.00096303.80325037.88158756-.51107621 1.90619177-.80325037 2.99903697-.80325037zm-6 1c-2.76142375 0-5 2.23857625-5 5 0 2.7614237 2.23857625 5 5 5 .74397391 0 1.44999672-.162488 2.08451611-.4539116-1.27652344-1.1000812-2.08451611-2.7287264-2.08451611-4.5460884s.80799267-3.44600721 2.08434391-4.5463015c-.63434719-.29121054-1.34037-.4536985-2.08434391-.4536985zm6 0c-.7439739 0-1.4499967.16248796-2.08451611.45391156 1.27652341 1.10008123 2.08451611 2.72872644 2.08451611 4.54608844s-.8079927 3.4460072-2.08434391 4.5463015c.63434721.2912105 1.34037001.4536985 2.08434391.4536985 2.7614237 0 5-2.2385763 5-5 0-2.76142375-2.2385763-5-5-5zm-1.4162763 7.0005324h-3.16744736c.15614659.3572676.35283837.6927622.58425872 1.0006671h1.99892988c.23142036-.3079049.42811216-.6433995.58425876-1.0006671zm.4162763-2.0005324h-4c0 .34288501.0345146.67770871.10025909 1.0011864h3.79948181c.0657445-.32347769.1002591-.65830139.1002591-1.0011864zm-.4158423-1.99953894h-3.16831543c-.13859957.31730812-.24521946.651783-.31578599.99935097h3.79988742c-.0705665-.34756797-.1771864-.68204285-.315786-.99935097zm-1.58295822-1.999926-.08316107.06199199c-.34550042.27081213-.65446126.58611297-.91825862.93727862h2.00044041c-.28418626-.37830727-.6207872-.71499149-.99902072-.99927061z" fill-rule="evenodd"></path></symbol><symbol id="icon-download-file" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.5046024 4c.27614237 0 .5.21637201.5.49209595v6.14827645l1.7462789-1.77990922c.1933927-.1971171.5125222-.19455839.7001689-.0069117.1932998.19329992.1910058.50899492-.0027774.70277812l-2.59089271 2.5908927c-.19483374.1948337-.51177825.1937771-.70556873-.0000133l-2.59099079-2.5909908c-.19484111-.1948411-.19043735-.5151448-.00279066-.70279146.19329987-.19329987.50465175-.19237083.70018565.00692852l1.74638684 1.78001764v-6.14827695c0-.27177709.23193359-.49209595.5-.49209595z" fill-rule="evenodd"></path></symbol><symbol id="icon-download" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"></path></symbol><symbol id="icon-editors" viewBox="0 0 18 18"><path d="m8.72592184 2.54588137c-.48811714-.34391207-1.08343326-.54588137-1.72592184-.54588137-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400182l-.79002171.32905522c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274v.9009805h-1v-.9009805c0-2.5479714 1.54557359-4.79153984 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4 1.09079823 0 2.07961816.43662103 2.80122451 1.1446278-.37707584.09278571-.7373238.22835063-1.07530267.40125357zm-2.72592184 14.45411863h-1v-.9009805c0-2.5479714 1.54557359-4.7915398 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.40732121-.7267788 2.64489414-1.8254829 3.3578652 2.2799093.9496145 3.8254829 3.1931829 3.8254829 5.7411543v.9009805h-1v-.9009805c0-2.1155483-1.2760206-4.0125067-3.2099783-4.8180274l-.7900217-.3290552v-1.02400184l.6301658-.40892721c.8482885-.55047139 1.3698342-1.489533 1.3698342-2.51900785 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400184l-.79002171.3290552c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274z" fill-rule="evenodd"></path></symbol><symbol id="icon-email" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-.0049107 2.55749512v1.44250488l-7 4-7-4v-1.44250488l7 4z" fill-rule="evenodd"></path></symbol><symbol id="icon-error" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm2.8630343 4.71100931-2.8630343 2.86303426-2.86303426-2.86303426c-.39658757-.39658757-1.03281091-.39438847-1.4265779-.00062147-.39651227.39651226-.39348876 1.03246767.00062147 1.4265779l2.86303426 2.86303426-2.86303426 2.8630343c-.39658757.3965875-.39438847 1.0328109-.00062147 1.4265779.39651226.3965122 1.03246767.3934887 1.4265779-.0006215l2.86303426-2.8630343 2.8630343 2.8630343c.3965875.3965876 1.0328109.3943885 1.4265779.0006215.3965122-.3965123.3934887-1.0324677-.0006215-1.4265779l-2.8630343-2.8630343 2.8630343-2.86303426c.3965876-.39658757.3943885-1.03281091.0006215-1.4265779-.3965123-.39651227-1.0324677-.39348876-1.4265779.00062147z" fill-rule="evenodd"></path></symbol><symbol id="icon-ethics" viewBox="0 0 18 18"><path d="m6.76384967 1.41421356.83301651-.8330165c.77492941-.77492941 2.03133823-.77492941 2.80626762 0l.8330165.8330165c.3750728.37507276.8837806.58578644 1.4142136.58578644h1.3496361c1.1045695 0 2 .8954305 2 2v1.34963611c0 .53043298.2107137 1.03914081.5857864 1.41421356l.8330165.83301651c.7749295.77492941.7749295 2.03133823 0 2.80626762l-.8330165.8330165c-.3750727.3750728-.5857864.8837806-.5857864 1.4142136v1.3496361c0 1.1045695-.8954305 2-2 2h-1.3496361c-.530433 0-1.0391408.2107137-1.4142136.5857864l-.8330165.8330165c-.77492939.7749295-2.03133821.7749295-2.80626762 0l-.83301651-.8330165c-.37507275-.3750727-.88378058-.5857864-1.41421356-.5857864h-1.34963611c-1.1045695 0-2-.8954305-2-2v-1.3496361c0-.530433-.21071368-1.0391408-.58578644-1.4142136l-.8330165-.8330165c-.77492941-.77492939-.77492941-2.03133821 0-2.80626762l.8330165-.83301651c.37507276-.37507275.58578644-.88378058.58578644-1.41421356v-1.34963611c0-1.1045695.8954305-2 2-2h1.34963611c.53043298 0 1.03914081-.21071368 1.41421356-.58578644zm-1.41421356 1.58578644h-1.34963611c-.55228475 0-1 .44771525-1 1v1.34963611c0 .79564947-.31607052 1.55871121-.87867966 2.12132034l-.8330165.83301651c-.38440512.38440512-.38440512 1.00764896 0 1.39205408l.8330165.83301646c.56260914.5626092.87867966 1.3256709.87867966 2.1213204v1.3496361c0 .5522847.44771525 1 1 1h1.34963611c.79564947 0 1.55871121.3160705 2.12132034.8786797l.83301651.8330165c.38440512.3844051 1.00764896.3844051 1.39205408 0l.83301646-.8330165c.5626092-.5626092 1.3256709-.8786797 2.1213204-.8786797h1.3496361c.5522847 0 1-.4477153 1-1v-1.3496361c0-.7956495.3160705-1.5587112.8786797-2.1213204l.8330165-.83301646c.3844051-.38440512.3844051-1.00764896 0-1.39205408l-.8330165-.83301651c-.5626092-.56260913-.8786797-1.32567087-.8786797-2.12132034v-1.34963611c0-.55228475-.4477153-1-1-1h-1.3496361c-.7956495 0-1.5587112-.31607052-2.1213204-.87867966l-.83301646-.8330165c-.38440512-.38440512-1.00764896-.38440512-1.39205408 0l-.83301651.8330165c-.56260913.56260914-1.32567087.87867966-2.12132034.87867966zm3.58698944 11.4960218c-.02081224.002155-.04199226.0030286-.06345763.002542-.98766446-.0223875-1.93408568-.3063547-2.75885125-.8155622-.23496767-.1450683-.30784554-.4531483-.16277726-.688116.14506827-.2349677.45314827-.3078455.68811595-.1627773.67447084.4164161 1.44758575.6483839 2.25617384.6667123.01759529.0003988.03495764.0017019.05204365.0038639.01713363-.0017748.03452416-.0026845.05212715-.0026845 2.4852814 0 4.5-2.0147186 4.5-4.5 0-1.04888973-.3593547-2.04134635-1.0074477-2.83787157-.1742817-.21419731-.1419238-.5291218.0722736-.70340353.2141973-.17428173.5291218-.14192375.7034035.07227357.7919032.97327203 1.2317706 2.18808682 1.2317706 3.46900153 0 3.0375661-2.4624339 5.5-5.5 5.5-.02146768 0-.04261937-.0013529-.06337445-.0039782zm1.57975095-10.78419583c.2654788.07599731.419084.35281842.3430867.61829728-.0759973.26547885-.3528185.419084-.6182973.3430867-.37560116-.10752146-.76586237-.16587951-1.15568824-.17249193-2.5587807-.00064534-4.58547766 2.00216524-4.58547766 4.49928198 0 .62691557.12797645 1.23496.37274865 1.7964426.11035133.2531347-.0053975.5477984-.25853224.6581497-.25313473.1103514-.54779841-.0053975-.65814974-.2585322-.29947131-.6869568-.45606667-1.43097603-.45606667-2.1960601 0-3.05211432 2.47714695-5.50006595 5.59399617-5.49921198.48576182.00815502.96289603.0795037 1.42238033.21103795zm-1.9766658 6.41091303 2.69835-2.94655317c.1788432-.21040373.4943901-.23598862.7047939-.05714545.2104037.17884318.2359886.49439014.0571454.70479387l-3.01637681 3.34277395c-.18039088.1999106-.48669547.2210637-.69285412.0478478l-1.93095347-1.62240047c-.21213845-.17678204-.24080048-.49206439-.06401844-.70420284.17678204-.21213844.49206439-.24080048.70420284-.06401844z" fill-rule="evenodd"></path></symbol><symbol id="icon-expand"><path d="M7.498 11.918a.997.997 0 0 0-.003-1.411.995.995 0 0 0-1.412-.003l-4.102 4.102v-3.51A1 1 0 0 0 .98 10.09.992.992 0 0 0 0 11.092V17c0 .554.448 1.002 1.002 1.002h5.907c.554 0 1.002-.45 1.002-1.003 0-.539-.45-.978-1.006-.978h-3.51zm3.005-5.835a.997.997 0 0 0 .003 1.412.995.995 0 0 0 1.411.003l4.103-4.103v3.51a1 1 0 0 0 1.001 1.006A.992.992 0 0 0 18 6.91V1.002A1 1 0 0 0 17 0h-5.907a1.003 1.003 0 0 0-1.002 1.003c0 .539.45.978 1.006.978h3.51z" fill-rule="evenodd"></path></symbol><symbol id="icon-explore" viewBox="0 0 18 18"><path d="m9 17c4.418278 0 8-3.581722 8-8s-3.581722-8-8-8-8 3.581722-8 8 3.581722 8 8 8zm0 1c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9zm0-2.5c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5c2.969509 0 5.400504-2.3575119 5.497023-5.31714844.0090007-.27599565.2400359-.49243782.5160315-.48343711.2759957.0090007.4924378.2400359.4834371.51603155-.114093 3.4985237-2.9869632 6.284554-6.4964916 6.284554zm-.29090657-12.99359748c.27587424-.01216621.50937715.20161139.52154336.47748563.01216621.27587423-.20161139.50937715-.47748563.52154336-2.93195733.12930094-5.25315116 2.54886451-5.25315116 5.49456849 0 .27614237-.22385763.5-.5.5s-.5-.22385763-.5-.5c0-3.48142406 2.74307146-6.34074398 6.20909343-6.49359748zm1.13784138 8.04763908-1.2004882-1.20048821c-.19526215-.19526215-.19526215-.51184463 0-.70710678s.51184463-.19526215.70710678 0l1.20048821 1.2004882 1.6006509-4.00162734-4.50670359 1.80268144-1.80268144 4.50670359zm4.10281269-6.50378907-2.6692597 6.67314927c-.1016411.2541026-.3029834.4554449-.557086.557086l-6.67314927 2.6692597 2.66925969-6.67314926c.10164107-.25410266.30298336-.45544495.55708602-.55708602z" fill-rule="evenodd"></path></symbol><symbol id="icon-filter" viewBox="0 0 16 16"><path d="m14.9738641 0c.5667192 0 1.0261359.4477136 1.0261359 1 0 .24221858-.0902161.47620768-.2538899.65849851l-5.6938314 6.34147206v5.49997973c0 .3147562-.1520673.6111434-.4104543.7999971l-2.05227171 1.4999945c-.45337535.3313696-1.09655869.2418269-1.4365902-.1999993-.13321514-.1730955-.20522717-.3836284-.20522717-.5999978v-6.99997423l-5.69383133-6.34147206c-.3731872-.41563511-.32996891-1.0473954.09653074-1.41107611.18705584-.15950448.42716133-.2474224.67571519-.2474224zm-5.9218641 8.5h-2.105v6.491l.01238459.0070843.02053271.0015705.01955278-.0070558 2.0532976-1.4990996zm-8.02585008-7.5-.01564945.00240169 5.83249953 6.49759831h2.313l5.836-6.499z"></path></symbol><symbol id="icon-home" viewBox="0 0 18 18"><path d="m9 5-6 6v5h4v-4h4v4h4v-5zm7 6.5857864v4.4142136c0 .5522847-.4477153 1-1 1h-5v-4h-2v4h-5c-.55228475 0-1-.4477153-1-1v-4.4142136c-.25592232 0-.51184464-.097631-.70710678-.2928932l-.58578644-.5857864c-.39052429-.3905243-.39052429-1.02368929 0-1.41421358l8.29289322-8.29289322 8.2928932 8.29289322c.3905243.39052429.3905243 1.02368928 0 1.41421358l-.5857864.5857864c-.1952622.1952622-.4511845.2928932-.7071068.2928932zm-7-9.17157284-7.58578644 7.58578644.58578644.5857864 7-6.99999996 7 6.99999996.5857864-.5857864z" fill-rule="evenodd"></path></symbol><symbol id="icon-image" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm-3.49645283 10.1752453-3.89407257 6.7495552c.11705545.048464.24538859.0751995.37998328.0751995h10.60290092l-2.4329715-4.2154691-1.57494129 2.7288098zm8.49779013 6.8247547c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v13.98991071l4.50814957-7.81026689 3.08089884 5.33809539 1.57494129-2.7288097 3.5875735 6.2159812zm-3.0059397-11c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm0 1c-.5522847 0-1 .44771525-1 1s.4477153 1 1 1 1-.44771525 1-1-.4477153-1-1-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-info" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"></path></symbol><symbol id="icon-institution" viewBox="0 0 18 18"><path d="m7 16.9998189v-2.0003623h4v2.0003623h2v-3.0005434h-8v3.0005434zm-3-10.00181122h-1.52632364c-.27614237 0-.5-.22389817-.5-.50009056 0-.13995446.05863589-.27350497.16166338-.36820841l1.23156713-1.13206327h-2.36690687v12.00217346h3v-2.0003623h-3v-1.0001811h3v-1.0001811h1v-4.00072448h-1zm10 0v2.00036224h-1v4.00072448h1v1.0001811h3v1.0001811h-3v2.0003623h3v-12.00217346h-2.3695309l1.2315671 1.13206327c.2033191.186892.2166633.50325042.0298051.70660631-.0946863.10304615-.2282126.16169266-.3681417.16169266zm3-3.00054336c.5522847 0 1 .44779634 1 1.00018112v13.00235456h-18v-13.00235456c0-.55238478.44771525-1.00018112 1-1.00018112h3.45499992l4.20535144-3.86558216c.19129876-.17584288.48537447-.17584288.67667324 0l4.2053514 3.86558216zm-4 3.00054336h-8v1.00018112h8zm-2 6.00108672h1v-4.00072448h-1zm-1 0v-4.00072448h-2v4.00072448zm-3 0v-4.00072448h-1v4.00072448zm8-4.00072448c.5522847 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.4477153-1.00018112 1-1.00018112zm-12 0c.55228475 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.44771525-1.00018112 1-1.00018112zm5.99868798-7.81907007-5.24205601 4.81852671h10.48411203zm.00131202 3.81834559c-.55228475 0-1-.44779634-1-1.00018112s.44771525-1.00018112 1-1.00018112 1 .44779634 1 1.00018112-.44771525 1.00018112-1 1.00018112zm-1 11.00199236v1.0001811h2v-1.0001811z" fill-rule="evenodd"></path></symbol><symbol id="icon-location" viewBox="0 0 18 18"><path d="m9.39521328 16.2688008c.79596342-.7770119 1.59208152-1.6299956 2.33285652-2.5295081 1.4020032-1.7024324 2.4323601-3.3624519 2.9354918-4.871847.2228715-.66861448.3364384-1.29323246.3364384-1.8674457 0-3.3137085-2.6862915-6-6-6-3.36356866 0-6 2.60156856-6 6 0 .57421324.11356691 1.19883122.3364384 1.8674457.50313169 1.5093951 1.53348863 3.1694146 2.93549184 4.871847.74077492.8995125 1.53689309 1.7524962 2.33285648 2.5295081.13694479.1336842.26895677.2602648.39521328.3793207.12625651-.1190559.25826849-.2456365.39521328-.3793207zm-.39521328 1.7311992s-7-6-7-11c0-4 3.13400675-7 7-7 3.8659932 0 7 3.13400675 7 7 0 5-7 11-7 11zm0-8c-1.65685425 0-3-1.34314575-3-3s1.34314575-3 3-3c1.6568542 0 3 1.34314575 3 3s-1.3431458 3-3 3zm0-1c1.1045695 0 2-.8954305 2-2s-.8954305-2-2-2-2 .8954305-2 2 .8954305 2 2 2z" fill-rule="evenodd"></path></symbol><symbol id="icon-minus" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-newsletter" viewBox="0 0 18 18"><path d="m9 11.8482489 2-1.1428571v-1.7053918h-4v1.7053918zm-3-1.7142857v-2.1339632h6v2.1339632l3-1.71428574v-6.41967746h-12v6.41967746zm10-5.3839632 1.5299989.95624934c.2923814.18273835.4700011.50320827.4700011.8479983v8.44575236c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-8.44575236c0-.34479003.1776197-.66525995.47000106-.8479983l1.52999894-.95624934v-2.75c0-.55228475.44771525-1 1-1h12c.5522847 0 1 .44771525 1 1zm0 1.17924764v3.07075236l-7 4-7-4v-3.07075236l-1 .625v8.44575236c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-8.44575236zm-10-1.92924764h6v1h-6zm-1 2h8v1h-8z" fill-rule="evenodd"></path></symbol><symbol id="icon-orcid" viewBox="0 0 18 18"><path d="m9 1c4.418278 0 8 3.581722 8 8s-3.581722 8-8 8-8-3.581722-8-8 3.581722-8 8-8zm-2.90107518 5.2732337h-1.41865256v7.1712107h1.41865256zm4.55867178.02508949h-2.99247027v7.14612121h2.91062487c.7673039 0 1.4476365-.1483432 2.0410182-.445034s1.0511995-.7152915 1.3734671-1.2558144c.3222677-.540523.4833991-1.1603247.4833991-1.85942385 0-.68545815-.1602789-1.30270225-.4808414-1.85175082-.3205625-.54904856-.7707074-.97532211-1.3504481-1.27883343-.5797408-.30351132-1.2413173-.45526471-1.9847495-.45526471zm-.1892674 1.07933542c.7877654 0 1.4143875.22336734 1.8798852.67010873.4654977.44674138.698243 1.05546001.698243 1.82617415 0 .74343221-.2310402 1.34447791-.6931277 1.80315511-.4620874.4586773-1.0750688.6880124-1.8389625.6880124h-1.46810075v-4.98745039zm-5.08652545-3.71099194c-.21825533 0-.410525.08444276-.57681478.25333081-.16628977.16888806-.24943341.36245684-.24943341.58071218 0 .22345188.08314364.41961891.24943341.58850696.16628978.16888806.35855945.25333082.57681478.25333082.233845 0 .43390938-.08314364.60019916-.24943342.16628978-.16628977.24943342-.36375592.24943342-.59240436 0-.233845-.08314364-.43131115-.24943342-.59240437s-.36635416-.24163862-.60019916-.24163862z" fill-rule="evenodd"></path></symbol><symbol id="icon-plus" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-print" viewBox="0 0 18 18"><path d="m16.0049107 5h-14.00982141c-.54941618 0-.99508929.4467783-.99508929.99961498v6.00077002c0 .5570958.44271433.999615.99508929.999615h1.00491071v-3h12v3h1.0049107c.5494162 0 .9950893-.4467783.9950893-.999615v-6.00077002c0-.55709576-.4427143-.99961498-.9950893-.99961498zm-2.0049107-1v-2.00208688c0-.54777062-.4519464-.99791312-1.0085302-.99791312h-7.9829396c-.55661731 0-1.0085302.44910695-1.0085302.99791312v2.00208688zm1 10v2.0018986c0 1.103521-.9019504 1.9981014-2.0085302 1.9981014h-7.9829396c-1.1092806 0-2.0085302-.8867064-2.0085302-1.9981014v-2.0018986h-1.00491071c-1.10185739 0-1.99508929-.8874333-1.99508929-1.999615v-6.00077002c0-1.10435686.8926228-1.99961498 1.99508929-1.99961498h1.00491071v-2.00208688c0-1.10341695.90195036-1.99791312 2.0085302-1.99791312h7.9829396c1.1092806 0 2.0085302.89826062 2.0085302 1.99791312v2.00208688h1.0049107c1.1018574 0 1.9950893.88743329 1.9950893 1.99961498v6.00077002c0 1.1043569-.8926228 1.999615-1.9950893 1.999615zm-1-3h-10v5.0018986c0 .5546075.44702548.9981014 1.0085302.9981014h7.9829396c.5565964 0 1.0085302-.4491701 1.0085302-.9981014zm-9 1h8v1h-8zm0 2h5v1h-5zm9-5c-.5522847 0-1-.44771525-1-1s.4477153-1 1-1 1 .44771525 1 1-.4477153 1-1 1z" fill-rule="evenodd"></path></symbol><symbol id="icon-search" viewBox="0 0 22 22"><path d="M21.697 20.261a1.028 1.028 0 01.01 1.448 1.034 1.034 0 01-1.448-.01l-4.267-4.267A9.812 9.811 0 010 9.812a9.812 9.811 0 1117.43 6.182zM9.812 18.222A8.41 8.41 0 109.81 1.403a8.41 8.41 0 000 16.82z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-facebook" viewBox="0 0 24 24"><path d="m6.00368507 20c-1.10660471 0-2.00368507-.8945138-2.00368507-1.9940603v-12.01187942c0-1.10128908.89451376-1.99406028 1.99406028-1.99406028h12.01187942c1.1012891 0 1.9940603.89451376 1.9940603 1.99406028v12.01187942c0 1.1012891-.88679 1.9940603-2.0032184 1.9940603h-2.9570132v-6.1960818h2.0797387l.3114113-2.414723h-2.39115v-1.54164807c0-.69911803.1941355-1.1755439 1.1966615-1.1755439l1.2786739-.00055875v-2.15974763l-.2339477-.02492088c-.3441234-.03134957-.9500153-.07025255-1.6293054-.07025255-1.8435726 0-3.1057323 1.12531866-3.1057323 3.19187953v1.78079225h-2.0850778v2.414723h2.0850778v6.1960818z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-twitter" viewBox="0 0 24 24"><path d="m18.8767135 6.87445248c.7638174-.46908424 1.351611-1.21167363 1.6250764-2.09636345-.7135248.43394112-1.50406.74870123-2.3464594.91677702-.6695189-.73342162-1.6297913-1.19486605-2.6922204-1.19486605-2.0399895 0-3.6933555 1.69603749-3.6933555 3.78628909 0 .29642457.0314329.58673729.0942985.8617704-3.06469922-.15890802-5.78835241-1.66547825-7.60988389-3.9574208-.3174714.56076194-.49978171 1.21167363-.49978171 1.90536824 0 1.31404706.65223085 2.47224203 1.64236444 3.15218497-.60350999-.0198635-1.17401554-.1925232-1.67222562-.47366811v.04583885c0 1.83355406 1.27302891 3.36609966 2.96411421 3.71294696-.31118484.0886217-.63651445.1329326-.97441718.1329326-.2357461 0-.47149219-.0229194-.69466516-.0672303.47149219 1.5065703 1.83253297 2.6036468 3.44975116 2.632678-1.2651707 1.0160946-2.85724264 1.6196394-4.5891906 1.6196394-.29861172 0-.59093688-.0152796-.88011875-.0504227 1.63450624 1.0726291 3.57548241 1.6990934 5.66104951 1.6990934 6.79263079 0 10.50641749-5.7711113 10.50641749-10.7751859l-.0094298-.48894775c.7229547-.53478659 1.3516109-1.20250585 1.8419628-1.96190282-.6632323.30100846-1.3751855.50422736-2.1217148.59590507z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-youtube" viewBox="0 0 24 24"><path d="m10.1415 14.3973208-.0005625-5.19318431 4.863375 2.60554491zm9.963-7.92753362c-.6845625-.73643756-1.4518125-.73990314-1.803375-.7826454-2.518875-.18714178-6.2971875-.18714178-6.2971875-.18714178-.007875 0-3.7861875 0-6.3050625.18714178-.352125.04274226-1.1188125.04620784-1.8039375.7826454-.5394375.56084773-.7149375 1.8344515-.7149375 1.8344515s-.18 1.49597903-.18 2.99138042v1.4024082c0 1.495979.18 2.9913804.18 2.9913804s.1755 1.2736038.7149375 1.8344515c.685125.7364376 1.5845625.7133337 1.9850625.7901542 1.44.1420891 6.12.1859866 6.12.1859866s3.78225-.005776 6.301125-.1929178c.3515625-.0433198 1.1188125-.0467854 1.803375-.783223.5394375-.5608477.7155-1.8344515.7155-1.8344515s.18-1.4954014.18-2.9913804v-1.4024082c0-1.49540139-.18-2.99138042-.18-2.99138042s-.1760625-1.27360377-.7155-1.8344515z" fill-rule="evenodd"></path></symbol><symbol id="icon-subject-medicine" viewBox="0 0 18 18"><path d="m12.5 8h-6.5c-1.65685425 0-3 1.34314575-3 3v1c0 1.6568542 1.34314575 3 3 3h1v-2h-.5c-.82842712 0-1.5-.6715729-1.5-1.5s.67157288-1.5 1.5-1.5h1.5 2 1 2c1.6568542 0 3-1.34314575 3-3v-1c0-1.65685425-1.3431458-3-3-3h-2v2h1.5c.8284271 0 1.5.67157288 1.5 1.5s-.6715729 1.5-1.5 1.5zm-5.5-1v-1h-3.5c-1.38071187 0-2.5-1.11928813-2.5-2.5s1.11928813-2.5 2.5-2.5h1.02786405c.46573528 0 .92507448.10843528 1.34164078.31671843l1.13382424.56691212c.06026365-1.05041141.93116291-1.88363055 1.99667093-1.88363055 1.1045695 0 2 .8954305 2 2h2c2.209139 0 4 1.790861 4 4v1c0 2.209139-1.790861 4-4 4h-2v1h2c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2h-2c0 1.1045695-.8954305 2-2 2s-2-.8954305-2-2h-1c-2.209139 0-4-1.790861-4-4v-1c0-2.209139 1.790861-4 4-4zm0-2v-2.05652691c-.14564246-.03538148-.28733393-.08714006-.42229124-.15461871l-1.15541752-.57770876c-.27771087-.13885544-.583937-.21114562-.89442719-.21114562h-1.02786405c-.82842712 0-1.5.67157288-1.5 1.5s.67157288 1.5 1.5 1.5zm4 1v1h1.5c.2761424 0 .5-.22385763.5-.5s-.2238576-.5-.5-.5zm-1 1v-5c0-.55228475-.44771525-1-1-1s-1 .44771525-1 1v5zm-2 4v5c0 .5522847.44771525 1 1 1s1-.4477153 1-1v-5zm3 2v2h2c.5522847 0 1-.4477153 1-1s-.4477153-1-1-1zm-4-1v-1h-.5c-.27614237 0-.5.2238576-.5.5s.22385763.5.5.5zm-3.5-9h1c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-success" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm3.4860198 4.98163161-4.71802968 5.50657859-2.62834168-2.02300024c-.42862421-.36730544-1.06564993-.30775346-1.42283677.13301307-.35718685.44076653-.29927542 1.0958383.12934879 1.46314377l3.40735508 2.7323063c.42215801.3385221 1.03700951.2798252 1.38749189-.1324571l5.38450527-6.33394549c.3613513-.43716226.3096573-1.09278382-.115462-1.46437175-.4251192-.37158792-1.0626796-.31842941-1.4240309.11873285z" fill-rule="evenodd"></path></symbol><symbol id="icon-table" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587l-4.0059107-.001.001.001h-1l-.001-.001h-5l.001.001h-1l-.001-.001-3.00391071.001c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm-11.0059107 5h-3.999v6.9941413c0 .5572961.44630695 1.0058587.99508929 1.0058587h3.00391071zm6 0h-5v8h5zm5.0059107-4h-4.0059107v3h5.001v1h-5.001v7.999l4.0059107.001c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-12.5049107 9c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.22385763-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1.499-5h-5v3h5zm-6 0h-3.00391071c-.54871518 0-.99508929.44887827-.99508929 1.00585866v1.99414134h3.999z" fill-rule="evenodd"></path></symbol><symbol id="icon-tick-circle" viewBox="0 0 24 24"><path d="m12 2c5.5228475 0 10 4.4771525 10 10s-4.4771525 10-10 10-10-4.4771525-10-10 4.4771525-10 10-10zm0 1c-4.97056275 0-9 4.02943725-9 9 0 4.9705627 4.02943725 9 9 9 4.9705627 0 9-4.0294373 9-9 0-4.97056275-4.0294373-9-9-9zm4.2199868 5.36606669c.3613514-.43716226.9989118-.49032077 1.424031-.11873285s.4768133 1.02720949.115462 1.46437175l-6.093335 6.94397871c-.3622945.4128716-.9897871.4562317-1.4054264.0971157l-3.89719065-3.3672071c-.42862421-.3673054-.48653564-1.0223772-.1293488-1.4631437s.99421256-.5003185 1.42283677-.1330131l3.11097438 2.6987741z" fill-rule="evenodd"></path></symbol><symbol id="icon-tick" viewBox="0 0 16 16"><path d="m6.76799012 9.21106946-3.1109744-2.58349728c-.42862421-.35161617-1.06564993-.29460792-1.42283677.12733148s-.29927541 1.04903009.1293488 1.40064626l3.91576307 3.23873978c.41034319.3393961 1.01467563.2976897 1.37450571-.0948578l6.10568327-6.660841c.3613513-.41848908.3096572-1.04610608-.115462-1.4018218-.4251192-.35571573-1.0626796-.30482786-1.424031.11366122z" fill-rule="evenodd"></path></symbol><symbol id="icon-update" viewBox="0 0 18 18"><path d="m1 13v1c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-1h-1v-10h-14v10zm16-1h1v2c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-2h1v-9c0-.55228475.44771525-1 1-1h14c.5522847 0 1 .44771525 1 1zm-1 0v1h-4.5857864l-1 1h-2.82842716l-1-1h-4.58578644v-1h5l1 1h2l1-1zm-13-8h12v7h-12zm1 1v5h10v-5zm1 1h4v1h-4zm0 2h4v1h-4z" fill-rule="evenodd"></path></symbol><symbol id="icon-upload" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.85576936 4.14572769c.19483374-.19483375.51177826-.19377714.70556874.00001334l2.59099082 2.59099079c.1948411.19484112.1904373.51514474.0027906.70279143-.1932998.19329987-.5046517.19237083-.7001856-.00692852l-1.74638687-1.7800176v6.14827687c0 .2717771-.23193359.492096-.5.492096-.27614237 0-.5-.216372-.5-.492096v-6.14827641l-1.74627892 1.77990922c-.1933927.1971171-.51252214.19455839-.70016883.0069117-.19329987-.19329988-.19100584-.50899493.00277731-.70277808z" fill-rule="evenodd"></path></symbol><symbol id="icon-video" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-8.30912922 2.24944486 4.60460462 2.73982242c.9365543.55726659.9290753 1.46522435 0 2.01804082l-4.60460462 2.7398224c-.93655425.5572666-1.69578148.1645632-1.69578148-.8937585v-5.71016863c0-1.05087579.76670616-1.446575 1.69578148-.89375851zm-.67492769.96085624v5.5750128c0 .2995102-.10753745.2442517.16578928.0847713l4.58452283-2.67497259c.3050619-.17799716.3051624-.21655446 0-.39461026l-4.58452283-2.67497264c-.26630747-.15538481-.16578928-.20699944-.16578928.08477139z" fill-rule="evenodd"></path></symbol><symbol id="icon-warning" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-checklist-banner" viewBox="0 0 56.69 56.69"><path style="fill:none" d="M0 0h56.69v56.69H0z"></path><clipPath id="b"><use xlink:href="#a" style="overflow:visible"></use></clipPath><path d="M21.14 34.46c0-6.77 5.48-12.26 12.24-12.26s12.24 5.49 12.24 12.26-5.48 12.26-12.24 12.26c-6.76-.01-12.24-5.49-12.24-12.26zm19.33 10.66 10.23 9.22s1.21 1.09 2.3-.12l2.09-2.32s1.09-1.21-.12-2.3l-10.23-9.22m-19.29-5.92c0-4.38 3.55-7.94 7.93-7.94s7.93 3.55 7.93 7.94c0 4.38-3.55 7.94-7.93 7.94-4.38-.01-7.93-3.56-7.93-7.94zm17.58 12.99 4.14-4.81" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round"></path><path d="M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5m14.42-5.2V4.86s0-2.93-2.93-2.93H4.13s-2.93 0-2.93 2.93v37.57s0 2.93 2.93 2.93h15.01M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round;stroke-linejoin:round"></path></symbol><symbol id="icon-chevron-down" viewBox="0 0 16 16"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"></path></symbol><symbol id="icon-eds-i-arrow-right-medium" viewBox="0 0 24 24"><path d="m12.728 3.293 7.98 7.99a.996.996 0 0 1 .281.561l.011.157c0 .32-.15.605-.384.788l-7.908 7.918a1 1 0 0 1-1.416-1.414L17.576 13H4a1 1 0 0 1 0-2h13.598l-6.285-6.293a1 1 0 0 1-.082-1.32l.083-.095a1 1 0 0 1 1.414.001Z"></path></symbol><symbol id="icon-eds-i-check-circle-medium" viewBox="0 0 24 24"><path d="M12 1c6.075 0 11 4.925 11 11s-4.925 11-11 11S1 18.075 1 12 5.925 1 12 1Zm0 2a9 9 0 1 0 0 18 9 9 0 0 0 0-18Zm5.125 4.72a1 1 0 0 1 .156 1.405l-6 7.5a1 1 0 0 1-1.421.143l-3-2.5a1 1 0 0 1 1.28-1.536l2.217 1.846 5.362-6.703a1 1 0 0 1 1.406-.156Z"></path></symbol><symbol id="icon-eds-i-chevron-down-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-chevron-down-small" viewBox="0 0 16 16"><path d="M13.692 5.278a1 1 0 0 1 .03 1.414L9.103 11.51a1.491 1.491 0 0 1-2.188.019L2.278 6.692a1 1 0 0 1 1.444-1.384L8 9.771l4.278-4.463a1 1 0 0 1 1.318-.111l.096.081Z"></path></symbol><symbol id="icon-eds-i-chevron-right-medium" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-eds-i-chevron-right-small" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-eds-i-chevron-up-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-close-medium" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-copy-link" viewBox="0 0 24 24"><path fill-rule="evenodd" clip-rule="evenodd" d="M19.4594 8.57015C19.0689 8.17963 19.0689 7.54646 19.4594 7.15594L20.2927 6.32261C20.2927 6.32261 20.2927 6.32261 20.2927 6.32261C21.0528 5.56252 21.0528 4.33019 20.2928 3.57014C19.5327 2.81007 18.3004 2.81007 17.5404 3.57014L16.7071 4.40347C16.3165 4.794 15.6834 4.794 15.2928 4.40348C14.9023 4.01296 14.9023 3.3798 15.2928 2.98927L16.1262 2.15594C17.6673 0.614803 20.1659 0.614803 21.707 2.15593C23.2481 3.69705 23.248 6.19569 21.707 7.7368L20.8737 8.57014C20.4831 8.96067 19.85 8.96067 19.4594 8.57015Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M18.0944 5.90592C18.4849 6.29643 18.4849 6.9296 18.0944 7.32013L16.4278 8.9868C16.0373 9.37733 15.4041 9.37734 15.0136 8.98682C14.6231 8.59631 14.6231 7.96314 15.0136 7.57261L16.6802 5.90594C17.0707 5.51541 17.7039 5.5154 18.0944 5.90592Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M13.5113 6.32243C13.9018 6.71295 13.9018 7.34611 13.5113 7.73664L12.678 8.56997C12.678 8.56997 12.678 8.56997 12.678 8.56997C11.9179 9.33006 11.9179 10.5624 12.6779 11.3224C13.438 12.0825 14.6703 12.0825 15.4303 11.3224L16.2636 10.4891C16.6542 10.0986 17.2873 10.0986 17.6779 10.4891C18.0684 10.8796 18.0684 11.5128 17.6779 11.9033L16.8445 12.7366C15.3034 14.2778 12.8048 14.2778 11.2637 12.7366C9.72262 11.1955 9.72266 8.69689 11.2637 7.15578L12.097 6.32244C12.4876 5.93191 13.1207 5.93191 13.5113 6.32243Z"></path><path d="M8 20V22H19.4619C20.136 22 20.7822 21.7311 21.2582 21.2529C21.7333 20.7757 22 20.1289 22 19.4549V15C22 14.4477 21.5523 14 21 14C20.4477 14 20 14.4477 20 15V19.4549C20 19.6004 19.9426 19.7397 19.8408 19.842C19.7399 19.9433 19.6037 20 19.4619 20H8Z"></path><path d="M4 13H2V19.4619C2 20.136 2.26889 20.7822 2.74705 21.2582C3.22434 21.7333 3.87105 22 4.5451 22H9C9.55228 22 10 21.5523 10 21C10 20.4477 9.55228 20 9 20H4.5451C4.39957 20 4.26028 19.9426 4.15804 19.8408C4.05668 19.7399 4 19.6037 4 19.4619V13Z"></path><path d="M4 13H2V4.53808C2 3.86398 2.26889 3.21777 2.74705 2.74178C3.22434 2.26666 3.87105 2 4.5451 2H9C9.55228 2 10 2.44772 10 3C10 3.55228 9.55228 4 9 4H4.5451C4.39957 4 4.26028 4.05743 4.15804 4.15921C4.05668 4.26011 4 4.39633 4 4.53808V13Z"></path></symbol><symbol id="icon-eds-i-download-medium" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-info-filled-medium" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-institution-medium" viewBox="0 0 24 24"><g><path fill-rule="evenodd" clip-rule="evenodd" d="M11.9967 1C11.6364 1 11.279 1.0898 10.961 1.2646C10.9318 1.28061 10.9035 1.29806 10.8761 1.31689L2.79765 6.87C2.46776 7.08001 2.20618 7.38466 2.07836 7.76668C1.94823 8.15561 1.98027 8.55648 2.12665 8.90067C2.42086 9.59246 3.12798 10 3.90107 10H4.99994V16H4.49994C3.11923 16 1.99994 17.1193 1.99994 18.5V19.5C1.99994 20.8807 3.11923 22 4.49994 22H19.4999C20.8807 22 21.9999 20.8807 21.9999 19.5V18.5C21.9999 17.1193 20.8807 16 19.4999 16H18.9999V10H20.0922C20.8653 10 21.5725 9.59252 21.8667 8.90065C22.0131 8.55642 22.0451 8.15553 21.9149 7.7666C21.7871 7.38459 21.5255 7.07997 21.1956 6.86998L13.1172 1.31689C13.0898 1.29806 13.0615 1.28061 13.0324 1.2646C12.7143 1.0898 12.357 1 11.9967 1ZM4.6844 8L11.9472 3.00755C11.9616 3.00295 11.9783 3 11.9967 3C12.015 3 12.0318 3.00295 12.0461 3.00755L19.3089 8H4.6844ZM16.9999 16V10H14.9999V16H16.9999ZM12.9999 16V10H10.9999V16H12.9999ZM8.99994 16V10H6.99994V16H8.99994ZM3.99994 18.5C3.99994 18.2239 4.2238 18 4.49994 18H19.4999C19.7761 18 19.9999 18.2239 19.9999 18.5V19.5C19.9999 19.7761 19.7761 20 19.4999 20H4.49994C4.2238 20 3.99994 19.7761 3.99994 19.5V18.5Z"></path></g></symbol><symbol id="icon-eds-i-mail-medium" viewBox="0 0 24 24"><path d="m19.462 0c1.413 0 2.538 1.184 2.538 2.619v12.762c0 1.435-1.125 2.619-2.538 2.619h-16.924c-1.413 0-2.538-1.184-2.538-2.619v-12.762c0-1.435 1.125-2.619 2.538-2.619zm.538 5.158-7.378 6.258a2.549 2.549 0 0 1 -3.253-.008l-7.369-6.248v10.222c0 .353.253.619.538.619h16.924c.285 0 .538-.266.538-.619zm-.538-3.158h-16.924c-.264 0-.5.228-.534.542l8.65 7.334c.2.165.492.165.684.007l8.656-7.342-.001-.025c-.044-.3-.274-.516-.531-.516z"></path></symbol><symbol id="icon-eds-i-menu-medium" viewBox="0 0 24 24"><path d="M21 4a1 1 0 0 1 0 2H3a1 1 0 1 1 0-2h18Zm-4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h14Zm4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h18Z"></path></symbol><symbol id="icon-eds-i-search-medium" viewBox="0 0 24 24"><path d="M11 1c5.523 0 10 4.477 10 10 0 2.4-.846 4.604-2.256 6.328l3.963 3.965a1 1 0 0 1-1.414 1.414l-3.965-3.963A9.959 9.959 0 0 1 11 21C5.477 21 1 16.523 1 11S5.477 1 11 1Zm0 2a8 8 0 1 0 0 16 8 8 0 0 0 0-16Z"></path></symbol><symbol id="icon-eds-i-user-single-medium" viewBox="0 0 24 24"><path d="M12 1a5 5 0 1 1 0 10 5 5 0 0 1 0-10Zm0 2a3 3 0 1 0 0 6 3 3 0 0 0 0-6Zm-.406 9.008a8.965 8.965 0 0 1 6.596 2.494A9.161 9.161 0 0 1 21 21.025V22a1 1 0 0 1-1 1H4a1 1 0 0 1-1-1v-.985c.05-4.825 3.815-8.777 8.594-9.007Zm.39 1.992-.299.006c-3.63.175-6.518 3.127-6.678 6.775L5 21h13.998l-.009-.268a7.157 7.157 0 0 0-1.97-4.573l-.214-.213A6.967 6.967 0 0 0 11.984 14Z"></path></symbol><symbol id="icon-eds-i-warning-filled-medium" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-expand-image" viewBox="0 0 18 18"><path d="m7.49754099 11.9178212c.38955542-.3895554.38761957-1.0207846-.00290473-1.4113089-.39324695-.3932469-1.02238878-.3918247-1.41130883-.0029047l-4.10273549 4.1027355.00055454-3.5103985c.00008852-.5603185-.44832171-1.006032-1.00155062-1.0059446-.53903074.0000852-.97857527.4487442-.97866268 1.0021075l-.00093318 5.9072465c-.00008751.553948.44841131 1.001882 1.00174994 1.0017946l5.906983-.0009331c.5539233-.0000875 1.00197907-.4486389 1.00206646-1.0018679.00008515-.5390307-.45026621-.9784332-1.00588841-.9783454l-3.51010549.0005545zm3.00571741-5.83449376c-.3895554.38955541-.3876196 1.02078454.0029047 1.41130883.393247.39324696 1.0223888.39182478 1.4113089.00290473l4.1027355-4.10273549-.0005546 3.5103985c-.0000885.56031852.4483217 1.006032 1.0015506 1.00594461.5390308-.00008516.9785753-.44874418.9786627-1.00210749l.0009332-5.9072465c.0000875-.553948-.4484113-1.00188204-1.0017499-1.00179463l-5.906983.00093313c-.5539233.00008751-1.0019791.44863892-1.0020665 1.00186784-.0000852.53903074.4502662.97843325 1.0058884.97834547l3.5101055-.00055449z" fill-rule="evenodd"></path></symbol><symbol id="icon-github" viewBox="0 0 100 100"><path fill-rule="evenodd" clip-rule="evenodd" d="M48.854 0C21.839 0 0 22 0 49.217c0 21.756 13.993 40.172 33.405 46.69 2.427.49 3.316-1.059 3.316-2.362 0-1.141-.08-5.052-.08-9.127-13.59 2.934-16.42-5.867-16.42-5.867-2.184-5.704-5.42-7.17-5.42-7.17-4.448-3.015.324-3.015.324-3.015 4.934.326 7.523 5.052 7.523 5.052 4.367 7.496 11.404 5.378 14.235 4.074.404-3.178 1.699-5.378 3.074-6.6-10.839-1.141-22.243-5.378-22.243-24.283 0-5.378 1.94-9.778 5.014-13.2-.485-1.222-2.184-6.275.486-13.038 0 0 4.125-1.304 13.426 5.052a46.97 46.97 0 0 1 12.214-1.63c4.125 0 8.33.571 12.213 1.63 9.302-6.356 13.427-5.052 13.427-5.052 2.67 6.763.97 11.816.485 13.038 3.155 3.422 5.015 7.822 5.015 13.2 0 18.905-11.404 23.06-22.324 24.283 1.78 1.548 3.316 4.481 3.316 9.126 0 6.6-.08 11.897-.08 13.526 0 1.304.89 2.853 3.316 2.364 19.412-6.52 33.405-24.935 33.405-46.691C97.707 22 75.788 0 48.854 0z"></path></symbol><symbol id="icon-springer-arrow-left"><path d="M15 7a1 1 0 000-2H3.385l2.482-2.482a.994.994 0 00.02-1.403 1.001 1.001 0 00-1.417 0L.294 5.292a1.001 1.001 0 000 1.416l4.176 4.177a.991.991 0 001.4.016 1 1 0 00-.003-1.42L3.385 7H15z"></path></symbol><symbol id="icon-springer-arrow-right"><path d="M1 7a1 1 0 010-2h11.615l-2.482-2.482a.994.994 0 01-.02-1.403 1.001 1.001 0 011.417 0l4.176 4.177a1.001 1.001 0 010 1.416l-4.176 4.177a.991.991 0 01-1.4.016 1 1 0 01.003-1.42L12.615 7H1z"></path></symbol><symbol id="icon-submit-open" viewBox="0 0 16 17"><path d="M12 0c1.10457 0 2 .895431 2 2v5c0 .276142-.223858.5-.5.5S13 7.276142 13 7V2c0-.512836-.38604-.935507-.883379-.993272L12 1H6v3c0 1.10457-.89543 2-2 2H1v8c0 .512836.38604.935507.883379.993272L2 15h6.5c.276142 0 .5.223858.5.5s-.223858.5-.5.5H2c-1.104569 0-2-.89543-2-2V5.828427c0-.530433.210714-1.039141.585786-1.414213L4.414214.585786C4.789286.210714 5.297994 0 5.828427 0H12Zm3.41 11.14c.250899.250899.250274.659726 0 .91-.242954.242954-.649606.245216-.9-.01l-1.863671-1.900337.001043 5.869492c0 .356992-.289839.637138-.647372.637138-.347077 0-.647371-.285256-.647371-.637138l-.001043-5.869492L9.5 12.04c-.253166.258042-.649726.260274-.9.01-.242954-.242954-.252269-.657731 0-.91l2.942184-2.951303c.250908-.250909.66127-.252277.91353-.000017L15.41 11.14ZM5 1.413 1.413 5H4c.552285 0 1-.447715 1-1V1.413ZM11 3c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Zm0 2c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Z" fill-rule="nonzero"></path></symbol></svg>
</div>
</footer>




    

    

<div class="c-site-messages message u-hide u-hide-print c-site-messages--nature-briefing c-site-messages--nature-briefing-email-variant c-site-messages--nature-briefing-redesign-2020 sans-serif c-site-messages--nature-briefing-cancer" data-component-id="nature-briefing-banner" data-component-expirydays="30" data-component-trigger-scroll-percentage="15" data-track="in-view" data-track-action="in-view" data-track-category="nature briefing" data-track-label="Briefing banner visible: Cancer">

    
    <div class="c-site-messages__banner-large">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close" data-track="click" data-track-category="nature briefing" data-track-label="Briefing banner dismiss: Cancer">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__form-container">

            <div class="grid grid-12 last">
                <div class="grid grid-4">
                    <img alt="Nature Briefing: Cancer" src="/static/images/logos/nature-briefing-logo-cancer-white-bc263e7d57.svg" width="373" height="40">
                    <p class="c-site-messages--nature-briefing__strapline extra-tight-line-height">Sign up for the <em>Nature Briefing: Cancer</em> newsletter — what matters in cancer research, free to your inbox weekly.</p>
                </div>
                <div class="grid grid-8 last">
                    <form action="https://www.nature.com/briefing/cancer" method="post" data-location="banner" data-track="signup_nature_briefing_banner" data-track-action="transmit-form" data-track-category="nature briefing" data-track-label="Briefing banner submit: Cancer">
                        <input id="briefing-banner-signup-form-input-track-originReferralPoint" type="hidden" name="track_originReferralPoint" value="CancerBriefingBanner">
                        <input id="briefing-banner-signup-form-input-track-formType" type="hidden" name="track_formType" value="DirectEmailBanner">

                        <input type="hidden" value="false" name="gdpr_tick" id="gdpr_tick_banner">
                        <input type="hidden" value="false" name="marketing" id="marketing_input_banner">
                        <input type="hidden" value="false" name="marketing_tick" id="marketing_tick_banner">
                        <input type="hidden" value="CancerBriefingBanner" name="brieferEntryPoint" id="brieferEntryPoint_banner">

                        <label class="nature-briefing-banner__email-label" for="emailAddress">Email address</label>

                        <div class="nature-briefing-banner__email-wrapper">
                            <input class="nature-briefing-banner__email-input box-sizing text14" type="email" id="emailAddress" name="emailAddress" value="" placeholder="e.g. jo.smith@university.ac.uk" required="" data-test-element="briefing-emailbanner-email-input">
                            
                            <input type="hidden" value="true" name="N:cancer" id="defaultNewsletter_banner">
                            <button type="submit" class="nature-briefing-banner__submit-button box-sizing text14" data-test-element="briefing-emailbanner-signup-button">Sign up</button>
                        </div>

                        <div class="nature-briefing-banner__checkbox-wrapper grid grid-12 last">
                            <input class="nature-briefing-banner__checkbox-checkbox" id="gdpr-briefing-banner-checkbox" type="checkbox" name="gdpr" value="true" data-test-element="briefing-emailbanner-gdpr-checkbox" required="">
                            <label class="nature-briefing-banner__checkbox-label box-sizing text13 sans-serif block tighten-line-height" for="gdpr-briefing-banner-checkbox">I agree my information will be processed in accordance with the <em>Nature</em> and Springer Nature Limited <a href="https://www.nature.com/info/privacy">Privacy Policy</a>.</label>
                        </div>
                    </form>
                </div>
            </div>

        </div>

    </div>

    
    <div class="c-site-messages__banner-small">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close" data-track="click" data-track-category="nature briefing" data-track-label="Briefing banner dismiss: Cancer">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__content text14">
            <span class="c-site-messages--nature-briefing__strapline strong">Get what matters in cancer research, free to your inbox weekly.</span>
            <a class="nature-briefing__link text14 sans-serif" data-track="click" data-track-category="nature briefing" data-track-label="Small-screen banner CTA to site" data-test-element="briefing-banner-link" target="_blank" rel="noreferrer noopener" href="/briefing/cancer/?brieferEntryPoint=CancerBriefingBanner">Sign up for Nature Briefing: Cancer
            </a>
        </div>

    </div>

</div>

    




<noscript>
    <img hidden src="https://verify.nature.com/verify/nature.png" width="0" height="0" style="display: none" alt="">
</noscript>




<script src="//content.readcube.com/ping?doi=10.1038/s41591-022-01829-9&amp;format=js&amp;last_modified=2022-07-21" async=""></script>

<kfm-ondwcahmieww></kfm-ondwcahmieww><div data-cc-ghost="" style="height: 352px;"></div><script type="text/javascript" id="fetch-contextual-ads-campaign-data" charset="">(function(){var g=function(a){a=new CustomEvent("campaignDataLoaded",{detail:a});document.dispatchEvent(a)},b=google_tag_manager["rm"]["50443292"](18);if(b){var k=1500;b=google_tag_manager["rm"]["50443292"](19);b="link"===b?google_tag_manager["rm"]["50443292"](20):google_tag_manager["rm"]["50443292"](21);var m=function(a,c){var h=!1,l=setTimeout(function(){h=!0;c(null)},k),d=new XMLHttpRequest;d.onload=function(){var e=null,f=[];if(200===d.status){try{e=JSON.parse(d.responseText)}catch(p){e={}}f=e.campaigns||[]}h||(clearTimeout(l),c(f.length?f.join(","):null))};d.open("GET",
"/platform/contextual?doi\x3d"+a);d.send()},n=function(a,c){a&&-1===a.indexOf("not set")?m(a,c):setTimeout(c,1)};n(b,function(a){window.campaignsForContextualAds=a;g(a);window.dataLayer.push({content:{article:{campaignID:a}}})})}else window.campaignsForContextualAds="",g(null)})();</script>
<script type="text/javascript" id="gtm-setup-accessdetailsloaded-handler" charset="">document.addEventListener("accessdetailsloaded",function(a){a=a.detail||{};var b={event:"update-access-details"};a.institutional_business_partner_ids&&a.resolved_by||console.log("BPID data could not be retrieved from /exposed-details");a.logged_in_to_sn_profile||console.log("logged_in_to_sn_profile could not be retrieved from /exposed-details");var c=a.institutional_business_partner_ids&&a.institutional_business_partner_ids.join?a.institutional_business_partner_ids.join(";"):"",d=a.resolved_by&&a.resolved_by.join?
a.resolved_by.join(";"):"",e=a.personal_business_partner_id_found,f=a.logged_in_to_sn_profile,g=a.snid;b.user={};b.user.profile={};b.user.profile.profileInfo={resolvedBy:d||null,bpid:c||null,personal:e||null,logged_in_to_sn_profile:f,snid:g||null};b.session={};b.session.authentication={};b.session.authentication.token=a.token||null;b.session.authentication.legacy={};window.dataLayer.push(b);window.idpUserDataLoaded=!0},!1);window.dataLayer.push({event:"accessdetailsloaded-handler-added"});
window.accessDetailsLoadedHandlerAdded=!0;</script><script type="text/javascript" id="gtm-mediatrust" charset="">var s=document.getElementsByTagName("script")[0],p=document.createElement("script");p.async="async";p.src="https://scripts.webcontentassessor.com/scripts/93dabb8d80079a87fec7bb6f67b807fce90e1688f8957ad7ad152bfd58ea01c2";s.parentNode.insertBefore(p,s);</script><script id="crossmark-script" text="" charset="" type="text/javascript" src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script><script type="text/javascript" id="polyfill-matches" charset="">Element.prototype.matches||(Element.prototype.matches=Element.prototype.matchesSelector||Element.prototype.mozMatchesSelector||Element.prototype.msMatchesSelector||Element.prototype.oMatchesSelector||Element.prototype.webkitMatchesSelector||function(a){a=(this.document||this.ownerDocument).querySelectorAll(a);for(var b=a.length;0<=--b&&a.item(b)!==this;);return-1<b});</script><script type="text/javascript" id="fetch-idp-user-data" charset="">(function(a){if("function"===typeof window.CustomEvent)return!1;var c=function(d,b){b=b||{};var e=document.createEvent("CustomEvent");e.initCustomEvent(d,b.bubbles||!1,b.cancelable||!1,b.detail||a);return e};c.prototype=window.Event.prototype;window.CustomEvent=c})();var parse=function(a,c){try{return 200===a?JSON.parse(c):null}catch(d){return null}},dispatch=function(a){a=new CustomEvent("accessdetailsloaded",{detail:a});document.dispatchEvent(a)},site=google_tag_manager["rm"]["50443292"](59),idpUrl;
switch(site){case "nature":idpUrl=-1<window.location.hostname.indexOf("local-www")||-1<window.location.hostname.indexOf("test-www")?"https://staging-idp.nature.com/exposed-details":"https://idp.nature.com/exposed-details";break;case "link":idpUrl=-1<window.location.hostname.indexOf("link-qa")?"https://staging-idp.springer.com/exposed-details":"https://idp.springer.com/exposed-details";break;case "springer":idpUrl=-1<window.location.hostname.indexOf("local-www")||-1<window.location.hostname.indexOf("test-www")?
"https://staging-idp.springer.com/exposed-details":"https://idp.springer.com/exposed-details"}if(void 0!==idpUrl){var transport=new XMLHttpRequest;transport.open("GET",idpUrl,!0);transport.withCredentials=!0;transport.onreadystatechange=function(){4===transport.readyState&&dispatch(parse(transport.status,transport.responseText))};transport.send()}else dispatch(null);</script><script src="https://verify.nature.com/verify/nature.min.js"></script><script type="text/javascript" id="create-ad-slots" charset="">function createAndLoadAds(){function h(b){"nature"===a&&google_tag_manager["rm"]["50443292"](87)(b);"bmc"!==a&&"springeropen"!==a||google_tag_manager["rm"]["50443292"](99)(b);("link"===a&&"oscar"===google_tag_manager["rm"]["50443292"](100)||"springer"===a||"link"===a&&!0===google_tag_manager["rm"]["50443292"](101))&&google_tag_manager["rm"]["50443292"](126)(b);"link"===a&&"bunsen"===google_tag_manager["rm"]["50443292"](127)&&google_tag_manager["rm"]["50443292"](152)(b);"link"===a&&"Core"===google_tag_manager["rm"]["50443292"](153)&&google_tag_manager["rm"]["50443292"](165)(b)}window.googletag=window.googletag||{cmd:[]};var a=google_tag_manager["rm"]["50443292"](166),e=google_tag_manager["rm"]["50443292"](168);
if(-1===window.location.search.indexOf("hide_ads\x3dtrue"))if(window.adSlots&&0!==Object.keys(window.adSlots).length)console.log("Ads previously loaded. Will not update ad slots until next page load.");else{window.adSlots||(window.adSlots={});window.getAd=function(b,f){for(var c in window.adSlots)if(-1<c.indexOf(b)){if("object"===f)return adSlots[c];if("slot"===f)return adSlots[c].slot}};googletag.cmd.push(function(){googletag.pubads().setPrivacySettings({limitedAds:e});console.log("limitedAds is ",
e);googletag.pubads().setRequestNonPersonalizedAds(google_tag_manager["rm"]["50443292"](170));googletag.pubads().enableSingleRequest();googletag.pubads().disableInitialLoad()});for(var g=document.querySelectorAll("[data-gpt]"),d=0;g[d];++d)h(g[d]);googletag.cmd.push(function(){googletag.enableServices()})}}createAndLoadAds();</script>
</body></html>